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Abstract  
The aims of this thesis are to establish the therapeutic value of two anti-glycan mAbs produced in-
house, to develop an immunisation protocol with the aim of improving the immunogenicity tumour-
associated glycolipids with the intention of producing therapeutically valuable mAbs and to 
determine the implication of a mAb with the ability to induce apoptosis in colorectal cancer. 
The anti-glycan mAbs 692/29 and 505/4 have previously been produced in-house and this study 
aimed to determine their fine specificity using a glycan array. 692/29 displayed binding 
predominantly to Lewis b as well as Lewis y-containing glycans. 505/4 was discovered to bind to 
sialyl Lewis a as well as sialyl di-Lewis a, with no cross-reactivity with other blood group antigens. 
This was compared to other anti-Lewis mAbs, with differences in specificity being observed. 
Characterisation of 505/4 mAb distribution showed binding to 80% of colorectal tumours and low 
levels of binding to normal tissues by IHC, suggesting it may be therapeutically useful. 
This thesis aimed to assess the ability of 505/4 and 692/29 to meditate immune mediated and non-
immune mediated cell death as well as to determine whether non-immune-mediated cell death 
would be a desirable therapeutic property. Resistance to apoptosis is one of the hallmarks of cancer 
cells and mAbs stimulating apoptosis may not be very effective. To investigate the significance of 
apoptosis in cancer a large tissue microarray of colorectal tumours was assessed for apoptosis and 
its relationship to patient prognosis. Cleaved caspase-3 is a good marker of apoptosis as it is the 
executioner caspase for both the extrinsic and intrinsic pathways. Immunohistochemical analysis of 
colorectal tumour samples revealed that a high expression of cleaved caspase-3 in tumour was 
associated with good prognosis in colorectal cancer. This suggested that some tumours were still 
susceptible to apoptotic death but some are resistant and an alternative mechanism of cell death 
may be an advantage in these tumours. High expression of cleaved caspase-3 in the tumour-
associated stroma was also an independent marker of good prognosis in colorectal cancer. This may 
be because apoptosis of the tumour-associated stroma reduces the level of pro-tumour signals 
  
vii 
 
originating from tumour-associated immune cells and stromal cells. As the tumour 
microenvironment can act in an immunosuppressive and pro-tumour manner, the ability of a mAb to 
induce direct cell death without the need for effector cells or complement would be an advantage. 
Lewis y and Lewis b are blood group antigens commonly overexpressed on the surface of a range of 
cancers. Characterisation of effector functions of 505/4 and 692/29 demonstrated that both mAbs 
have the ability to mediate apoptosis by antibody dependent cellular cytotoxicity, complement 
dependent cytotoxicity and cause direct cell death in an oncosis-like manner. Comparison with other 
anti-Lewis mAbs demonstrated that a number of anti-Lewis mAbs can induce direct cell death 
independently of apoptosis. Thus, they could effectively target apoptotic sensitive and resistant 
colorectal cancers.  
Tumours aberrantly express glycolipids and these molecules may be involved in a number of cellular 
pathways. In addition a large proportion of anti-glycan mAbs, including 505/4 and 692/29 in this 
thesis, have displayed the ability to induce direct cell death. Therefore this thesis aimed to develop 
an immunisation protocol capable of increasing the immunogenicity of tumour-associated glycolipid 
for the production of anti-tumour glycolipid mAbs directed against ovarian cancer. This study 
suggests that the incorporation of tumour glycolipid into liposomes and their immunisation along 
ǁŝƚŚƚŚĞŝE<dĐĞůůĂĚũƵǀĂŶƚɲ-galactosylceramide, elicits an anti-tumour glycolipid immune response, 
which can yield IgG mAbs capable of binding a high proportion of ovarian cancers.  
In summary, this thesis confirmed specificity of 692/29 to Lewis y and Lewis b and 505/4 to sialyl 
Lewis a and sialyl di-Lewis a. Furthermore, this thesis demonstrated a promising tissue distribution 
of 505/4 in vitro. Characterisation of mAb effector functions suggest that both Lewis y and sialyl 
Lewis a directed mAbs have the ability to cause direct cell death, independently of apoptosis in 
antigen positive cells, as well as the ability to cause immune-mediated cell death. This may be an 
important factor in the immune-suppressive tumour microenvironment. Furthermore, this thesis 
provides the basis for the production of new anti-glycolipid antibodies that may also be able to 
induce direct cell death. 
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Chapter 1 Introduction 
1.1 Cancer 
Cancer is defined by the uncontrolled growth of cells, the invasion of the surrounding tissue and 
metastasis. Cancer is one of the leading causes of death in the modern world, with 298,000 new 
cases of cancer diagnosed each year in the UK, and more than 1 in 3 people developing some form 
of cancer through their life (CRUK, 2010). This relates to 1 in 4 deaths in the UK. Colorectal cancer is 
the second most common of cancer death, after lung cancer, with ovarian cancer being the fourth 
most common form of cancer in women, accounting for 6% of death in women (CRUK, 2010; NICE, 
2003b).  
1.1.1 Treatment of colorectal and ovarian cancer 
The current recommendation for treatment of colorectal cancer is surgery, with 80% of patients 
undergoing surgery. Of these patients about 40% remain disease free. Surgery is not possible in the 
remaining 20% as the disease is too far progressed for any curative treatment (NICE, 2004). 
Following surgery, patients receive a six month course of oxaliplatin in combination with infusional 
5-florouracil (FU) plus folinic acid (FOLFOX) or irinotecan in combination with infusional 5-FU plus 
folinic acid (FOLFIRI) as first line treatment of colorectal cancer. Both FOLFOX and irinotecan alone 
are recommended as subsequent therapy options (NICE, 2008). Oral analogues of 5-FU capecitabine 
and tegafur in combination with uracil and folinic acid are also recommended for first line treatment 
of colorectal cancer (NICE, 2003a). Monoclonal antibodies (mAbs) directed at vascular endothelial 
growth factor (VEGF; bevacizumab) and the epidermal growth factor receptor (EGFR; cetuximab) 
have been approved for the treatment of metastatic colorectal cancer and will be discussed further 
in a later section (section 1.2.14). 
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The early stages of ovarian cancer are asymptomatic resulting in patients presenting at more 
advanced stages. Surgery is usually the first form of treatment in ovarian cancer; however, removal 
of the whole tumour is not possible in most cases, due to the advanced stage. Platinum-based 
therapy alone or in combination with paclitaxel is used as first and second line chemotherapy (NICE, 
2003b). Despite advances in the treatment of other cancers, ovarian cancer treatment has not 
changed over the past decade, advocating further study into alternative treatments. More recently, 
alternative treatments, including small molecule inhibitors and mAbs, have shown promise against 
ovarian cancer. The presence of breast cancer susceptibility gene 1 (BRCA1) and breast cancer 
susceptibility gene 2 (BRCA2) deficient ovarian cancers has lead to the study of small molecule poly 
(ADP-ribose) polymerase (PARP-1) inhibitors. PARP-1 is a DNA repair protein involved in base 
excision repair that repairs single strand DNA breaks (Shrivastav et al., 2008). In tumours deficient in 
BRCA1/BRCA2 mediated repair, the inhibition of PARP-1 leads to the accumulation double-stranded 
DNA breaks during replication, resulting in apoptosis of the tumour cell. A range of PARP-1 inhibitors 
have shown stabilisation or regression of ovarian cancers with BRCA1 or BRCA2 mutations, including 
olaparib (AZD2281) which has shown anti-tumour activity in a number of  phase I clinical trials (Fong 
et al., 2010; Khan et al., 2011).  
More recently the immune system in general and mAbs in particular are emerging as leading players 
in the fight against cancer. 
1.2 Immunity 
1.2.1 The B cell 
B cells, also known as B lymphocytes produce antibodies when stimulated. They are produced and 
mature in the bone marrow. A key component of B cells is their B cell receptor (BcR) which binds 
specific antigens. The BcR is a multiprotein cross-membrane complex; that contains membrane 
bound immunoglobulin (mIg) consisting of Ig heavy (Ig-H) and light (Ig-L) chains and the associated 
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Ig-ɲĂŶĚ/Ő-ɴŚĞƚĞƌŽĚŝŵĞƌ(Reth & Wienands, 1997). It is expressed once a small pre-B cell becomes 
an immature B cell (Fig 1.1). The Ig-H and Ig-L chains are required for the recognition of antigens, 
which results in signal transduction inside the cell mediated by the Ig-ɲ ĂŶĚ /Ő-ɴ ĐŚĂŝŶƐ ? ǁŚŝĐŚ
contain immunoreceptor tyrosine-based activation motifs (ITAM) in their cytoplasmic domains (Reth 
& Wienands, 1997). Cross-linking of a number of BcRs on the cell surface by antigen leads to the 
translocation of the BcR and co-stimulatory molecules to lipid rafts, where protein-tyrosine kinases 
(PTK), such as LYN reside (Reth & Wienands, 1997). However, a recent model has been proposed 
where BcRs can exist as either active monomers, providing a survival signal for the B cell or as 
 ‘ĐůŽƐĞĚ ?ŽůŝŐŽŵĞƌƐ ? ƚŚĂƚĂƵƚŽ inhibit their activation. In the presence of antigen, the equilibrium is 
shifted towards more active monomers, allowing signalling. Only a polyvalent antigen can keep the 
BcR monomers apart, therefore allowing their activation (Yang & Reth, 2010). Whether oligomeric 
BcR are activated or monomeric BcR are cross-linked by antigen, LYN and other tyrosine kinases then 
phosphorylate the ITAM of Ig-ɲ ĂŶĚ /Ő-ɴ (Kurosaki, 2002). This provides a binding site for SCR-
homology 2 (SH2) binding proteins such as PI3K and VAV. Activation of PI3K and VAV leads to 
downstream signalling. 
The activation of the BcR can either be promoted or inhibited by a number of co-receptors present 
on the surface of the B cell. The CD19-CD21 complex is a tetrameric complex consisting of CD19, 
CD21, CD81 and leu13 that is co-ligated to the BcR via binding C3d-tagged antigens and enhances 
BcR signalling (Tedder et al., 1997). This occurs by CD21 binding the C3d-tagged antigen (Cherukuri 
et al., 2001a). The coupling CD19/CD21 to the BcR reduces the B cell activation threshold due to the 
phosphorylation of the ITAM on CD19 by tyrosine kinases, as well as increasing translocation of the 
BcR to lipid rafts and prolonging the activation signal (Cherukuri et al., 2001a; Cherukuri et al., 
2001b). An example of an inhibitory co-receptor expressed on B cells is CD22 (Nitschke, 2009). CD22 
is a membrane protein that is a member of the sialic acid-binding immunoglobulin-like (Siglec) family 
which specifically recognise sialic acids attached to the terminal regions of cell-surface 
glycoconjugates (Crocker et al., 2007). CD22 contains three cytoplasmic immunoreceptor tyrosine-
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based inhibitory motifs (ITIM) which are phosphorylated by LYN upon activation of the BcR (Smith et 
al., 1998). Phosphorylation of the ITIMs leads to the recruitment of SHP-1, a protein tyrosine 
phosphate. SHP-1 inhibits BcR activation by interfering with tyrosine kinase activity (Nitschke & 
Tsubata, 2004). CD22 can also recruit positive signalling molecules such as PI3K (Crocker et al., 
2007). 
1.2.2 B cell maturation 
Maturation of a B cell serves to create a large population of immunoglobulin-diverse cells that can 
recognise a large number of antigens. In order to protect an individual against all potential antigens 
in its environment it must be capable of producing at least 10
7
 different antibody specificities. To 
ĂĐŚŝĞǀĞ ƚŚŝƐ ĂŵŽƵŶƚ ŽĨ ĚŝǀĞƌƐŝƚǇ Ă ůĂƌŐĞ ƉƌŽƉŽƌƚŝŽŶ ŽĨ ĂŶ ŝŶĚŝǀŝĚƵĂů ?Ɛ E ǁŽƵůĚ ďĞ ŶĞĞĚĞĚ ?This 
diversity is therefore created by genetic rearrangement. Diversity arises at four molecular levels; 
joining and rearrangement of variable region gene segments, somatic hypermutation (SHM) of the 
rearranged variable regions, class switch recombination (CSR) of heavy chain constant genes and 
gene conversion of variable genes (Maul & Gearhart, 2010). The rearrangement of variable region 
genes occurs during B cell maturation and the genetic rearrangement and expression of 
immunoglobulin genes mark the distinct stages of B cell maturation from stem cell to immature B 
cell (Fig 1.1).  The stem cell has no rearrangement of its light and heavy chain immunoglobulin genes. 
The assembly of the heavy chain variable region requires two rearrangements involving three 
different types of gene segments, V, D and J (Early et al., 1980). The DH and JH segments are fused 
first, marking the progression of the stem cell to early pro-B cell (Fig 1.2). The rearrangement of the 
VH segment marks the progression to the late pro-B cell. There are nine alternative C region 
sequences (each with multiple exons) with only the Cʅ and Cɷ sequences initially transcribed. The 
primary transcript can then be spliced one of two ways to generate mRNAs that encode ʅ or ɷ H 
chains with identical V domains. Additional diversity is created by imprecise joining/junctional  
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Figure 1.1 Maturation of B cells. Germline unrearranged immunoglobulin heavy chain D and J regions are 
rearranged forming the early pro-B cell, followed by v region rearrangement, marking the transition to late 
pro-ĐĞůůƐ ?dƌĂŶƐŝĞŶƚĞǆƉƌĞƐƐŝŽŶŽĨƚŚĞʅĐŚĂŝŶĂƚƚŚĞƐƵƌĨĂĐĞŵĂƌŬƐƚŚĞƚƌĂŶƐŝƚŝŽŶƚŽůĂƌŐĞƉƌĞ-B cell before V-J 
region rearranging denotes the small pre-B cell. Expressions of mIg at the surface after both the heavy and 
light chain have been rearranged results in the immature B cell. 
 
 
Figure 1.2 Rearrangement and expression of the H chain locus. D and J regions are fused marking the 
progression of stem cell to early pro-B cell. Rearrangement of the V region is then followed by the 
transcription of either Cʅ or Cɷ ?The primary transcript can then be spliced in two ways yielding an H chain with 
either a Cʅ
 
or Cɷ domain, with an identical variable region.  
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diversity. This involves a loss of nucleotides at the joining between segments (Sakano et al., 1979). In 
the heavy chain additional nucleotides may be added which is referred to as N region insertion. 
Rearrangement is controlled by the presence of conserved heptamer and nonamer DNA sequences 
adjacent to the gene segments (recombination signal sequences; RSS). They are separated by 12 or 
23 bp. The RSS are recognised by a complex of lymphocyte-specific recombination proteins RAG1 
and RAG2. These cleave the DNA between the coding sequence and RSS. The coding strands are 
then rejoined (which can lead to junctional diversity or N region insertion) to give a rearranged gene 
segment. The recombination machinery can only join sequences separated by 12 or 23 bp, (12/23 
rule) therefore only allowing the correct segments to be joined (Cooper, 2000). In the absence of 
RAG proteins, B cells cannot mature (Mombaerts et al., 1992). dƌĂŶƐŝĞŶƚĞǆƉƌĞƐƐŝŽŶŽĨƚŚĞʅĐŚĂŝŶĂƚ
the cell surface marks the progression of the late pro B cell to a large pre-B cell. Up to this point the 
light chain remains un-rearranged. dŚĞʃůŝŐŚƚĐŚĂŝŶůŽĐƵƐĐŽŶƐŝƐƚƐŽĨŶƵŵĞƌŽƵƐsƐĞŐŵĞŶƚƌĞŐŝŽŶƐ, 
numerous J segment regions and a unique Cʃexon. A DNA rearrangement event (either looping out 
and deletion or inversion) fuses one V segment to one J segment forming a single exon (Fig 1.3), 
marking the transition of large pre-B cell to a small pre-B cell. The V/J exon is then transcribed 
together with the J exons downstream of the V/J exon and the Cʃ exon. The transcript is then 
transcribed and spliced to form mRNA. In this step, the un-rearranged J segments that were 
ĚŽǁŶƐƚƌĞĂŵŽĨƚŚĞs ?:ĞǆŽŶĂƌĞƌĞŵŽǀĞĚĂƐƉĂƌƚŽĨƚŚĞŝŶƚƌŽŶĚƵƌŝŶŐZEƐƉůŝĐŝŶŐ ?ƚƚŚĞʄ>ĐŚĂŝŶ
locus, there are 6-9 alternative Cʄ exons, each with a nearby Jʄ segment. DNA rearrangement fuses a 
V segment with a J segment and its associated C segment (Fig 1.4), marking the last step 
rearrangement, forming the immature B cell with rearranged light and heavy chains and mIg 
expressed on the cell surface.  
As mentioned above, the production of rearranged variable regions during B cell maturation is only 
one way in which diversity of Ig is produced. Upon antigen recognition, somatic hypermutation 
(SHM) and class switch recombination (CSR) occur, further increasing the diversity of B cell Ig 
response. SHM produces point mutations throughout the rearranged V region and selection in  
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Figure 1.3 The assembly ĂŶĚĞǆƉƌĞƐƐŝŽŶŽĨƚŚĞʃ>ĐŚĂŝŶůŽĐƵƐ ? Looping out or inversion results in fusion of V 
segments to J segments and a unique Cʃexon, marking the transition of large pre-B cell to small pre-B cell. 
RNA splicing results in the removal of downstream J regions, leaving one V, J and C region. 
 
 
Figure 1.3 dŚĞĂƐƐĞŵďůǇŽĨƚŚĞʄ>ĐŚĂŝŶůŽĐƵƐ ?ƚƚŚĞʄůŽĐƵƐ ?ƚŚĞƌĞĂƌĞ ?-9 C segments each with a nearby J 
segment. DNA rearrangement fused a V segment with a J segment and its associated C segment, marking the 
last rearrangement, forming the immature B cell. 
 
germinal centres occurs for high-affinity antibody-producing cells against a certain antigen. 
Therefore, the implication of mutation in the V gene is to generate antibodies with high affinity to 
antigens. CSR is region-specific recombination that replaces the heavy chain C region gene from Cʅ to 
other downstream CH genes. This results in the B cell expressing IgG, IgE, or IgA isotypes, without 
Vț Vț VțQ J1     J2 J3 J4 J5 Cț
V/J joining
V/J3 J4 J5 Cț
Transcription
RNA splicing
Rearranged gene
Primary transcript
kappa mRNA
VJ3Cț
VȜ VȜ  VȜQ J1 CȜ   J2 CȜ J3 CȜ
VȜ/J3 CȜ
Unrearranged
lamba locus
Rearranged lamda locus
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affecting affinity for the antigen. Both SHM and CSR occur after antigen stimulation of the B cell and 
are controlled by the B cell specific enzyme activation-induced deaminase (AID; (Maul & Gearhart, 
2010; Muramatsu et al., 2000)). AID deaminates cytosine to uracil in single stranded DNA (Dickerson 
et al., 2003). Depending on how the uracil is processed in the DNA, mutations can occur. Mutations 
at C:G by AID-dependent insertion of uracil can occur by being left in, resulting in a C to T transition, 
the uracil could be removed by uracil glycosylase, leading to an abasic site, which can be filled with 
low fidelity DNA polymerase, resulting in mutation (Petersen-Mahrt et al., 2002). AID also induces 
staggered nick cleavage in the switch ƌĞŐŝŽŶ ?ǁŚŝĐŚŝƐ ? ?ƚŽĐŽŶƐƚĂŶƚƌĞŐŝŽŶĐŽĚŝŶŐƌĞŐŝŽŶƐĂŶĚƌŝĐŚŝŶ
tandem repeats, allowing looping out deletion of coding regions (Rush et al., 2004). Both functions 
require different domains of the AID protein (Shinkura et al., 2004). 
The production of auto-antibodies (antibodies directed at self-antigens) is avoided through the 
termination of B cells recognising self-antigens, termed clonal deletion. This is initiated in the bone 
marrow by the binding of self-antigens to the mIg on the immature B cells. Continuous binding of a 
self-antigen to the mIg causes arrested development, blocking the acquirement of additional surface 
molecules, such as IgD, the L-selectin lymph node homing receptor and complement receptors 1 and 
2 which are required for the B cell to enter the blood stream and migrate to the spleen and lymph 
nodes to become mature B cells. This subsequently results in cell death (Hartley et al., 1993).  
1.2.3 Humoral immune response 
During B cell maturation, the B cells have developed independently of antigens. Once in the spleen 
and lymph nodes, mature B cells can encounter antigens, triggering a humoral response. 
MHC-mediated response 
Mature B cells continually move through secondary lymphoid organs, searching for antigen. Once 
antigen has been encountered, the B cell acts as an antigen presenting cell (APC) by binding protein 
antigen via the BcR. Binding of the BcR with antigen and its subsequent activation (as described 
above) leads to the BcR and antigen being endocytosed. This is followed by the antigen being 
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processed in the cell, forming small antigenic peptides. B cells then move to the boundary between 
B and T cell follicles and present antigen to helper T cells in the groove of the major 
histocompatability complex (MHC). Specifically, proteolytic peptides from extracellular pathogens 
are presented by MHC-II to CD4+ T cells, with peptides from intracellular pathogens being presented 
by MHC-I to CD8+ T cells. Polysaccharides are processed into low molecular weight carbohydrates 
and presented by MHC-II to CD4+ T cells (Cobb et al., 2004). As well as the co-receptors described 
earlier, B cells also express CD40, which binds to the CD40 ligand (CD40L) on T cells during antigen 
presentation. Binding of CD40 to CD40L leads to B cell antibody production directed at the antigen 
and is essential for the development of B cell memory (Foy et al., 1994; Wu et al., 1995). The 
importance of CD40-CD40L interaction is observed in the x-linked hyper-IgM syndrome (HIM), which 
is the result of a mutation in CD40L, resulting in reduced B cell proliferation and low or absent levels 
of IgG, IgD and IgA (Aruffo et al., 1993). 
CD1-mediated response 
B cells can also recognise and present lipid antigens in a similar way to peptides, but without the 
need for T cell help (thymus independent). Lipid antigens are internalised in the same way, but are 
presented by the MHC-I-like cell surface molecules, cluster of differentiation-1 (CD1). In humans, 
there are five subsets of CD1 molecules; CD1a, CD1b, CD1c, CD1d and CD1e. Each subset is 
specialised to bind a specific type of lipid antigen, based on differences in the antigen binding groove 
(Barral & Brenner, 2007). All mammals tested so far have CD1 molecules, although mice only have 
CD1d (Barral & Brenner, 2007). CD1 molecules share sequence homology and overall structure with 
MHC class I molecules comprising of a heavy chain with three extracellular domains that are non-
covalently associated witŚɴ2-ŵŝĐƌŽŐůŽďƵůŝŶ ?ɴ2m). The overall molecule consists of up to 4 pockets 
 ? ? ? ? ?& ?ĂŶĚd ? )ĂŶĚĂŶƚŝŐĞŶƉŽƌƚĂůƐ  ? ?ĂŶĚ& ? ?(Moody et al., 2005)). The CD1 molecules can be 
categorised into three groups based on sequence analysis; group 1 consists of CD1a, CD1b and CD1c, 
group 2 consists of CD1d and CD1e makes up group 3, although CD1e does not have a known 
function in antigen presentation (Angenieux et al., 2000). Both dendritic cells (DCs; (van den Elzen et 
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al., 2005)) and B cells can use the low-density lipoprotein receptor (LDL-R) to endocytose 
apolipoprotein E (ApoE)-bound lipid antigens, with B cells also being able to take up lipid antigens via 
the BcR (Allan et al., 2009). The lipid antigens are then processed in the cell and loaded onto CD1 
molecules in the ER with the help of microsomal triglyceride transfer protein (MTP or MTTP; (Zeissig 
et al., 2010)). The importance of MTP can be seen in the autosomal recessive disorder 
abetalipoproteinemia, where mutation in the MTP gene leads to the inability of APCs to present lipid 
antigens via any of the CD1 molecules (Zeissig et al., 2010). The CD1-lipid complex is then displayed 
at the cell surface for presentation to T cells. Group 1 CD1 molecules display lipid antigens to CD1-
restricted T cells specific for microbial lipid antigens, and have higŚůǇ ĚŝǀĞƌƐĞ ɲ ĂŶĚ ɴ dZ ĐŚĂŝŶƐ ?
Group 2 (CD1d) molecules are specifically recognised by semi invariant NKT (iNKT) cells. iNKT cells 
express a semi-ŝŶǀĂƌŝĂŶƚɲ ?ɴdZǁŝƚŚ ƚŚĞɲĐŚĂŝŶďĞŝŶŐǀĂƌŝĂďůĞ(Cohen et al., 2009b). iNKT cells 
exist in a resting state where they are partially activated, leading to a faster, innate-like response 
when recognising lipid antigen. Once activated iNKT cells produce IL-4 and IFN-ɶ ǁŚŝĐŚ ůĞĂĚƐ ƚŽ
activation of DCs (Fujii et al., 2003), which in turn release IL-12, further activating the iNKT cells 
(Tomura et al., 1999). As well as the fast response and activation of innate immune cells, iNKT cells 
have also been shown to provide help for B cells, increasing B cell proliferation and Ig production, 
through the ligation of CD40 and release of IFN-ɶ(Galli et al., 2003; Leadbetter et al., 2008).  
Differentiation of B cells 
Once activated by antigen and receiving a second signal from helper T cells, B cells can either 
differentiate into plasma cells, or memory B cells. The level of certain chemokine receptors (CXCR5, 
CCR7 and CXCR4) expressed on the B cell and the level of their ligands expressed in different areas of 
the secondary lymphoid organs determine whether the B cells migrate along the germinal centre 
(GC) pathway or plasmablast pathway. In the GC follicle, B cells differentiate into memory B cells, 
with the help of follicular helper T cells. The follicular helper T cells provide signals for B cell survival 
and Ig production (Breitfeld et al., 2000). These B cells are long lived and have high affinity for their 
antigen and enable the triggering of second immune response. If faced with the same antigen they 
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are able to divide rapidly into antibody producing cells, generating a faster, longer-lasting and more 
effective response to the infection. B cells that migrate along the plasmablast pathway to 
extrafollicular foci differentiate to form plasma B cells (MacLennan et al., 2003). These plasma cells 
have undergone class switching, but have low levels of hypermutation (Gatto & Brink, 2010).  
 
Figure 1.4 Schematic representation of secondary lymphoid organ in relation to B cell differentiation. B cells 
encounter antigen and receive help from helper T cells (Blue) at the B and T cell zone margin. B cells expressing 
the CXCL12 receptor, CXCR5 and have lost expression of the EB12L receptor, EB12 (Grey box) migrate along 
the GC pathway to the GC, which is where they undergo somatic hypermutation and class switching, yielding 
GC memory B cells. B cells without the CXCR5 receptor and positive for the EB12 receptor migrate to 
extrafollicular regions high in EB12L and differentiate into plasma B cells. 
1.2.4 Antibody Structure 
Antibodies (immunoglobulins) are soluble glycoproteins found in serum and tissue fluids and are 
produced in response to contact with immunogenic foreign molecules (antigens) as part of adaptive 
immunity (Schroeder & Cavacini, 2010). Antibodies can be divided into two parts according to their 
function. The variable fragment (Fv) binds specifically to the antigen epitope and the constant region 
(Fc) gives effector functions, such as complement activation or binding to Fc receptors on effector 
cells (Fig 1.5). Each antibody contains 2 Ig-L and 2 Ig-H. The Ig-L is made up of one variable and one 
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constant region, and the Ig-H is made up of one variable, and 3-4 constant regions. There are 5 
classes of human antibody, IgG, IgM, IgA, IgD and IgE (Table 1.1). Each has the same basic four-
polypeptide chain structure (Fig. 1.5).  
 
Figure 1.5 A schematic representation of an antibody. The antibody is made up of 4 polypeptide chains, 2 
light chains (blue) and 2 heavy chains (orange) linked by disulphide bonds. Antigen binding sites (semi- 
transparent) are located at the amino (N) terminal ends of the chains in the Fab region. The Fc region is 
responsible for binding C1q and Fc receptors on effector cells. 
Table 1.1 Summary of antibody types.  
Name Types Description Number of 
monomers 
IgA 2 Mucosal areas preventing colonisation of 
pathogens. Also in saliva, tears and breast milk 
1, 2 or 3 
IgD 1 Antigen receptor on mature B cells  1 
IgE 14 Binds to allergens triggering histamine release.  1 
IgG 4 Provides majority of antibody-based immunity 
against invading pathogens. Only antibody 
capable of crossing the placenta to foetus 
1 
IgM 1 Expressed as receptor on B cell. Also secreted in 
early stages of humoral immunity 
5 
The principle differences between the classes of antibodies are the amino acid sequence of the 
ŚĞĂǀǇ ĐŚĂŝŶ ĐŽŶƐƚĂŶƚ ƌĞŐŝŽŶƐ ĂŶĚ ƚŚĞ ŶƵŵďĞƌ ŽĨ /Ő  ‘ŵŽŶŽŵĞƌƐ ? Žƌ  ‘ƵŶŝƚƐ ? ƚŚĂƚ ĨŽƌŵ ƚŚĞ ĂŶƚŝďŽĚǇ
structure. The IgM class makes up 10% of total Ig in normal serum and one IgM is a pentamer made 
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up of five Ig units. This gives it 10 identical antigen-binding sites. It is the predominant antibody in 
the early primary response in humans and in mice. It can also be found on the surface of B cells 
(BcR). IgG consists of 4 subclasses (IgG1, IgG2, IgG3 and IgG4) and makes up 75% of total Ig in normal 
serum (IgG1, IgG2, IgG3, IgG4 are 70%, 20%, 8% and 2% of normal serum IgG). Mouse IgG also 
consists of 4 subclasses, named IgG1, IgG2a, IgG2b and IgG3. IgG is the predominant antibody in the 
secondary response in humans. IgGs bind to Fc receptors on lymphocytes and monocytes and act as 
opsonins. IgA is made up of two subclasses IgA1 and IgA2 and makes up 10% of normal serum total 
Ig. IgA exists mainly as a monomer in serum but is present as either a dimer or trimer in secretions. It 
is specialised for transport to areas in which antibody producing B cells are normally absent (e.g. the 
gut and mucous membranes). IgD is present in the serum at low levels and is present as a monomer. 
IgD is found on the surface of B cells and is often co-expressed with IgM. It allows specific antigen 
binging by the B cell leading to proliferation. IgE is also present at low levels in the serum and exists 
as a monomer. IgE has roles in response to some parasites, hypersensitivity and allergy. Contact of 
IgE to antigen leads to the release of inflammatory agents, such as histamine. One characteristic of 
the immune response is that antibodies have the ability to bind specifically to their respective 
antigen and this is fundamental to an immune response. Each antigen has a set of antigenic 
determinants, epitopes, which are bound by the antibody. Each antigen may have repeated epitopes 
(e.g. polysaccharides) or consist of a range of different epitopes (e.g. most proteins). A hapten is a 
compound of a low molecular weight that is itself not immunogenic, but becomes immunogenic 
when conjugated to a carrier. The second main characteristic of the immune response is its large 
diversity. 
1.2.5 Antibody Glycosylation 
Immunoglobulins are glycoproteins with the number and location of glycosylation varying between 
antibody isotype (Fig 1.6). Glycosylation of antibodies play an important role in the structure and 
function of the antibody (Arnold et al., 2007). Glycosylation of antibodies can be N-linked, O-linked 
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or oligomannose glycans. The most heavily glycosylated isotypes are IgM, IgD and IgE, with Ig-H 
glycosylation making up 12-14% of total antibody weight. IgG are the most lightly glycosylated with 
Ig-H glycosylation making up 2-3% of the total weight. The Ig-L is not glycosylated in any of the 
antibody isotypes (Rudd & Dwek, 1997). 
For IgG antibodies, there is a conserved N-linked glycosylation site at asparagine (Asn)-297 on each 
of the 2 CH2 domains. The core of this glycan is conserved throughout the isotype and is made up of 
a bi-antennary heptasaccharide consisting of N-acetlyglucosamine and mannose. Each Asn-297 site 
displays one of a family of 32 glycans that can be assigned to 3 subsets, giving IgG-G0, IgG-G1 and 
IgG-G2. IgG-G2 glycans have both arms terminating in galactose residues, IgG-G1 have a galactose 
missing from one of the arms, exposing a glucosylamine residue and in IgG-G0, neither arm 
terminates with a galactose, exposing a glucosylamine residue on both arms. IgG-G0, IgG-G1 and 
IgG-G2 make up 86% of the total IgG serum levels, with the remaining 14% being made up of IgG-G1 
and IgG-G2 antibodies with sialylated glycans. Furthermore, the glycan present on Asn-297 can differ 
within the same molecule. The glycan at Asn-297 has been found to be crucial in maintaining an 
open conformation of the Ig-Hs allowing interaction of the IgG with C1 in complement activation and 
Fc-&ĐɶZ ŝŶƚĞƌĂĐƚŝŽŶƐ (Anthony & Ravetch, 2010). The addition of sialic acid to the Asn-297 glycan, 
present in about 10% of IgG (Arnold et al., 2007) has been shown to act in an anti-inflammatory 
ŵĂŶŶĞƌƚŚƌŽƵŐŚŝŶƚĞƌĂĐƚŝŽŶǁŝƚŚƚŚĞŝŶŚŝďŝƚŽƌǇ&ĐZ ?&ĐZɶZ// ?dŚƌŽƵŐŚƚŚĞƐƚƵĚǇŽĨĂƉĂŶĞůŽĨ/Ő'-Fc 
with truncated glycoforms, Mimura et al., were able to show that glycosylation was key to the 
thermodynamic stability, quaternary structure and functional activity of IgG (both C1 and FcR 
(Mimura et al., 2000). 
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Figure 1.6 Structure and glycosylation properties of immunoglobulins. Ig-Ls (blue) and Ig-Hs (orange) interact 
via disulphide bridges (black). Sites of N-glycosylation (red), oligomannose glycans (green) and clusters of O-
glycosylation (blue). Numbers relate to amino acid residues. Figure adapted from (Arnold et al., 2007). 
1.2.6 Effector mechanisms of antibodies 
The first mechanism of antibodies is the recognition of antigen and subsequent internalisation by 
the BcR, as described above. Once the B cell has been activated and antibody secreted, the antibody 
can then block the adherence of bacteria to host cells, neutralise toxins and viruses, activate the 
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complement cascade via the classical pathway (CDC) and activate antibody dependent cell-mediated 
cytotoxicity (ADCC). 
1.2.7 Complement 
The complement cascade is a major effector function of the humoral branch of immunity (Reviewed 
(Lambris et al., 2008; Walport, 2001a; Walport, 2001b). The cascade consists of more than thirty 
soluble glycoproteins synthesised mainly by liver hepatocytes, tissue macrophages and epithelial 
cells of the gastrointestinal (GI) and genitourinary tracts. The components of the cascade interact, 
activation each other in a regulated enzymatic manner. The complement cascade can be activated 
via three pathways, the classical, alternative (Kinoshita, 1991) and the lectin route, with all ending 
with the formation of the membrane attack complex (MAC or terminal complement complex; TCC). 
The MAC is able to induce lysis of many types of cells, including bacteria and viruses.  
1.2.8 Complement cascade 
The classical pathway (Fig 1.8a) is initiated by the binding of antibody to its antigen on a whole cell. 
Binding of the antibody to its antigen results in a conformational change within the Fc region of the 
IgG or IgM. This exposes a complement binding site, where the complement component C1 can 
bind. C1 is made up of six identical units of C1q, made up of a globular head with a long collagen-like 
tail, C1r and C1s (Fig 1.8b). Upon C1 binding to the antibody-antigen complex, C1q followed by C1r 
undergo conformational changes, activating C1r protease which cleaves C1s. The cleavage of C1s 
forms an active enzyme which cleaves C4 and C2, leading to the formation of C4a and C4b. These 
form a complex with C2, C4abC2a. C4abC2a is the C3/C5 convertase of the classical pathway. It is 
able to cleave multiple C3 and C5 molecules, which magnifies the initial signal. 
The alternative pathway activates the complement cascade independently of antibody (Fig 1.8a). It is 
initiated by various cell surface constituents that are foreign to the host. The alternative pathway is 
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Figure 1.8 Complement cascade. The complement cascade (a) is activated by the binding of C1 (b) to the antibody-antigen complex.
a) 
b) 
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continually activated at low levels in the plasma. C3 is present at high levels in the plasma and C3b is 
produced by spontaneous cleavage of C3. This is possible through the hydrolysis of the thioester 
ďŽŶĚŝŶ ? ? ?ďŝƐƚŚĞŶĂďůĞƚŽďŝŶĚƚŽƚŚĞƉůĂƐŵĂƉƌŽƚĞŝŶ ‘ĨĂĐƚŽƌ ? ?Factor B is then cleaved by a 
ƉƌŽƚĞĂƐĞ  ‘ĨĂĐƚŽƌ  ? ? ůĞĂĚŝŶŐ ƚŽ ƚŚĞ ĨŽƌŵĂƚŝŽŶ ŽĨ Ă ĂŶĚ ď. Bb remains associated with the C3Bb 
complex, resulting in a C3 convertase capable of converting C3 to C3a and C3b. Most of the C3b 
formed is quashed by hydrolysis, but some attaches covalently to host cells or pathogens. Bound 
C3b is then able to bind factor B, allowing its cleavage by factor D, giving Ba and Bb. This results in 
the formation of the alternative pathway C3 convertase C3bBb.  
The lectin pathway uses a protein similar to C1q to trigger the complement cascade, the mannose 
binding lectin (MBL; Fig 1.8a). MBL binds specifically to mannose residues or other sugars arranged 
in a uniform pattern on pathogens. As host cells do not display mannose-containing molecules in a 
uniform manner, MBL does not bind to host cells. MBL is a six-headed molecule similar to C1q that 
associates with mannose-associated serine proteases-1 and -2, which are homologous to C1r and 
C1s. This complex binds to the pathogen cell surface and activates C4 and C2 is a similar fashion to 
C1 in the classical pathway, resulting in the same C3 convertase formed from C2b and C4a and b. The 
formation of C3 convertase is the convergence of all three pathways. In the classical and lectin 
pathways C5 convertase is formed by the binding of C3b to C4b2b (classical and lectin pathways) or 
to C3bBb (alternative pathway). C5 then binds to the C3b subunit of the C5 convertase, allowing it to 
be cleaved by C2b (classical or lectin pathway) or Bb (alternative pathway), forming C5a and C5b. 
The production of C5b initiates the assembly of the terminal complement components. C5b binds to 
C6 which is in turn recognised by C7. The C5bC7 complex binds to the membrane of the pathogen as 
well as to C8 and C9. Polymerisation of C9 enables penetration of the cell membrane, MAC 
development and the subsequent lysis of the cell.  
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Regulation of the complement cascade  
Activation of the complement cascade is very rapid, due to the magnification of signal with each 
ƐƚĞƉ ?dŚĞŶĂƚƵƌĂůƐƚĂƚĞŽĨƚŚĞĂůƚĞƌŶĂƚŝǀĞƉĂƚŚǁĂǇŝƐƚŽ ‘ƚŝĐŬŽǀĞƌ ?ŽŶƚŚĞƐƵƌĨĂĐĞŽĨĂůůĐĞůůƐ ?Due to 
these factors, unregulated activation of the pathway would result in uncontrolled activation of the 
cascade, causing harm to host cells and the exhaustion of complement proteins. Due to these 
reasons, the complement cascade is tightly regulated along the cascade. There are three types of 
complement inhibitory proteins; fluid phase regulators, membrane-bound regulators and 
membrane-bound complement receptors. Due to the non-specific way that C3b is able to bind to 
host cells or pathogens, complement-regulatory proteins are present on the surface of host cells, 
preventing the progression of the complement cascade. Membrane bound complement inhibitory 
proteins include CD35 (complement receptor 1; CR1), CD21 (complement receptor 2), CD46 
(membrane cofactor protein; MCP), CD55 (decay activation receptor; DAF) and CD59. These 
receptors act to attenuate the activation of the complement cascade. 
For example, the glycoprotein CD46 can exist as four isoforms due to alternative splicing and is 
expressed on all cells. CD46 acts as a cofactor (cofactor activity; CA) for factor 1, cleaving C3b and 
C4b into enzymatically inactive forms (iC3B and C4c respectively; (Liszewski et al., 1991)). CD55 is 
also a glycoprotein membrane receptor and can act as a cofactor for CD46, as well as causing decay 
accelerating activity of convertases (Brodbeck et al., 2000). CD55 can bind to C4bC2b leading to the 
dissociation of C2a from C4b. 
Complement receptors are commonly upregulated on cancer cells, providing a mechanism for 
tumours to avoid complement mediated cell death (Thorsteinsson et al., 1998; Watson et al., 
2006a).  
 
 
  
20 
 
1.2.9 Antibody dependent cellular cytotoxicity 
ADCC is an important effector function of antibodies that recruit effector cells to kill target cells 
(Janeway, 2001). When an antibody binds to its antigen on a target cell via the Fab region, it can also 
bind to an FcR on innate immune effector cells such as basophils, neutrophils, monocytes and 
macrophages via the Fc region of the antibody. Binding of the antibody to the effector cell causes 
activation of the cell to release cytokines and cytotoxic granules (Fig 1.9). There are three classes of 
FcR; FĐɲ ?&Đɸ ĂŶĚ&Đɶ. There is only one type of &Đɲ ?&ĐɲZ/ ?ĂůƐŽŬŶŽǁŶĂƐ ? ? ?/ƚŝƐĂŵĞŵďĞƌ of the 
 
Figure 1.9 Antibody dependent cellular cytotoxicity. Upon antibody binding to the antigen on the target cell, 
an effector cell can be recruited via Fc-&ĐƌĞĐĞƉƚŽƌďŝŶĚŝŶŐ ?ůĞĂĚŝŶŐƚŽƚŚĞƌĞůĞĂƐĞŽĨĐǇƚŽŬŝŶĞƐŝŶĐůƵĚŝŶŐ/&Eɶ
and cytotoxic granules containing perforin and granzymes. This results in target cell lysis.  
 
immunoglobulin family and is expressed on neutrophils, eosinophils, monocytes and some 
ŵĂĐƌŽƉŚĂŐĞƐ ? /ƚ ďŝŶĚƐ /Ő ĂŶƚŝďŽĚǇ ĂŶĚ ƐŝŐŶĂůƐ ǁŚĞŶ ĐŽƵƉůĞĚ ƚŽ ƚǁŽ &ĐɶZ ? dŚĞƌĞ ĂƌĞ ƚǁŽ &ĐZƐ
ďĞůŽŶŐŝŶŐƚŽƚŚĞ&ĐɸĐůĂƐƐ ?ŽŶĞŚŝŐŚĂĨĨŝŶŝƚǇ ?&ĐɸZ/ )ĂŶĚŽŶĞůŽǁĂĨĨŝŶŝƚǇ ?&ĐɸZ// )ƌĞĐĞƉƚŽƌ ?dŚĞɸĐůĂƐƐ
of receptors are involved in the allergic response and bind IgE. There are six types of Fc receptors for 
/Ő'  ?&ĐɶZ ) ? &ĐɶZ/ ? &ĐɶZ// ? &Đɶ// ? &ĐɶZ// ? &ĐɶZ/// ĂŶĚ &ĐZɶ/// ? KĨ ƚŚĞ Ɛŝǆ ? ĨŝǀĞ ĂƌĞ ĂĐƚŝǀĂƚŝŶŐ
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receptors, ǁŝƚŚ&ĐɶZ//ƚŚĞŽŶůǇŬŶŽǁŶŝŶŚŝďŝƚŽƌǇƌĞĐĞƉƚŽƌ (Nimmerjahn & Ravetch, 2008). Each of 
the receptors are predominantly found on specific cell types, summarised in Table 1.2. There are two 
types of FcR which can be split based upon their function; activating and ŝŶŚŝďŝƚŝŶŐƌĞĐĞƉƚŽƌƐ ?&ĐɶZ/ ?
&ĐɶZ//ĂŶĚ&Đɶ///ĂƌĞĂĐƚŝǀĂƚŝŶŐƌĞĐĞƉƚŽƌƐĂŶĚĨƵŶĐƚŝŽŶǀŝĂƚŚĞITAM in the intracellular domain of 
the receptor recruiting activating signalling pathways, wŚĞƌĞĂƐ ƚŚĞ &ĐZɶ// ƌĞĐƌƵŝƚƐ ŝŶŚŝďŝƚŽƌǇ
signalling pathways through an ITIM in its cytosolic domain. 
Table 1.2 Summary of human FcR classes. 
Receptor Antibody 
Ligand 
Affinity Cell Distribution Effect of antibody binding 
&ĐɲZ/ IgA High Monocytes 
Macrophages 
Neutrophils 
Eosinophils 
Phagocytosis 
Cell activation 
Activation of respiratory burst 
Induction of microbe killing 
FcɸRI IgE High Mast cells 
Eosinophils 
Basophils 
Langerhan's cells 
Release of inflammatory 
mediators 
FcɸRII IgE Low B cells 
Eosinophils 
>ĂŶŐĞƌŚĂŶ ?Ɛ cells 
Cleavage of receptor forming 
soluble fragments  
&ĐɶZ/ IgG High Macrophages 
Neutrophils 
Eosinophils 
Dendritic cells 
ADCC 
Endocytosis  
 
&ĐɶZ// IgG Low Macrophages 
Neutrophils 
Eosinophils 
Platelets 
>ĂŶŐĞƌŚĂŶ ?Ɛ cells 
Uptake 
Granule release 
&ĐɶZ// IgG Low B cells 
Mast cells 
Macrophages 
Neutrophils 
Eosinophils 
No uptake 
Inhibition of stimulation 
&ĐɶZ/// IgG Low NK cells 
Macrophages 
Induction of killing 
&ĐɶZ/// IgG Low Eosinophils 
Macrophages 
Neutrophils 
Mast cells 
Follicular 
dendritic cells 
Induction of killing 
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1.2.10 Antibody dependent cellular phagocytosis 
Antibody dependent cellular phagocytosis is a mechanism by which either murine IgG3 or human 
IgG1 can mediate, ƚŚƌŽƵŐŚ ůŽǁ ĂĨĨŝŶŝƚǇ &ĐɶZ  ?&cɶZ// ĂŶĚ &cɶZ/// ), phagocytosis of target cells by 
monocyte-derived macrophages (Munn et al., 1991). 
1.2.11 Monoclonal antibodies 
Due to the two main characteristics of antibodies, their high degree of specificity and ability to cause 
target cell death, research has been targeted at creating antibodies to be used as therapeutics. 
1.2.12 Monoclonal antibody production 
Monoclonal antibodies can be produced in two ways. The first and most common is a method based 
ƵƉŽŶ ǁŽƌŬ ĐĂƌƌŝĞĚ ŽƵƚ ŝŶ ƚŚĞ  ? ? ? ? ?Ɛ ďǇ <ŽŚůĞƌ ĂŶĚ DŝůƐƚĞŝŶ ǁŚŽ ƐƚĂƚĞĚ  ‘^ƵĐŚ ĐƵůƚƵƌĞƐ ĐŽƵůĚ ďĞ
ǀĂůƵĂďůĞĨŽƌŵĞĚŝĐĂůĂŶĚŝŶĚƵƐƚƌŝĂůƵƐĞ ?(Kohler & Milstein, 1975). The method involves immunising 
an animal with antigen, leading to an immune response. The splenocytes from a responsive animal 
are then fused with myeloma cells using polyethylene glycol (PEG) producing a hybridoma. 
Splenocytes are unable to survive in culture, leaving the unfused myeloma cells and hybridomas 
(Kohler & Milstein, 1975). The hybridomas are selected for in hypoxanthine, methotrexate, 
thymidine (HMT) or hypoxanthine, amninopterin, thymidine (HAT)-supplemented media. Myeloma 
cells are unable to synthesise the enzyme hypoxanthine guanine phosphoribosyl transferase 
(HGPRT). HAT and HMT contain aminopterin or methotrexate respectively that block the de novo 
synthesis of DNA. This makes the cells rely on the salvage pathway to synthesise DNA. The salvage 
pathway requires HGPRT to allow complete synthesis of DNA. Since the unfused myeloma cells do 
not have the HGPRT enzyme, they are unable to replicate and therefore die, leaving the hybridomas 
only. The hybridomas maintain the immortal properties of the myeloma cell and secrete antibody. 
The resulting hybridomas are then grown at low density in multi-well plate format and screened for 
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binding to antigen. Positive wells are then isolated and re-grown at low density, with the aim of 
producing a clone of cells from the same hybridoma cell, to produce one mAb. Once a clone has 
been isolated, the hybridoma is transferred to serum-free media and grown in large quantities to 
increase antibody production (Glassy et al., 1988). 
The second method of antibody production is using the phage-display library method. Gene 
segments encoding the variable region of antibodies are fused to the genes responsible for the 
synthesis of the coat protein of bacteriophage. The bacteriophage is then used to infect bacteria, 
resulting in antigen-binding sites being coated on the outside of the bacteria. A library of different 
phage each having the ability to display a different antigen-binding site are available. The antigen 
target is then added, with the bacteriophage that binds to the complementary antigen being 
selected. The phage can then be used to infect fresh bacteria, to increase phage numbers. The 
variable genes can then be recovered and joined to genes encoding the rest of the antibody 
molecule. The gene sequence can then be transfected into cells that secrete the antibody in a similar 
fashion to hybridomas (Winter & Milstein, 1991). 
1.2.13 Monoclonal antibodies for therapeutic use 
The first monoclonal antibody used for treatment was described in 1982 (Miller et al., 1982). An 
anti-idiotype mAb was used to treat patients with B cell lymphoma with one patient showing a 
complete remission for a period of 17 years. This finding set off a field of research focussed on the 
use of antibodies for the treatment of many diseases. Early animal and human trials of mAbs failed 
to reproduce the results observed in 1982. Despite a large proportion of homology between murine 
and human Ig, murine mAbs were recognised by the host (e.g. patient) immune system, leading to 
the development of human anti-mouse antibodies (HAMA), inactivating and removing murine mAbs 
(Tjandra et al., 1990). Due to the host immune response to murine mAbs, subsequent doses of the 
mAb could be cleared more quickly. However, adverse effects or symptoms, for example allergic 
response, upon repeated doses were rare and usually easily reversed (Khazaeli et al., 1994). One 
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exception to the problems associated with murine mAbs was the transplant rejection mAb, 
Muromonab-CD3 (Orthoclone OKT- ? ? )ĂƉƉƌŽǀĞĚŝŶ ? ? ? ?. Muromonab has the ability to reverse the 
rejection of transplantation when administered intravenously (Fung et al., 1987). Muromonab-CD3 
works by binding to CD3 on the surface of mature T cells and due to the association of CD3 with the 
TCR, muromonab-CD3 blocks the binding of the TCR to antigen, thereby modulating the antigen 
response to the transplant by blocking antigen recognition and function of cytotoxic T cells (Norman, 
1995). 
Chimerisation of murine mAbs 
Due to the immunogenicity, fast clearance in vivo and the weaker ability to induce effector 
functions, murine mAbs were engineered producing chimeric mAbs (Presta, 2006). Chimeric mAbs 
are produced by mouse variable regions being cloned into a mammalian expression vector that 
contains human heavy and light chain constant regions, resulting in a human mAb with mouse 
variable regions (Birch & Racher, 2006). The production of chimeric mAbs reduced the HAMA 
response seen with fully murine mAbs, with the first chimeric mAb, abciximab (ReoPro) being 
approved by the U.S. Food and Drug Administration (FDA) in 1994 (Kohmura et al., 1993). Abciximab 
is used to inhibit platelet aggregation during percutaneous coronary intervention (also known as 
coronary angioplasty) by binding the glycoprotein GPIIb/IIIb. Despite fears that the murine variable 
regions of the chimeric mAb may still be able to produce a HAMA response in vivo, chimeric 
antibodies have been very successful in the clinic with a further four being approved by the FDA for 
use in the clinic and chimeric mAbs still being entered into clinical trials (Figure 1.10; (Rossi et al., 
2010)).  
Humanisation of murine mAbs 
Despite the success of chimeric mAbs, immunogenicity can be a problem with some mAbs, leading 
to the production of mAbs with a reduced proportion of murine sequence (Liu et al., 2008). To 
achieve this, the CDR regions from the murine variable region were spliced into a human antibody, 
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Figure 1.10 Trends in mAb trials. Data showing the number of murine, chimeric, humanised and fully human 
mAbs to enter clinical trials between 1990 and 2008. The figure is adapted from (Nelson et al., 2010). 
 
resulting in mAbs with a greater proportion of human sequence (Jones et al., 1986). Most approved 
therapeutic antibodies are either chimeric or humanised, with most of new mAbs entering clinical 
entering clinical trials worldwide being fully human (Figure 1.10; (Reichert, 2008)). Despite the high 
percentage of human antibody region, humanised antibodies can still be immunogenic, eliciting a 
human-anti-humanized (HAHA) response in vivo (Hwang & Foote, 2005). A study comparing the 
immunogenicity of murine, chimeric and humanised mAbs revealed that all three types displayed 
ůĞǀĞůƐŽĨŝŵŵƵŶŽŐĞŶŝĐŝƚǇ ?ƌĂŶŐŝŶŐĨƌŽŵ ‘ŶĞŐůŝŐŝďůĞ ?ƚŽ ‘ŵĂƌŬĞĚ ? ?dŚĞƐƚƵĚǇĂůƐŽshowed that the main 
impact of humanising on immunogenicity is reduction of the  ‘marked ? category of immunogenicity, 
with comparable levels of tolerable and negligible immunogenicity with chimerised mAbs (Hwang & 
Foote, 2005). However, a reduction in immunogenicity after humanising a mAb should not be 
assumed as one study has shown that despite humanising the anti-glycoprotein murine mAb A33, 
the humanised mAb (huA33) still showed high levels of HAHA response in vivo (Ritter et al., 2001). 
Further engineering of humanised antibodies has also been employed to reduce HAHA responses, 
such as removal of T cell epitopes. This is achieved by immunogenic epitopes of the mouse region 
being replaced with non-T cell reactive sequences reducing the HAHA response. These are known as 
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deimmunised antibodies (Peng et al., 2005). Fully human mAbs have also been developed by 
creating transgenic mice. By introducing almost the entire set of human immunoglobulin genes into 
mice with an inactivated murine antibody system, fully human antibodies can be produced in mice 
(e.g. HuMab mouse
 ?
; (Fishwild et al., 1996)). An example of this is the FDA approved anti-CD20 mAb 
ofatumumab (Teeling et al., 2004). 
Interestingly, a study into the immunogenicity of murine, chimeric and humanised mAbs showed 
that the most effective reduction in immunogenicity of mAbs was the move from murine to chimeric 
mAbs, due to most in vivo responses targeted at the Fc region (Hwang & Foote, 2005). 
Engineering of mAbs 
As well as efforts to reduce the immunogenicity of mAbs for therapy by increasing human portion of 
the mAb, research has focussed on engineering the mAb to increase the in vivo effect of mAbs 
(Kubota et al., 2009). Research is centred on increasing in vivo efficacy, by increasing the ability to 
induce ADCC and CDC and the in vivo half-life of the mAb. The first step in the induction of potent 
ADCC is having the correct isotype. Simply, the choice between IgG1 and IgG2 is made depending on 
whether effector function is desired (IgG1) or not (IgG2; (Salfeld, 2007)). This is because the IgG1 
ŝƐŽƚǇƉĞ&ĐƌĞŐŝŽŶŚĂƐƚŚĞĂďŝůŝƚǇƚŽďŝŶĚ&ĐɶZƐŽŶŝŵŵƵŶĞĞĨĨĞĐƚŽƌĐĞůůƐ ?ůĞĂĚŝŶŐƚŽĂƐǁĞůůĂƐ
binding C1q, initiating CDC. If the use of effector functions is desired, steps can be taken to increase 
its in vivo potency (Strohl, 2009). One mechanism of increasing in vivo function centres around the 
premise that higher levels of therapeutic mAb are required to produce optimal levels of ADCC in vivo 
due to the presence of an excess of endogenous IgG (Preithner et al., 2006). One way in which this 
can be combated is through the defucosylation of the N-glycosylation in the Fc region at Asn-297 of 
IgG1 (Okazaki et al., 2004). The N-glycosylation at Asn-297 is a biantennary structure containing a 
mannosyl-chito-biose core to which GlcNac, fucose, galactose, mannose and/or sialic acid are 
attached (Yamane-Ohnuki & Satoh, 2009). Removal of the fucose residue at Asn-297 leads to a 
ƐƵďƚůĞ ĐŽŶĨŽƌŵĂƚŝŽŶĂů ĐŚĂŶŐĞ ? ƚŚĂƚ ůĞĂĚƐ ƚŽ Ă ŝŶĐƌĞĂƐĞĚ ĂĨĨŝŶŝƚǇ ĨŽƌ ƚŚĞ &ĐɶZƐ ? ǁŝƚŚ ŶŽ ĞĨĨĞĐƚ ŽŶ
antigen affinity or ability to induce CDC (Niwa et al., 2005) ?dŚŝƐŝŶĐƌĞĂƐĞĚĂĨĨŝŶŝƚǇĨŽƌ&ĐɶZƌĞůĂƚĞƐto 
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an increase in ADCC. The effect of defucosylation on ADCC potency can be over 100-fold, as seen 
with a defucosylated anti-CD20 mAb produced in a FUT8 knockout Chinese hamster ovary cell line 
(Yamane-Ohnuki et al., 2004) or the defucosylated anti-CD20 mAb GA101. GA101 is produced in cells 
overexpressing the recombinant b1,4-N-acetylglucosaminyltransferase III (GnT-III), which shows 
greater B cell depletion than rituximab in ex vivo CLL samples (Patz et al., 2011). Another example is 
the anti-CC-chemokine receptor-4 (CCR4) defucosylated mAb KW-0761, which showed highly 
enhanced ADCC in vitro as well as complete and partial responses in patients with relapsed CCR4 
positive adult T-cell leukaemia-lymphoma (ATL) or peripheral T-cell lymphoma (PTCL) at 10-20 times 
lower doses than other mAbs (Yamamoto et al., 2010). As well as the defucosylation of Asn-297, 
studies have also shown that computational and high throughput screening techniques to produce 
amino acid-substituted Fc regions with an increased capacity to induce ADCC (Shields et al., 2001). 
Examples of this include the anti-CD20 mAbs ocrelizumab and AME-133, which have mutated Fc 
regions and induce enhanced ADCC compared to Rituximab (Weiner et al., 2010). 
As well as the ability to induce effector mechanisms, the half-life of a mAb is important in a 
therapeutic setting. The FcRn plays an important role of IgG homeostasis in mammals and the 
interaction between IgG Fc region and FcRn is pH-dependent; IgG bind to the FcRn with high affinity 
at pH 6, but as the pH is raised to 7.4, the binding affinity decreases. If a mAb can bind FcRn at pH 6 
with a high affinity, in the acidic endosome, then the mAb would be recycled to the membrane and 
released, whereas, if the mAb bound with a higher affinity at pH 7.4, it would bind less effectively to 
the FcRn in the endosome, resulting in the mAb being degraded. Therefore, the ability to bind FcRn 
at pH 6 results in the prolonged serum half-life of a mAb (Yeung et al., 2009). An example of this is 
the humanized anti-respiratory sincytial virus (RSV) mAb, MEDI-524-YTE, which has been engineered 
ǁŝƚŚĂƚƌŝƉůĞĂŵŝŶŽĂĐŝĚŵƵƚĂƚŝŽŶ ? ‘zd ? )ŝŶƚŚĞ&ĐƌĞŐŝŽŶ ?dŚŝƐůĞĂĚƚŽĂ 4-fold increase in serum half-
life in cynomolgus monkeys, compared with the unmutated mAb (Dall'Acqua et al., 2006). 
Another mechanism of antibody engineering is the production of bispecific mAbs. Bispecific mAbs 
are engineered to bind to two antigens with one monomer, with each antibody arm specific for a 
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different epitope. This allows a mAb to inhibit or activate two separate targets. An example is the 
EU-approved mAb catumaxomab, which is used in the treatment of malignant ascites when other 
treatment has failed. Catumaxomab binds the adhesion molecule, epithelial cell adhesion molecule 
(EpCAM) with one arm and the T cell antigen CD3 with the other. This enables the mAb to target 
tumours by binding EpCAM, which is upregulated on various carcinomas, while simultaneously 
binding and CD3, stimulating T cells with the other arm. This allows T cell-mediated killing of EpCAM 
positive tumour cells, as well as Fc region mediated activation of ADCC (Seimetz et al., 2010). 
However, it relies on the close proximity of tumour and T cells, which may not be achievable in other 
settings. 
1.2.14 Approved monoclonal antibodies 
As of May 2011, there are 23 therapeutic mAbs approved by the FDA, with ten of these targeting 
cancers (Table 1.3). 
CD20 
CD20 antigen is expressed on the surface of all B cells, but not on stem cells, making it an idea mAb 
target for lymphoma treatment. Rituximab (Rituxan) was the first mAb to be approved for the 
treatment of cancer (FDA, 1997; James & Dubs, 1997). Rituximab is a chimeric antibody with human 
IgG1ʃ constant region and mouse variable regions. The mAb has been shown to induce lysis of CD20+ 
B cells and is approved for the treatment of CD20+ B cell, non-Hodgkin ?s lymphoma and for 
moderately to severe rheumatoid arthritis (FDA, 2002). Studies have shown that rituximab is a very 
potent inducer of CDC (Cragg et al., 2003) and is also able to induce in vivo cell death by ADCC as 
well as directly inducing cell arrest and death (Cragg et al., 2003; Janas et al., 2005; Pedersen et al., 
2002; Shan et al., 1998; van Meerten et al., 2006). Rituximab has been shown to cause direct cell 
death by cross-linking CD20 and translocation of CD20 to lipid rafts. This creates close-proximity with 
src-family kinases and induces a number of signalling events including protein tyrosine  
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Table 1.3 List of currently FDA approved mAbs. MAbs targeting cancers are in bold. 
Year 
approved 
by FDA 
Product (Trade Name) Target Source Indication 
1986 Muromanab-CD3 
(Orthoclone®) 
CD3 Murine Transplant rejection 
1994 ďĐŝǆŝŵĂď ?ZĞŽWƌŽ ? ) GPIIb/IIIb Chimeric Percutaneous transluminal 
coronary angioplasty 
1997 ZŝƚƵǆŝŵĂď ?ZŝƚƵǆĂŶ ? ? CD20 Chimeric B cell lymphoma 
1997 Dacliximab (Zenapax®) IL-2r Humanised Transplant rejection 
1998 Basiliximab 
(Simulect®) 
IL-2r Chimeric Transplant rejection 
1998 Infliximab 
(REMICADE®) 
TNF Chimeric ƌŽŚŶ ?ƐĚŝƐĞĂƐĞ ?ZŚĞƵŵĂƚŽŝĚ
arthritis 
1998 Palivizumab 
 ?^ǇŶĂŐŝƐ ? ) 
Respiratory 
Syncytial 
Virus (RSV) 
Humanised RSV in infants 
1998 Trastuzumab 
(Herceptin®) 
HER2 Humanised Breast cancer, prostate cancer 
lymphomas, 
2000 Gemtuzumab 
ozogamicin 
 ?DǇůŽƚĂƌŐ ? ? 
CD33 Humanised Acute Myelogenous Leukaemia 
2001 Alemtuzumab 
(Campath®) 
CD52 Humanised B cell chronic lymphocytic 
leukaemia 
2002 Irbritumomab 
tituxetanytium 
(Zevalin®) 
CD20 Murine 
with 
yttium90 or 
indium111 
Non-HŽĚŐŬŝŶ ?ƐůǇŵƉŚŽŵĂ 
2002 Adalimumab 
 ?,hD/Z ? ) 
TNF Human Moderate to severe 
rheumatoid arthritis 
2003 Tositumomab & 
Tositumomab I
131
 
(Bexxar®) 
CD20 Murine 
with 
Iodine131 
Low grade Non-,ŽĚŐŬŝŶ ?Ɛ
Lymphoma 
2003 Omalizumab (Xolair®) IgE Humanised Severe (allergic) asthma 
2004 ĞƚƵǆŝŵĂď ?ƌďŝƚƵǆ ? ? EGFR Chimeric Colorectal cancer, head and 
neck cancer 
2004 Bevacizumab 
 ?ǀĂƐƚŝŶ ? ? 
VEGF Humanised Metastatic colorectal cancer, 
non-small cell lung cancer, 
metastatic breast cancer 
2004 Natalizumab 
(TYSABRI®) 
ɲ ?ƐƵďƵŶŝƚ
ŽĨɲ ?ɴ ? 
Humanised Multiple sclerosis, CrohŶ ?Ɛ
disease 
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2006 Panitumumab 
 ?sĞĐƚŝďŝǆ ? ? 
EGFR Human Metastatic colorectal cancer 
2006 Ranibizumab 
 ?>hEd/^ ? ) 
VEGF-A Humanised 
Fab 
Wet Macular Degeneration 
2007 Eculizumab (Soliris®) CD59 Humanised Paroxysmmal nocturnal 
hemoglobinuria 
2008 Certolizumab pegol 
(CIMZIA®) 
TNF-ɲ Humanised 
Fab 
Morbus Crohn, rheumatoid 
arthritis 
2009 Golimumab 
 ?^ŝŵƉŽŶŝ ? ) 
TNF-ɲ Human Rheumatoid & psoriatic 
arthritis, active ankyosing 
sponylitis 
2009 Ustekinumab 
 ?^ƚĞůĂƌĂ ? ) 
IL12/IL23 Human Moderate to severe psoriasis 
2009 Canakinumab (Ilaris®) IL- ?ɴ Human Cryopyrin-associated periodic 
syndrome 
2009 ĞŶŽƐƵŵĂď ?WƌŽůŝĂ ? ) RANKL Human Postmenopausal women with 
risk of osteoporosis 
2009 Ofatumumab 
(Arzerra®) 
CD20 Human Chronic lymphocytic leukaemia 
2010 Belimumab 
(Benlysta®)  
BLyS Human  Systemic lupus erythematosus 
2011 Ipilimumab (Yervoy) CTLA-4 Human Malignant melanoma 
 
phosphorylation, activation of protein kinase C and upregulation of Myc (Shan et al., 1998). This lipid 
raft recruitment has been shown to lead to calcium ion (Ca
2+
) influx and cell death in target cells 
(Janas et al., 2005). 
As CD20 had been shown to be a good target for the mAb therapy, the murine parent molecule of 
rituximab has been used in radioimmunotherapy. The rituximab murine mAb was linked to tiuxetan, 
a chelating agent that provides a high affinity binding site for radionuclides. To this site, 90-yttrium 
(
90
Y) has been conjugated, forming the mAb 
90
Y-irbritumomab (Zevalin) that was approved by the 
FDA in 2002 for cancer therapy (Stern & Herrmann, 2005). The murine parent of rituximab was 
chosen as its higher immunogenicity promotes a more rapid clearance of the antibody from the 
circulation. 
90
Y-irbritumomab is used to treat low grade non-,ŽĚŐŬŝŶ ?ƐůǇŵƉŚŽŵĂ ?NHL). It can cause 
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tumour cell ĚĞĂƚŚ ŝŶĚƵĐĞĚ ďǇ ɴ-particles from 90Y or by the induction of apoptosis in a similar 
fashion to rituximab. 
131
I-tositumomab (Bexxar
 ?
) is a murine IgG2a, anti-CD20 mAb that is used for the treatment of NHL 
(Cheung et al., 2009). Patients receive a dose of unconjugated tositumomab, before receiving 
further does of the radiolabelled 
131
I-tositumomab. The 
131
I isotope enables tositumomab to deliver 
gamma photons and beta particles directly to the tumour and surrounding area, as well as inducing 
ADCC and CDC (Davis et al., 2004; Stern & Herrmann, 2005). Tositumomab has also been shown to 
induce direct cell death in CD20+ cell lines (Cardarelli et al., 2002). 
Fundamental differences between rituximab and tositumomab allow them to be split into two 
groups; type I (rituximab) and type II (tositumomab; (Cragg & Glennie, 2004). Type-I anti-CD20 mAbs 
have the ability to translocate CD20 into lipid rafts, whereas, type II mAbs do not. Differences in their 
effector functions has also been noted (Cardarelli et al., 2002; Cragg et al., 2003), leading to debate 
as to which type of antibody would be better therapeutically. Tositumomab shows an higher level of 
direct cell death than rituximab (Cardarelli et al., 2002), whereas, rituximab is a more potent inducer 
of CDC in vitro than tositumomab, due to its ability to redistribute to lipid rafts, creating a high 
concentration of mAb (Cragg et al., 2003). However, it has been suggested that the potent induction 
of CDC by rituximab in vivo may lead to the reduction of CD20 molecules on the B cell as a result of 
C3b deposition after type-I mAb binding, due to the shaving reaction (Li et al., 2007). Furthermore, 
deposited C3b may inhibit interaction between the Fc region of rituximab and the CD16 receptor on 
natural killer (NK) cells, reducing the activation of NK cells (Wang et al., 2008). Therefore, the 
efficiency of CDC mediated by rituximab may reduce the level of CD20 on the surface of B cells and 
also block ADCC, thereby reducing the efficacy of Rituximab in vivo. However, type-II anti-CD20 
mAbs do not induce CDC. More recently, rituximab and tositumomab were compared for in vivo 
efficacy by engineering type-I and type-II mAbs with the same mouse isotype. In this study, the level 
of B cell depletion was measured and the type-II mAb provided a longer depletion of B cells from the 
  
32 
 
blood and secondary lymphoid organs than the type-I mAb, suggesting that type-II anti-CD20 mAbs 
may be better in the treatment of B cell diseases (Beers et al., 2008). 
Differences in the mechanism of cell death induced by rituximab and tositumomab have also been 
observed. Studies have shown that rituximab induces direct cell death in a caspase-independent 
manner, with the influx of Ca
2+
 being noted as an important factor (Daniels et al., 2008; Stanglmaier 
et al., 2004). Whereas tositumomab-mediated cell death has been shown to occur in a more 
classical-apoptotic manner, when the mAb is cross-linked on the cell surface (Shan et al., 1998). 
More recently, ofatumumab (Arzerra or HuMax-CD20, previously 2F2), a fully human IgG1 mAb, 
produced in transgenic mice and was approved for the treatment of two groups of patients with 
chronic lymphocytic leukaemia; those refractory to fludarabine and alemtuzumab and patients not 
considered for alemtuzumab treatment by the FDA under the accelerated approval process (FDA, 
2009). Ofatumumab binds to the small loop epitope of CD20 (differently to rituximab and 
tositumomab). Ofatumumab has been characterised as a type I anti-CD20 mAb due to its ability to 
recruit CD20 to lipid rafts (Teeling et al., 2004). As expected of a type I anti-CD20 mAb, ofatumumab 
induces CDC, however, ofatumumab is a more potent inducer of CDC than rituximab in vivo due to 
its slower rate of dissociation from the antigen (Teeling et al., 2004; Teeling et al., 2006). A recent 
abstract at the American Society of Hematology showed that ofatumumab can also induce ADCC at 
lower antibody concentrations than rituximab in vitro when human peripheral blood mononuclear 
cells (PBMCs) were incubated with ARH-77 lymphoma cells and mAb (Craigen, 2009). A number of 
clinical studies have been undertaken using ofatumumab in chronic lymphocytic leukaemia (CLL) and 
follicular lymphoma (FL) with response rates ranging from 11 to 58% (Lin, 2010). Despite being a 
fully human mAb, some adverse effects have been observed upon mAb administration. Most 
commonly; neutropenia, pneumonia, pyrexia, cough, diarrhoea, anaemia, fatigue, dyspnoea, rash, 
nausea, bronchitis, and upper respiratory tract infections (FDA, 2009). Larger clinical trials will 
provide a better understanding on the efficacy of ofatumumab in a clinical setting. 
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HER2 
Trastuzumab (Herceptin) is a humanised IgG1ʃ derived from a murine mAb (Stancovski et al., 1991) 
and produced in Chinese hamster ovary cells (Goldenberg, 1999). Trastuzumab targets the tyrosine 
kinase receptor, human epidermal growth factor receptor 2 (HER2) which is overexpressed on 25-
30% of breast cancers due to gene amplification (Slamon et al., 1987). Trastuzumab was approved 
for the treatment of metastatic breast cancer patients whose tumours overexpress the HER2 protein 
in 1998 (FDA, 1998) and is now approved for adjuvant treatment of HER-2-overexpressing node 
positive or node negative breast cancer as well as in combination with chemotherapy for HER2-
overexpressing metastatic gastric cancer patients (FDA, 2010). HER2 cannot dimerise itself and has 
no ligand biding site. It can however dimerise with other members of the HER family and has an 
intracellular signalling domain. The most common heterodimer is HER1/2 and the most potent is 
HER2/3 (Olayioye et al., 2000). Trastuzumab acts by blocking HER2, thereby inhibiting dimerisation 
and activation of the receptor by epidermal growth factor (EGF), transforming growth factor ɲ
 ?d'&ɲ )ĂŶĚŽƚŚĞƌŐƌŽǁƚŚĨĂĐƚŽƌƐ(Valabrega et al., 2007). This inhibits intracellular signalling via PI3K 
and AKT, reducing cell proliferation and can increase apoptosis (Delord et al., 2005). Trastuzumab 
has also been shown to inhibit angiogenesis (Klos et al., 2003). Trastuzumab is also thought to inhibit 
HER2 cleavage and subsequent release into the serum (Molina et al., 2001). Although research has 
mainly focussed on the mechanism by which trastuzumab blocks the HER2 receptor and the impact 
that has on cell proliferation and death, trastuzumab is also an IgG1 and therefore has the ability to 
induce ADCC. Studies have shown that trastuzumab can induce ADCC in vitro and in vivo (Gennari et 
al., 2004; Gianni, 2008). As previously described, engagement of effector cells with the mAb-tumour 
cell complex is mediated via FcR on the effector cells via the antibody Fc region. A study showed a 
decreased level of trastuzumab activity in &ĐɶZ ŬŶŽĐŬŽƵƚ ŵŝĐĞ ĐŽŵƉĂƌĞĚ ƚŽ ǁŝůĚ-type, suggesting 
that the induction of ADCC has an important role in vivo (Clynes et al., 2000). Furthermore, a recent 
ƐƚƵĚǇƐŚŽǁĞĚƚŚĂƚƉŽůǇŵŽƌƉŚŝƐŵƐŝŶ&ĐɶZ///ĂŚĂĚĂƐŝŐŶŝĨŝĐĂŶƚĞĨĨĞĐƚŽŶĐůŝŶŝĐĂůŽƵƚĐŽŵĞŽĨƉĂƚŝĞŶƚƐ
treated with trastuzumab, with patients homozygous for Valine/Valine at amino acid 158 having the 
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best clinical outcome, due to a higher affinity between antibody and the Valine-containing FcR on 
effector cells (Musolino et al., 2008). 
More recently, the humanised IgG1 anti-HER/2 mAb, pertuzumab (2C4, Omnitarg) has been shown 
to inhibit dimerisation of HER2 in vivo, by binding at a different site on HER/2 to trastuzumab, 
thereby blocking intracellular signalling (Adams et al., 2006). Recent trials of pertuzumab 
administered in combination with trastuzumab in patients who progressed after trastuzumab 
treatment have shown promising results, with an objective response rate of 24.2% in 66 patients 
(Baselga et al., 2010). 
CD33 
 Gemtuzumab ozogamicin (Mylotarg) is a humanised IgG4 antibody conjugated to the anti-tumour 
drug calicheaŵŝĐŝŶɶ1. Gemtuzumab binds to CD33, a myeloid-specific, transmembrane receptor that 
binds sialic acids and is involved in cell adhesion. More significantly, it is expressed on leukemic 
blast, but not heamapoietic stem cells in most (~90%) acute myeloid leukaemia (AML) patients 
(Dinndorf et al., 1986). In order to increase the potency of mAb treatment, calicheamicin ɶ1 was 
conjugated to gemtuzumab (Sievers et al., 1999) ?ĂůŝĐŚĂĞŵŝĐŝŶɶ1 belongs to the enemtine class of 
antibiotics isolated from the bacteria Micromonospora echinospora (Zein et al., 1988). Calichaemicin 
contains an enediyne moiety that binds and cleaves double stranded DNA in a site specific manner, 
resulting in apoptosis of the cell (Walker et al., 1992). Gemtuzumab ozogamicin was approved for 
the treatment of acute myelogenous leukaemia in 2000. Unfortunately, a post-approval trial failed 
to show any clinical benefit of the gemtuzumab ozogamicin compared with chemotherapy alone 
with several deaths occurring in the groups of patients receiving gemtuzumab. As a result of this 
trial, the mAb was withdrawn from therapy in the US and UK in June 2010 (FDA, 2010). 
CD52 
Alemtuzumab (Campath), a humanised rat IgG1ʃ binds to CD52, a glycosylphosphatidylinositol (GPI)-
anchored protein expressed on mature lymphocytes, but not on stem cells (Hale et al., 1988; 
Hernandez-Campo et al., 2007). It has a good therapeutic value due to CD52 expression on all low 
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grade B cell lymphomas and most high grade B cell NHLs (Salisbury et al., 1994). Alemtuzumab is 
used in the treatment of B cell chronic lymphocytic leukaemia, the most common adult leukaemia in 
the western hemisphere and is undergoing clinical trials for the treatment of multiple sclerosis 
(Barten et al., 2010; Ries et al., 2000). Alemtuzumab has been shown to cross-link CD52 on the cell 
surface, leading to growth inhibition and subsequent cell death (Rowan et al., 1998), although 
research suggests that direct cell death is not the prominent mechanism of action in vivo (Zent et al., 
2008). More significantly in vivo ŝƐĂůĞŵƚƵǌƵŵĂď ?ƐĂďŝůŝƚǇƚŽŝŶĚƵĐĞĂŶĚ(Golay et al., 2004; 
Hu et al., 2009; Zent et al., 2008). 
EGFR 
Cetuximab (Erbitux) was the first monoclonal antibody approved for the treatment of advanced 
colorectal cancer (2004; (FDA, 2004)). Since its approval for colorectal cancer it has also been 
approved for the treatment of head and neck cancers (FDA, 2006). Cetuximab is a chimeric IgG1 that 
blocks EGFR (Goldstein et al., 1995). The mechanism of action centres around its ability to bind to 
the EFGR with a higher affinity than EGF (Goldstein et al., 1995). This blocks the phosphorylation of 
the EGFR and inhibition of the RAS/RAF/MAPK, STAT, and PI3K/AKT signalling pathways (El-Rayes & 
LoRusso, 2004). This effects cell cycle progression, reduces angiogenesis, promotes apoptosis and 
decreases proliferation (Baselga, 2001; Mukohara et al., 2005; Peng et al., 1996). As well as 
inhibition of EGFR signalling, cetuximab has also been shown to induce ADCC, but not CDC in vitro 
(Kawaguchi et al., 2007; Kimura et al., 2007). 
Panitumumab (Vectibix; formally ABX-EGF) is a fully human IgG2 monoclonal antibody and was 
developed using XenoMouse technology (Yang et al., 2001). It was approved for use in the treatment 
of advanced colorectal cancer in 2007. Panitumumab binds to the EGFR with a very high affinity, 
therefore, the inability of the IgG2 mAb to induce potent ADCC and CDC responses should reduce 
toxicity to normal cells. Upon binding, panitumumab blocks the binding of EGFs and causes 
internalisation of the receptor, preventing downstream signalling (Yang et al., 2001). This leads to 
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inhibition of cell cycle progression, reduces angiogenesis, promotion of apoptosis and decreases 
proliferation. As a fully human mAb, the frequency of infusion reactions has been lower than 
observed in comparison to cetuximab (Cohenuram & Saif, 2007). 
VEGF 
Bevacizumab (Avastin) is a humanised IgG1 mAb that reacts with and neutralises vascular 
endothelial growth factor (VEGF). It was approved for the treatment of metastatic colorectal cancer 
in 2004 (Hurwitz et al., 2004) and for the treatment of nonsquamous, non-small cell lung cancer 
(NSCLC) in 2006 (Cohen et al., 2007) and for the treatment of glioblastoma multiforme (GBM; 
(Cohen et al., 2009a)). VEGF is upregulated in many tumours and bevacizumab is thought to have 
anti-vascular effects in vivo (Willett et al., 2004). Specifically by decreasing vascular volume and 
microvascular density, and alteration of blood flow, restoring normality (Willett et al., 2004). More 
recently, bevacizumab has been trialled in ovarian cancer with promising results, which may prompt 
Roche to apply for FDA approval of bevacizumab for the treatment of ovarian cancer (Roche, 2011). 
CTLA-4 
Ipilimumab is a fully human mAb approved by the FDA for the treatment of malignant melanoma in 
March 2011 (Ledford, 2011). Ipilimumab ?Ɛ target is the inhibitory receptor cytotoxic T lymphocyte 
antigen-4 (CTLA-4) present on T cells (Krummel & Allison, 1995). The mAb does not induce ADCC or 
CDC, but by blocking CTLA-4, T cell activation is increased, allowing a tumour targeted T cell 
response via APC presented melanoma antigens (Tarhini et al., 2010). Unsurprisingly, the non-
specific upregulation of T cell activation can lead to severe side effects, which need to be carefully 
monitored. However, despite adverse effects, studies have shown an increased survival in stage III 
and IV melanoma patients when compared to gp100 alone (a melanoma antigen). Patients received 
either ipiliummab, gp100 or both, with both Ipilimumab groups showing a significantly greater 
survival compared to the gp100 group (21.6%, 23.5% and 13.7% at 24 months (Hodi et al., 2010)) 
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All currently approved mAbs recognise protein antigens; however, mAbs recognising glycolipids are 
becoming increasingly interesting. 
1.3 Glycolipids 
The term lipid describes a molecule that is insoluble in water, but is soluble in organic solvents. 
Lipids can be roughly separated into three groups; simple or neutral lipids, complex lipids and 
proteolipids. Simple lipids can be segregated into the groups, fatty acids, waxes, triglycerides and 
sterols. Complex lipids have polar properties and can be divided into; phospholipids, arsonolipids, 
glycolipids and lipoamino acids. The third group of lipids are proteolipids, which are fatty acylated 
proteins.  
The human cell membrane is made up predominantly of phospholipids, which form a bilayer due to 
their hydrophilic, phosphate-containing head and hydrophobic fatty-acid tails. Lipids make up ~50% 
of an animal cell membrane which relates to about 10
9
 lipid molecules per cell (Alberts, 2002). 
Glycolipids consist of a lipid tail with a carbohydrate head (Fig 1.11) and constitute about 5% of lipid 
molecules in the outer monolayer (Alberts, 2002). 
 
Figure 1.11 A glycolipid. Glycolipids consist of two lipid tails (fatty acids or fatty acid and sphingosine) and a 
polar glycolsylated head (sugar). 
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Table 1.4 Types of glycolipid and their function. 
Type of glycolipid Lipid base Sub-classes Location Function 
Glycoglycerolipid Glycerol Neutral 
glycoglycerolipids 
Glycophospholipids 
Sulfoglycoglycerolipids 
Chloroplast of 
plants and 
algae, mucosal 
lining of 
stomach 
Mechanical and 
chemical protection 
 
Glycosylphosphati
dylinositols (GPI) 
Dilichols 
(poly 
prenyls) 
Variations on glycan 
side chains 
Lipid anchor variation; 
diaclglycerol, 
alkylacylglycerol or 
ceramide 
Outer leaflet of 
membrane 
(Associate with 
lipid rafts) 
Anchors proteins to 
membrane via 
phosphoethanolamin
e linker 
Glycosphingolipids 
(GSL) 
Ceramide Lacto 
Globo 
Ganglioside 
 
Series 
Outer leaflet of 
membrane 
(associate with 
glycosynapses) 
Associate with 
functional proteins  
Role in cell adhesion, 
motility, growth  
Galactosylceramide 
  
Glycolipids can be divided into three main groups, glycoglycerolipids, glycosylphosphatidylinositols 
(GPI) and glycosphingolipids (GSL) based on the type of lipid component (Table 1.4). 
Glycoglycerolipids are lipids consisting of either mono or oligosaccaharides linked to the hydroxyl 
group of glycerol, these are mainly found in plants, algae and bacteria where they are involved in 
photosynthetic membranes, but can also be found in animals, although expression is limited (Holzl & 
Dormann, 2007). In humans, they are normally found in the testes and nervous system and stomach 
wall at low levels, however, they have been observed in the colorectal carcinoma cell line HT29 
(Pahlsson et al., 2001). They are important membrane components, sulphated glycoglycerolipids are 
an important factor in the mucosal lining of the stomach wall, protecting it from mechanical and 
chemical damage (Urich, 1994). GPIs contain a carbohydrate or glycosyl groups linked to 
phosphatidylinositols. They are widespread in nature and are a post-translational modification of 
many proteins, positioned at the C-terminus of the protein, allowing anchoring of the protein to the 
outer leaflet of the cell membrane (GPI-anchored proteins; (Paulick & Bertozzi, 2008)). They are 
known to partition to lipid rafts, and be involved in signal transduction. For example GPI-anchored 
proteins play an important role in TCR signalling (Horejsi, 2003). They have been shown to be 
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involved in prion diseases and are important for the amplification and spread of prion activity from 
cell to cell (Bate et al., 2010; Priola & McNally, 2009). GSLs are a major component of the human 
plasma membrane and are normally found in the outer membrane of cells. Approximately 300 
different GSL have been identified and they, along with glycoproteins form a layer of carbohydrates 
over the cell membrane, protecting the cell from chemical and mechanical damage (Chester, 1998; 
Varki, 1993). As well as the protection of cells, research has shown that GSLs perform a range of 
functional roles on the cell surface and subsequent signalling (Hakomori Si, 2002). They have also 
been implicated in a number of diseases, including cancer and GSL-lysosomal storage diseases 
(Ginzburg et al., 2004; Hakomori & Zhang, 1997). 
1.3.1 Synthesis and structure of GSL 
GSL biosynthesis begins with ceramide (a sphingosine and a fatty acid). Ceramide is synthesised 
through one of three pathways (Fig 1.12). The first involves the hydrolysis of sphingomyelin and is 
catalysed by a group of enzymes named sphingomyelinases (SMases). SMases are distinguished by 
different pH optima and therefore referred to as acid, neutral or alkaline SMases (Levade & 
Jaffrezou, 1999). SMases are rapidly activated by diverse stress signals (Ballou et al., 1996). In turn, 
SMase hydrolyses the phosphodiester bond of sphingomyelin forming ceramide and phosphocholine 
(Levade & Jaffrezou, 1999). The de novo pathway of ceramide involves the condensation of 
pamitoyl-CoA and serine by serine pamitoyl transferase to form 3-keto-dihydrosphingosine. In turn, 
3-keto-dihydrosphingosine is reduced to dihydrosphingosine. This is then acylated to produce 
dihydroceramide. Finally, formation of ceramide is completed by dihydroceramide desaturase which 
removes the two hydrogen atoms (Merrill et al., 1997). The third pathway involves the degradation 
of sphingolipids and glycosphingolipids in endosomes and lysosomes. Fragments of the plasma 
membrane containing GSLs to be degraded are endocytosed and traffic to lysosomes (Sandhoff & 
Kolter, 1996). In the lysosomes, GSLs are de-glycosylated by exohydrases, which cause the stepwise 
release of monosaccharides from the sphingolipid. The sphingomyelin is then converted to ceramide  
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Figure 1.12 Schematic diagram of ceramide synthesis through various pathways. De novo synthesis involves 
the condensation of palmitoyl-CoA and ceramide. Ceramide can also be scavenged through the hydrolysis of 
sphingomyelin or through the condensation shingolipids or Synthesis of ceramide. Figure taken from (Won et 
al., 2007). 
by SMase, as in the sphingomyelin hydrolysis pathway (Kitatani et al., 2008). Once ceramide has 
been synthesised through the various pathways, it has an important role as a second messenger in a 
variety of cellular pathways, including apoptosis, senescence, differentiation, proliferation and cell 
cycle arrest (Mathias et al., 1998). As well as its role in cell physiology, ceramide acts as the base of 
GSLs. Most commonly, a glucose (Glc) is added to the ceramide by the Type I transmembrane 
protein glucosylceramide (GlcCer) synthase, forming GlcCer (Ichikawa & Hirabayashi, 1998; Sprong 
et al., 1998) ? 'ĂůĂĐƚŽƐĞ  ?'Ăů ) ŝƐ ƚŚĞŶ ĂĚĚĞĚ ƚŽ 'ůĐĞƌ ďǇ ɴ-1,4-galactosyltranferases forming 
lactosylceramide (LacCer) in the lumen of the Golgi apparatus (Fig 1.13; (Lannert et al., 1994; Won et 
al., 2007)). LacCer is the acceptor for various transferases that generate three major classes of GSLs; 
Lacto(neo), globo series and gangliosides (Fig 1.14; (Hettmer et al., 2004)). Alternatively, Gal can be 
added to the ceramide forming GalCer which in turn leads to the synthesis of less common 
structures, including GM4 and sulfatide (Fig 1.14; (Won et al., 2007)). 
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Figure 1.13 The structure of LacCer. The core complex for most GSLs. Ceramide is produced through the 
sphingomyelin hydrolysis, de novo or salvage pathways and is made up of sphingosine and a fatty acid. To the 
ceramide Glc is added followed by Gal, producing LacCer. The addition of more monosaccharides can produce 
hundreds of different GSLs. Alternatively Gal can be added before Glc to the ceramide producing GalCer.  
1.3.2 Function of GSLs 
As established above, GSLs perform many functions on the surface of cells. One main characteristic 
of GSLs that allows them to perform such versatile roles is their ability to form clusters. These 
clusters are able to interact with functional molecules on the cell surface. These clusters are termed 
'glycosynapses' and have been characterised using a range of cancer cell lines in vitro,  (Fig 
1.15;(Hakomori, 2002)). Significantly, they have contrasting properties with lipid rafts (Table 1.5), 
another form of cluster present on the cell surface involved in signal transduction, studied using 
living cells in vitro, for example, B and T cells and a number of cancer cell lines (Lingwood & Simons, 
2010). Glycosynapses rely on the ability of GSLs to bind via cis-carbohydrate to carbohydrate 
interactions, forming clusters in membrane and interact with functional proteins. Currently 3 types 
of glycosynapses have been described.  “'ůǇĐŽƐǇŶĂƉƐĞ  ? ? ƌĞƉƌĞƐĞŶƚƐ Ă '^>-GSL or GSL-binding 
protein interactions between cells, mediated by the glycosyl epitope of the GSL. The GSL are 
ĂƐƐŽĐŝĂƚĞĚǁŝƚŚƐŝŐŶĂůƚƌĂŶƐĚƵĐĞƌƐĂŶĚĂƌĞĂůƐŽƐƚĂďŝůŝƐĞĚďǇƉƌŽƚĞŽůŝƉŝĚƉƌŽƚĞŝŶ ? “'ůǇĐŽƐǇŶĂƉƐĞ ? ?is 
the term used for cell to cell adhesion based on O-linked mucin-type glycoproteins that are 
recognised by carbohydrate binding proteins. The O-linked glycans and the recognising proteins are 
ĂƐƐŽĐŝĂƚĞĚ ǁŝƚŚ ƐŝŐŶĂů ƚƌĂŶƐĚƵĐĞƌƐ ?  “'ůǇĐŽƐǇŶĂƉƐĞ  ? ? ƌĞĨĞƌƐ ƚŽ the adhesion of a cell to the 
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extracellular membrane (ECM), which is mediated by N-glycosylated adhesion receptors complexed 
with tetraspanin and GSL (Mitsuzuka et al., 2005). 
 
 
Figure 1.14 Schematic representation of the major pathways of ganglioside biosynthesis. The 
monosialoganglioside GM3, derived from lactosylceramide, is the common precursor for both 'a' and 'b' 
pathway gangliosides. Each ganglioside species consists of a ceramide backbone (CER), and a carbohydrate 
chain (Glc=glucose, Gal=galactose, GalNAc=N-acetylgalactosamine) containing one or more sialic acid (SA) 
residues. 'a' and 'b' pathway gangliosides downstream of GD1b/GM1a synthase were designated complex 'a' 
(CaG) and complex 'b' (CbG) gangliosides, respectively. Parallel steps in both pathways are catalysed by the 
same glycosyltransferases of the Golgi apparatus (Li and Ladisch, 1997): GD3 synthase (ɲ-2,8-sialyltransferase), 
GM2/GD2 synthase (ɴ-1,4-N-acetylgalactosaminyltransferase); GD1b/GM1a synthase (ɴ-1,3-
galactosyltransferase); GT1b/GD1a synthase (ɴ-2,3-sialyltransferase); GQ1b/GT1a synthase (ɲ-2,8-
sialyltransferase). Adapted from (Hettmer et al., 2004). 
 
 
GD3 synthase 
GD1b/GM1a synthase 
GT1b/GD1a synthase 
GQ1b/GT1a synthase 
GD2/GM2 synthase 
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Table 1.5 Contrasting properties of lipid raft and glycosynapses. Adapted from Hakomori, 2008. 
Lipid Raft Glycosynapse 
1% Triton X-100 insoluble 1% Triton X 100 soluble 
0.5% Brij95 insoluble 
Cholesterol-dependent (disrupted by 
cholesterol-binding reagent) 
Cholesterol-independent (resistant to 
cholesterol-binding reagent) 
Tetraspanin-independent Tetraspanin dependent 
Diameter 10nm to <100nm Diameter >100nm, usually 500-1000nm 
Highly mobile Less mobile  W non-mobile  
Not involved in cell adhesion Involved in cell adhesion with concurrent 
signalling 
 
Figure 1.15 Schematic representations of glycosynapses. (A) Type 1 glycosynapse with GSL clusters, 
proteolipid  tetraspanin (PLtsp), and growth factor receptor. Clusters of GSLs are organized with signal 
ƚƌĂŶƐĚƵĐĞƌ ŵŽůĞĐƵůĞƐ  ?dĂ ? dď ) ? ^ƚŝŵƵůĂƚŝŽŶ ŽĨ '^> ƌĞŐŝŽŶ  ‘ ‘Ă ? ? ĐĂƵƐĞƐ ƐƚƌŽŶŐ ƐŝŐŶĂůŝŶŐ  ‘ ‘ǆ ? ? ƚŚƌŽƵŐŚ dĂ, 
ǁŚĞƌĞĂƐƐƚŝŵƵůĂƚŝŽŶŽĨ ƌĞŐŝŽŶ  ‘ ‘ď ? ?ĐĂƵƐĞƐǁĞĂŬĞƌ ƐŝŐŶĂů ŶŐ  ‘ ‘Ǉ ? ?ƚŚƌŽƵŐŚdďďĞĐĂƵƐĞŽĨ ƚŚĞƉƌĞƐĞŶĐĞŽĨ ƚŚĞ
blocking factor PLtsp. The growth factor EGF-R can be located in a GSL-rich domain. Signalling by tyrosine 
phosphorylation can be blocked by association of EGF-R with GSL. Binding of GSL to EGF-R may result from 
interaction of GSL with carbohydrates N-linked to EGF-R. (B) Type 2 glycosynapse with mucin-type 
transmembrane glycoprotein at cholesterol-rich membrane domain. Examples are shown for MUC1 and 
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PSGL1. The tandem repeat units of MUC1 and PSGL, have multiple O-linked structure with glycosyl adhesion 
epitope and are organized with various signal transducers (TDa, TDb, TDc). In human and mouse T-cell lines, 
cSrc, lck56, Lyn, Fyn, and CD45 are detected. Both MUC1 and PSGL1 are associated with a membrane domain 
rich in cholesterol (indicated by yellow rods). Cells expressing type 2 glycosynapse are capable of binding to 
cells expressing P-selectin, E-selectin, or siglecs. (C) Type III glycosynapses contain N-glycosylated 
transmembrane adhesion receptors (usually integrin; ITR) complexed with tetraspanins (Tsp) and GSLs. Type 3 
glycosynapse with integrin receptor (ITR) having ɲ- and ɴ-subunits and tetraspanin (Tsp.). N-glycosylation (pink 
oval chains) of ITR is essential for connection and stabilization of ɲ5- and ɴ1-subunits and also for interaction 
of ITR with tetraspanin CD82. Figure taken from (Hakomori, 2002). 
 
Glycosynapse-1  
GSLs can form clusters and are organised with cytoplasmic signal transducers and proteolipid 
tetraspanin (Fig 1.15; (Iwabuchi et al., 1998)). These synapses can also contain growth factors. The 
main GSL in these synapses mediates cell adhesion that in turn leads to activation of cytoplasmic 
signal transducers (e.g. TDa, TDb, TDc). This activation leads to downstream signalling and changes in 
transcription factor expression. This can lead to increased cell adhesion, spreading and enhanced cell 
motility (Iwabuchi et al., 1998; Kojima & Hakomori, 1991). The impact of GSL activation can be 
reduced by the presence of an inhibitor in the synapse (e.g. Pltsp; (Hakomori Si, 2002)). If a growth 
factor is associated with a type I synapse (e.g. EGFR) its activation would be inhibited by 
phosphorylation via linkage of the GSL to carbohydrates associated with EGFR (Zhou et al., 1994). 
Glycosynapse-2 
Type II glycosynapses involve transmembrane mucin-type glycoproteins (e.g. mucin-1 [MUC1] or P-
selectin glycoprotein ligand-1 [PSGL-1]) in cholesterol-rich regions of the membrane, but not GSLs 
(Fig 1.15). They associate with cytoplasmic signal transducers (Tda, Tdb, Tdc). Activation of the 
mucin-type glycoproteins by P-selectin, E-selectin and others ligands lead to signal transduction and 
changes in transcription factors, as in type I synapses (Suzuki & Kojima, 2007).  
Glycosynapse-3 
The third type of glycosynapse contains transmembrane adhesion receptors (such as integrin 
receptor [ITR]) complexed with tetraspanin and GSLs (Fig 1.15). Both GD2, GD3 and GM3 
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gangliosides have been shown to be associated with the tetraspanin CD51 in glycosynapses (Thorne 
et al., 2007). Their presence in the glycosynapse is essential for the receptors to be N-glycosylated to 
ĂůůŽǁĐŽŶŶĞĐƚŝŽŶƚŽ ?ĂŶĚƐƚĂďŝůŝƐĂƚŝŽŶŽĨƚŚĞɲ ?ĂŶĚɴ ?ƐƵďŶŝƚƐŽĨƚŚĞ/dZĂŶĚĨŽr interaction with 
tetraspanin (Zheng et al., 1994). Alteration of this glycosylation effects interaction of integrin with 
tetraspanin, leading to significant inhibition or promotion of cell motility (Ono et al., 2000). The 
activation of transmembrane receptors in type III glycosynapses also leads to intracellular signalling 
and changes in transcription factor expression (Zheng et al., 1993). 
1.3.3 Mechanisms of altered expression of glycans 
Hakomori and colleagues formulated the concept that the alteration of glycolipids on cancer cells 
occurs due to incomplete and neosynthesis of glycans. Studies since then have shown that not only 
are glycolipids altered on cancer cells, but a wide variety of carbohydrate determinants are altered 
on cancer cells (Dabelsteen, 1996; Reis et al., 2010). 
Incomplete synthesis 
Originally, the overexpression of some glycans on the surface of cancer cells was thought to be due 
to the increased transcription of glycosyltransferases involved in their synthesis. However, studies 
have shown that the level of glycosyltransferase transcription was not increased compared to 
normal cells. Further studies have shown that cancer cells lack the transferases to complete 
synthesis of some carbohydrate determinants due to silencing of the genes responsible. This is due 
to DNA methylation of genes encoding transferases involved in glycan production and histone 
deacetylation (Kawamura et al., 2008). 
 One example is sialyl Lewis x, which is used as a serum marker in a number of epithelial-derived 
tumours, for example breast (Wei et al., 2010). Increased expression of this glycan on tumour cells is 
caused by the DNA hypermutation and histone deacetylation and therefore silencing of genes 
involved in the sulphation of sialyl Lewis x. The inability of cancer cells to form sialyl 6-sulpho Lewis 
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x, a glycan on normal cells that acts as a ligand for Siglec-7, means the increase of the non-sulphated 
sialyl Lewis x, which is a ligand for E-selectin, endothelial cell leukocyte adhesion molecule-1 (ELAM-
1). This leads to increased tumour cell adhesion and motility, resulting in increased metastasis (St Hill 
et al., 2011; Wei et al., 2010). 
Neo-synthesis 
As well as the incomplete synthesis of glycans on tumour cells, glycans can be further expressed 
through a neo-synthesis mechanism (Kannagi et al., 2008). Neo-synthesis is mediated by hypoxic 
regions of solid tumours, resulting in the enhanced transcription of glycosyltransferases and sugar 
transporters, including fucosyltransferase VII (FUT7), ST3Gal-I (ST3O),UDP-galactose transporter-1 
(UGT1) and glucose-transporter-type-I (GLUT1; (Koike et al., 2004; Ogawa et al., 1997)). These 
factors are increased in cancer, leading to the increased expression of glycans including E-selectin 
ligands sialyl Lewis x and a (Koike et al., 2004).  
1.3.4 Aberrant expression of glycosyl epitopes in cancer  
Glycosylation of proteins as well as lipids, as described above, is important for their function. For 
example, glycosylation of immunoglobulins are important in maintaining the structure as well 
function of Ig. It has long been established that both glycolipids and glycoproteins are aberrantly 
expressed on the surface of cancer cells (Dennis et al., 1999; Hakomori, 1985; Hakomori & 
Murakami, 1968), giving the cancer enhanced mobility, adhesion and proliferation. Cancers can gain 
significant advantages from alterations in glycosylation of glycoproteins, glycolipids and 
proteoglycans. 
Fucosylation 
Fucosylation is a common modification of O- and N-linked glycosylation on both glycolipids and 
glycoproteins. Upregulation of enzymes involved in the addition of fucose residues to glycans can 
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lead to an increase in fucosylation in cancer. &ŽƌĞǆĂŵƉůĞ ?ɲ-fetoprotein (AFP) is increased in chronic 
hepatitis and liver diseases, but fucosylated AFP is overexpressed only in hepatocarcinomas (HCC). 
For this reason, it was approved as a tumour marker for HCC by the FDA in 2005 (Moriwaki & 
Miyoshi, 2010). Upregulation of fucosylated AFP in HCC is due to an increase in fucosylation enzymes 
such as ĨƵĐŽƐǇůƚƌĂŶƐĨĞƌĂƐĞƐ ? ŐƵĂŶŽƐŝŶĞ  ? ?-diphosphate (GDP)-fucose synthetic enzymes and GDP-
fucose transporter (Miyoshi et al., 2008). Interestingly, a decrease in fucosylation can lead to escape 
from NK cell-mediated tumour surveillance, leading to reduced TRAIL-mediated death of cancer cells 
(Moriwaki & Miyoshi, 2010). 
Glycoproteins 
Approximately half of eukaryotic proteins are glycosylated with either N- or O-linked glycans. Both 
N- and O-glycans can be affected during cancer progression. N-glycosylation consists of an 
oligosaccharide chain N-linked to asparagine within the sequence Asn-X-Ser/Thr, where X is any 
amino acid except proline (Varki, 2009). N-glycans are produced as a precursor which is transferred 
onto the protein in the ER. Further processing of the glycan then occurs in the ER, with glucose 
removal and addition which helps in protein folding. Once in the Golgi apparatus, the glycan is 
completed. O-glycosylation consists of a glycan linked to a serine or threonine residue. The first step 
in O-glycosylation involves the addition of GalNAc to the serine or threonine, forming the Tn antigen, 
the core 1 structure. This is then synthesised by Gal-transferase, adding a Gal to the GalNAc, forming 
the T antigen (Core 1; (Peter-Katalinic, 2005)). Either the T or Tn antigen can be sialylated forming 
sialyl-Tn, sialyl-T or disialyl-Tn or disialyl-T antigens. dŚĞ ĞŶǌǇŵĞ ĐŽƌĞ  ? ɴ ? ? ?-N-
acetylglucosaminyltransferase (C2GnT1) adds a GlcNAc to GalNAc, initiating the core 2 extension. 
C2GnT1 is the key branching enzyme in core 2 O-glycan biosynthesis. Further glycosyltransferases 
then add more residues to the glycan, with the addition of sialic acid terminating the glycan. 
Examples of core 2 O-glycans are the Lewis and ABO-glycan based blood group antigens that can be 
present on glycoproteins as well as glycolipids (Marionneau et al., 2001). Both N- and O-linked 
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glycans on membrane bound and secreted proteins can be altered on cancers (Feizi, 1985). Mucins 
are highly O-glycosylated due to their high density of serine/threonine residues. Mucins have altered 
glycosylation on cancer cells, due to either termination of normal glycans, or the addition of unusual 
terminal structures, most commonly the sialylation of the terminal saccharide. An example of 
altered glycosylation of glycoproteins is the increased level of N-linked glycan acceptor sequence 
motifs in the variable region of surface Ig in follicular lymphoma (Zhu et al., 2002). The extra sites for 
N-linked glycosylation are introduced through somatic mutation and are tumour specific. 
Furthermore, the glycans commonly terminated with mannose residues, unlike most glycoproteins, 
which usually exist as precursors in the ER, before being further modified in the Golgi (Rudd & Dwek, 
1997). Recently, it has been shown that the increased level of mannosylated glycans on the surface 
Ig of follicular lymphoma cells increases binding to C-type lectins, such as mannose receptor (MR) 
and DC-specific intracellular adhesion molecule-3-grabbing nonintegrin (DC-SIGN) expressed on 
innate immune cells, including DCs and macrophages, providing the FL with survival signals (Coelho 
et al., 2010).  
GSLs 
There have been a range of human tumour-associated GSL antigens found. The Lewis antigen blood 
groups expressed on GSLs can be altered and overexpressed on a range of cancers. Many of these 
glycosylated epitopes can be defined as tumour-associated antigens (e.g. ɴ ?'ůĐEĐďƌĂŶĐŚŝŶŐŝŶN-
linked structure, sialyl Lewis a, sialyl Lewis
 
x
 
in O-linked glycans and Lewis y
 
in either O- or N-linked 
glycan structure (Hakomori Si, 2002) .Tumour cells can gain significant advantages from alterations 
in the glyocalyx. A range of gangliosides (GD2, GD3, GM2) have been shown to be overexpressed on 
the cell membrane of neuroblastomas and melanomas. Studies have shown that some gangliosides 
can be shed into the tumour microenvironment (Chang et al., 1997). For example, GM2, GM3 and 
GD1a gangliosides have been shown to be shed by medulloblastoma cell lines (Chang et al., 1997). 
One possible mechanism by which tumour-promoting is the internalisation of gangliosides by 
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activated T cells, triggering their apoptosis via the intrinsic pathway (Sa et al., 2009), providing a 
mechanism for cancers to evade the immune system. The glycolipid isoglobotetraosylceramide 
(IsoGb4) has been shown to be a marker of metastasis and overexpressed on tumours, with limited 
expression on normal tissue (Brodin et al., 1986). Furthermore, a mAb directed against IsoGb4 has 
been shown to induce apoptosis in target cells (Zhong et al., 2001). 
Proteoglycans 
Proteoglycans are composed of a core protein with covalently attached glycosaminoglycan (GAG) 
side chains. The GAG side chains are linear polysaccharides consisting of a disaccharide repeat made 
up of an unronic acid and acetylated amino sugar. The chain can be sulphated at various sites, 
leading to areas of high sulphation that provide a docking site for a variety of protein ligands 
including cytokines, growth factors, enzymes and ECM. Heparin sulphate proteoglycans (HSPGs) 
have N-acetlyglucosamine and glucuronic/iduronic acid disaccharide named heparin sulphate and 
are expressed on all cells. The existence of a range of classes of core proteins as well as variation in 
disaccharide chains means that HSPGs are a large heterogeneous family. The heterogenic nature of 
HSGPs means that a cell can respond to its microenvironment in different ways. Due to the ability of 
HSGPs to interact with a range of ligands, they have a range of functions including cell adhesion to 
the ECM by binding laminin and fibronectin, ECM degradation through interaction with heparanase 
and growth factor sequestering by binding fibroblast growth factor or hepatocyte growth factor 
(Sasisekharan et al., 2002). Studies have shown that HSPGs are aberrantly expressed on a range of 
ĐĂŶĐĞƌƐ ? ǁŚŝĐŚ  ‘ŚŝũĂĐŬƐ ? ƚŚĞ ĨƵŶĐƚŝŽŶƐ ƚŚĂƚ ,^'WƐ ƉĞƌĨŽƌŵ ? ĐŽŶƚƌŝďƵƚŝŶŐ ƚŽ ƉƌŽŐƌĞƐƐŝŽŶ ŽĨ ĐĂŶĐĞƌƐ
through angiogenesis, promoting tumour growth and metastasis (Blackhall et al., 2001; Sasisekharan 
et al., 2002). 
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1.3.5 Glycolipids as targets for monoclonal antibodies 
The alteration of glycan structures, on glycolipids, glycoproteins and proteoglycans suggests that 
they may be good targets for mAb therapy. Targeting tumour-restricted glycans on glycolipids that 
may be involved in the optimal functioning of membrane proteins involved in a variety of cell 
signalling pathways with mAbs could inhibit the pro-tumour activity of the altered molecules, 
leading to tumour cell death, as well as utilising the effector mechanisms of mAbs; ADCC, CDC and 
direct cell death. MAbs that target tumour-specific glycolipid and glycan antigens have been 
reported. 
GD2 
GD2 is a disalylganglioside antigen expressed on the surface of tumours of neuroectodermal origin, 
including neuroblastoma and melanoma (Mujoo et al., 1987). In addition GD2 is also expressed on 
glioma and non-small cell lung cancer (Mujoo et al., 1987). It is abundantly expressed on 100% of 
neuroblastoma tumours, regardless of stage (Wu et al., 1986). Normal tissue expression is limited to 
neurons, skin melanocytes, and peripheral fibres. Furthermore, GD2 has been shown to be involved 
in cell growth and differentiation and apoptosis (Yoshida et al., 2002).  
A number of anti-GD2 mAbs have been produced, including 14.G2a, ch14.18 (Barker et al., 1991; 
Frost et al., 1997), ch.60C3 (Alvarez-Rueda et al., 2007), 3F8 (Kramer et al., 2007), and KM8138 
(Nakamura et al., 2001) to target neuroblastoma, melanoma, and non-small cell lung cancers. 
Currently, the use of antiGD2 mAbs in clinical trials in conjunction with chemotherapy is the 
mainstay of neuroblastoma therapy (Modak & Cheung, 2007). The benefit of targeting GD2 on the 
surface of cells is that unlike other gangliosides studied, GD2 is not shed by the cells into the 
microenvironment (Kramer et al., 1998). The first anti-GD2 mAb tested was the murine mAb 3F8, 
which was produced by immunising BALB/c mice with a range of neuroblastoma cell lines (Cheung et 
al., 1985). 3F8 has shown significant anti-tumour effect against neuroblastoma alone (Cheung et al., 
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1998) as well as when administered with granulocyte-macrophage colony-stimulating factor 
(GMCSF; (Kushner et al., 2001)), or radiolabelled with I
131
 (Kramer et al., 2000). Despite promising 
clinical studies, 3F8 showed HAMA responses in vivo, limiting the therapeutic value. 14.18 is an IgG3 
murine mAb targeted to GD2 and 14.G2a is a class-switch variant developed to enhance the ADCC 
effect of the mAb. When administered with IL-2, 14.G2a showed minimal effectiveness and suffered 
similar HAMA responses to 3F8 (Frost et al., 1997).  
To overcome the HAMA responses seen with the murine mAbs, chimeric mAbs ch14.18 and c.60C3 
were produced. ch14.18 was shown to be more effective than its murine counterpart, with overall 
survival greater than with maintenance therapy (Frost et al., 1997). Recently, a phase I study with 
ch14.18 administered with GMCSF and IL-2 was undertaken to ascertain the dose-limiting toxicity of 
the therapy (Gilman et al., 2009). The chimeric mAb c.60C3 was cloned from the murine anti-GD2 
mAb 60C3 and has been shown to induce ADCC and CDC in vitro and suppress tumour growth in vivo 
(Alvarez-Rueda et al., 2007). The humanised mAb Hu18K322A was created from ch14.18 in order to 
increase the half-life of the mAb in vivo. As well as being humanised, Hu18K22A was engineered with 
an amino acid change in the Fc region at position 322 and produced in the YB2/0 cell line rather than 
CHO lines, which lacks fucosylation in the Fc region, with the purpose of increasing the efficacy of 
CDC and ADCC in vivo (Yang & Sondel, 2010). 
GD3 
The ganglioside GD3 has been described as a melanoma marker due to its overexpression (Tsuchida 
et al., 1989) and as a valid target for mAb therapy due to anti-GD3 mAb-mediated melanoma cell 
lysis being observed with the mAb MB3.6 (Cheresh et al., 1985). During apoptosis, GD3 is rapidly 
synthesized from ceramide by a sialyltransferase resident in the Golgi apparatus. It then relocates to 
the mitochondria where it contributes to the opening of the mitochondrial permeability transition 
pore complex, followed by the release of cytochrome c and other pro-apoptotic factors (Malisan & 
Testi, 2002). R24 is a mouse mAb that recognises GD3 and has undergone numerous clinical trials 
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(Chapman et al., 1990). It has been used to treat melanoma patients and in one trial showed a 
complete response in one patient that lasted 2 years and a partial response in one patient that 
lasted 2 months (Kirkwood et al., 2000). It also displayed a human anti-mouse antibody response in 
patients, but the low level of response meant that the antibody was not humanised (Kaminski et al., 
1999).  
GM2 
GM2 is a expressed at low levels in most normal tissues, but is highly expressed in certain cancers 
including melanoma (Portoukalian et al., 1979). It is a strongly immunogenic ganglioside as reflected 
by the fact that anti-GM2 IgM antibodies have been detected in some patients with dysimmune 
neuropathies (Cavanna et al., 2001). GM2 has also been shown to associate with lipid rafts (Tomioka 
et al., 2009). DMF10.167.4 is a hamster mAb raised against a murine T cell lymphoma cell line and 
has been shown to induce apoptosis of that cell line in vitro (Fernandes et al., 1999). Subsequently it 
was found to bind to GM2 and could bind to both melanoma and small cell lung cancer cell lines, but 
showed minimal binding to normal tissues (Retter et al., 2005). Its ability to induce apoptosis in a 
range of cell lines in vitro also transferred to in vivo studies, where it was shown to inhibit the 
formation of tumours in murine models (Retter et al., 2005).  
Other glycan-targeting mAbs 
RAV12 is a chimeric mAb that has been shown to bind ĂŵŝŶŝŵĂůĞƉŝƚŽƉĞŽĨ'Ăůɴ ?- ?'ůĐEĐɴ ?-3Gal 
on the N-linked carbohydrate antigen RAAG12, which has been observed on 90% of intra-abdominal 
tumours, but also on mucosal and glandular/ductal epithelium (Coberly et al., 2009; Loo et al., 
2007). RAV12 has been shown to directly kill the colorectal cancer cell Colo 205 in vitro 
independently of apoptosis by oncosis (Loo et al., 2007). A study has shown that RAAG12 is present 
on insulin-like growth factor-I receptor (IGF-IR) and binding of RAV12 leads to increased 
phosphorylation of IGF-IR in RAAG12 positive cell lines, leading to accelerated desensitisation of the 
Akt/PKB pathway (Li & Li, 2007). A recent phase I study in 33 recurrent adenocarcinoma patients 
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showed some anti-tumour activity of RAV12, although toxicity of the mAb precluded the delivery of 
maximal doses (Burris et al., 2010). 
Interestingly, F77, a mAb targeted at an as of yet unidentified glycolipid target, is also able to induce 
direct cell death by oncosis. The mAb has been shown to bind to a large proportion of both primary 
and metastatic prostate cancer specimens by immunohistochemistry (Zhang et al., 2010a). F77 is 
proposed to induce oncosis by recruiting antigen to lipid rafts and through the production of large 
membrane pores (Zhang et al., 2010a). 
1.4 Cell death 
Cell death is a term that covers a range of pathways and mechanisms by which a cell may die. The 
most studied is apoptosis. Apoptosis involves tightly regulated, energy requiring intracellular 
mechanisms. It has a key role in both the development and homeostasis of all multi-cellular 
organisms. For example, apoptosis contributes to the normal development of foetal and pre-natal 
lungs (Schittny et al., 1998) and is involved with the removal of damaged cells that could become a 
danger to the organism and the removal of a cell with DNA damage (Green & Martin, 1995) or virally 
infected cells (Shibata et al., 1994). Apoptosis is sometimes referred to as programmed cell death, 
although this is a misuse of the term programmed cell death as this term can be used to describe 
other forms of non-accidental cell death, such as pryoptosis (Majno & Joris, 1995). All forms of cell 
death have distinct morphologies that distinguish themselves from each other (Fig 1.16).  
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Figure 1.16 Cell death pathways. Different forms of cell death exist, each with distinct characteristics. Upon 
stimuli, a cell can die by apoptosis which is a result of the initiation of the caspase-cascade, followed by the 
cleavage of DNA. It is characterised by initial cytoplasmic and nuclear shrinkage followed by blebbing of the 
cell surface, leading to the formation of apoptotic bodies which are phagocytosed. Cell membrane integrity is 
maintained throughout. Alternatively, apoptotic bodies can undergo necrosis, causing a low level of 
inflammation. Autophagy involves the formation of autophagosomes inside the dying cell, which contain a 
large amount of cytoplasmic contents, and are degraded by the lysosome. Autophagic cells can also be 
phagocytosed. Oncosis describes cellular and organelle swelling, with increased cell membrane permeability 
before the release of inflammatory cellular contents. Pryoptosis involves the activation of caspase-1 after 
bacterial infection leading to cell lysis and the release of pro-inflammatory cytokines and bacteria. Necrosis 
described the end point of inflammatory cell death, characterised by loss of cell membrane integrity and the 
uncontrolled release of intracellular, inflammatory contents. Figure taken from (Fink & Cookson, 2005). 
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1.4.4 Apoptotic Pathways 
Apoptosis occurs in a variety of physiological conditions. Initially, cell membrane integrity is 
maintained and nuclear fragmentation occurs by the cleavage of DNA by activation of endogenous 
endonucleases. The cell fragments into apoptotic bodies that are phagocytosed by neighbouring 
cells and degraded (Fig 1.16). Alternatively, apoptotic bodies can reach necrosis, releasing their 
inflammatory contents. Apoptosis is mediated by a family of cysteine aspartyl-specific proteases, 
caspases. This family of 14 proteases are expressed as inactive precursors or zymogens (pro-
caspases), of which 7 mediate apoptosis (Table 1.6).  
Table 1.6 Properties of the members of the caspase family. Adapted from (Vermeulen et al., 2005).  
Name of caspase Other names Tetrapeptide preference Function 
Caspases important for execution and signalling events of apoptosis 
Caspase - 2 ICH-1/mNedd2 DEHD/VDVAD Initiator 
Caspase - 8 MACH/FLICE/Mch5 LETD/IETD Initiator 
Caspase - 9 ICE-LAP6/Mch6 LEHD Initiator 
Caspase - 10 Mch4, FLICE2 IEAD/DMQD Initiator 
Caspase - 3 CPP32/Apopain/Yama DEVD Effector 
Caspase - 6 Mch2 VEID/VEHD Effector 
Caspase - 7 Mch3/ICE-LAP3/CMH-1 DEVD Effector 
Caspases involved in control of inflammation 
Caspase - 1 ICE WEHD/YEVD  Pryoptosis 
Caspase - 4 TX/ICH-2/ICErel-II LEVD/(W/L)EHD   
Caspase - 5 TY/ICErel-III (W/L)EHD   
mCaspase - 11 ICH-3      
mCaspase - 12        
Caspase - 13 ERICE      
mCaspase - 14 MICE       
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These caspases are activated by proteolysis following apoptotic stimuli (Los et al., 1999; Manimala et 
al., 2007). Apoptotic stimuli can be from either intracellular of extracellular sources. For example, 
irreparable DNA damage, telomere shortening, withdrawal of growth factors, hypoxia, oncogene 
induction or immune response. These stimuli lead to the intrinsic or extrinsic pathways of apoptosis.  
1.4.2 Intrinsic Pathway 
The intrinsic (mitochondrial-dependent) pathway (Fig 1.17) is initiated by intracellular apoptotic 
stimuli as described above. The main step in the intrinsic pathway is the release of cytochrome c 
from the mitochondria. The mechanism by which this occurs is not entirely clear. According to some 
authors, (Scarlett & Murphy, 1997; Vander Heiden & Thompson, 1999) cytochrome c release is 
preceded by mitochondrial swelling, leading to a disruption of the membrane. However, more 
recent research has shown that the formation of pores at the contact sites of the outer and inner 
membranes of the mitochondria (Vermeulen et al., 2005) cause the release of cytochrome c. These 
pores, termed mitochondrial permeability transition pore complexes (PTPC; Fig 1.18), are comprised 
of the adenine translocator (ANT) at the inner membrane and the voltage-dependent anion channel 
(VDAC) at the outer membrane, (also known as porin) as well as other proteins; hexokinase II (HKII), 
mitochondrial creatine kinase (mtCK), cyclophilin D (Cyp-D) and peripheral benzodiazepine receptor 
(PRB). Intrinsic pathway activation and consequently the formation of pores, is caused by cell stress, 
free radical damage or growth factor deprivation. These factors lead to the dephosphorylation of the 
intracellular protein complex 14-3-3/Bad. This releases Bad from 14-3-3, allowing it to disrupt Bcl-2 
homodimers (an anti-apoptotic protein; Table 1.8) on the outer membrane of the mitochondrion. 
The pro-apoptotic protein Bax also disrupts Bcl-2:Bcl-XL heterodimers on the mitochondria 
membrane. Bax and Bad also form homodimers on the outer membrane of the mitochondria. This 
break-up and formation of dimers disrupts the balance of anti- and pro-apoptotic proteins on 
membrane. This is thought to cause high levels of matrix Ca
2+
 and Mg
2+
 concentration and high levels 
of ADP/ATP leading to pore opening and cytochrome c release (Schinzel et al., 2005). Along with 
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Figure 1.17 Simplified schematic diagram of the intrinsic pathway. Apoptotic stimuli cause the 
dephosphorylation of 14.3.3/Bad allowing Bad to disrupt anti-apoptotic protein dimers (e.g. Bcl-2/Bcl-2) on the 
mitochondria outer membrane. The pro-apoptotic protein Bax disrupts other anti-apoptotic dimers. This 
causes an imbalance in apoptotic signals, leading to PTPC formation in the mitochondria membrane. Bax 
complexes with the PTPC allowing the release of cytochrome c. Cytochrome c binds to Apaf-1 causing 
oligomerisation in the presence of ATP. Procaspase-9 is recruited (forming the apoptosome) and activated 
forming caspase-9. This then allows the activation of effector caspases, such as caspase-3. Effector caspases 
then cleave nuclear structural proteins and DNA repair proteins (such as laminins and PARP respectively). 
Caspase-3 cleaves ICAD allowing CAD to cleave DNA. 
 
Figure 1.18 A schematic representation of the PTPC. Comprised of the VADC (also known as porin), ANT and 
other proteins which include; HK, PRB, mtCK and Cyp-D. 
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Table 1.8 Members of the Bcl-2 family 
 
 
 
 
cytochrome c the pro-apoptotic proteins Smac/Diablo (second mitochondria-derived
 
activator of 
caspases/direct IAP-binding protein with low pI), apoptosis inducing factor (AIF), Omi/HtrA2 and 
endonuclease G are released (Susin et al., 2000). The PTPC has been shown to physically and 
functionally interact with Bax (Boya et al., 2001; Szewczyk & Wojtczak, 2002) allowing the normally 
narrow PTPC to widen allowing release of cytochrome c and apoptosis inhibitory protein (AIP). Upon 
release of cytochrome c from the mitochondria, the consensus nucleotide binding domain of Apaf-1 
is hydrolysed in the presence of ATP. Cytochrome c then binds to Apaf-1 promoting oligomerisation 
of Apaf- ?ĨŽƌŵŝŶŐĂ ůĂƌŐĞ  ‘ĂƉŽƉƚŽƐŽŵĞ ?ĐŽŵƉůĞǆ  ? ? ? ?ƚŽ1400 kDa)(Levade & Jaffrezou, 1999; Los, 
2002; Luo et al., 1998). The apoptosome then recruits procaspase-9 via its caspase recruitment 
domain (CARD) and is activated through auto-catalysis. The activated caspase-9 is released from the 
complex (Levade & Jaffrezou, 1999). Caspase-9 then in turn activates downstream effector caspases 
such as caspase-3, -6, and -7 (Fig 1.17) (Levade & Jaffrezou, 1999; Li et al., 1997). Effector caspases 
translocate to the nucleus where they can cause DNA fragmentation by the cleavage of DNA repair 
proteins and structural nuclear proteins (such as PARP and laminin respectively). Caspase-3 cleaves 
ICAD allowing CAD to cleave DNA. Alongside caspase activation, AIF and endonuclease G induce 
nuclear chromatin condensation as well as large scale DNA fragmentation (Susin et al., 2000).  
1.4.3 Extrinsic pathway 
The extrinsic (receptor-dependent) pathway involves the activation of caspases via receptors 
belonging to the tumour necrosis factor (TNF)-receptor superfamily at the plasma membrane (Fig 
1.19). The family includes Fas (Apo-1/CD95), TNF-receptor-1 (TNF-R1), death receptor-3 (DR3 or TNF-
Anti-apoptotic 
proteins 
Pro-apoptotic 
proteins 
Bcl-2 Bad 
Bcl-XL Bax 
 Bid 
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receptor-related apoptosis-mediating protein [TRAMP] or Apo-3), TNF-related apoptosis-inducing 
ligand receptor-1 (TRAIL-R1 or DR4), TRAIL-R2 (DR5 or Apo-2) and DR6 (Izban et al., 1999; Vermeulen 
et al., 2005). The most studied death receptor is Fas, which is activated by the Fas-ligand (FasL). FasL 
(for example on the surface of a CTL) or agonistic antibodies, such as the anti-Apo-1 mAb, bind to 
the Fas receptor (Dhein et al., 1992). As FasL is homo-trimeric it causes trimerisation of the Fas 
receptor. This activation leads to the recruitment of the adaptor molecule Fas-associated death 
domain (FADD; made up of CAP1 and CAP2) that binds to Fas via the death domain (DD) in its 
cytoplasmic region. The complex formed is referred to as the death receptor-induced signalling 
complex (DISC). In addition to a DD, FADD also contains a death effector domain (DED) that recruits 
the DED-containing procaspase-8 to the DISC (Medema et al., 1997). Procaspase-8 is then 
proteolytically activated forming caspase-8 which in turn activates effector caspases (e.g. caspase-3 
and -7). This mechanism for caspase activation is similar for most death receptors. For example the 
ligand TNF-ɲďŝŶĚƐƚŽŝƚƐƌĞĐĞƉƚŽƌdE&-R1 causing receptor trimerisation and the recruitment of the 
TNF-R-associated death domain protein (TRADD; Fig 1.19; (Shen et al., 2002)). The DD of TRADD 
interacts with the DD of FADD, allowing the recruitment of procaspase-8 (Stennicke et al., 1998). In 
addition to death receptors, four decoy receptors that belong to the TNFR family have been 
identified (DcR1/TRID, DcR2/TRUNDD, DcR3 and osteoprotegrin (OPG)). Decoy receptors compete 
with death receptors for ligand binding, thereby inhibiting ligand-induced apoptosis. Decoy 
receptors are either devoid of an intracellular DD (DcR1/TRID) or have a partially deleted DD 
(DcR2/TRUNDD). Therefore, ligand can bind the cell via the decoy receptor and does not provide a 
pro-apoptotic signal. Alternatively, both DcR3 and OPG are secreted and bind FasL and TRAIL 
respectively, blocking apoptosis (Sheikh & Fornace, 2000; Van Poznak et al., 2006).  
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Figure 1.19 Two examples of death receptors involved in the extrinsic pathway. FasL binds to the Fas 
receptor, causing trimerisation. This allows binding of the adaptor molecule FADD to the DD of Fas. 
Procaspase-8 clusters at the receptor completing the DISC. Binding of procaspase-8 to the DED of FADD causes 
cleavage of the initiator caspase, allowing the activated caspase-8 to activate downstream caspases, such as 
caspase-3. Caspase-8 can also cleave BID which, when activated causes release of cytochrome c from the 
mitochondria, initiating the intrinsic pathway. T cells or activated macrophages release TNF-ɲwhich trimerises 
the TNF-R1. TRADD binds to the intracellular DD of TNF-R1. The DD of TRADD recruits FADD, completing the 
DISC. FADD binds procaspase-8 causing activation by cleavage. Activation of caspase-3 is followed by the 
cleavage of ICAD, releasing CAD, which cleaves the DNA. Also, DNA repair proteins and structural nuclear 
proteins, such as PARP and laminins respectively, are inactivated by cleavage. 
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1.4.1 Oncosis 
Oncosis is an example of non-apoptotic cell death (Fig 1.16). Oncosis was first proposed in 1910 by 
von Recklinghausen and is accompanied by cellular and organelle swelling, blebbing, and increased 
membrane permeability (Majno & Joris, 1995) as well as non-specific DNA damage (Jugdutt & Idikio, 
2005). Therefore, oncosis differs from apoptosis with respect to the fact that the cell swells then dies 
 ?ŽŶĐŽ ? 'ƌĞĞŬ ĨŽƌ  ‘ƐǁĞůůŝŶŐ ? Žƌ ŵĂƐƐ ) ĂŶĚ ĂŶ ĂƉŽƉƚŽƚŝĐ ĐĞůů ŝŶŝƚŝĂůůǇ ĚĞĐƌĞĂƐĞƐ ŝŶ ĐĞůůƵůĂƌ ǀŽůƵŵĞ, 
followed by budding of the cell membrane before the formation of apoptotic bodies (apoptosis from 
Greek; apó meaning from and ptósis meaning a fall). Cellular swelling in oncosis is followed by the 
breakdown of the cell membrane and the release of intracellular components and inflammation (Fig 
1.16). The term oncosis is widely used to describe cell death as a result of ischemia in various 
diseases, such as acute myocardial infarction and acute renal and liver failure (Chu et al., 2007; 
Gujral et al., 2003; Jugdutt & Idikio, 2005). The oncotic hallmark of cellular swelling has been shown 
to be due to ion pump failure due to a lack of ATP (Cao et al., 2010; Majno & Joris, 1995). It has been 
thought that oncosis is an un-regulated event with a cell swelling beyond its capacity resulting in the 
cell bursting. However, studies have shown that biochemical mechanisms lead to oncotic cell death. 
For example, influx of sodium and Ca
2+
 leads swelling of the cell (Chen et al., 2002; Trump & 
Berezesky, 1996). Also the influx of Ca
2+
 has been shown to activate calpain, which has been shown 
to mediate the degradation of several cytoskeletal proteins, resulting in membrane permeability 
(Cao et al., 2010; Liu et al., 2004). Calpain has also been shown to disrupt the mitochondria via 
cleavage of Bid, the pro-apoptotic protein, initiating a cell death pathway that is either independent 
or dependent on caspases (Chen et al., 2002).  
1.4.2Autophagy 
Autophagy is derived from the Greek meaning phagy-to eat and auto-oneself and is a mechanism 
used to degrade proteins and cytosolic organelles. Large amounts of cytoplasmic contents are 
sequestered in a double membrane vacuole termed autophagosomes, before being delivered to the 
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lysosome for degradation (Levine & Klionsky, 2004). The formation of autophagosomes is also 
observed in cell survival in conditions of limited nutrients, through the degradation of a large 
amount of cytoplasmic materials. An interesting example of this can be seen in apoptosis-deficient 
tumours where the induction of autophagy results in cell survival, avoiding necrosis and 
inflammation (Degenhardt et al., 2006). Autophagy consists of two pathways which vary on the way 
cytoplasmic material is delivered to the lysosome. Microautophagy involves cytoplasm being 
engulfed directly at the lysosome surface by invagination, whereas macroautophagy involves the 
creation of double-membrane vacuoles from the cell membrane that engulf a large proportion of the 
cytoplasmic (Fink & Cookson, 2005). Autophagy has also been observed as a mechanism of cell 
death, characterised by the degradation of cellular components in autophagic vacuoles of dying cells 
(Fig 1.16). Autophagic cell death is triggered when elimination of a large number of cells is required. 
It functions to cause cell death as well as providing a way for the cell to be disposed when 
phagocytes are unable to cope with the large numbers of cells (Levine & Klionsky, 2004).  
1.4.3 Pryoptosis 
Pryoptosis, from the Greek meaning pryo-fire or fever and ptosis-falling off which relates to its 
proinflammatory nature (Fig 1.16). Pryoptosis results from infection of cells with bacterial 
pathogens, such as Salmonella and Shigella species. Bacterial infection triggers the activation of 
caspase-1, a non-apoptotic member of the caspase family, which processes the proforms of IL- ?ɴ
and IL-18 into active forms, leading to the death of the host cell along with the release of IL- ?ɴĂŶĚ
IL-18 proinflammatory cytokines (Fig 1.16; (Foss et al., 2001)). It is thought that pryoptosis is a form 
of host defence, sacrificing one cell to produce a proinflammatory signal. An example of pryoptosis 
can be seen in the invasion of Salmonella into the epithelial cells of the gut before non-vacuole 
bacteria hyper-replicate, causing cell extrusion and pryoptosis, resulting in the release of pro-
inflammatory cytokines and release of Salmonella which is either cleared by immune cells or re-
invades other epithelial cells (Knodler et al., 2010). 
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Aim of thesis 
The aims of this thesis are to establish the therapeutic value of two anti-glycan mAbs produced in-
house, to develop an immunisation protocol with the aim of improving the immunogenicity tumour-
associated glycolipids able to produce therapeutically valuable mAbs and to determine the 
significance of a mAb with the ability to induce apoptosis in colorectal cancer. 
MAbs have been shown to utilise various mechanisms to yield anti-tumour effects including ADCC, 
CDC, by blocking cellular pathways and by inducing cell death directly. The latter has been shown to 
be mediated via classical apoptosis as well as independently of apoptosis. The first aim of this thesis 
is to establish whether mAbs directed at colorectal cancer would benefit from mediating apoptosis 
of the tumour directly or by inducing cell death independently of apoptosis, as observed with a 
number of anti-glycan mAbs. This will be achieved by quantifying the level of cleaved caspase-3 in a 
large cohort of colorectal cancer patients by immunohistochemistry.  
A panel of five IgG mAbs recognising the Lewis y/b hapten were previously produced in house 
following immunisation with rat anti-idiotypic antiserum to C14, an IgM Lewis y/b hapten mAb. The 
mouse IgG3 mAb 692/29 was selected for further characterisation in this thesis based on its 
distribution on a large number of colorectal primary tumours and lack of normal tissue binding by 
IHC. This mAb has previously been shown to have specificity for both Lewis y and Lewis b glycan 
antigens by thin layer chromatography and cause direct cell death independently of effector cells or 
complement. Therefore, the aim was to confirm the fine specificity of the mAb as well as further 
characterise its functional effector mechanisms, including its ability to cause direct cell death. 
The mAb 505/4 is a mouse IgG1 monoclonal antibody produced by immunising with whole colorectal 
cancer cells. Preliminary experiments have shown that it binds to a range of colorectal cancer cell 
lines and that its antigen is a sialylated glycan. Therefore, the aim was to further characterise 505/4 
and evaluate its suitability for use as a therapeutic mAb. To achieve this, the antigen would be 
  
64 
 
characterised, binding to tumour and normal tissues would be assessed and its ability to mediate 
effector functions would be determined.  
MAbs have been proven to be successful forms of cancer treatment with 7 currently approved for 
clinical use in cancer (June 2011) with all mAbs approved targeting protein antigens. Glycolipids have 
been shown to be aberrantly expressed on the surface of cancer cells. Furthermore, glycolipids are 
thought to be essential membrane components and have been associated with various functional 
membrane proteins. Glycolipids have been shown to be involved in a range of cell signalling 
pathways, for example, cell adhesion and growth. Therefore it is likely that glycolipids act on the cell 
surface as accessory molecules to functional membrane proteins and are required for optimal 
functional activity of their associated molecules. The aim of this thesis was to develop a protocol 
designed to produce mAbs directed at tumour-associated glycolipids, for therapeutic use. 
Specifically, to produce mAbs that showed specificity for tumour glycolipids, with minimal binding 
and have a functional effect in blocking the activity of the glycolipid. A therapeutically valuable mAb 
would also be able to induce traditional mAb-mediated anti-tumour effects. MAbs have been shown 
to induce direct cell death of tumour cells both via apoptosis and independently of apoptosis. 
Interestingly, a striking number of anti-glycan and anti-glycolipid mAbs have been shown to induce 
direct cell death, independently of apoptosis. 
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Chapter 2 Materials and Methods 
All procedures were carried out using aseptic technique where appropriate and relevant safety 
regulations were followed. Standard protocols were either developed or followed for all assays and, 
where necessary, modifications were incorporated into the protocols for use in specific conditions. 
All animal work was carried out under a Home Office approved project licence (Licence number 
40/2936). All reagents were purchased from Sigma (UK) unless otherwise stated. 
2.1 mAbs and Human cancer cell line culture 
2.1.1 Commercial mAbs 
Cleaved caspase-3 (Asp175) mAb was purchased from Cell Signalling Technology, (MA, USA). 7LE, 
CA19.9 and 2-25 LE were purchased from Abcam (Cambridge, UK). The human activating anti-Fas 
mAb was purchased from Upstate (now part of Millipore, MA, USA). The anti-MHC-II (HLA DP DQ DR 
clone WR18 mAb was purchased from AbD Serotec (Oxford, UK) and anti-HLA-ABC (clone W6/32) 
was purchased from eBioscience (CA, USA). Anti-CD46 was purchased from BD Pharmingen (NJ, USA) 
and anti-CD59 mAb (clone BRIC 229) was purchased from International Blood Group Reference 
Laboratory (IBGRL; Bristol, UK). 
2.1.2 In house production of mAbs  
505/4 was isolated from the 505/4 mouse hybridoma produced by immunising whole colorectal 
cancer cell lines, 692/29 was isolated from 692/29 mouse hybridoma produced from an anti-idiotype 
rat mAb raised against whole colorectal cancer cells, 692/42 was isolated from 692/42 mouse 
hybridoma produced in the same fusion as 692/29 and BR96 was isolated from HB10036 hybridoma 
purchased from the ATCC. All hybridomas were maintained in serum-free hybridoma media 
(Invitrogen Scotland, UK) and spent media collected regularly. Once enough supernatant was 
collected (~2 litres), it was filtered through Whatman paper beĨŽƌĞƐƚĞƌŝůŝƐŝŶŐƚŚƌŽƵŐŚĂ ? ? ?ʅŵ filter. 
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Supernatant was passed over a Protein G Sepharose column overnight. A standard glycine release 
protocol was followed to collect the IgG from the column. Table 2.1 shows the reagents used for 
antibody purification. 20ml of buffer C ran over the protein G Sepharose column at a speed of 1 ml 
per minute to equilibrate the column (using a vacuum pump). Spent culture supernatant was run 
then over the column overnight at 4
o
C. 50ml of buffer C was then passed over the column to remove 
residual supernatant and balance the pH. 20ml of glycine was slowly added, preventing disruption of 
Protein G and allowed to run through at 1ml per minute. 1ml fractions were collected in 1.5ml 
ĞƉƉĞŶĚŽƌĨ ƚƵďĞƐ ĐŽŶƚĂŝŶŝŶŐ  ? ? ?ʅů ŽĨ dƌŝƐ-HCl. 20ml of buffer C was then ran over the column to 
equilibrate the column. The samples were analysed by spectrophotometry with protein 
concentration being determined by reading optical density at 280nm, referenced against a sample of 
 ?ŵůŐůǇĐŝŶĞ ? ? ? ?ʅůdƌŝƐ-HCl. The samples containing antibody were pooled and either injected into a 
Slide-a-Lyze cassette (Thermo Scientific, MA, USA) or placed into dialysis tubing, before placing in 
500ml of sterile PBS and samples dialysed for 24 hours at 4
o
C. The purified antibody was then 
quantified by spectrophotometry and indirect immunofluorescence assay (Section 2.6.2).  
Table 2.1 Reagents for antibody purification fro culture supernatant using Protein G sepharose column. All 
ĐŽŵƉŽŶĞŶƚƐŽďƚĂŝŶĞĚĨƌŽŵ^ŝŐŵĂĂŶĚĂůůƌĞĂŐĞŶƚƐ ? ? ?ʅŵĨŝůƚĞƌ-sterilised. 
Reagent Composition 
100mM Glycine-HCl pH 2.7 0.75g of Glycine 
100ml of distilled water 
Adjust pH to 2.7 with 5M HCl 
1M Tris-HCl 0.303g of Tris base 
25ml distilled water 
Adjust pH to 9 with 5M HCl 
Na2HPO4 (Buffer A) 3.04g Na2HPO4 
100ml of distilled water 
NaH2PO4 ( Buffer B) 2.76g of NaH2PO4 
100ml of distilled water 
Buffer C Add Buffer B to Buffer A until pH=7.4 
2.1.3 Biotin and FITC labelling of mAbs 
For fluorescein isothiocyanate (FITC) labelling, 1mg antibody was dialysed into carbonate buffer (pH 
9.0) overnight at 4
o
C in either dialysis tubing or a Slide a Lyze cassette. FITC powder was dissolved at 
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1mg/ml in acetone and 20- ? ?ʅŐ ?ŵů FITC per mg of antibody was dried in a glass bijoux. Once the 
acetone had evaporated, the antibody was removed from dialysis tubing/cassette and added to the 
glass bijoux. The bijoux was then shaken for 1 hour at room temperature (RT). To biotinylate 
antibody, ~1mg of antibody was dialysed into PBS overnight at 4
o
C. Once dialysed, the antibody was 
ŵŝǆĞĚǁŝƚŚ  ? ? ?ʅů  ?ŵŐ ?ŵůE,^-LC-biotin in dH2O while vortexing. The antibody and biotin mixture 
was incubated at RT for 45min. 
After incubation of antibody with FITC or biotin, a PD10 column (GE Healthcare, Buckinghamshire, 
UK) was washed with 25ml PBS before adding the FITC-antibody or biotin-antibody solution. 20ml 
PBS was then added and 1ml fractions collected in 1.5ml eppendorf tubes. The samples were 
analysed by spectrophotometry with protein concentration being determined by reading optical 
density at 280nm, referenced against a sample of PBS or dH2O. The samples containing antibody 
were pooled and either injected into a Slide a Lyze cassette (Thermo Scientific, MA, USA) or placed 
into dialysis tubing, before placing in 500ml of sterile PBS and samples dialysed for 24 hours at 4
o
C. 
The purified antibody was then quantified by spectrophotometry and indirect immunofluorescence 
assay (Section 2.6.2).  
2.2 Cell culture 
All cell culture was carried out using aseptic technique in a class II safety cabinet.  
2.2.1 Cell lines and hybridomas 
All Human cancer cell lines were maintained in RPMI 1640 supplemented with 10% heat inactivated 
(HI) newborn calf serum (NBCS) unless otherwise stated. NS0 cells were maintained in 10% HI foetal 
calf serum (FCS)-supplemented RPMI 1640. Hybridomas were maintained in 10% HI FCS-
supplemented RPMI 1640 and 1x HAT supplement (0.136g hypoxanthine, 0.00176g aminopterin and 
0.0388g thymidine per 500ml media). Cell lines are summarised in Table 2.2. 
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Table 2.2 Summary of cell lines used.  
Cell Line Origin Type 
791T Produced in house Human ostesarcoma 
C170 Produced in house Human colon adenocarcinoma 
Colo 201 ECACC # 87091201 Human Caucasian colon adenocarcinoma from primary 
tumour 
Colo 205 ECACC # 87061208 Human Caucasian colon adenocarcinoma isolated from 
ascites of same patient as Colo 201 
DLD1 ECACC # 90102540 Human colon adenocarcinoma 
HT29 ECACC # 91072201 Human Caucasian colon adenocarcinoma from primary 
tumour 
HUVEC Produced in house Primary human umbilical vein endothelial cells isolated 
from umbilical cords, used up to passage 6 
Jurkat ECACC # 88042803 Human leukemic T cell lymphoblast 
LoVo ECACC # 87060101 Human colon adenocarcinoma 
SW480 ECACC # 87092801 Human colon adenoma 
SW620 ECACC # 87051203 Human colon adenocarcinoma, established from lymph 
nodes of same patient as SW620 
MCF-7 ECACC # 86012803 Human breast adenocarcinoma 
MCF10A ATCC # CRL-10317 Non-tumourigenic epithelial cell line from mammary gland 
MDA-MB-231 ECACC # 92020424 Human breast adenocarcinoma 
MKN-45 ATCC # CCL-171 Human gastric adenocarcinoma 
MRC-5 ECACC # 05090501 Normal human foetal lung 
NS0 ECACC #85110503 
 
Mouse (BALB/c) lymphoblastoid myeloma 
OAW28 ECACC # 85101601 Human ovarian tumour epithelial from cystadenocarcinoma 
OAW42 ECACC # 85073102 Human ovarian tumour epithelial from cystadenocarcinoma 
OVCA 433 Gift from Gift from 
Department of 
Obstetrics and 
Gynaecology, Royal 
Derby Hospital 
Human ovarian serous cystadenocarcinoma 
OVCAR-3 ATCC # HTB-161 Poorly differentiated papillary human ovarian 
adenocarcinoma 
OVCAR-4  Human ovarian adenocarcinoma 
SK-OV3 ECACC # 91091004 
 
Human ovarian adenocarcinoma 
T47D ECACC # 85102201 Human breast ductal carcinoma 
  
2.2.2 Maintenance of cell lines and hybridomas 
All stock cells were obtained from liquid nitrogen storage. The cells were submerged in a 37
o
C water 
bath to ensure complete thawing. Cells were transferred to 25ml universal tubes and 1ml of 
complete media, cell specific, was added drop-wise to the cells under agitation. A further 5ml of 
complete media was added slowly to the tubes whilst gentle agitation was supplied. The volume was 
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then increased with complete media to 25ml and the tubes were centrifuged at 150g for 5min at RT. 
The supernatant was aspirated from the cell pellets which were resuspended in complete media. All 
cells were then washed with complete media and finally resuspended in media and transferred to 
T25 tissue culture flasks (Corning). All cells were cultured at 37
o
C in 5% CO2 and were maintained by 
regular replacement of complete culture media and splitting to maintain log phase growth. If large 
cell numbers were required, cells were transferred to T175 culture flasks. Cells were cultured until 
approximately 80% confluency was reached, at which point they were split in order to maintain 
healthy cultures. Supernatant was aspirated from adherent cell lines and replaced with 10ml 1 x 
Trypsin/EDTA and incubated for 10min at 37
o
C. Non- adherent lines were transferred to 50ml tubes 
and centrifuged at 150g for 5min. Trypsinised cells were transferred to 25ml universal tubes and 
complete media was added up to 25ml total volume (serum contained in the media inactivates 
trypsin activity). Tubes were centrifuged at 100g for 5min at RT and all supernatants were aspirated 
from the pellets. Cells were resuspended in 10ml of complete media and 1ml was transferred to a 
new flask and the cells were maintained. Cells which were to be used in experimental procedures 
were counted using a haemocytometer with trypan blue, staining for viability assessment and used 
as stated. Some cells were frozen in order to maintain stocks and were resuspended at 5x10
6
 
cells/ml in 5% DMSO (dimethyl sulfoxide)/FCS (v/v) and 1ml was added per cryovial (Nalgene, USA). 
Vials were frozen by reducing the temperature by 1
o
C per minute to a temperature of -80
o
C by 
placing the vials in isopropanol containers, at which point cells were transferred to liquid nitrogen 
storage (-170
o
C).  
2.3 Immunohistochemical analysis  
2.3.1 Tissue preparation 
Immunohistochemistry (IHC) exploits the specific interaction between an antibody and its antigen to 
estimate expression of that antigen on a section of tissue. IHC can be performed on freshly frozen 
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tissue or formalin fixed paraffin embedded (FFPE) tissue which can be kept for many years. This 
study used both frozen and FFPE tissue, using an ovarian and colorectal tumour microarray (TMA), as 
well as whole sections and a FFPE normal tissue array, purchased from either Super Bio Chips (Seoul, 
Korea) or AMS Biotechnology (Abingdon, UK). All tissues require the same technique, with slight 
alterations depending on type of tissue, antigen and antibody. 
The colorectal cancer TMA produced and validated by our group needed to be reproduced before 
staining with further markers could be carried out. Therefore, a TMA was constructed as described 
previously (Kononen et al., 1998). For each tumour, 5ʅm section slides stained with haematoxylin-
eosin were first used to locate representative areas of viable tumour tissue. 0.6mm needle core-
biopsies from the corresponding areas on the paraffin-embedded tumour blocks were then placed at 
pre-specified coordinates in recipient paraffin array blocks (Fig 2.1) using a manual tissue-arrayer 
(Beecher Instruments, Sun Prairie, WI). Array blocks were constructed with between 80 W150 cores in 
each, with analysis of a single core from each case. Fresh 5ʅm sections were obtained from each 
TMA block and placed on coated glass slides to allow the immunohistochemical procedures to be 
performed, preserving maximum tissue antigenicity. 
 
Figure 2.1 Production of a TMA block. A core is taken from the donor tumour and inserted into a pre-drilled 
hole in the recipient block. Once the TMA is completed, sections of the TMA can be cut and mounted on 
microscope slides ready for staining. 
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 ?ʅŵ ƐĞĐƚŝŽŶƐ ŽĨ dD or whole sections were cut as close to the date of staining as possible to 
minimise any degradation of antigen. Slides were then mounted onto positively charges slides to 
improve tissue adherence (Superfrost Plus, Surgipath Europe, Peterborough, UK). The control tissues 
used were of the tissue used in that experiment. 
To remove the paraffin-wax from FFPE slides, the slides were heated in a dry oven at the melting 
point of wax (60
o
C) for 20min and were immediately placed in a xylene (BDH, Poole, UK) to dissolve 
the paraffin for 20min. The tissue was then rehydrated through a series of graded alcohols of 100%, 
90% and 70% ethanol. All reagent baths were in a fume hood.  
2.3.2 Antigen retrieval  
Although chemically fixing and heating tissue to 60
o
C of tissue leads to the denaturation of the 
antigenic epitopes, treating tissue using antigen retrieval solutions and heat has been shown to help 
antigens regain immunogenicity (Shi et al., 1991). In this study, antigen retrieval was heat mediated 
in citrate buffer at pH 6.0 (Table 2.1). The sixth sense setting on a Whirlpool microwave (Whirlpool, 
UK) was used to keep the solution at boiling point for 20min. 
2.3.3 Prevention of non-specific binding 
A primary antibody is designed to bind to a specific epitope in order to detect antigen presence. If 
there is no antigen, then no staining should be seen. However, antibodies can undergo non-specific 
hydrophobic interactions with tissue in the absence of their specific marker, producing non-specific 
staining. To prevent this, normal swine serum (NSS; Dako, Ely, UK) was applied to the sections and 
also used in diluting the primary antibody. NSS contains proteins which interact with and mask non-
specific hydrophobic binding sites, blocking antibody interaction with these sites. 
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2.3.4 Application of primary antibody 
The optimal working dilution for a primary antibody is defined as the dilution that gives the most 
intense staining with the least amount of background staining. The level of staining can be affected 
by many factors including; how the tissue was originally fixed, the concentration, age and method of 
storage of the antibody, the retrieval method used and length of incubation. For these reasons, 
antibody activity can vary between laboratories. Therefore, all primary antibodies used were first 
titrated on a series of whole sections prior to the full experiment. Primary antibodies used are 
displayed in table 2.3. The optimum concentrations were determined by subjective visual 
assessment using a light microscope. The negative control used had all the reagents applied apart 
from the primary antibody, confirming that all staining seen was due to the primary antibody 
reacting with its antigen.  
Table 2.6 List of primary antibodies used in IHC. 
Antigen Antibody Name 
(Clone) 
Antibody 
Type 
Company Dilution 
Sialyl di-Lewis a 505/4 Mouse IgG In house 1:300 
Lewis a 7LE Mouse IgG Abcam (Cambridge, 
UK) 
1:1000 
Sialyl Type I 
precursor 
CA19.9 Mouse IgG Abcam (Cambridge, 
UK) 
1:200 
Large fragment of 
active caspase-3 
(Asp175) 
Cleaved Caspase-
3, Asp175 (5A1E) 
Rabbit IgG Cell Signalling (MA, 
USA) 
1:00 
MHC-II Anti- HLA DP DQ 
DR (WR18) 
Mouse IgG2 AbD Serotec, 
(Oxford UK) 
1:100 
Unknown F019/1A7 Mouse IgG1 In-house 1:100 
2.3.5 Washing 
The slides were housed in a humidity chamber for the duration of the experiment. Thorough 
washing of the sections was performed using PBS (Table 2.4) to avoid drying out of the sections. 
Washing also removed excess reagent from the previous step. 
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Table 2.4 The in-house production of solutions used in IHC. All reagents obtained from Sigma. 
Solution Materials Quantity Method 
Citrate buffer 
X10 
concentration 
Citric acid H2O 21g Working 
dilution: 
Dilute 1:10, 
adjust pH to 
6.0 using 5-
10mmol HCl 
NaOH pellets 10g 
dH2O 1000ml 
PBS X10 NaCl 80g Working 
dilution: 
Adjust pH to 
7.4 and add 
additional 
dH2O to 
1000ml 
KCl 2g 
Na2HPO4 14.4g 
KH2PO4 2.4g 
dH2O 800ml 
0.5% copper 
sulphate 
solution 
CuSO4 2.5g To make 
500ml of 0.5% 
CuSO4 add 
2.5g of CuSO4 
to 500ml dH2O 
and add the 
4g NaCl 
NaCl 4.0g 
dH2O 500ml 
 
2.3.6 ABC method 
As well as recognition of an antigen by the antibody, IHC requires an amplification step to allow 
visualisation of antibody binding (Fig 2.2). dŚĞŵĞƚŚŽĚƵƐĞĚĂƐĞĐŽŶĚĂƌǇĂŶƚŝďŽĚǇ ? “ ? ?ůĂďĞůůĞĚ
with multiple molecules of biotin that recognises the primary antibody. The reagents streptavidin 
 ? “ ? ) ĂŶĚ  “ ?  ?ďŝŽƚŝŶ ĐŽŵƉůĞǆĞĚ ǁŝƚŚ ,ZW ) ǁĞƌĞŵŝǆĞĚ ĂŶĚ ĂůůŽǁĞĚ ƚŽ ĂƐƐŽĐŝĂƚĞ ĨŽƌ  ? ?ŵŝŶ ? ĨƚĞƌ
associĂƚŝŶŐƚŽĨŽƌŵ “ ? ?ƚŚĞŵŝǆƚƵƌĞǁĂƐĂĚĚĞĚƚŽƚŚĞƚŝƐƐƵĞĂůůŽǁŝŶŐƚŚĞĐŽŵƉůĞǆƚŽďŝŶĚƚŽĞĂĐŚ
biotin site on the secondary antibody, multiplying the sites available for chromogen binding. The 
ABC method was carried out using a commercial kit from Dako (StreptABC Complex/HRP, 
Mouse/Rabbit).  “ ?A?ƐƚƌĞƉƚĂǀŝĚŝŶ ŝŶ  ? ? ? ?ŵŽů ?>PBS, 15mmol NaN3 ?Ɖ,  ? ? ?ĚŝůƵƚĞĚƚŽ  ? P ? ? ? ?  “ ?A?
biotinylated horseradish peroxidase in 0.01mol/L PBS, 15mmol/ NaN3 ?Ɖ, ? ? ?ĚŝůƵƚĞĚƚŽ ? P ? ? ? ? “ ?A?
biotinylated goat anti-mouse/rabbit secondary antibody diluted to 1:100. Many tissues (including 
colorectal) exhibit endogenous avidin binding activity, which can lead to non-specific staining. 
Therefore, before the primary antibody was added, the tissue was incubated with avidin and then 
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biotin (Avidin-Biotin blocking kit; Vector Labs, CA, USA). This saturates any avidin binding sites, and 
ĂůƐŽ ƐƚŽƉƐ ĂŶǇ ďŝŽƚŝŶ ďŝŶĚŝŶŐ ďǇ ĂĚĚŝŶŐ ĞǆĐĞƐƐ ďŝŽƚŝŶ ? dŚŝƐ ƉƌĞǀĞŶƚƐ ĂŶǇ  “ ? from binding non-
specifically. 
 
Figure 2.2 ABC amplification method. The biŽƚŝŶǇůĂƚĞĚ  ?ƚƌŝĂŶŐůĞ ) ƐĞĐŽŶĚĂƌǇ ĂŶƚŝďŽĚǇ  ? “ ? ) ďŝŶĚƐ ƚŽ ƚŚĞ
ƉƌŝŵĂƌǇĂŶƚŝďŽĚǇďŽƵŶĚƚŽŝƚƐĂŶƚŝŐĞŶ ?^ƚƌĞƉƚĂǀŝĚŝŶ ? “ ? )ĂŶĚďŝŽƚŝŶ-,ZW ? “ ? )ĂƌĞƉƌĞ-incubated before adding 
to the tissue. Due to streptavidin ?s ability to bind four molecules of biotin, it can bind more than one molecule 
of biotin-HRP, amplifying the signal. 
2.3.7 Visualisation of the primary antibody 
In order to visualise the primary antibody-secondary antibody-streptavidin-biotin-HRP complex to 
determine antigen expression, the chromogen 3, 3 ?-diaminobenzidine (DAB; Dako) was used. On 
oxidation by HRP, DAB produces a brown product which can be seen on microscopy. 
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Endogenous peroxidase in tissues can non-specifically oxidise DAB. In order to prevent this, the 
endogenous peroxidase activity was blocked before antigen retrieval using 0.3% hydrogen peroxide 
in methanol.  
After application of DAB, the staining was darkened by the addition of 0.5% copper sulphate in 0.8% 
sodium chloride (Table 2.4) and haematoxylin (Vector Labs) was used to counterstain the 
background blue.  
In order to preserve the slides, they were dehydrated in a series of alcohols (70%, 90% and 100% 
ethanol) before clearing in xylene. A coverslip was then added on top of the tissue using distyrene, 
plasticiser and xylene (DPX; BDH). This was performed in a fume hood and the slides were left 
overnight to allow the DPX to dry and excess xylene to evaporate. 
2.3.8 IHC protocol 
The techniques described above are condensed into the following protocol. 
Tissue array sections were first deparaffinised with xylene, rehydrated through graded alcohol and 
immersed in methanol containing 0.3% hydrogen peroxide for 20min to block endogenous 
peroxidase activity. In order to retrieve antigenicity, sections were immersed in 500ml of pH 6.0 
citrate buffer and heated for 20min on the 6
th
 sense setting of a microwave. Endogenous 
avidin/biotin binding was blocked using an avidin/biotin blocking kit (Vector Labs). In order to block 
non-specific binding of the primary antibody, all sections were then treated with 100ʅl of 1/5 NSS in 
PBS for 15min. 
Test sections were incubated with 100ʅl of primary antibody diluted in PBS for 1 hour at 22oC or 
overnight at 4
o
C. Positive control tissue comprised whole sections of colorectal cancer tissue stained 
ǁŝƚŚɴ ?-microglobulin at 1/1000 dilution (in PBS; Dako). The primary antibody was omitted from the 
negative control, which was left incubating in NSS. 
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After washing with PBS, all sections were incubated with 100ʅl of biotinylated goat anti-
mouse/rabbit immunoglobulin (Dako) diluted 1:100 in NSS, for 30min. Sections were washed again 
in PBS and incubated with 100ʅl of pre-formed streptavidin-biotin/horseradish peroxidase (HRP) 
complex (Dako) for 60min at RT. Subsequently, visualisation of antigen expression was achieved 
using DAB. Finally, sections were lightly counterstained with haematoxylin (Dako), dehydrated in 
alcohol, cleared in xylene (Genta Medica, York, UK) and mounted with distyrene, plasticizer and 
xylene (DPX; BDH). 
2.3.10 Evaluation of staining 
In order to allow permanent storage of the slides, they were imaged at x20 using a NanoZommer 2.0 
slide imaging system (Hamamatsu, Higashi-ku, Japan). Expression of markers on the tissue was 
analysed using the images in the NanoZoomer Digital Pathology Virtual Slide Viewer (Hamamatsu). 
Screening of marker expression was performed concurrently by two investigators with previous 
experience of scoring, blinded to the clinical information. For H score, cores were briefly analysed 
and representative cores of negative, weak, moderate and strong cores were used as guides for the 
whole TMA. As well as the intensity of the staining, the percentage of positively stained tumour cells 
was estimated. The two scores were then combined to form the H score, where H= percentage cells 
stained X intensity (range=0-300). For the active caspase-3 staining, a different approach was used 
due to the lower levels of staining. Using the NanoZoomer Slide Viewer, the area of both tumour and 
stroma were measured (Fig 2.3) and number of positive cells in each area counted. A value of 
positive cells per mm
2
 was then calculated. 
2.3.11 Data processing 
Following scoring, data needed appropriate grouping to facilitate statistical analysis. This was most 
commonly achieved using a binary cut off of either negative-positive, or high-low, (either side of the 
median). In the case of active caspase-3 staining where the scores of number of positive cells per 
  
77 
 
mm
2
 ranged from 0 cells/mm
2
 to 14000 cells/mm
2
 the program X-Tile (Yale University, CT, USA) was 
used to determine low/high expression groups. 
 
Figure 2.3 CRC core from TMA. A CRC core from the TMA stained with anti-cleaved caspase-3. The area of 
tumour and tumour associated stroma are measured using the freehand area tool in NanoZoomer Slide 
Viewer. The number of positive cells can then be counted and expressed as number of positive cells per mm
2
. 
Image is taken at x8 original magnification. 
 
2.4 Immunohistochemical staining of colorectal TMA for cleaved capsase-3 
and MHC-II expression 
2.4.1 Patient study and design 
The study population comprised a series of 462 consecutive patients undergoing elective surgical 
resection of a histologically proven sporadic primary colorectal cancer at the University Hospital, 
Nottingham, UK (Table 2.5; (Duncan et al., 2007; Durrant et al., 2003; McGilvray et al., 2009; 
Simpson et al., 2010; Ullenhag et al., 2007; Watson et al., 2005; Watson et al., 2006b). These 
patients were treated between 1st January 1994 and 31st December 2000; this time period allowed 
meaningful assessment of the prognostic markers studied. All patients treated during this time-
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frame were considered eligible for inclusion in the study. Tumours were classified as mucinous 
carcinoma, when more than 50% of tumour volume consisted of mucin (Kakar et al., 2004). 
Table 2.5 Clinicopathological variables for colorectal TMA patient cohort (n = 462). 
Variable Categories Frequency of total 
cohort (%) 
Gender Male 266 (58) 
Female 199 (42) 
Age (years) Median 72 
Range 58-93 
Status Alive 169(37) 
Dead 293(63) 
Tumour Grade Well differentiated 29 (6) 
Moderately differentiated 353 (77) 
Poorly differentiated 71 (15) 
Unknown 8 (2) 
Tumour Site Colon 238 (52) 
Rectum 181 (39) 
Unknown 43 (9) 
TNM Stage 0 (Tis) 3 (1) 
1 69 (15) 
2 174 (28) 
3 155 (33) 
4 54 (12) 
Unknown 7 (2) 
Extramural 
Vascular Invasion 
Negative 224 (48) 
Positive 128 (28) 
Unknown 110 (24) 
Histological Type Adenocarcinoma 392 (85) 
Mucinous carcinoma 51 (11) 
Columnar carcinoma 4 (1) 
Signet ring carcinoma 7 (1) 
Unknown 8 (2) 
 2.4.2 Clinicopathological variables for the patient cohort (n = 462) 
Only cases where the relevant pathological material was unavailable were excluded from the study. 
Follow-up was calculated from time of resection of the original tumour with all surviving cases being 
censored for data analysis at 31st December 2003, this produced a median follow up of 37 months 
(range 0 W116) for all patients and 75 months (range 36 W116) for survivors. 
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A prospectively maintained database was used to record relevant clinicopathological data, with data 
provided from the UK Office for National Statistics; this was available in more than 99% of cases. The 
information collected was independently validated through case note review of deceased patients. 
Disease specific survival was used as the primary end point; however, data was also collected on the 
various other relevant clinical and histopathological parameters these are summarised in table 2.4. 
Adjuvant chemotherapy consisting of FOLFOX was reserved for those patients with positive lymph 
nodes, although, surgical and adjuvant treatment was at the discretion of the supervising physician. 
Prior ethical review of the study was conducted by the Nottingham Local Research and Ethics 
Committee, who granted approval for the study. 
Construction of the array blocks incorporated a wide spectrum of electively resected colorectal 
tumours and was found to be broadly representative of the colorectal cancer population in the UK. 
266 (58%) patients were male and 196 (42%) female. The median age at the time of surgery was 72 
years, consistent with a median age at diagnosis of colorectal cancer of 70 W74 years in the UK (Quinn 
MJ, 2001). 69 (15%) tumours arrayed were tumour, node metastasis (TNM) stage 1, 174 (38%) stage 
2, 155 (34%) stage 3 and 54 (11%) stage 4; there were 3 cases of in-situ disease. These figures are 
comparable with national figures for distribution of stage 1 W4 at diagnosis of 11, 35, 26 and 29% 
respectively (NICE, 2004). The majority of tumours (392, 85%) were adenocarcinomas, and were 
most frequently of a moderate histological grade (353, 77%). 128 (28%) tumours were noted to have 
histological evidence of extramural vascular invasion, 224 (48%) had no evidence of vascular 
invasion, and this information was not available in 110 (24%) cases. 
At the time of censoring for data analysis 228 (49%) patients had died from their disease, 64 (14%) 
were deceased from all other causes, and 169 (37%) were alive. The median five-year disease-
specific survival for the cohort was 58 months, comparable with the national average of 
approximately 45% five-year survival for colorectal cancer in the UK (NICE, 2004). 
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2.4.3 Monoclonal antibody binding to ovarian cancer and normal tissue TMA  
New mAbs were screened for normal and tumour binding on an ovarian cancer TMA and a normal 
tissue TMA (AA9 Human, Normal organs; Super bio Chips, Seoul, Korea).  
The ovarian cancer TMA represents a cohort of 362 patients with primary ovarian cancer treated at 
Nottingham University Hospitals between 2000 and 2007. Staging of the cancers was performed 
using the International Federation of Obstetrics and Gynaecology (FIGO) criteria. All patients 
included in this study were treated according to the current standard chemotherapy regimens with 
either single agent carboplatin in 65 patients (41.4%) or platinum-based combination chemotherapy 
in 89 patients (56.7%), with 3 patients refusing chemotherapy. Platinum-resistant cases were 
defined as patients who progressed on first-line platinum chemotherapy during treatment or who 
relapsed within 6 months after treatment. All patients underwent surgery; over 44% of cases (n=69) 
were deemed to be suboptimally debulked (tumour remaining <1 cm) after initial surgery. Patients 
were followed-up by physical examination, computed tomography, and CA-125 levels. Haematoxylin 
and eosin-stained sections from the tumours of these patients were reviewed by a gynaepathologist 
blinded to the clinical data and pathological diagnosis. For each tumour, a review of its type and 
differentiation was also carried out by SD. Clinical data associated with each case was collected and 
recorded from the patients ?notes or via the hospital ?s electronic records (NotIS). Such information 
included: patients ?age at diagnosis, FIGO stage, extent of surgical cyto-reduction, and the type, 
duration and response to chemotherapy. Details of adjuvant treatment, disease-specific survival 
(DSS) and overall survival (OS) were documented for all patients. Survival was calculated from the 
operation date until 30th of May 2008 when any remaining survivors were censored. Median follow 
up was 36 months. Ethical approval to collect the samples and relevant data for the study was 
granted by the Nottinghamshire Local Research Ethics Committee.  
The normal tissue TMA contained 59 cores representing 38 normal organs. Each core was 
categorised according to the origin of the sample; normal tissue from a non-cancer patient, normal 
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tissue from a cancer patient, but the cancer involves an unrelated organ, normal tissue adjacent to 
the cancer. The tissue type and category is detailed in Table 2.6.  
 
Table 2.6 Details of normal tissue TMA and tissue type. 
Core 
Number 
Organ Associated lesion Tissue type Tissue 
type
1
 
1 Skin Breast cancer B 
2 Skin breast cancer Breast cancer B 
3 Subcutis Fatty abdomen A 
4 Breast  Breast cancer C 
5 Breast Breast cancer C 
6 Spleen  Stomach cancer B 
7 Spleen Stomach cancer B 
8 Lymph node Stomach cancer B 
9 Lymph node Stomach cancer B 
10 Skeletal Muscle angiosarcoma B 
11 Nasal mucosa  Chronic sinusitis A 
12 Lung Metastatic cancer of lung (from 
stomach) 
B 
13 Lung  Lung cancer C 
14 Bronchus Lung cancer C 
15 Heart  No abnormal finding A 
16 Salivary gland Oropharyngeal cancer B 
17 Liver Hepatocellular carcinoma C 
18 Liver Stomach cancer B 
19 Liver Hepatocellular carcinoma C 
20 Gallbladder Rectal cancer B 
21 Pancreas Stomach cancer B 
22 Pancreas Pancreas islet cell tumour C 
23 Tonsil Chronic tonsillitis A 
24 Oesophagus Oesophageal cancer C 
25 Oesophagus Oesophageal cancer C 
26 Stomach Body stomach cancer C 
27 Stomach Body stomach cancer C 
28 Stomach Antrum stomach cancer C 
29 Stomach Smooth muscle stomach cancer C 
30 Duodenum  Ampulla of Vater cancer C 
31 Small bowel Pseudomyxoma peritonei B 
32 Small bowel Colonic diverticulosis A 
33 Appendix Metastatic cancer of ovary (from 
stomach) 
B 
34 Colon Rectal cancer C 
35 Colon Colon cancer C 
36 Rectum Rectal cancer C 
37 Kidney Cortex renal cell carcinoma C 
38 Kidney Cortex renal cell carcinoma C 
39 Kidney  Medulla renal cell carcinoma C 
40 Urinary bladder Invasive bladder carcinoma C 
41 Prostate Bladder cancer B 
                                                          
1
 Tissue type denotes the following catagories; A. Normal tissue from a non-cancer patient; B. Normal tissue 
from a cancer patient, but the cancer involves unrelated organ; C. Normal tissue adjacent to the cancer. 
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42 Prostate  Bladder cancer B 
43 Seminal vesicle  Bladder cancer B 
44 Testis Prostate cancer B 
45 Endometrium Proliferative benign ovarian neoplasm A 
46 Endometrium, Secretory ovarian cancer B 
47 Myometrium Adenomyosis A 
48 Uterine cervix Leiomyoma A 
49 Salpinx Cervix cancer B 
50 Ovary Ovary cancer C 
51 Placenta Mature placenta A 
52 Placenta Mid-trimester placenta A 
53 Umbilical cord Mature placenta A 
54 Adrenal gland Renal cell carcinoma B 
55 Thyroid Thyroid cancer C 
56 Thymus Lymphoid hyperplasia A 
57 Brain White matter no abnormal finding A 
58 Brain Gray matter no abnormal finding A 
59 Cerebellum  No abnormal finding A 
 
2.5 Screening of mAbs on The Consortium for Functional Glycomics array 
2.5.1 Screening on glycan array 
505/4, 692/29 and BR96 were FITC labelled and sent to the Consortium for Functional Glycomics 
where they were screened against between 311 and 460 glycans. Briefly, synthetic and mammalian 
glycans with amino linkers were printed onto N-hydroxysuccinimide (NHS)-activated glass 
ŵŝĐƌŽƐĐŽƉĞƐůŝĚĞƐ ?WƌŝŶƚĞĚƐůŝĚĞƐǁĞƌĞŝŶĐƵďĂƚĞĚǁŝƚŚ ?ʅŐ ?ŵůŵďĨŽƌ ?ŚŽƵƌďĞĨŽƌĞĚĞƚĞĐƚŝŶŐŵďƐ
with Alexa488-conjugated goat anti-mouse IgG. Slides were then dried before scanning. 2-25 LE 
screening data was obtained from the Consortium for Functional Glycomics database. 
2.6 In vitro functional studies of mAbs, murine serum and hybridoma 
supernatants 
In order to characterise mAbs, murine serum and hybridoma supernatant, a range of in vitro assays 
were used.  
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2.6.1 Analysis of antibody binding to cancer cells 
Indirect immunofluorescence analysed by flow cytometry 
Flow cytometry was used to study the level of binding by antibodies, or hybridoma supernatant to a 
range of cell lines. Flow cytometry was also used to assess the level of binding of mAbs to normal 
cells including fresh hepatocytes or primary HUVECs below passage 6. The cell lines described 
previously (Table 2.2) were harvested and counted by diluting cells 1:1 with trypan blue, to ascertain 
cell viability, and counting using a haemocytometer. For cell binding assays the cells were plated at 
1x10
5
 per well in a Nunc, round bottomed 96 well plate (Thermo Fisher Scientific, Waltham, MA, 
USA). The plate was then centrifuged (100g, 5min; ALC Multispeed centrifuge PK121, Jencons, UK) 
and supernaƚĂŶƚ ĨůŝĐŬĞĚ ŽƵƚ ďĞĨŽƌĞ ƚŚĞ ĂĚĚŝƚŝŽŶ ŽĨ  ? ?ʅů ŽĨ ĂŶƚŝďŽĚǇ ? ƐĞƌƵŵ Žƌ ŚǇďƌŝĚŽŵĂ
supernatant diluted in 2% NBCS/PBS. Most commonly, the mAb or hybridoma supernatant was 
ŝŶĐƵďĂƚĞĚ ŽŶ ŝĐĞ ĨŽƌ  ? ŚŽƵƌ ? ďĞĨŽƌĞ ƚŚĞ ĂĚĚŝƚŝŽŶ ŽĨ  ? ? ?ʅů W^ ƚŽ ǁĂƐŚ ? dŚĞ ƉůĂƚĞ ǁĂƐ ƚŚĞŶ
centrifuged at 100g, 5min before removing the supernatant. A labelled secondary antibody was then 
added at the relevant concentration (See table 2.7 for list of secondary mAbs and working dilutions) 
diluted in PBS. Most commonly the secondary antibody was incubated on ice for 1 hour. After 
incubation with the secondary, 200ʅůW^ǁĂƐĂĚĚĞĚ to wash, before centrifuging (100g, 5min). The 
ƐƵƉĞƌŶĂƚĂŶƚǁĂƐ ĨůŝĐŬĞĚ ĨƌŽŵ ƚŚĞ ƉůĂƚĞ ďĞĨŽƌĞ ƚŚĞ ĐĞůůƐ ǁĞƌĞ ƌĞƐƵƐƉĞŶĚĞĚ ŝŶ  ? ? ?ʅů W^ ? dŚĞ ĐĞůůƐ
ǁĞƌĞ ƚŚĞŶ ƚƌĂŶƐĨĞƌƌĞĚ ƚŽ Ă &^ ƚƵďĞ ďĞĨŽƌĞ ĂĚĚŝŶŐ ĂŶ ĞǆƚƌĂ  ? ? ?ʅů  ?A? ĨŽƌŵĂůĚĞŚǇĚĞ ? dŚĞ
fluorescence of the cells was then analysed on a flow cytometer (Beckman Coulter, FC5000 
(Beckman Coulter, CA, USA). After acquisition of the data was analysed using Windows Multiple 
Document Interface (WinMDI) 2.9 software (Joseph Trotter, Scripps Research Institute, La Jolla, CA, 
USA). 
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Table 2.7 Details of secondary antibodies.  
Antibody name Company Dilution 
Polyclonal rabbit anti-
mouse Ig-FITC 
Dako 1:100 
Polyclonal rabbit anti-
mouse IgM-FITC 
Dako 1:100 
Polyclonal rabbit-anti 
mouse IgG-HRP 
Dako 1:1000 
Polyclonal rabbit anti-
mouse Ig-HRP 
Dako 1:1000 
Polyclonal rabbit anti-
mouse IgM-HRP 
Dako 1:1000 
 
Enzyme-linked immunosorbent assay  
The analysis of the level of binding of antibodies to cell lines was also carried out using enzyme 
linked immunosorbent assay (ELISA). ELISAs allows a large number of hybridoma supernatants, 
antibody or serum dilutions to be measured in one assay more easily than by flow cytometry. 
However, it is limited to cells that adhere to the plastic tissue culture plate. 
First, cells were harvested from cell culture and counted as previously described. Cells were plated at 
1x10
5
 cells per well in a Nunc, flat-bottomed 96 well tissue culture plate (Thermo Fisher Scientific, 
MA, USA) ?ĞůůƐǁĞƌĞƚŚĞŶŝŶĐƵďĂƚĞĚŝŶ ? ? ?ʅůŐƌŽǁƚŚŵĞĚŝĂĨŽƌ2-3 days in tissue culture conditions 
(37
o
C, 5%CO2) until the cells were confluent. Once confluent the growth media was removed 
ĐĂƌĞĨƵůůǇďĞĨŽƌĞƚŚĞƉůĂƚĞǁĂƐĞŝƚŚĞƌĨŝǆĞĚǁŝƚŚ ? ? ?ʅů ?A?ĨŽƌŵĂůĚĞŚǇĚĞĨŽƌ ?ŚŽƵƌŽŶŝĐĞ ?ĨŽůůŽǁĞĚ
by washing well in PBS and blocking with 200ʅů  ?A? ďŽǀŝŶĞ ƐĞƌƵŵ ĂůďƵŵŝŶ  ?BSA; PAA, Pasching, 
Austria)/PBS for 1 hour on ice, or the cells were blocked without fixing. Subsequent to 
ĨŝǆŝŶŐ ?ďůŽĐŬŝŶŐŽƌďůŽĐŬŝŶŐ ?ƚŚĞĐĞůůƐǁĞƌĞŝŶĐƵďĂƚĞĚǁŝƚŚ ? ?ʅůŽĨŚǇďƌŝĚŽŵĂƐƵƉĞƌŶĂƚĂŶƚŽƌŵďƐĂƚ
various concentrations, diluted in 0.1% BSA/PBS. This was carried out on ice for 1 hour before 
ǁĂƐŚŝŶŐǁŝƚŚW^y ? ? ? ?ʅůƐĞĐŽŶĚĂƌǇĂŶƚŝďŽĚǇůĂďĞůůĞĚǁŝƚŚŚŽƌƐĞƌĂĚŝƐŚƉĞƌŽǆŝĚŝƐĞ ?,ZW )ǁĂƐƚŚĞŶ
added at the relevant concentration (Table 2.7) and incubated on ice for 1 hour. The plate was then 
washed X3 with PBS. The cells were then incubated with  ? ? ?ʅů of 0.2ml of 1.5mg/ml  ? ? ? ?-Azinobis [3-
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ethylbenzothiazoline-6-sulfonic acid]-diammonium salt  ?d^ )ĂŶĚ ? ?ʅů ? ?A?,2O2 solution in 10ml of 
0.1M citrate buffer. The plate was then left in the dark to allow any HRP to oxidise the ABTS, yielding 
a green end product. The plate was then read at 405nm using an absorbance microplate reader 
(Anthos htII, originally Anthos Labtec, now part of Beckman Coulter). 
Homophilic binding analysis 
A number of monoclonal antibodies have been shown to bind to antigen and also to a separate and 
distinct binding domain on VH on itself. The ability of an antibody to bind to itself is termed 
homophilic binding. To test whether a mAb displayed homophilic characteristics, mAb was titrated 
on a cell line up to a high concentration with saturation not being reached with a homophilic mAb. A 
second assay used to test a mAbs ability to bind homophilically involved the incubation of cells with 
a very high concentration of un-labelled mAb and then competing with FITC-labelled mAb. These 
assays are described below. 
Cells were harvested from culture and counted as previously described. 1x10
5
 cells were plated per 
well before centrifugation (100g, 5min, RT ) ? dŚĞ ƐƵƉĞƌŶĂƚĂŶƚ ǁĂƐ ƌĞŵŽǀĞĚ ďĞĨŽƌĞ ĂĚĚŝŶŐ  ? ?ʅů
antibody at 0.1- ? ?ʅŐ ?ŵůƉĞƌǁĞůůŽƌ ? ? ?ʅŐ ?ŵůƵŶůĂďĞůůĞĚŵďŝŶW^ ?dŚĞĂŶƚŝďŽĚǇǁĂƐŝŶĐƵďĂƚĞĚ
ǁŝƚŚƚŚĞĐĞůůƐĨŽƌ ?ŚŽƵƌŽŶŝĐĞďĞĨŽƌĞĂĚĚŝŶŐ ? ? ?ʅůW^ƚŽǁĂƐŚ ? The plate was centrifuged (100g, 
 ?ŵŝŶ ?Zd )ďĞĨŽƌĞ ƌĞŵŽǀŝŶŐ ƚŚĞ ƐƵƉĞƌŶĂƚĂŶƚ ?  ? ?ʅůŽĨĂŶƚŝ-Ig-FITC labelled antibody (titration assay; 
Dako) was added to the cells that received a titration of mAb, whereas FITC-labelled mAb at 1, 3 and 
 ? ?ʅŐ ?ŵů ǁĂƐ ĂĚĚĞĚ ƚŽ ƚŚĞ ĐĞůůƐ ƚŚĂƚ ƌĞĐĞŝǀĞĚ  ? ? ?ʅŐ ?ŵů ƵŶůĂďĞůůĞĚ ŵď  ?ĐŽŵƉĞƚŝƚŝŽŶ ĂƐƐĂǇ ) ? dŚĞ
cells were then incubated for a further 1 hour on ice. After incubation with the secondary antibody 
or FITC-ůĂďĞůůĞĚŵď ?ƚŚĞĐĞůůƐǁĞƌĞǁĂƐŚĞĚǁŝƚŚ ? ? ?ʅůW^ďĞĨŽƌĞĐĞŶƚƌŝĨƵŐĂƚŝŽŶ ? ?00g, 5min, RT) 
ĂŶĚƌĞŵŽǀĂůŽĨƐƵƉĞƌŶĂƚĂŶƚ ?dŚĞĐĞůůƐǁĞƌĞƌĞƐƵƐƉĞŶĚĞĚŝŶ ? ? ?ʅů ?A?ĨŽƌŵĂůĚĞŚǇĚĞĂŶĚƚƌĂŶƐĨĞƌƌĞĚ
ƚŽ&^ƚƵďĞƐ ? ĨƵƌƚŚĞƌ  ? ? ?ʅůW^ǁĂƐĂĚĚĞĚ ƚŽƚŚĞ ƚƵďĞƐ  ?ƚŽƚĂů  ? ? ?ʅů ?  ? ? ?A? ĨŽƌŵĂůĚĞŚǇĚĞ ?W^ )
before the cells was analysed by flow cytometry. 
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In order to determine whether the binding of one antibody resulted in the exposure of other 
antigenic sites on the cell surface, binding of mAb to fresh and formaldehyde-fixed cells was 
compared. Cells were harvested and counted as previously described. 5x10
6
 cells were incubated in 
 ? ? ?ʅů ?A?formaldehyde (fixed) while 5x106 cells were incubated in PBS (fresh). Cells were re-counted 
before plating 1x10
5
 per well before centrifugation at 100g, 5min, RT. The supernatant was removed 
before ĂĚĚŝŶŐ ? ?ʅůĂŶƚŝďŽĚǇĂt 0.1- ? ?ʅŐ ?ŵůƉĞƌǁĞůůƚŽďŽƚŚĨƌĞƐŚĂŶĚĨŝǆĞĚĐĞůůƐ ?dŚĞĂŶƚŝďŽĚǇǁĂƐ
ŝŶĐƵďĂƚĞĚ ǁŝƚŚ ƚŚĞ ĐĞůůƐ ĨŽƌ  ? ŚŽƵƌ ŽŶ ŝĐĞ ďĞĨŽƌĞ ĂĚĚŝŶŐ  ? ? ?ʅů W^ ƚŽ ǁĂƐŚ ? dŚĞ ƉůĂƚĞ ǁĂƐ
centrifuged (100g ?  ?ŵŝŶ ? Zd ) ďĞĨŽƌĞ ƌĞŵŽǀŝŶŐ ƚŚĞ ƐƵƉĞƌŶĂƚĂŶƚ ?  ? ?ʅů ŽĨ ĂŶƚŝ-IgG-FITC labelled 
antibody (Dako) was added to each well before incubating on ice for 1 hour. The cells were washed a 
ĨŝŶĂů ƚŝŵĞǁŝƚŚ  ? ? ?ʅůŽĨW^ďĞĨŽƌĞďĞŝŶŐĐĞŶƚƌŝĨƵŐĞĚĂƚ ? ? ?g, 5min, RT and the supernatant was 
ƌĞŵŽǀĞĚ ?dŚĞĐĞůůƐǁĞƌĞƌĞƐƵƐƉĞŶĚĞĚŝŶ  ? ? ?ʅů  ?A?ĨŽƌŵĂůĚĞŚǇĚĞĂnd transferred to FACS tubes. A 
ĨƵƌƚŚĞƌ ? ? ?ʅůW^ǁĂƐĂĚĚĞĚƚŽƚŚĞƚƵďĞƐďĞĨŽƌĞƚŚĞĐĞůůƐǁĂƐĂŶĂůǇƐĞĚďǇĨůŽǁĐǇƚŽŵĞƚƌǇ ? 
2.6.3 Analysis of binding to cancer cell glycolipid extraction 
In order to test whether a mAb, serum or hybridoma supernatant binds to glycolipid, glycolipid was 
extracted from cancer cells before screening by ELISA. 
Glycolipid extraction 
In order to extract glycolipid from cancer cells, 10
8
 cells were required. Therefore, colorectal and 
ovarian cancer cell lines were grown in large quantities, harvested and stored at -80
o
C until needed. 
Cells were harvested either with (adherent) or without (non-adherent) trypsin-EDTA. The cells were 
washed three times in PBS to remove trypsin and growth media. The cells were centrifuged 
resuspended in 1ml PBS and transferred to a 1.5ml eppendorf, before centrifuging at 850g, 2min in a 
bench-top microfuge. The supernatant was removed and eppendorf tubes stored at -80
o
C. For 
glycolipid extraction 5-10x10
8
 cells were thawed at RT before the addition of 3ml 100% methanol. 
After pooling cells from eppendorf tubes in 3ml methanol in a 15ml tube (Falcon) an additional 6ml 
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100% chloroform was added (final ration 2:1 chloroform: methanol). The tube was then rock and 
rolled overnight at 4
o
C. The resulting emulsion was split into 9 eppendorf tubes (1ml each) before 
centrifugation at 850g, 30min. The result of this centrifugation was two aqueous phases separated 
by a solid phase ƚǁŽůŝƋƵŝĚƐůĂǇĞƌƐĂ ‘ůŝƉŝĚ ?ůĂǇĞƌ ?ůĂǇĞƌ ? )ĂŶĚĂŶĂƋƵĞŽƵƐůĂǇĞƌ ?ůĂǇĞƌ ? )ƐĞƉĂƌĂƚĞĚby 
ĂƐŽůŝĚ ‘ĚĞŶĂƚƵƌĞĚƉƌŽƚĞŝŶ ?ůĂǇĞƌ ?ůĂǇĞƌ ? ?&ŝŐ ? ? ? ?dhe aqueous phases were separated.  
 
Figure 2.4 Result of 2:1 chloroform: methanol glycolipid extraction of cancer cell lines. Centrifugation of the 
ĞŵƵůƐŝŽŶƌĞƐƵůƚƐŝŶƚǁŽůŝƋƵŝĚƐůĂǇĞƌƐĂ ‘ůŝƉŝĚ ?layer (layer 2) and an aqueous layer (layer 3) separated by a solid 
 ‘ĚĞŶĂƚƵƌĞĚƉƌŽƚĞŝŶ ?ůĂǇĞƌ ?ůĂǇĞƌ ? ) ? 
 
Analysis of mAb, serum and hybridoma supernatant binding to glycolipid  
In order to characterise the binding of antibodies to glycolipid, the layers resulting from extraction 
were prepared. Layer 1, made up of denatured proteins was dissolved in DMSO; Layer 2 was dried 
down under N2 gas before resuspending in PBS. After preparation of the layers, they were diluted 
between 1:10 to 1:3000 before adding to a 96 well polystyrene plate. The extracted layers were 
dried to the plate overnight at 40
o
C. Before addition of mAb, serum or hybridoma supernatant, the 
plate was blocked with 2 ? ?ʅů  ?A? ^ ?W^ ĨŽƌ  ? ŚŽƵƌ ŽŶ ŝĐĞ ? dŚĞ ^ ǁĂƐ ƌĞŵŽǀĞĚ ďĞĨŽƌĞ  ? ?ʅů
antibody sample was added to the plate. The plate was then incubated for 1 hour on ice, before 
ǁĂƐŚŝŶŐ ƚŚƌĞĞ ƚŝŵĞƐ ŝŶ W^ ? ǆĐĞƐƐ W^ ǁĂƐ ƌĞŵŽǀĞĚ ďǇ ĚĂďďŝŶŐ ŐĞŶƚůǇ ŽŶ ƚŝƐƐƵĞ ƉĂƉĞƌ ?  ? ?ʅů
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secondary antibody (rabbit anti-mouse IgM/anti-mouse IgG/anti-mouse Ig-HRP) was added and 
incubated for a further hoƵƌŽŶŝĐĞ ? ? ? ?ʅůd^ƐŽůƵƚŝŽŶwas added to each well and developed in 
the dark. The optical density of the plate was determined on an absorbance plate reader at 405nm.  
Binding of 692/29 to Lewis y and Lewis b glycans 
The ability of 692/29 to bind to Lewis y and Lewis b glycans (IsoSep, Sweden) was tested by ELISA. 
 ? ? ?ʅů ? ?ʅŐ ?ŵů>ĞǁŝƐǇ-human serum albumin (HSA) or Lewis b-HSA diluted in 1% BSA/PBS per well 
was incubated in a 96 well flat-bottomed ELISA plate overnight at 4
o
C. Supernatant was removed 
ďĞĨŽƌĞďůŽĐŬŝŶŐƚŚĞƉůĂƚĞǁŝƚŚ ? ? ?ʅů ?A?^ ?W^ ?dŚĞ^ǁĂƐƌĞŵŽǀĞĚďĞĨŽƌĞĂĚĚŝŶŐ ? ?ʅů ? ? ?Žƌ
 ? ?ʅŐ ?ŵů ? ? ? ? ? ?Žƌ ? ?ʅŐ ?ŵů ? ? ? ? ?ĂƐĂŶĞŐĂƚŝǀĞĐŽŶƚƌŽl. The plate was incubated on ice for 1 hour 
ďĞĨŽƌĞǁĂƐŚŝŶŐ ?ƚŝŵĞƐŝŶĂW^ďĂƚŚ ? ? ?ʅů ? P ? ? ? ?ĂŶƚŝ-IgG-HRP (Dako) was added per well and the 
plate was incubated on ice for a further 1 hour. The plate was then washed 4 times in a PBS bath 
before antibody bŝŶĚŝŶŐǁĂƐĂƐƐĞƐƐĞĚƵƐŝŶŐ ? ? ?ʅůd^ƐŽůƵƚŝŽŶ ?ĂƐĂďŽǀĞ )ƉĞƌǁĞůů ?dŚĞƉůĂƚĞǁĂƐ
then allowed to develop in the dark before the optical density of the plate was determined on an 
absorbance plate reader at 405nm.  
Sodium periodate treatment of cells and mAb binding 
Sodium periodate can be used to oxidise carbohydrates on the surface of cells without disturbing 
protein or lipids. It can therefore be used to determine whether an antibody binds to a carbohydrate 
determinant on cells, through a lack of binding in a whole cell ELISA format as follows.  
Cells were harvested and plated as the whole cell ELISA described previously. On the day of the 
ĞǆƉĞƌŝŵĞŶƚ ? ? ? ?ʅů ?A?ŐůƵƚĞƌĂůĚĞŚǇĚĞ ?W^ǁĂƐĂĚĚĞĚƚŽĞĂĐŚ ǁĞůůĂŶĚƚŚĞƉůĂƚĞŝŶĐƵďĂƚĞĚŽŶŝĐĞĨŽƌ
1 hour. The plate was ƚŚĞŶ ǁĂƐŚĞĚ ƚŚƌĞĞ ƚŝŵĞƐ ŝŶ W^ ďĞĨŽƌĞ ƚŚĞ ĂĚĚŝƚŝŽŶ ŽĨ  ? ? ?ʅů  ? ?  ? ? ? ĂŶĚ
1.25mmol/L sodium periodate (in sodium acetate buffer pH 4.5). The plate was then incubated for 2 
hours at 37
o
C. The plate was then washed three times with PBS before blocking with 200ʅů  ?A?
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^ ?W^ĨŽƌ ?ŚŽƵƌŽŶŝĐĞ ? ? ?ʅůŽĨĂŶƚŝďŽĚǇǁĂƐƚŚĞŶĂĚĚĞ ƚŽƚŚĞƐŽĚŝƵŵƉĞƌŝŽĚĂƚĞ-treated cells 
and the rest of the ELISA carried as previously described.  
2.6.4 Analysis of antibody mediated direct cell death 
The ability of an antibody to cause direct cell death of its target cell may be a useful characteristic for 
therapy. A range of assays were used to investigate whether mAbs could induce direct cell death of 
cancer cells and the mechanism of killing observed.  
Antibody-mediated propidium iodide uptake  
In order to quantify the percentage of dead cells after antibody treatment, propidium iodide (PI) was 
used. PI is a 668Da fluorescent molecule that can be taken up by dying and dead cells, but not live 
cells. Once in the cell, PI intercalates between DNA bases. The fluorescence of cells can then be 
measured to ascertain a proportion of dead cells. Cells were harvested and counted as described 
previously. The cells were then plated at 5x10
4
 cells per well in a Nunc round-bottomed tissue 96 
well plate. The plate was then centrifuged (100g ?  ?ŵŝŶ ) ĂŶĚ ƐƵƉĞƌŶĂƚĂŶƚ ƌĞŵŽǀĞĚ ?  ? ?ʅů ŵď Žƌ
hybridoma supernatant in 2.5% NBCS was then added to the cells for a range of incubation periods, 
from 10min to overnight at either 4
o
C, RT (22
o
C) or 37
o
C. For the last  ? ?ŵŝŶŽĨƚŚĞŝŶĐƵďĂƚŝŽŶ ? ? ?ʅů
ŽĨ ? P ? ?W/ ? ?ŵŐ ?ŵů )ŝŶW^ǁĂƐĂĚĚĞĚ ?ĨƚĞƌƚŚĞ ? ?ŵŝŶŝŶĐƵďĂƚŝŽŶ ? ? ? ?ʅůǁĂƐĂĚĚĞĚƚŽƚŚĞĐĞůůƐĂŶĚ
ƚŚĞǇ ǁĞƌĞ ƚƌĂŶƐĨĞƌƌĞĚ ƚŽ &^ ƚƵďĞƐ ? Ŷ ĂĚĚŝƚŝŽŶĂů  ? ? ?ʅů W^ ǁĂƐ ĂĚĚĞĚ ƚŽ ƚŚĞ ƚƵďĞƐ ďĞĨŽƌĞ
analysing fluorescence by flow cytometry. 
In order to determine whether PI uptake observed was the result of cell death, cell viability and 
number was measured over 5 days of antibody treatment. Cells were harvested and counted as 
described previously. 1x10
5
 cells were plated in a 24 well flat-bottomed plate (Nunc) and incubated 
ǁŝƚŚ ? ? ?ʅů ? ?ʅŐ ?ŵůŵďŝŶ ? ?A?E^ƐƵƉƉůĞŵĞŶƚĞĚŵĞĚŝĂ ?ĞůůƐǁĞƌĞŝŶĐƵďĂƚĞĚĨŽƌ ? ? ? ? ?Žƌ ? ? ?
hours at 37
o
C, 5%CO2. After each incubation the supernatants were removed and cells were 
ƚƌǇƉƐŝŶŝƐĞĚǁŝƚŚ  ? ? ?ʅůƚƌǇƉƐŝŶ ?dA. Cells were transferred to 1.5ml eppendorf tubes and washed 
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with 1ml media before centrifuging at 3200g, 1.5min, RT in a microfuge. Cells were resuspended in 
 ?ŵůŵĞĚŝĂĨŽƌĐĞůůĐŽƵŶƚĂŶĚǀŝĂďŝůŝƚǇĐŚĞĐŬ ? ? ?ʅůĐĞůůƐǁĞƌĞĂĚĚĞĚƚŽ ? ?ʅůƚƌǇƉĂŶďůƵĞĂŶĚĐŽƵŶted 
using a haemocytometer.  
In order to establish whether the live cells remaining after antibody treatment were resistant to 
mAb-mediated cell death, the cells were harvested after 5 days and were subjected to further mAb 
treatment and compared to untreated cells. The cells were harvested and cell number and viability 
checked, as above. 5x10
4
 mAb treated or fresh, untreated cells were plated in a 96 round bottomed 
plate (Nunc) before centrifuging (100g ? ?ŵŝŶ ?Zd )ĂŶĚƌĞŵŽǀĂůŽĨƐƵƉĞƌŶĂƚĂŶƚ ? ? ?ʅůŽĨ ? ?Žƌ ? ?ʅŐ ?ŵů
mAb in 2.5% NBCS was then added and the cells were incubated at 37
o
C, 5%CO2 overnight. For the 
ůĂƐƚ ? ?ŵŝŶŽĨƚŚĞŝŶĐƵďĂƚŝŽŶ ? ? ?ʅůŽĨ ? P ? ?W/ ? ?ŵŐ ?ŵů )ŝŶW^ǁĂƐĂĚĚĞĚ ?ĨƚĞƌƚŚĞ ? ?ŵŝŶŝŶĐƵďĂƚŝŽŶ ?
 ? ? ?ʅůǁĂƐĂĚĚĞĚƚŽƚŚĞĐĞůůƐĂŶĚƚŚĞǇǁĞƌĞƚƌĂŶƐĨĞƌƌĞĚƚŽ&^ƚƵďĞƐ ?ŶĂĚĚŝƚŝŽŶĂů ? ? ?ʅůW^ǁĂƐ
added to the tubes before analysing fluorescence by flow cytometry. 
To check whether live cells after 5 days of mAb treatment expressed the same level of antigen as 
mAb-untreated cells, 1x10
5
 mAb treated or fresh, untreated cells were plated in a 96 round 
bottomed plate (Nunc) before centrifuging (100g ? ?ŵŝŶ ?Zd )ĂŶĚƌĞŵŽǀĂůŽĨƐƵƉĞƌŶĂƚĂŶƚ ? ? ?ʅůŽĨ ? ? ? ?
 ? ? ?Žƌ  ?ʅŐ ?ŵůŵď ŝŶW^ǁĂƐ ƚŚĞŶĂĚĚĞĚĂŶĚ ƚŚĞĐĞůůƐǁĞƌĞ ŝŶĐƵďĂƚĞĚŽŶ ŝĐĞ ĨŽƌ  ?ŚŽƵƌbefore 
ĂĚĚŝŶŐ  ? ? ?ʅů W^ to wash. The plate was centrifuged (100g, 5min, RT) before removing the 
ƐƵƉĞƌŶĂƚĂŶƚ ?  ? ?ʅů ŽĨ ĂŶƚŝ-IgG-FITC labelled antibody (Dako) was added to each well before 
ŝŶĐƵďĂƚŝŶŐ ŽŶ ŝĐĞ ĨŽƌ  ? ŚŽƵƌ ? dŚĞ ĐĞůůƐ ǁĞƌĞ ǁĂƐŚĞĚ Ă ĨŝŶĂů ƚŝŵĞ ǁŝƚŚ  ? ? ?ʅů ŽĨ W^ ďĞĨŽƌĞ ďĞŝng 
centrifuged at 100g, 5min, RT and the supernatant was removed. The cells were resuspended in 
 ? ? ?ʅů ?A?ĨŽƌŵĂůĚĞŚǇĚĞĂŶĚƚƌĂŶƐĨĞƌƌĞĚƚŽ&^ƚƵďĞƐ ?ĨƵƌƚŚĞƌ ? ? ?ʅůW^ǁĂƐĂĚĚĞĚƚŽƚŚĞƚƵďĞƐ
 ?ƚŽƚĂů ? ? ?ʅů ? ? ? ?A?ĨŽƌŵĂůĚĞŚǇĚĞ ?W^ )ďĞĨŽƌĞƚŚĞĐĞůůƐǁĂƐĂŶĂůǇƐed by flow cytometry. 
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Detection of mAb-mediated cell death in the presence of cross-linking antibody 
To determine whether mAbs unable to induce direct cell death can with the aid of cross-linking 
mAbs, rabbit anti-mouse Ig and goat anti-rabbit Ig immunoglobulins were used. Cells were harvested 
and counted as described previously. The cells were then plated at 5x10
4
 cells per well in a Nunc 
round-bottomed tissue 96 well plate. The plate was then centrifuged (100g, 5min) and supernatant 
ƌĞŵŽǀĞĚ ? ? ?ʅů ? ?Žƌ ? ?ʅŐ ?ŵůŵďǁŝƚŚŽƌǁŝƚŚŽƵƚ ? P ? ?ƌĂďďŝƚĂŶƚŝ-mouse Ig and goat anti-rabbit Ig 
immunoglobulins or hybridoma supernatant in 2.5% NBCS was added to the cells. The plate was 
then incubated overnight at 37
o
C, 5% CO2 ? &Žƌ ƚŚĞ ůĂƐƚ  ? ?ŵŝŶ ŽĨ ƚŚĞ ŝŶĐƵďĂƚŝŽŶ ?  ? ?ʅů ŽĨ  ? P ? ? W/
 ? ?ŵŐ ?ŵů )ŝŶW^ǁĂƐĂĚĚĞĚ ?ĨƚĞƌƚŚĞ ? ?ŵŝŶŝŶĐƵďĂƚŝŽŶ ? ? ? ?ʅůǁĂƐĂĚĚĞĚƚŽƚŚĞĐĞůůƐĂŶĚƚŚĞǇwere 
ƚƌĂŶƐĨĞƌƌĞĚ ƚŽ &^ ƚƵďĞƐ ? Ŷ ĂĚĚŝƚŝŽŶĂů  ? ? ?ʅů W^ ǁĂƐ ĂĚĚĞ ƚŽ ƚŚĞ ƚƵďĞƐ ďĞĨŽƌĞ ĂŶĂůǇƐŝŶŐ
fluorescence by flow cytometry. 
Inhibition of cell death with pan-caspase inhibitor 
Apoptosis is mediated by a family of proteases named caspases. Their activation results in the death 
of a cell. In order to establish whether antibody-mediated uptake of PI is either dependent or 
independent of caspases (i.e. via apoptosis or an alternative pathway) a pan caspase-inhibitor was 
used. Cells were harvested and 5x10
4
 cells were added to each well. As ǁĞůůĂƐĂŶƚŝďŽĚǇ ? ? ?ʅDŽĨ-
VAD-FMK (carbobenzoxy-valyl-alanyl-aspartyl-[O-methyl]-fluoromethylketone; Promega, WI, USA) 
was added to the cells. Z-VAD-FMK is a pan caspase inhibitor that irreversibly binds to the catalytic 
site of caspase proteases, inhibiting apoptosis. The cells, antibody and inhibitor were incubated 
overnight at 37
o
C, 5% CO2 ?  ? ? ?ʅŐ W/ ǁĂƐ ƚŚĞŶ ĂĚĚĞĚ ƚŽ ƚŚĞ ĐĞůůƐ  ? ?ŵŝŶ ƉƌŝŽƌ ƚŽ ƚŚĞĞŶĚ ŽĨ ƚŚĞ
incubation. The plate was then centrifuged and supernatant removed. The plate was then incubated 
overnight at 37
o
C, 5% CO2 ?&ŽƌƚŚĞůĂƐƚ ? ?ŵŝŶŽĨƚŚĞŝŶĐƵďĂƚŝŽŶ ? ? ?ʅůŽĨ ? P ? ?W/ ? ?ŵŐ ?ŵů )ŝŶW^ǁĂƐ
ĂĚĚĞĚ ?ĨƚĞƌƚŚĞ ? ?ŵŝŶŝŶĐƵďĂƚŝŽŶ ? ? ? ?ʅůǁĂƐĂĚĚĞĚƚŽƚŚĞĐĞůůƐ ĂŶĚƚŚĞǇǁĞƌĞƚƌĂŶƐĨĞƌƌĞĚƚŽ&^
tubes. An additional 20 ?ʅů W^ ǁĂƐ ĂĚĚĞĚ ƚŽ ƚŚĞ ƚƵďĞƐ ďĞĨŽƌĞ ĂŶĂůǇƐŝŶŐ ĨůƵŽƌĞƐĐĞŶĐĞ ďǇ ĨůŽǁ
cytometry. 
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Analysis of mAb-mediated pore formation on the cell surface  
As well as apoptosis, mAbs can also induce cell death of target cells directly in an apoptosis-
independent manner. One mechanism by which this can occur is oncosis. Oncosis is a caspase-
independent mechanism of cell death characterised by the swelling of a cell and the formation of 
large pores on the cell surface. One way by which oncosis can be assessed is through the uptake of 
larger-sized FITC-labelled dextran beads.  
Therefore, cells were harvested and plated at 1x10
5 ĐĞůůƐ ?ǁĞůůďĞĨŽƌĞĂĚĚŝŶŐ ? ?ʅů ? ?Žƌ ? ?ʅŐ ?ŵůŵď
(for anti-&ĂƐƚƌĞĂƚŵĞŶƚŽĨ:ƵƌŬĂƚĐĞůůƐ ? ? ?ʅů ? ? ?Žƌ ? ? ?ŶŐ ?ŵůĂŶƚŝďŽĚǇǁĂƐƵƐĞĚ ) ?/ŶĂĚĚŝƚŝŽŶƚŽƚŚĞ
antibody, 0.1mg of 3000, 40,000 or 500,000Da dextran-FITC beads were added (Invitrogen). The 
plate was incubated overnight at 37
o
C, 5% CO2 ? ? ?ŵŝŶƉƌŝŽƌƚŽƚŚĞĞŶĚŽĨƚŚĞ ŝŶĐƵďĂƚŝŽŶ ? ? ? ?ʅŐW/
ǁĂƐĂĚĚĞĚƚŽƚŚĞĐĞůůƐ ? ? ? ?ʅůW^ǁĂƐĂĚĚĞĚƚŽĞĂĐŚǁĞůů ?ƚŚĞ ƉůĂƚe centrifuged (100g, 5min RT) and 
ƐƵƉĞƌŶĂƚĂŶƚƌĞŵŽǀĞĚƚǁŝĐĞ ?dŚĞĐĞůůƐǁĞƌĞƌĞƐƵƐƉĞŶĚĞĚŝŶ ? ? ?ʅůW^ĂŶĚƚƌĂŶƐĨĞƌƌĞĚƚŽ&^ƚƵďĞƐ ?
ŶĂĚĚŝƚŝŽŶĂů ? ? ?ʅůW^ǁĂƐĂĚĚĞĚƚŽĞĂĐŚƚƵďĞďĞĨŽƌĞĂŶĂůǇƐŝƐƚŚĞĐĞůůƐďǇĨůŽǁĐǇƚŽŵĞƚƌǇ ? 
2.6.5 Antibody dependent cellular cytotoxicity and complement dependent cytotoxicity 
assays 
In order to establish whether mAbs or hybridoma supernatant could induce ADCC and CDC, 
chromium-51 (Cr
51
) release assays were carried out. 
Target cells were harvested and 2x10
6
 ĐĞůůƐŝŶĐƵďĂƚĞĚǁŝƚŚ ? ?ʅůCr51 in 1ml 10% NBCS-supplemented 
RPMI for 1 hour at 37
o
C. For the ADCC assay, peripheral blood mononuclear cells (PBMC) were 
isolated from a human blood sample taken on the day of the experiment. Whole blood was diluted 
1:2 in RPMI before layering on histopaque-1077 in a 50ml centrifuge tube. The blood was then 
centrifuged at 425g, 20min, with the brake not on. PBMCs were isolated from the 50ml tube and 
washed twice in 20ml RPMI. For the CDC assay, serum was isolated from whole blood by allowing 
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the blood to clot at RT for 1-2 hour. The tube was then centrifuged at 425g, 10min. Serum was 
pipetted off leaving behind the clot. Care was taken not to lyse red blood cells in the clot. 
After the 1 hour incubation with Cr
51
, the target cells were washed twice with 20ml RPMI, counted 
and plated at 5 x 10
3
 ĐĞůůƐŝŶ ? ?ʅůƉĞƌǁĞůů ?dŽƚŚĞƚĂƌŐĞƚĐĞůůƐ ? ?ǆ ? ?5 PBMCs or isolated serum were 
ĂĚĚĞĚŝŶ ? ? ?ʅůĂůŽŶŐǁŝƚŚ ? ?ʅůy ?ĐŽŶĐĞŶƚƌĂƚĞĚŵď ?ŚǇďƌŝĚŽŵĂƐƵƉĞƌŶĂƚĂŶƚ ?ŐŝǀŝŶŐĂƚŽƚĂůǀŽůƵŵĞ
of targeƚĐĞůůƐ ?ĞĨĨĞĐƚŽƌƐ ?ĂŶƚŝďŽĚǇŽĨ  ? ? ?ʅůƉĞƌǁĞůů ?dŚĞƉůĂƚĞǁĂƐ ƚŚĞŶŝŶĐƵďĂƚĞĚĂƚ  ? ?oC, 5% CO2 
for 4 hours. For maximum and spontaneous Cr
51
 release, Triton X100 detergent (12%) or irrelevant Ig 
(respectively) was added to control wells. After the 4 hour incubĂƚŝŽŶ  ? ?ʅůƐƵƉĞƌŶĂƚĂŶƚǁĂƐƚĂŬĞŶ
and transferred to 96 well lumaplate (Packard Bioscience, Groningen, Netherlands) containing solid 
scintillant and the plate was left air-dry overnight at RT. The plate was then analysed on a Topcount 
scintillation counter (Canberra Packard, Pangbourne, UK). The relative percentage cell lysis was 
calculated as a percentage of maximum lysis (Triton X100  W spontaneous).  
2.7 Immunisations 
2.7.1 Preparation of whole cancer cells  
Cancer cells were harvested from culture on the day of immunisation as previously described. Cells 
were washed twice in sterile PBS before resuspending in PBS at 5 x 10
7
 cells per ml. Cells were stored 
at 4
o
C until used. 
2.7.2 Preparation of glycolipid 
Glycolipid was extracted from whole cancer cells as described previously (Section 2.5.2). The 
eppendorf used to dry down Layer 2 under N2 gas was weighed before and after drying. The 
glycolipid was then resuspended in PBS at 10mg/ml. Glycolipid was then stored in the fridge until 
used.  
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2.7.3 Preparation of liposomes 
Cholesterol, dicetylphosphate (DCP) and phosphocholine (PC) were suspended in 2:1 chloroform: 
methanol at 1mg/ml. Cancer cell line glycolipid extract was dried down in a pre-weighed round-
bottomed flask using a rotary evaporator at 60
o
C. The resulting lipid film was resuspended at 
1mg/ml in 2:1 chloroform: methanol. The 1mg/ml solutions were mixed in a round bottomed flask at 
various ratios (Table 2.8) to a total volume of 10ml and 10 mgs of lipids. The mixture was then dried 
down using a rotary evaporator at 60
o
C until all chloroform and methanol had evaporated, leaving a 
uniform lipid film on the inside of the flask. 1ml dH2O was then added to the film and vigorously 
shaken until all lipids were resuspended in the 1ml dH2O. All work with chloroform and methanol 
was carried out in a fume hood. 
Table 2.8 Liposome constituents. dƵŵŽƵƌ ŐůǇĐŽůŝƉŝĚ ĚĞŶŽƚĞĚ ďǇ d'> ĂŶĚ ɲ-galactosylceramide depicted by 
ɲ'ĂůĞƌ ? 
Liposome Cholesterol 
(mg) 
DCP 
(mg) 
PC 
(mg) 
TGL extract (mg) ɲGalCer 
(mg) 
Total 
(mg) 
90% TGL 0.00 0.00 0.40 9.60 0.00 10.00 
90% TGL + 
ɲ'ĂůĞƌ 
0.00 0.00 0.00 9.57 0.43 10.00 
10% TGL 3.25 0.46 4.61 1.68 0.00 10.00 
10% TGL + 
ɲ'ĂůĞƌ 
3.23 0.46 3.91 1.68 0.72 10.00 
2.5% TGL 3.34 0.47 5.76 0.43 0.00 10.00 
2.5% TGL + 
ɲ'ĂůĞƌ 
3.32 0.47 5.04 0.43 0.74 10.00 
2.7.4 Adjuvants 
ůŽŶŐ ǁŝƚŚ ŐůǇĐŽůŝƉŝĚ ? ŵŝĐĞ ƌĞĐĞŝǀĞĚ ĞŝƚŚĞƌ ĐŽŵƉůĞƚĞ Žƌ ŝŶĐŽŵƉůĞƚĞ &ƌĞƵŶĚ ?Ɛ ĂĚũƵǀĂŶƚ
subcutaneously and intraperitionealy respectively at a ratio of 1:1 with cancer cell glycolipid-extract. 
 ? ?ʅŐWŽůǇ ?/ P ) ?/ŶǀŝǀŽŐĞŶ ? ?h^A) was immunised with each whole cell immunisation in the same 
site as the cells. CD4 cell depletion prior to whole cell immunisation was achieved by immunising 
 ? ? ?ʅůd/-207 (at 1mg/ml; anti-CD4 antibody produced in-house from TIB-207 hybridoma (American 
Type Culture Collection) intraperitionealy on day 0, 7 and 14 as well as with the whole cell 
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immunisation. ɲ-ŐĂůĂĐƚŽƐǇůĐĞƌĂŵŝĚĞ ?ɲGalCer; Alexis Biochemicals, Nottingham, UK) was used as an 
adjuvant for liposome immunisation and was incorporated into the liposomes at a concentration 
relating to 10ʅŐƉĞƌ ? ? ?ʅůŝŵŵƵŶŝƐĂƚŝŽŶ ? 
2.7.5 Immunisation protocol 
BALB/c mice were used aged between 6 and 8 weeks (Charles River, UK) and cared for by the staff at 
the Biomedical Services Unit at the University of Nottingham. Prior to any immunisation protocol, 
sera were collected via a tail bleed extraction. The blood was centrifuged at 8500g, 5min to remove 
the blood cells and the serum was stored at -20
o
C to be used a negative control in screening assays. 
Immunisations were carried out at two weekly intervals in a maximum volume of 200ʅů (sample 
diluted in PBS) using a 1ml insulin syringe (BD Bioscience, Spain). In the cases where an adjuvant was 
used, the immunogen and adjuvant were combined in 1:1 ratio and administered intravenously, 
subcutaneously or intraperitionealy. Seven days post-immunisation, serum was collected via tail 
bleed extraction as previously described.  
2.7.6 Analysis of antibody response to immunisations 
Antibody responses to immunisations were assessed using the whole cell ELISA technique described 
previously (Section 2.5.1) where the sera from mice were serially diluted at concentrations ranging 
from 1:100, to 1:100,000. After the addition of HRP-conjugated secondary antibody and ABTS 
solution, the level of antibody response was compared to the pre-bleed serum control. 
2.7.7 Isolation of splenocytes 
Mice were sacrificed as per schedule 1 protocol (cervical dislocation) and sprayed with 70% ethanol 
to sterilise the working area. Using several sets of sterile dissecting instruments, the spleens were 
removed from the mice. Excess fat and connective tissue was removed and the spleen was 
transferred to a sterile 100mm Petri dish. 5ml of serum free RPMI 1640 was added to the dish and 
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the spleen was washed with the media using a syringe and 25-guage needle. The media was passed 
through the spleen several times and finally the spleen was homogenised with sterile forceps. The 
homogenate was passed through sterile gauze into a universal 25ml tube, total volume was 
increased to 25ml with serum free RPMI, and the tube centrifuged at 100g for 10min. The media was 
aspirated off, leaving approximately 1ml remaining in the cone of the tube. The cells were 
resuspended in 5ml serum free media and counted using trypan blue.  
2.7.8 Collection of large quantities of sera from immunised mice 
Cardiac blood was collected using insulin syringes (Microfine 11-100 insulin 12.7mm syringe, 1ml 
capacity; Becton Dickinson, France) at the time of splenocyte collection. 
2.7.9 Fusion of Mice splenocytes with NS0 myeloma cells 
Mice producing the highest sera titres are chosen to generate antibody-producing hybridomas. NS0 
cells were harvested, resuspended in serum free RPMI and counted for fusion with splenocytes. Cells 
were combined in a ratio of 1: 5 (NS0: splenocytes) e.g. (2x10
7
: 1x10
8
) in a universal 25ml tube and 
centrifuged for 5min at 150g. The supernatant was aspirated and the combined cell pellet was 
ƌĞƐƵƐƉĞŶĚĞĚ ŝŶ  ? ? ?ʅů ƉŽůǇĞƚŚǇůĞŶe glycol (PEG) gradually over 1min. The PEG breaks the lipid 
membranes and allows fusion of the cell populations. The cells were agitated for 1min prior to the 
addition of 1ml of serum free RPMI 1640 which was added over 1min while continuing to agitate. A 
further 5ml of serum free media was added to the cell suspension over a min while continuing to 
agitate and finally the volume was slowly increased to 25ml with serum free media. The suspension 
was centrifuged for 5min at 150g and the supernatant was removed. The cells were resuspended in 
15ml hybridoma media (RPMI 1640, 10% FCS plus HAT supplement). The cell suspension was spread 
evenly across a 96 well plate and the cells were incubated at 37
o
C for approximately 8 days, by 
which time successful hybridomas had grown. Cells were re-fed approximately every two days with 
fresh hybridoma media. Following 8 days supernatants were collected and analysed for the presence 
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of antibodies, using the whole cell ELISA and flow cytometry protocols described previously (Section 
2.5.1). Positive wells were harvested, washed in complete media and spread across 96 well plates at 
0.3 cells per well to acquire a clone. The plate was then screened for positive wells by whole cell 
ELISA. Positive wells were grown until a sufficient number of cells was obtained to spread across a 96 
well plate at 0.3 cells per well for a second time. If the resulting number of colonies equalled ~30 and 
all hybridomas were positive, the hybridoma was considered a clone. 
2.8 Statistical analysis of data 
2.8.1 Immunohistochemical analysis 
Statistical analysis of the study data was performed using the SPSS package (version 16 for Windows, 
SPSS Inc., IL, USA). Pearson ʖ2 chi-square tests were used to determine the significance of 
associations between categorical variables. Disease-specific survival calculations included all patients 
whose death related to colorectal cancer. In contrast, patients whose deaths resulted from non-
colorectal cancer related causes were censored at the time of death. Kaplan-Meier curves were used 
to assess factors which influenced survival. The statistical significance of differences in disease-
specific survival between groups with differing caspase expression was estimated using the log-rank 
test. The Cox proportional-hazards model was used for multivariate analysis in order to determine 
the relative risk and independent significance of individual factors. In all cases p-values < 0.05 were 
considered as statistically significant. 
2.8.2 Other analysis 
The mean and standard deviations of data were calculated in Microsoft Excel. Significant difference 
between two sets of data was calculated using a two-tailed Students T Test with p<0.05 accepted as 
a significant difference. 
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Chapter 3 Cleaved caspase-3 expression in colorectal cancer  
3.1 Background 
MAbs have been shown to induce direct cell death of cancer target cells. In order to determine the 
ƚŚĞƌĂƉĞƵƚŝĐǀĂůƵĞŽĨĂŵď ?ƐĂďŝůŝƚǇƚŽŝŶĚƵĐĞĚŝƌĞĐƚĐĞůůĚĞĂƚŚŝŶĚependently of apoptosis, this study 
determined the level of apoptosis in colorectal cancer using a large TMA cohort. One of the 
hallmarks of cancers is their ability to accumulate mutations that confer increased growth and the 
ability to metastasize and avoid apoptosis (Hector & Prehn, 2009; Yang et al., 2009). Resistance to 
apoptosis can occur via the extrinsic or intrinsic pathways. The extrinsic pathway is triggered by 
ligands such as TRAIL and Fas ligand. Cancer therapies targeting Fas ligand were of limited value due 
to hepatotoxicity (Klos et al., 2003) and the observation that most colorectal cancers are resistant to 
Fas-mediated killing (O'Connell et al., 2000). In contrast, early results suggested that cancer was 
more sensitive to TRAIL-mediated apoptosis (Wiley et al., 1995). However, there has been conflicting 
evidence that colorectal cancer is resistant to TRAIL mediated lysis (Hale et al., 1988) due to over-
expression of decoy receptor 3 (Mild et al., 2002) or over-expression of the inhibitor FLICE-like-
inhibitory protein-long (FLIP-L; (Ullenhag et al., 2007)). In line with these observations, clinical trials 
with the pro-apoptotic ligand Apo2L/TRAIL or TRAIL receptor blocking antibodies have shown mixed 
responses (Ashkenazi & Herbst, 2008). As well as resistance to extrinsic stimuli, colorectal cancer 
cells accumulate a range of mutations that give rise to aberrant levels of apoptotic proteins. For 
example the anti-apoptotic protein, Bcl-2, is progressively increased during colorectal cancer 
progression (Krajewska et al., 2008) whereas expression of the pro-apoptotic proteins Bax and Bak 
decreases (Coppola et al., 2008; Duckworth & Pritchard, 2009). Over 50% of colorectal cancer 
patients express a mutated, inactive form of p53 leading to resistance to apoptosis. Indeed, the p53 
negative/Bcl-2 positive phenotype is an independent indicator of good prognosis in colorectal cancer 
(Watson et al., 2005). Recent studies have shown that both DCC and UNC5C are dependence 
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receptors that induce apoptosis in the absence of ligand (Mazelin et al., 2004). Both of these 
receptors are frequently deleted in colorectal cancer increasing resistance to apoptosis. 
Apoptosis within the tumour environment may be a consequence of nutrient deprivation due to 
excessive proliferation without an adequate blood supply or due to immune attack. Tumours express 
a range of stress related molecules which act like Toll-like receptors (TLRs) and alert the immune 
system to the danger (Nausch & Cerwenka, 2008; Waldhauer & Steinle, 2008). This process is 
termed immune surveillance. In a recent addition to this theory it has become clear that the 
transformed cells can acquire further mutations which make them resistant to the immune response 
(Dunn et al., 2005). There is then a period of immune equilibrium where the tumour mutates and 
the immune system adapts to continue to control tumour growth. This can last for many years and T 
cell infiltration, expression of MHC class I and the IFN-ɶŝŶĚƵĐĞĚƚƌĂŶƐĐƌŝƉƚŝŽŶĨĂĐƚŽƌSTAT-1 continue 
to be strong independent prognostic factors even in established colorectal tumours (Galon et al., 
2006; Simpson et al., 2010). MHC-II expression is induced on epithelial, endothelial and fibroblast 
cells and is up regulated on T cells and macrophages by IFN-ɶ. MHC-II expression on tumour cells and 
within stroma may therefore be a good marker of immune surveillance. Ultimately, if the immune 
system is sculpting the tumour ƉŚĞŶŽƚǇƉĞ ? Ă ƉƌŽĐĞƐƐ ƚĞƌŵĞĚ  “ŝŵŵƵŶĞ ĞĚŝƚŝŶŐ ? ? ƚŚĞtumour may 
become resistant to immune attack. One consequence of immune editing is alteration of the tumour 
microenvironment which becomes increasingly immunosuppressive. Tumours down-regulate stress 
molecules and fail to alert the immune response (Jordanova et al., 2008; McGilvray et al., 2009; 
Watson et al., 2006c). They also secrete immunosuppressive cytokines such as IL-10, TGF-ɴĂŶĚ VEGF 
(Fukumura et al., 1998), which condition the tumour-associated macrophages (TAM) within the 
tumour to the M2 phenotype (Sica et al., 2008) and induce the trans-differentiation of fibroblasts 
into activated smooth-muscle fibroblasts, termed myofibrobasts (or carcinoma-associated 
fibroblasts [CAFs]). M2 macrophages and CAFs induce tissue repair, remodelling, angiogenesis, 
promoting tumour growth and metastasis, through the secretion of matrix-degrading enzymes and 
immunosuppressive cytokines (Mantovani et al., 2007).  
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The complexity of the roles that each component of the tumour microenvironment plays poses the 
question as to whether cell death of the tumour or tumour-associated stroma leads to a better or 
worse prognosis in cancer. Apoptosis mediated by either the intrinsic or extrinsic pathways results in 
cleavage of caspase-3. Caspase-3 is also rarely mutated in colorectal cancer (Soung et al., 2004) and 
is therefore an ideal marker for measuring apoptosis in these tumours. The CC3 mAb used in this 
study has previously been shown to bind specifically to the cleaved fragment of capase-3 in archival 
paraffin-embedded IHC (Gown & Willingham, 2002) as well as only to the large cleaved fragment of 
caspase-3 by western blot (Cheong et al., 2003; Garnier et al., 2003). This study therefore aims to 
measure the level of apoptosis both within the stroma and in tumour cells using the validated CC3 
mAb and to correlate this with MHC-II expression as a marker of immune surveillance in a large 
cohort of colorectal cancers utilising high-throughput tissue microarray technology. 
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3.2 Results  
3.2.1 Clinical and pathological data 
The clinicopathological features of the 462 cases included in the present study are shown in Table 
3.1. Patients had a median follow-up of 37 months (range 0 to 116) and there were slightly more 
male than female patients (58% and 42% respectively). 52% of tumours were of colonic origin and 
39% of rectal origin, and in 9% of cases the site was not recorded. Well-differentiated tumours 
comprised 6% of the series, while 77% showed moderate differentiation and 15% were poorly 
differentiated. Examination of the standard clinicopathological features identified the expected 
associations between DSS and TNM stage (log-rank=211.37, p<0.0001), DSS correlated with 
extramural vascular invasion (log-rank=44.30, p<0.0001) but not with differentiation (log-rank=5.75, 
p=0.12). 
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Table 3.1 Clinicopathological variables for the patient cohort (n = 462) and cores stained for both tumour and 
tumour-associated stroma with CC3 (n=334). 
Variable Categories Frequency of 
total cohort (%) 
Frequency of 
stained cohort (%) 
Gender Male 266 (58) 197(59) 
 Female 199 (42) 137(41) 
Age (years) Median 72 72 
 Range 58-93 57-93 
Status Alive 169(37) 114(34) 
 Dead 293(63) 220(66) 
Tumour Grade Well differentiated 29 (6) 23(7) 
 Moderately differentiated 353 (77) 253(76) 
 Poorly differentiated 71 (15) 53(16) 
 Unknown 8 (2) 5(2) 
Tumour Site Colon 238 (52) 174(52) 
 Rectum 181 (39) 129(39) 
 Unknown 43 (9) 31(9) 
TNM Stage 0 (Tis) 3 (1) 2(1) 
 1 69 (15) 44(15) 
 2 174 (28) 110(38) 
 3 155 (33) 99(34) 
 4 54 (12) 31(11) 
 Unknown 7 (2) 5(2) 
Extramural Vascular 
Invasion 
Negative 224 (48) 164(49) 
Positive 128 (28) 91(27) 
 Unknown 110 (24) 79(24) 
Histological Type Adenocarcinoma 392 (85) 289(87) 
 Mucinous carcinoma 51 (11) 34(10) 
 Columnar carcinoma 4 (1) 3(1) 
 Signet ring carcinoma 7 (1) 4(1) 
 Unknown 8 (2) 4(1) 
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3.2.2 CC3 expression 
Analysis of CC3 was possible in 334 of the total 462 cores (72%) with the remainder being lost during 
antigen retrieval or not demonstrating viable tumour cells in the core. Due to the large loss of cores, 
the clinicopathological data for the 334 samples was confirmed to be similar to the original cohort 
(Table 3.1). The majority of staining was seen in the nucleus of both tumour and tumour-associated 
stromal cells. The majority of tumours had less than 1000 cells/mm
2
 of CC3 positive tumour cells and 
less than 2000 cells/mm
2
 in tumour-associated stroma. There were 43 (13%) samples that had a low 
level of CC3 in tumour cells and 178 (56%) of samples that had a low level of CC3 expression in the 
tumour-associated stroma (Table 3.2). Examples of CC3 staining of tumour and tumour-associated 
stroma are demonstrated in figure 3.1. 
 
Table 3.2 Numbers of tumour specimens negative and positive for CC3 expression. 
Marker Level of Expression Number of specimens (%) 
CC3 Tumour  
  Low 43 (13) 
  High 314(87) 
  Total 334(100) 
 Tumour-associated stroma  
  Low 178(56) 
  High 142(44) 
  Total 320(100) 
MHC-II Tumour   
  Negative 386(94) 
  Positive 27(6) 
  Total 413(100) 
 Tumour-associated stroma  
  Negative 213(51) 
  Positive 202(49) 
  Total 415(100) 
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Figure 3.1 Representations of positive and negative staining with CC3 and MHC-II. Samples depicting both 
negative tumour and tumour-associated stromal cells (a), only positive tumour cells (b), only positive tumour-
associated stromal cells (c), and both positive tumour and tumour-associated stromal cells (d) of CC3. Negative 
staining of both tumour and tumour-associated stroma (e), positive tumour and tumour associated stroma (f) 
and positive tumour associated stroma only MHC-II staining (g). All at X20 original magnification. 
 
 
 
 
 
 
 
 
 
 
e) f) 
g) 
c) b) a) 
d) 
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3.2.3 Markers of apoptosis and inflammation: Bcl2, p53, CD3, CD68, CD16 and MHC-II 
expression  
This array has previously been stained for the presence of stromal and intratumoural T cells using 
the CD3 marker (Simpson et al., 2010). Similarly the presence of macrophages or NK cells was 
enumerated using the CD68 or CD16 markers (Simpson et al., 2010). Expression of Bcl-2 and p53 
have previously been reported (Watson et al., 2005). As a marker of IFN-ɶ ŝŶĚƵĐĞĚ ĂĐƚŝǀĂƚŝŽŶ ?
expression of MHC-II on tumour cells and stroma associated cells was measured. It was possible to 
measure MHC-II expression in 413 of the total 462 cores (89%) with the remainder being lost during 
antigen retrieval or not demonstrating viable tumour cells in the core. Examples of MHC-II staining 
of tumour and tumour-associated stroma are demonstrated in figure 3.1. The majority of cores were 
negative for MHC-II expression in tumour cells (386 negative, 27 positive). 213 cores were negative 
for tumour-associated stroma staining, with 202 showing positive staining for MHC-II (Table 3.2). Of 
the cores stained with MHC-II, 286 were stained successfully with CC3. 
3.2.4 Relationship between CC3 expression and standard clinicopathological variables  
The relationship between CC3 expression in the tumour and tumour-associated stroma and standard 
clinicopathological variables and ŵĂƌŬĞƌƐŽĨŝŵŵƵŶĞĂĐƚŝǀĂƚŝŽŶǁĂƐŵĞĂƐƵƌĞĚƵƐŝŶŐƚŚĞWĞĂƌƐŽŶʖ2 
test. Expression of CC3 in the tumour associated significantly with TNM stage and distant metastases 
(p=0.047, 0.005 respectively; Table 3.3). There was no correlation between the expression of CC3 in 
tumour-associated stroma with any standard clinicopathological variables, including stage (Table 
3.3). 
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Table 3.3 Univariate analysis of patient and tumour in relationship to active caspase 3 expression in tumour 
and tumour-associated stroma. CC3 staining of tumour and tumour-associated stroma was correlated with 
ƐƚĂŶĚĂƌĚĐůŝŶŝĐŽƉĂƚŚŽůŽŐŝĐĂůǀĂƌŝĂďůĞƐƵƐŝŶŐƚŚĞɍ2 test. Values <0.05 are accepted to be significant. 
 
Variable ɍ2 test (p value) 
CC3 expression MHC-II expression 
Tumour Tumour-associated 
stroma 
Tumour Tumour-associated 
stroma 
Gender 0.832 0.579 0.116 0.656 
Tumour Site 0.729 0.364 0.757 0.058 
Tumour Type 0.110 0.470 0.518 0.577 
Tumour Grade 0.196 0.266 0.036 0.190 
ƵŬĞ ?Ɛ^ƚĂŐĞ 0.026 0.298 0.157 0.706 
TNM Stage 0.047 0.462 0.007 0.969 
Distant Metastases 0.005 0.188 0.237 0.989 
Extramural vascular 
invasion 
0.775 0.368 0.249 0.049 
Stromal MHC-II 
expression 
0.151 0.020 - - 
Tumoural MHC-II 
expression 
0.008 0.347 - - 
CD3- Intratumoural 0.557 0.525 0.002 0.002 
CD3- Tumour-associated 
stroma 
0.821 0.569 0.001 0.001 
CD16 0.762 0.490 0.002 0.004 
CD68 0.631 0.313 0.865 <0.001 
p53 0.616 0.919 0.069 0.394 
Bcl-2 0.681 0.290 0.362 0.145 
 
3.2.5 Relationship between MHC-II expression and standard clinicopathological variables 
The relationship between MHC-II expression in tumour and tumour-associated stroma and standard 
ĐůŝŶŝĐŽƉĂƚŚŽůŽŐŝĐĂů ǀĂƌŝĂďůĞƐ ǁĂƐ ŵĞĂƐƵƌĞĚ ƵƐŝŶŐ ƚŚĞ WĞĂƌƐŽŶ ʖ2 test. Expression of MHC-II in the 
tumour associated significantly with TNM stage and tumour grade (p=0.007 and 0.036 respectively; 
Table 2). There was no correlation between the expression of MHC-II in tumour-associated stroma 
with any standard clinicopathological variables, including stage (Table 3.3).  
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3.2.6 Relationship between CC3 expression and markers of immune activation and 
apoptosis 
The immune system and in particular the presence of T cells, has been shown to have strong 
prognostic significance in colorectal cancer. The relationship between CC3 expression in tumour and 
tumour-associated stroma and markers of immune activation was therefore measured using the 
WĞĂƌƐŽŶʖ2 test. Expression of CC3 in the tumour associated significantly with MHC-II expression in 
tumour cells (p=0.008; Table 3.3) but not with the number of CD68, CD16 or CD3 positive cells or Bcl-
2 or p53. There was no correlation between the expression of CC3 in tumour-associated stroma with 
the number of CD68, CD16 or CD3 positive cells or Bcl-2 or p53. However, there was a significant 
correlation with stromal expression of MHC-II (p=0.020; Table 3.3). 
3.2.7 Relationship between MHC-II expression and markers of immune activation and 
apoptosis 
IFN-ɶ, produced by NK cells, NKT and T cells has been shown to play a central role in immune 
surveillance. It induces MHC-II expression on tumour cells and upregulates expression on stromal 
cells. The relationship between MHC-II expression in the tumour and tumour-associated stroma and 
markers of immune activation was measured using the PeĂƌƐŽŶʖ2 test. Expression of MHC-II in the 
tumour associated significantly with expression of CD3 T cells either within the tumour (p=0.002; 
Table 3.3) or within the stroma (p=0.001; Table 3.3) and expression of CD16 positive cells 
(macrophage and NK cells; p=0.002; Table 3.3) but not with the number of CD68 positive cells or Bcl2 
or p53. Expression of MHC-II in the tumour associated stroma was significantly associated with 
expression of CD3 T cells either within the tumour (p=0.002; Table 3.3) or within the stroma 
(p=0.001; Table 3.3), expression of CD16 positive cells (macrophage and NK cells; p=0.004; Table 3.3) 
and with the number of CD68 positive cells (macrophages; p=0.001; Table 3.3) but not with Bcl2 or 
p53.  
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3.2.8 Relationship between CC3 expression and survival 
Kaplan-Meier plots were used to analyse the relationship between low and high expression of CC3 
and disease-specific survival. Figure 3.2a and table 3.4 demonstrate that patients with a higher level 
of tumour CC3 expression have a greater mean survival (p=0.029; 73 months) than those with a 
lower level of CC3 expression (53 months). This is echoed in the tumour-associated stroma with a 
higher expression having a greater mean survival (p=0.009, 79 mean months versus 63 months; Fig 
3.2b). When tumour cell expression of CC3 cells was compared to tumour-associated stromal cell 
expression, patients that show low expression of CC3 in the tumour and tumour-associated stroma 
had the worst survival (43 months), with patients with high tumour CC3 expression/high tumour-
associated stromal CC3 displaying the best survival (80 months; p=0.009). Patients with high tumour 
and low tumour-associated stromal CC3 expression or patients with low tumour and high tumour 
associated-stroma CC3 expression had a similar survival (66 and 71 months respectively; Fig 3.2c). 
 
Table 3.4 Mean survival of patients.  
Marker Level of expression Mean survival 
(months) 
CC3 Tumour  
 Low 53 
 High 73 
 Tumour-associated stroma  
 Low 63 
 High 79 
 Tumour versus tumour-associated stroma  
 Low tumour/low tumour-associated stroma (0) 43 
 Low tumour/high tumour-associated stroma (1) 71 
 High tumour/low tumour-associated stroma (2) 66 
 High tumour/high tumour-associated stroma (3) 80 
MHC-II Tumour  
 Low 71 
 High 85 
 Tumour-associated stroma  
 Low 69 
 High 75 
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Figure 3.2 Kaplan-Meier plot for disease-specific survival relative to CC3 an MHC-II expression. a) CC3 low-
expression in tumour cells (Low) vs. CC3 high-expression in tumour cells High; p=0.029). b) Low CC3 expression 
in tumour-associated stroma (Low) vs. high CC3 high expression in tumour-associated stroma (High). p = 0.009. 
c) Groups of CC3 low-expression in both tumour and tumour-associated stroma (0), CC3 low-expression in 
tumour, high expression in tumour-associated stroma (1), CC3 high-expression in tumour, low expression in 
tumour-associated stroma (2) and CC3 high-expression in both tumour and tumour-associated stroma (3) p = 
0.009. Where Tumour low/high = 0-60/61-max cells/mm
2
 and tumour-associated stroma low/high = 0-
104/max cells/mm
2
. d) MHC-II negative-expression in tumour cells (Negative) vs. MHC-II positive-expression in 
tumour cells (Positive; p=0.029). e) Negative MHC-II expression in tumour-associated stroma (Negative) vs. 
positive MHC-II positive expression in tumour-associated stroma (Positive; p=0.009). 
3.2.9 Relationship between MHC-II expression and survival 
Kaplan-Meier plots were used to analyse the relationship between negative and positive expression 
of MHC-II and DSS. Figures 3.2d, e and table 3.4 demonstrate that the level of MHC-II expression in 
either the tumour or tumour-associated stromal cells had no significant influence on patient survival 
(p=0.103 and 0.214).  
3.2.10 Multivariate analysis of CC3 expression and standard clinicopathological variables 
In order to determine the relative influences of CC3 and other patient and tumour variables known 
to affect prognosis, a multivariate analysis was performed using the Cox proportional hazards model. 
The variables included were those that have been shown to be significantly related to DSS on 
Positive 
Negative 
p=0.214 
e) 
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univariate analysis (extramural vascular invasion and TNM stage). In this model, extramural vascular 
invasion (p<0.001) and TNM stage (p=0.005) were seen to retain independent prognostic 
significance (Table 3.5a.). Low expression of CC3 in tumour-associated stroma was also seen to be an 
independent prognostic marker (CI 95% 0.359-0.823, p=0.004). Previous studies in our group have 
shown that both the presence of intra-tumoural T cells (ITTC) and reduced MHC-I expression are 
independent prognostic factors (Simpson et al., 2010). Multivariate analysis was therefore 
performed to see if tumour-associated stroma CC3 expression was independent of these factors and 
TMN stage and extramural vascular invasion. Analysis showed that only tumour-associated stroma 
CC3 expression (p=0.005) and TNM stage (p<0.001) retained their independent prognostic 
significance (Table 3.5b). 
Table 3.5 Cox multivariate regression analysis of variables in relation to disease specific survival. Multivariate 
analysis using the Cox proportional hazards model for CC3 in tumour-associated stroma, extramural vascular 
invasion and TNM (a) and for ITCC and MHC-I expression (b). 
 
 
 
 
 
 
Variable  Hazard Ratio 95% CI p value 
Extramural vascular invasion Negative 1   
Positive 1.191 1.191-2.728 0.005 
TNM Stage 0-II 1   
III-IV 0.267 0.165-0.432 <0.001 
CC3 tumour-associated stroma 
expression 
Low 1   
High 0.544 0.359-0.823 0.004 
Variable  Hazard Ratio 95% CI p value 
Extramural vascular invasion Negative 1   
Positive 0.638 0.394-1.034 0.068 
TNM Stage 0-II 1   
III-IV 3.733 2.141-6.506 <0.001 
ITCC Low 1   
High 1.310 0.825-2.080 0.253 
MHC-I Low 1   
High 0.549 0.219-1.376 0.201 
CC3 tumour-associated stroma 
expression 
Low 1   
High 0.490 0.299-0.804 0.005 
a) 
b) 
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3.3 Discussion 
Cancer is a complex interaction of transformed epithelial and associated stromal cells. Perturbation 
of this complex relationship can lead to tumour cell apoptosis. However, resistance to apoptosis has 
been shown to be a key factor in tumour progression. Colorectal cancer can become resistant to 
apoptosis by a wide variety of mechanisms including mutation of apoptotic regulators, upregulation 
of anti-apoptotic molecules and down regulation of pro-apoptotic molecules (Yang et al., 2009). CC3 
expression was therefore used to determine the level of apoptosis in both the tumour and the 
associated stroma cells in a large, representative cohort of colorectal cancer patients from the UK. In 
this study we have shown that high levels of CC3 both within tumour cells and within the tumour-
associated stroma correlates with good prognosis. Furthermore, CC3 expression within stromal cells 
was an independent prognostic marker.  
The value of apoptosis as a prognostic marker remains unclear due largely to the contradictory 
results of previous studies (Koornstra et al., 2003). The majority of early studies used transferase-
mediated nick end labelling (TUNEL) to detect fragmented DNA in apoptotic cells. The TUNEL 
method has two main disadvantages; firstly the labelling of DNA fragments also marks necrotic and 
autolytic cells (Gown & Willingham, 2002) and secondly, the method requires pre-treatment steps, 
which needs careful optimization and may be source of variation between studies. Our findings are 
in concurrence with studies that assessed apoptosis by measuring caspase-3 activity. A low level of 
CC3 activity in the tumour was shown to result in a greater risk of recurrence in a cohort of 117 stage 
III rectal cancer patients (de Heer et al., 2007). A lower level of caspase-3 activation, measured by 
western blots, in the tumours of 60 colorectal cancer significantly correlated with a greater risk of 
recurrence (Jonges et al., 2001). It has also been shown that the level of caspase-3 like protease 
activity increased with cancer progression (Leonardos et al., 1999) . As shown in this study, Koelink 
et al., found that a greater than median level of caspase activity (measured by the level of caspase-3-
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degraded cytokeratin 18 product, the M30 antigen) in tumour-associated stroma, correlated with 
increased survival in a cohort of 211 colorectal cancer patients (Koelink et al., 2009).  
It is logical that a higher level of CC3 in the tumour would predict a better prognosis, as a greater 
level of apoptosis would suggest a less aggressive tumour. We have also shown that this correlates 
with the level of MHC-II on tumour cells. This may be related to the expression of IFN-ɶ as this is the 
only cytokine that can upregulate expression of MHC-II on epithelial cells (Giroux et al., 2003). It has 
been shown that transformation induces stress related molecules which are recognised by innate 
immune cells with the subsequent release of IFN-ɶ (Dunn et al., 2005). The strong correlation 
between MHC-II on tumours and CD3, CD16 and CD68 expression suggests that IFN-ɶ ŵĂǇ ďĞ
produced by NK cells, M1 macrophages or T cells. The correlation between CC3 and MHC-II suggests 
that IFN-ɶŵĂǇďĞƌĞƐƉŽŶƐŝďůĞĨŽƌƚŚĞƚƵŵŽƵƌĐĞůůĂƉŽƉƚŽƐŝƐĂŶd good prognosis. This is supported by 
previous studies showing that the stress related protein MICA (Watson et al., 2006c) and ITTC are 
markers of good prognosis in colorectal cancer (Simpson et al., 2010).  
 As the tumour becomes increasingly resistant to immune control, the balance in the stroma may be 
tipped in favour of cells enhancing angiogenesis and metastases. The strong association with stromal 
apoptosis and stromal cell MHC-II expression suggests that one of these key cells may be 
macrophages which constitutively express MHC-II. Studies have shown that M2 macrophages can 
express a range of proteases that remodel the ECM and can express angiogenic factors, such as 
VEGF, that promote tumour metastasis (Pollard, 2004). The tumour also secretes stroma-modulating 
factors, including basic fibroblast growth factor (bFGF), TGF-ɴ and members of the VEGF family 
(Fukumura et al., 1998). These factors disrupt the normal tissue homeostasis and act in both a 
paracrine and autocrine fashion and lead to the remodelling of the ECM, activation of angiogenesis 
and the transdifferentiation of fibroblasts into CAFs. CAFs have been shown to be present in 
colorectal tumour progression (Adegboyega et al., 2002; Tsujino et al., 2007). CAFs in turn act in a 
pro-tumour manner by secreting growth factors and additional proteases that stimulate tumour 
growth, migration, angiogenesis and progression. A study demonstrated that CAFs can also promote 
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progression of non-tumourigenic prostatic epithelial cells, leading to tumour growth (Olumi et al., 
1999). A study has shown that TGF-ɴƉƌŽŵŽƚĞƐĞǆƉƌĞƐƐŝŽŶŽĨĨŝďƌŽďůĂƐƚĂĐƚŝǀĂƚŝŽŶƉƌŽƚĞŝŶ ?&W )ŽŶ
CAFs and that this expression promotes the proliferation, migration and invasion of the ovarian 
cancer cell line HO-8910PM in vitro (Chen et al., 2009). More recently, in has been shown that a FAP-
expressing, mesenchymal-originated, stromal cell can suppress the immune system in a murine 
tumour microenvironment and when removed, cytokine mediated killing of the tumour was 
observed (Kraman et al., 2010). Thus, cancers have low levels of CC3 in both the tumour itself and its 
associated stroma are most aggressive and lead to a poor prognosis (median survival 43 months). 
However, if the tumour grows too rapidly, it could outcompete the stroma for nutrients and oxygen 
resulting in stromal death and consequently tumour death. Thus tumours with high CC3 levels in 
both their tumour and stroma have less aggressive tumours and better prognosis (median survival 
80 months). 
The independent significance of apoptosis in tumour-associated stroma in colorectal cancer suggests 
that tumour microenvironment targeted therapy may be beneficial. An example is bevacizumab 
which binds to VRGF, blocking the VEGF expressed by the tumour from binding to VEGFR on vascular 
endothelium, promoting angiogenesis. Bevacizumab, a VEGF-A-specific humanized mAb, blocks 
binding of VEGF to VEGFR and is approved for treatment in colorectal, breast and non-small cell lung 
cancers (Shih & Lindley, 2006). VEGFRs have also been targeted, with ramucirumab, a fully human 
mAb targeted at VEGFR2 showing inhibition of vascularisation in a phase I trial (Spratlin et al., 2010). 
It has recently been demonstrated that a DNA vaccine directed against the CAF marker FAP 
significantly suppressed primary tumour and pulmonary metastases in a murine model, with no 
significant side effects (Wen et al., 2010). 
In conclusion, our study has shown that high expression of CC3 in tumours correlates with good 
prognosis and with the expression of MHC-II on tumour cells. This suggests that IFN-ɶand therefore 
immune cells may have a role to play in controlling colorectal cancer growth. High expression of CC3 
in tumour-associated stroma was also associated with good prognosis and is an independent 
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prognostic factor in colorectal cancer. This may be because apoptosis of the tumour-associated 
stroma reduces the level of pro-tumour signals and therefore the tumour has reduced proliferation, 
migration, angiogenesis and metastasis. This study further highlights the importance of tumour-
associated stroma in colorectal cancer as a possible new therapeutic target.  
The complex way in which a tumour protects itself from the immune system can result in an 
inflammatory, pro-tumour phenotype of immune effector cells in the tumour microenvironment, 
which suggests that mAb-induced immune mediated mechanisms of tumour death may not always 
be possible. Therefore the ability of a mAb to induce direct cell death may be vital in tumours with 
an immune suppressed environment. 
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Chapter 4 Characterisation of Lewis y/b mAb specificity and in vitro 
functionality 
4.1 Introduction 
Studies have shown that epithelial-derived tumours have an increased level of glycans compared 
with normal tissue, making them good tumour markers and potential therapeutic targets 
(Dabelsteen, 1996; Hakomori, 1985; Kannagi et al., 2008). Many of the mAbs targeting these glycans 
show direct non-apoptotic killing activity against tumours in vitro (Kelly et al., 2006). SC104 mAb has 
been shown to bind and directly kill colorectal tumours and inhibit growth in vivo (Durrant et al., 
2006). F77, an anti-prostate cancer mAb, has been shown to bind a glycolipid on the surface of 
prostate cancer cells and inhibit growth in vivo (Zhang et al., 2010a). RAV12 is a chimeric mAb that 
has been shown to bind ĂŵŝŶŝŵĂůĞƉŝƚŽƉĞŽĨ'Ăůɴ ?- ?'ůĐEĐɴ ?-3Gal on the N-linked carbohydrate 
antigen RAAG12, which is expressed on 90% of intra-abdominal tumours. RAV12 has been shown to 
directly kill the colorectal cancer cell line Colo 205 in vitro by oncosis as well as anti-tumour activity 
in a phase I study (Burris et al., 2010; Coberly et al., 2009; Loo et al., 2007). BR96, an anti-Lewis-y 
mAb has been shown to cause cellular cytotoxicity in Lewis y-positive cells in vitro as well as 
mediating ADCC and CDC (Hellstrom et al., 1990). We have previously described 692/29, a mouse 
IgG3 mAb whose antigenic target is a unique but shared epitope on both Lewis b and Lewis y. Binding 
of the mAb inhibits growth of colorectal tumours in vivo by an uncharacterised mechanism. The 
Lewis y and Lewis b antigens are tetrasaccharides and are extensions of the H blood group galactose-
glucosamine. Although both are mostly expressed throughout foetal development and are gradually 
lost after birth, Lewis y and Lewis b can be expressed on normal cells in the GI tract at low levels 
(Sakamoto et al., 1986; Sakamoto et al., 1989). Tumours have been shown to overexpress both Lewis 
y and Lewis b, making them good targets for mAb therapy (Abe et al., 1986; Itzkowitz, 1992; Kim et 
al., 1986). As glycans, Lewis y and Lewis b can be expressed on GSLs as well as glycoproteins on the 
cell surface. GSLs have been shown to be functional molecules that can effect tumour cell growth, 
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adhesion, metastasis and proliferation (Hakomori Si, 2002). This has lead to a number of trials 
targeting these functional glycans with mAb therapy (Kelly et al., 2006; Saleh et al., 2000).  
In this study we sought to investigate the fine specificity of Lewis y and Lewis b mAbs to their 
antigen/s and the effect that this had on in vitro binding and functionality. This may determine 
whether the ability to bind both Lewis y and Lewis b could be of therapeutic benefit. 
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 4.2 Results 
4.2.1 Defining the epitopes recognised by the Lewis y/b antibodies using the Consortium 
for Functional Glycomics glycan array 
Studies have shown that due to the subtleties observed in antibody binding to tumour cells and the 
high level of similarity between some carbohydrate groups, including blood group antigens, many 
antibodies have been found to cross-react with other related carbohydrates (Manimala et al., 2007). 
The recognition of Lewis y as a good therapeutic target has lead to the production of a number of 
anti-Lewis y mAbs. Despite being presented as Lewis-y specific mAbs, some have been shown to 
cross-react with other blood group antigens. To confirm that 692/29 could bind to both Lewis y and 
Lewis b, the mAb was screened against Lewis y and Lewis b glycans by ELISA. Figure 4.1 shows that 
692/29 binds to both Lewis y and Lewis b glycans. In order to clarify their fine specificity the anti-
Lewis y/b mAb 692/29 and the anti-Lewis y mAb BR96 were assessed and compared to the published 
specificity data for 2-25 LE (an anti-Lewis b mAb) from the Consortium for Functional Glycomics. 
Binding of 692/29 to the array reflects that seen with the ELISA, with the mAb binding most strongly 
to Lewis b, glycans containing Lewis b and also to tri-Lewis y and its variants (Fig 4.2a). Analysis of 
the 2-25 LE binding data shows strong binding to Lewis b, with some cross-reactivity to Lewis a and 
Lewis a-x. Weak binding can also be seen against sialyl Lewis a-x, with no binding to Lewis y (Fig 
4.2b). BR96 shows strong binding to Lewis y as well as a range of Lewis y variants (Lewis y-x, Lewis y-
x-x) and more weakly to Lewis x. BR96 does not bind to Lewis b (Fig 4.2c). A representation of the 
glycans and their structures bound by each mAb is displayed in Table 4.1.  
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Figure 4.1 Binding of 692/29 to Lewis b and Lewis y antigens.  ? ? ?ʅů  ? ?ʅŐ ?ŵů>ĞǁŝƐď-HSA and Lewis y-HSA 
were incubated on an ELISA plate before blocking and the addition of 10-1ʅŐ ?ŵů  ? ? ? ? ? ? ?Binding of 692/29 
probed with anti-IgG-HRP. Error bars representing standard deviation of quadruplicate wells are included for 
all data points. * indicates significant binding where p<0.05. Data is representative of 2 seperate experiments. 
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Figure 4.2. The fine specificity differs between the anti-Lewis y and Lewis b mAbs. The binding of 692/29 (a), 
2-25 LE (b) and BR96 (c) to the Consortium for Functional Glycomics glycan array. Where a=Lewis a, b=Lewis b, 
y=Lewis y, x-Lewis x, D- = Di, T- = Tri, S- = sialyl, Ex- = extended, ʔ denotes a mannose containing glycan, and y-
x= Lewis y-Lewis x. 
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Table 4.1 Details of glycan binding by 692/29 (a), 2-25 LE (b) and BR96 (c) to the glycan array. A blue squares 
represents glucosylamine, yellow circles represents galactose, red triangles represent fucose, green circles 
represent mannose and purple diamond represents sialic acid. Sp denotes the length of spacer between glycan 
and slide. Percentage of best binder refers to the level of binding in relation to the glycan bound best by each 
mAb. 
Glycan 
No. 
Glycan Name Percentage 
of best 
binder (%) 
Structure 
57 Fuca1-2Galb1-3(Fuca1-
4)GlcNAcb-Sp8 
Lewis b 100 
 
66 Fuca1-2Galb1-4(Fuca1-
3)GlcNAcb1-3Galb1-
4(Fuca1-3)GlcNAcb1-
3Galb1-4(Fuca1-
3)GlcNAcb-Sp0 
Lewis y-x-
x 
50 
 
381 Fuca1-2Galb1-3(Fuca1-
4)GlcNAcb1-3(Galb1-
4GlcNAcb1-6)Galb1-
4Glc-Sp21 
Lewis x- 
containing 
glycan 
45 
 
382 Fuca1-2Galb1-3(Fuca1-
4)GlcNAcb1-3(Galb1-
4(Fuca1-3)GlcNAcb1-
6)Galb1-4Glc-Sp21 
Lewis b-x 
containing 
glycan 
37 
 
114 Galb1-3(Fuca1-
4)GlcNAcb1-3Galb1-
4(Fuca1-3)GlcNAcb-Sp0 
Lewis a-x 27 
 
68 Fuca1-2Galb1-4(Fuca1-
3)GlcNAcb-Sp8 
Lewis y 26 
 
118 Galb1-3(Fuca1-
4)GlcNAcb-Sp8 
Lewis a 23 
 
116 Galb1-3(Fuca1-
4)GlcNAcb-Sp0 
Lewis a 19 
 
200 Fuca1-3(Galb1-
4)GlcNAcb1-2Mana1-
3(Fuca1-3(Galb1-
4)GlcNAcb1-2Mana1-
6)Manb1-4GlcNAcb1-
4GlcNAcb-Sp20 
Lewis a-
containing 
glycan 
18 
 
a) 
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65 Fuca1-2Galb1-4(Fuca1-
3)GlcNAcb1-3Galb1-
4(Fuca1-3)GlcNAcb-Sp0 
Lewis y-x 14 
 
Glycan No. Glycan Name Percentage 
of best 
binder (%) 
Structure 
57 Fuca1-2Galb1-3(Fuca1-
4)GlcNAcb-Sp8 
Lewis b 100 
 
117 Galb1-3(Fuca1-
4)GlcNAc-Sp8 
Lewis a 92 
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Glycan 
No. 
Glycan Name Percentage 
of best 
binder (%) 
Structure 
71 &ƵĐɲ ?- ?'Ăůɴ ?- ? ?&ƵĐɲ ?-
 ? )'ůĐEĐɴ-Sp0 
Lewis y 100 
 
69 &ƵĐɲ ?- ?'Ăůɴ ?- ? ?&ƵĐɲ ?-
 ? )'ůĐEĐɴ ?- ?'Ăůɴ ?-
 ? ?&ƵĐɲ ?-  )'ůĐEĐɴ-Sp0 
Lewis y-x 94 
 
118 Galb1-3(Fuca1-
4)GlcNAcb-Sp8 
Lewis a 90 
 
119 Galb1-3(Galb1-
4GlcNAcb1-6)GalNAca 
Type-2 
containing 
glycan 
84 
 
114 Galb1-3(Fuca1-
4)GlcNAcb1-3Galb1-
4(Fuca1-3)GlcNAcb-Sp0 
Lewis a-x 79 
 
274 Galb1-3(Neu5Aca2-
3Galb1-4GlcNacb1-
6)GalNAca-Sp14 
Sialylated 
Type-2 
containing 
glycan 
48 
 
217 Neu5Aca2-3Galb1-
3(Fuca1-4)GlcNAcb1-
3Galb1-4(Fuca1-
3)GlcNAcb-Sp0 
Sialyl 
Lewis a-x 
40 
 
218 Galb1-3(Fuca1-
4)GlcNAcb-Sp0 
Lewis a 33 
 
c) 
b) 
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72 &ƵĐɲ ?- ?'Ăůɴ ?- ? ?&ƵĐɲ ?-
 ? )'ůĐEĐɴ-Sp8 
Lewis y 87 
 
70 &ƵĐɲ ?- ?'Ăůɴ ?- ? ?&ƵĐɲ ?-
 ? )'ůĐEĐɴ ?- ?'Ăůɴ ?-
 ? ?&ƵĐɲ ?-  )'ůĐEĐɴ ?-
 ?'Ăůɴ ?- ? ?&ƵĐɲ ?-  )'ůĐEĐɴ-
Sp0 
Lewis y 84 
 
103 'Ăůɲ ?- ? ?&ƵĐɲ ?-  )'Ăůɴ ?-
 ? ?&ƵĐɲ ?-  )'ůĐEĐɴ-Sp0 
Lewis y-x-
x 
74 
 
104 'Ăůɲ ?- ? ?&ƵĐɲ ?-  )'Ăůɴ ?-
 ? ?&ƵĐɲ ?-  )'ůĐEĐɴ-Sp8 
Lewis y-x-
x 
70 
 
151 'Ăůɴ ?- ? ?&ƵĐɲ ?-  )'ůĐEĐɴ ?-
 ?'Ăůɴ ?- ? ?&ƵĐɲ ?-  )'ůĐEĐɴ-
Sp0 
Di-Lewis X 51 
 
152 'Ăůɴ ?- ? ?&ƵĐɲ ?-  )'ůĐEĐɴ ?-
 ?'Ăůɴ ?- ? ?&ƵĐɲ ?-
 ? )'ůĐEĐɴ ?- ?'Ăůɴ ?-
 ? ?&ƵĐɲ ?-  )'ůĐEĐɴ-Sp0 
Tri-Lewis 
X 
42 
 
361 &ƵĐɲ ?- ?'Ăůɴ ?- ? ?&ƵĐɲ ?-
 ? )'ůĐEĐɴ ?- ?DĂŶɲ ?-
 ? ?&ƵĐɲ ?- 'Ăůɴ ?- ? ?&ƵĐɲ ?-
 ? )'ůĐEĐɴ ?- ?DĂŶɲ ?-
 ? )DĂŶɴ ?- ?'ůĐEĐɴ ?-
 ?'ůĐEɴ-Sp20 
Extended 
Lewis y 
16 
 
149 'Ăůɴ ?- ? ?&ƵĐɲ ?-  )'ůĐEĐɴ-
Sp0 
Lewis X 7 
 
446 &ƵĐɲ ?- ?'Ăůɴ ?- ? ?&ƵĐɲ ?-
 ? )'ůĐEĐɴ ?- ? ?&ƵĐɲ ?-
 ?'Ăůɴ ?- ? ?&ƵĐɲ ?-
 ? )'ůĐEĐɴ ?- ? )DĂŶɲ ?-
 ? ?&ƵĐɲ ?- 'Ăůɴ ?- ? ?&ƵĐɲ ?-
 ? )'ůĐEĐɴ ?- ?DĂŶɲ ?-
 ? )DĂŶɴ ?- ?'ůĐEĐɴ ?-
 ?'ůĐEĐɴ-Sp12 
Extended 
Lewis y 
6 
 
 
4.2.2 Binding characteristics of anti-Lewis y/b mAbs on a range of antigen positive cell 
lines 
  
125 
 
In order to establish whether the subtlety in antigen recognition observed on the glycan array 
between the three mAbs related to a difference in binding characteristics to cells in vitro, 692/29 
(Lewis y/b), 2-25 LE (Lewis a/b) and BR96 (Lewis y) were screened against a range of Lewis y and 
Lewis b positive cell lines (Fig 4.3a-h). All of the cell lines bound all three mAbs although to varying 
amounts, with the exception of MKN45. There were clear differences in antigen expression across 
the different cell lines, with C170 and Colo 205 expressing the greatest level of the Lewis y and b 
antigens. C170 expressed more Lewis y and Colo 205 more Lewis b. Several of the cell lines were 
Lewis b (2-25 LE) negative (OVCAR-3, OAW28, SW480) but demonstrated positive staining for the 
Lewis y antigen with BR96 and 692/29. MKN45 was the only cell line that was negative for both 
Lewis y and b antigens. Most cell lines with Lewis y antigen show similar levels of 692/29 and BR96 
binding (OVCAR-3, SW480, HT29). However, both C170 and OAW28 cells show distinct binding of 
692/29 and BR96, which may reflect the subtle differences in structures recognised by the mAbs on 
the glycan array. In both C170 and OAW28, BR96 binds at a higher level than 692/29, which may 
reflect a higher affinity for the Lewis y antigen. Interestingly, in all cells lines and irrespective of the 
ůĞǀĞůŽĨĂŶƚŝŐĞŶ ?ĂŶƚŝďŽĚǇďŝŶĚŝŶŐǁĂƐŶŽƚƐĞĞŶƚŽƐĂƚƵƌĂƚĞ ?ĞǀĞŶĂƚ ? ?ʅŐ ?ŵů ? 
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Figure 4.3 Differences in binding pattern relate to a difference in in vitro cell line binding. C170 (a), Colo 205 
(b), HT29 (c), LoVo (d) OVCAR-3 (e), OAW28 (f), MKN45 (g) and SW480 (h) cells were incubated with 0.1-
 ? ?ʅŐ ?ŵů 692/29, BR96 and 2-25 LE. ǆĂŵƉůĞƐŽĨďŝŶĚŝŶŐŽĨ  ? ?ʅŐ ?ŵůirrelevant IgG (i), 692/29 (j), 2-25 LE (k) 
and BR96 (l) histograms to C170 cells. All cell lines were plated at 1x10
5
 cells per well and incubated with the 
mAbs. Binding of mAbs to the cells was probed with an anti-mouse IgG-FITC mAb before analysing the cells by 
flow cytometry. An irrelevant IgG mAb was used as a negative control (geometric mean 10). Data is 
representative of at least 3 experiments. 
4.2.3 Determining self-binding (homophilic binding) of the Lewis antibodies. 
In each of the cell lines used the anti-Lewis mAbs failed to show antigen saturation, as observed with 
similar concentrations of anti-CD46 and CD59 mAbs  ?&ŝŐ  ? ? ? ) ? ŽŶĐĞŶƚƌĂƚŝŽŶƐ ĂƐ ŚŝŐŚ ĂƐ  ? ?ʅŐ ?ŵů
were still showing increases in fluorescence levels. This unusually high level of binding of antibodies 
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has been observed before in homophilic binding antibodies, where mAbs bind to antigen and 
homophilically to themselves. To investigate the possibility of homophilic binding, C170 cells were 
ŝŶĐƵďĂƚĞĚǁŝƚŚ ? ? ?ʅŐ ?ŵůof unlabelled anti-Lewis mAb. After brief washing this was followed by the 
addition of FITC-labelled mAb. Despite the large amount of unlabelled mAb, both 692/29 and BR96 
FITC-conjugated mAbs were still able to bind to the cells to the same extent as when no unlabelled 
mAb was present (Fig 4.5). However, some inhibition of 2-25LE FITC-conjugated binding was 
observed. These results suggest that at low antibody concentrations the antibody binds to antigen 
but at higher concentrations may also binds to itself. It is possible that binding of one antibody 
results in the exposure of other antigenic sites on the cell surface. This possibility was examined by 
titrating the mAbs on paraformaldehyde fixed and fresh cells. No difference in binding was observed 
between fixed and fresh cells (Fig 4.6). It has been reported that some homophilic mAbs can also 
cross react, homophilically, with others. In order to test this possibility the two antibodies 
recognising Lewis y (BR96 and 692/29) were assayed cytometrically, on the cell line was shown to 
only expresses Lewis y, OAW28 (Fig 4.3). Cells were incubated with a 100ʅg/ml concentration of 
BR96-FITC, washed and then incubated with 1- ? ?ʅŐ ?ŵů692/29-biotin, before detecting with 
streptavidin-PE/Cy5. Figure 4.7a shows that despite incubating cells with a high level of BR96-FITC, 
suggesting the coating of Lewis y antigens on the cell surface, 692/29-biotin was still able to bind to 
the cells, as detected by streptavidin PE/Cy5. Figure 4.7b shows that BR96-FITC is not displaced from 
the cells and is still present. To study binding of BR96 to 692/29, the reverse was undertaken; with 
figure 4.7c showing that BR96-FITC binding is not inhibited by  ? ? ?ʅŐ ?ŵů 692/29-biotin, with both 
mAbs being detected on the cells (Fig 4.7d). 
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Figure 4.4 Saturation of CD46 and CD59 binding to Colo 205 cells. Colo 205 cells were plated at 1x10
5
 cells per 
well and incubated with 0.1- ? ?ʅŐ ?ŵů  ? ? ? ? ?Žƌ  ? ? ? ? ? ?. Binding of the mAbs was probed with an anti-
mouse IgG-FITC mAb before analysing the cells by flow cytometry. An irrelevant IgG mAb was used as a 
negative control (geometric mean 10). Data is representative of at least 3 experiments. 
 
Figure 4.5 Saturation of C170 cells with mAbs does not inhibit the binding of additional labelled 692/29 and 
BR96 mAb. C170 cells were plated at 1x10
5
 cells round-bottomed ǁĞůů ƉůĂƚĞƐ ĂŶĚ ƐĂƚƵƌĂƚĞĚ ǁŝƚŚ  ? ? ?ʅŐ ?ŵů
unlabelled 692/29, BR96 and 2-25 LE. The cells were washed and the resuspended cells were treated with 
increasing concentrations (1, 3 and  ? ?ʅŐ ?ŵů ) either on top of unlabelled mAb or  ? ?ʅŐ ?ŵů ůĂďĞůůĞĚŵďǁĂƐ
added to cells alone (far left column). The cells were then analysed by flow cytometry. Results are expressed as 
Ă ƉĞƌĐĞŶƚĂŐĞ ŽĨ ďŝŶĚŝŶŐ ŽĨ  ? ?ʅŐ ?ŵů &/d-labelled antibody alone. Data is representative of at least 3 
experiments. 
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Figure 4.6 Fixing cells does not decrease the level of mAb binding to C170 cells. C170 cells were fixed for 
15mins on ice in 1% formaldehyde before 0.1-3 ?ʅŐ ?ŵů  ? ? ? ? ? ?  ?Ă ) ?  ?-25 LE (b) or BR96 (c) was added to the 
fixed or fresh cells. Binding of mAb was detected with anti-mouse IgG FITC before analysing the cells by flow 
cytometry. Data is representative of at least 3 experiments. 
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Figure 4.7 Cross-reactivity of 692/29 with BR96. Kt ? ? ĐĞůůƐ ǁĞƌĞ ŝŶĐƵďĂƚĞĚ ǁŝƚŚ  ? ? ?ʅŐ ?ŵů Z ? ?-FITC 
ďĞĨŽƌĞďĞŝŶŐŝŶĐƵďĂƚĞĚǁŝƚŚ ? ? ?ĂŶĚ ? ?ʅŐ ?ŵů692/29-biotinylated. Cells were then probed for 692/29-biotin 
binding with streptavidin-PE/Cy5. Binding of 692/29-biotin is not inhibited by the pre-incubation of cells with 
BR96-FITC (a) which can be seen as both mAbs are present on the cells (b) The reverse was undertaken, 
incubating OAW28 cells with  ? ? ?ʅŐ ?ŵů  ? ? ? ? ? ?-biotin before adding 1- ? ?ʅŐ ?ŵů Z ? ?-FITC. The presence of 
692/29-biotin was detected by streptavidin PE/Cy5. Binding of BR96-FITC is not inhibited by 692/29-biotin (c) 
with both mAbs still present on the cells (d) when compared to the negative control (e). Data is representative 
of at least 3 experiments. 
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4.2.4 Induction of ADCC and CDC in cancer cells by 692/29, BR96 and 2-25 LE  
The strong binding of the mAbs to cell lines should result in either ADCC in the presence of effector 
cells or CDC in the presence of complement. The ability of 692/29, BR96 and 2-25 LE to induce ADCC 
and CDC in vitro was tested using Lewis y/b positive target cells and either PBMCs isolated from 
human blood (ADCC) or serum isolated from human blood (CDC). Figure 4.8 shows that 692/29 is 
able to induce ADCC in cell lines that display a high level of binding (Colo 205), but is unable to 
induce ADCC in cells with lower levels of binding (OVCAR3, OAW28). 2-25 LE is also able to induce 
ADCC in Colo 205 cells but not in the cell lines that fail to express Lewis b (OVCAR3, OAW28). BR96 is 
able to induce ADCC in OAW28, and OVCAR3 cells despite the fact that it binds quite weakly to the 
latter cell line (Fig 4.8a-c).  
Figure 4.8e shows that 692/29 is able to induce CDC in Colo 205 and LoVo cells but not in the weak 
binding cell lines; SW480, OVCAR3, OAW28, MKN45 or HT29. In contrast, BR96 is able to induce CDC 
in Colo 205, LoVo, OAW28, SW480, and OVCAR-3, despite the fact that it binds quite weakly to the 
latter two lines. It does however fail to induce CDC in the very low and negative cell lines HT29 and 
MKN45. CDC induced by 2-25 LE is restricted to Colo 201 cells.  
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Figure 4.8 ADCC and CDC assays. Titration of anti-Lewis y and b mAbs on Colo 205 (a), OAW28 (b), OVCAR-3 (c) 
and a histogram showing the levels of CDC lysis observed in a range of colorectal and ovarian cancer cells (d). 
Cells were incubated with 692/29 2-25 LE and BR96 along with either PBMCs extracted from human blood (a, 
b, c) or 10% human serum (d) for 4 hours at 37
o
C. Cell lysis was measured by Cr
51
 release. All data points have 
error bars, but may be obscured by marker. * represents p<0.05. 
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4.2.5 Induction of cell death in colorectal cancer cells by 692/29, BR96 and not 2-25 LE 
BR96 has previously been shown to induce membrane permeability, causing PI uptake. To determine 
if the differences in antigen recognition influenced the direct killing of the Lewis mAbs, they were 
incubated with a panel of cell lines expressing different levels of antigen. Membrane perturbation 
was assessed using PI uptake. 692/29 induces PI uptake in C170, Colo 205, LoVo and OVCAR-3. Little 
PI uptake was observed in cells with low levels of Lewis y/b expression; HT29 and OAW28 cells (Fig 
4.9). BR96 induces PI uptake in C170, Colo205, HT29 and LoVo cells, despite binding weakly to HT29 
(Fig 4.9). 2-25 LE fails to induce PI uptake in any of the cell lines, despite showing strong binding to 
C170 and Colo 205. Histograms of PI uptake are shown for C170 and summarised as percentage 
uptake for all cell lines (Fig 4.9g-j). In order to confirm PI uptake corresponded to cell death C170 
cells were incubated with 692/29 for 5 days and cell number measured. Initially the number of cells 
decreased overnight before continuing to grow at the same rate as untreated cells (Fig 4.10a). Figure 
4.10b and c shows that the surviving cells expressed similar levels of antigen to untreated cells after 
the 5 days and were not resistant to killing as they were susceptible to a new dose of 692/29. 
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Figure 4.9 Both 692/29 and BR96 induce direct cell death in a range of cell lines with 2-25 LE unable to 
induce direct cell death. C170 (a), Colo 205 (b), OVCAR-3 (c), OAW28 (d), HT29 (e) and LoVo (f) cells were 
incubated with 0- ? ?ʅŐ ?ŵů ? ? ? ? ? ? ?Z ? ? ? ?-25 LE or an isotype control overnight at 37o ? ?ʅŐW/was added to 
each well 30mins before harvesting cells and detecting fluorescence by flow cytometry. Histograms of C170 
uptake of PI after incubation with isotype control (g), 692/29 (h), 2-25 LE (i) and BR96 (j). Data is representative 
of at least 3 experiments. 
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Figure 4.10 692/29 induces cell death of C170 cells over 5 days and the resulting cells express the same level 
of antigen as untreated cells which can then subsequently killed by 692/29. Cells were incubated with 
 ? ?ʅŐ ?ŵů692/29 and incubated at 37oC for 5 days. Cell numbers were assessed on days 0, 1, 3 and 5 using a 
trypan blue assay (a). Binding of 692/29 to 692/29-treated and untreated cells was compared by screening 
cells with 0.1, 0.3, 1ʅŐ ?ŵů ? ? ? ? ? ?ĂŶĚďŝŶĚŝŶŐƉƌŽďĞĚ with rabbit anti-mouse IgG-FITC (b). 692/29-treated and 
ƵŶƚƌĞĂƚĞĚĐĞůůƐǁĞƌĞŝŶĐƵďĂƚĞĚŽǀĞƌŶŝŐŚƚǁŝƚŚĂĨƌĞƐŚĚŽƐĞŽĨ ? ? ? ? ?ʅŐ ?ŵů ? ? ? ? ? ? ?W/ǁĂƐƚŚĞŶĂĚĚĞĚƚŽĐĞůůƐ
before analysing by flow cytometry (c). Data is the average of at 3 separate experiments, with error bars 
present, but may be obscured by data points. 
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4.2.6 Cross-linking the IgG1 mAb 2-25 LE does not induce direct cell death  
The anti-Lewis b mAb 2-25 LE demonstrated highest binding to Colo 205 and LoVo cell lines but fails 
to induce PI uptake and cell death. IgG3s reportedly have the ability to dimerise which may promote 
the killing observed with 692/29 and BR96. As 2-25 LE is an IgG1, it and 692/42, an IgG1 isotype 
recognising the same epitope on Lewis y and Lewis b as 692/29 (unpublished data), was screened for 
killing with and without the addition of rabbit anti-mouse and goat anti-rabbit cross-linking 
antibodies. Figure 4.11 shows that the addition of cross-linking antibodies increases the killing seen 
with 692/42 (IgG1), but did not further enhance 692/29 (IgG3) or promote killing with 2-25 LE (IgG1). 
 
 
 
Figure 4.11. Cross-linking the IgG1 2-25LE does not induce cell death in Colo 205 cells. Colo 205 cells were 
ŝŶĐƵďĂƚĞĚ ǁŝƚŚ  ? ?ʅŐ ?ŵů  ? ? ? ? ? ? ?  ? ? ? ? ? ? ĂŶĚ  ?-25LE either alone, or with rabbit anti-mouse or rabbit anti-
mouse and goat anti-rabbit mAbs. Cells were then incubated overnight and PI uptake was measured (a). PI 
uptake in cells incubated with irrelevant IgG control (b), 692/29 (c), 692/42 (d)and 2-25 LE (e) or with rabbit 
anti-mouse and goat anti-rabbit Ig (f, g, h and i). Results representative of two independent experiments. 
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4.2.7 692/29 and BR96 induce cell death via an alternative mechanism to apoptosis  
A number of anti-glycan mAbs, including BR96, have been shown to cause PI uptake by membrane 
perturbation, independently of apoptosis. To investigate whether 692/29 also caused cell death 
independently of apoptosis, cells were incubated with mAbs in the presence or absence of a pan 
caspase inhibitor, z-FMK-vad ?&ŝŐƵƌĞ ? ? ? ?ƐŚŽǁƐƚŚĂƚĚĞƐƉŝƚĞƚŚĞĂĚĚŝƚŝŽŶŽĨ ? ?ʅDǌ-FMK-vad, only 
low levels of inhibition of cell death were observed with 692/29 or BR96, while anti-Fas mediated 
killing of Jurkat cells was almost completely inhibited by z-FMK-vad. To further investigate if the cell 
death was mediated on metabolically active cells, mAb induce death was measured after incubation 
of C170 cells at 22
o
C and 4
o
C. Figure 4.13 shows that 692/29 and BR96 could induce uptake of PI at 
both 22 and 4
o
C (Fig 4.13a and b). 
The induction of PI uptake in the presence of a pan caspase inhibitor and at both 22 and 4
o
C, 
suggested that the mechanism of direct cell death was not of the type I, caspase-mediated apoptosis 
but may be related to oncosis, type II or type III caspase-independent mechanisms. Oncosis is 
associated with plasma membrane damage, caused by the formation of large pores in the 
membrane. Therefore, FITC-conjugated dextran beads ranging from 3kMW to 500kMW in size were 
used to study the size of pore formation induced by 692/29 and BR96. Anti-Fas mediated killing of 
Jurkat cells displayed uptake of only the smaller sized beads, compared to the membrane disruption 
with saponin that showed no discrimination in bead uptake (Fig 4.14). Similarly, figure 4.14 shows 
that the 3, 40 and 500k MW dextran beads were able to diffuse into 692/29 and BR96 treated cells, 
leading to an increased level of fluorescence when compared to the untreated and 2-25 LE-treated 
controls. This suggests that the size of pores formed on the cell surface by 692/29 and BR96 are 
larger than 500K MW.  
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Figure 4.12 692/29 and BR96 mediated killing of C170 cells is not inhibited by pan caspase inhibitor. C170 
cells were incubated with  ? ?ʅŐ ?ŵů  ? ? ? ? ? ? ?  ?-25 LE and BR96 with and without a pan caspase inhibitor 
overnight at 37
o
C, 5% CO2. Jurkat cells were ŝŶĐƵďĂƚĞĚ ǁŝƚŚ  ? ? ?ʅŐ ?ŵů ĂŶƚŝ-Fas as a positive control. PI was 
added to all cells before fluorescence was detected by flow cytometry. Histograms are shown depicting IgM 
isotype control incubated with Jurkat cells without (b) and with pan caspase inhibitor (c), or with anti-Fas mAb 
without (d) and with pan caspase inhibitor (e), IgG isotype control incubated with C170 cells without (f) and 
with pan caspase inhibitor (g), C170 cells incubated with 692/29 (h), 2-25 LE (i) and BR96 (l) without inhibitor 
and with pan caspase inhibitor (i, k and m). Data is representative of at least 3 experiments. 
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Figure 4.13 692/29 and BR96 kill C170 cells at both 4 and 22
o
C. 5x10
4
 C170 cells were incubated with 10 and 
30ʅŐ ?ŵůŽĨ ? ? ? ?29 (a), BR96 (b) or 2-25 LE (c) overnight at 4oC or 22oC or 5 x 104 Jurkat cells were incubated 
with 0, 250 and 500ng/ml anti-Fas mAb overnight at 4
o
C or 22
o
C (d). PI was added to the cells before analysing 
the percentage of dead cells using flow cytometry. Irrelevant-IgG was used as a negative control. Data is 
representative of at least 3 experiments. 
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Figure 4.14 Uptake of dextran beads upon 692/29, 2-25 LE and BR96 treatment. C170 cells were incubated 
ǁŝƚŚ  ? ?ʅŐ ?ŵů ŵď ĂŶĚ  ? ?  ? ? ? ĂŶĚ  ? ? ?< Dt ĚĞǆƚƌĂŶ-FITC beads or PI overnight before measuring uptake 
using flow cytometry. 30min treatment with 0.4% saponin was used as a positive control. Anti-Fas treatment 
of Jurkat cells overnight was used as a negative control for 500k MW dextran uptake (a). Histograms depict 
uptake of 500K MW dextran-FITC in C170 cells incubated with irrelevant IgG (b), 692/29 (c), 2-25 LE (d), BR96 
(e) and 0.4% saponin (f) or Jurkat cells incubated with irrelevant Ig (g) or 500ng/ml anti-Fas (h). Data is 
representative of at least 3 separate experiments. 
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4.3 Discussion  
One major value of mAbs as therapeutic agents is their ability to bind to a specific epitope, which 
can lead to specific targeting of the mAb in vivo and to less toxicity compared to conventional 
therapeutics, such as chemotherapy and radiotherapy. A further advantage is a mAbs ability to 
recruit the immune system to kill target cells, either by ADCC or CDC. Furthermore, as described 
previously, mAbs have also been shown to cause cytotoxicity directly, without the need of immune 
effector cells. 
Lewis antigens have been proven to be over-expressed on a range of tumours making them good 
tumour markers (Abe et al., 1986; Hakomori, 1985; Itzkowitz, 1992; Madjd et al., 2005; Masayuki et 
al., 1995; Sakamoto et al., 1986; Sakamoto et al., 1989). MAbs recognising these haptens were 
therefore assessed for their therapeutic potential. As more recent studies have shown that the cross 
reactivity of anti-glycan mAbs has been underestimated (Manimala et al., 2007), the specificity of 
binding of 692/29 and BR96 was confirmed on the Consortium for Functional Glycomics glycan array. 
These results were compared to array binding data for 2-25 LE obtained from the Consortium 
database. The array confirmed that BR96 binds to its described antigen Lewis y but also reacts with a 
range of Lewis y variants (Lewis y-x, Lewis y-x-x) and more weakly to Lewis x and that 2-25 LE binds 
to Lewis b, with cross-reactivity with Lewis a and a-x. 629/29 binds most strongly to Lewis b and 
glycans containing Lewis b and also to tri-Lewis y and its variants. This is an interesting and novel 
feature as Lewis y or b mAbs have previously been described, including BR96 and 2-25 LE, but only 
one has been reported to bind both antigens (Brodin et al 1987). However, this mAb has 
haemagglutinating properties suggesting it cross-reactivity with H antigen and so would not be 
useful therapeutically. Furthermore, it has been shown that two independently produced anti-Lewis 
y mAbs (BR96 and 3S193) bind to structurally similar epitopes of Lewis y, and do not cross-react with 
b, suggesting a convergence of antigen binding to one more immunogenic epitope (Ramsland et al., 
2004). 692/29 has previously been shown to bind to both Lewis y and b on a high percentage of 
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ovarian, colorectal, and gastric cancers (Durrant et al., 1993); Unpublished data. In order to observe 
whether the fine specificity of the Lewis y/b mAbs influenced binding to cells, the mAbs were 
screened against a range of colorectal and ovarian cancer cell lines. This revealed that the binding 
differed between the mAbs, despite cells being antigen positive, suggesting that the in vivo 
distribution of the mAbs may also differ. This would explain the lack of gastrointestinal binding with 
692/29 (Unpublished data) when compared to BR96, which bound strongly to large intestine and 
caused dose limiting toxicity (Saleh et al., 2000). 
Each mAb bound to a range of colorectal cancer cell lines without saturation being reached, 
suggesting they may bind in a homophilic manner. This was confirmed when the presence of 
 ? ? ?ʅŐ ?ŵů ƵŶůĂďĞůůĞĚ ŵď ĚŝĚ ŶŽƚ ŝŶŚŝďŝƚ ƚŚĞ ďŝŶĚŝŶŐ ŽĨ ĨƵƌƚŚĞƌ ŵď ? &ƵƌƚŚĞƌmore, incubation of 
Kt ? ?ĐĞůůƐ ?>ĞǁŝƐďŶĞŐĂƚŝǀĞ ?>ĞǁŝƐǇƉŽƐŝƚŝǀĞ )ǁŝƚŚ ? ? ?ʅŐ ?ŵůŽĨ ? ? ? ? ? ? ?ĚŝĚŶŽƚŝŶŚŝďŝƚďŝŶĚŝŶŐŽĨ
FITC-conjugated BR96 to the cells, suggesting that BR96 may have the ability to not only bind to 
itself, but also to 692/29. These results do not exclude the possibility that there was very high levels 
of Lewis y that could not be saturated even with very high levels of mab. ,ŽǁĞǀĞƌ ? ? ? ?ʅŐ ?ŵůŽĨŵď
contains ~2x10
13
 molecules of antibody. If this fails to saturate there must be a very high frequency 
of the epitope. It may be more likely that multiple mAb molecules were bound to each glycan. 
Conversely, the presence of Lewis y on glycolipids and glycoproteins and the high level of 
unsaturable binding may suggest a very high level of Lewis y on cancer cells, which would be 
therapeutically beneficial.  
It has been observed that mouse IgG3 mAb have a tendency to aggregate in solution (Grey et al., 
1971) and that this is due to Fc-Fc interaction, causing dimerisation. They may therefore aggregate 
on the cell surface. However, 2-25 LE is an IgG1 and also displays properties of homophilic binding. 
Furthermore, binding of antibodies via the CDR regions has been reported, increasing the binding 
antibodies avidity for the antigen. Evidence of this phenomenon has been seen in both mouse and 
human anti-PC mAbs (Halpern et al., 1991; Kang et al., 1987). Their studies show that both mouse 
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and human mAbs purified from sera can bind to PC and also to each other (including mouse mAb-
human mAb and human mAb-mouse mAb binding). They found that this self-binding could be 
inhibited by the binding of a peptide to the CDR2 (Halpern et al., 1991) and that this is due to a 
conserved sequence in the variable region (Kang et al., 1987). This group also conjugated the 
variable region sequence responsible for homophilic binding to non-homophilic antibodies, including 
an anti-CD20 mAb, showing greater inhibition of growth and cell death than with non-conjugated 
anti-CD20 mAb (Zhao et al., 2002). 
ADCC and CDC assays were carried out against cells that have high and low expression of the Lewis 
y/b antigens using 692/29 and BR96. BR96 was able to induce ADCC and CDC on cells with both high 
and low levels of antigen expression, whereas 692/29 and 2-25 LE were more selective only 
mediating ADCC and CDC on cells with high antigen expression. As both Lewis y and Lewis b is 
expressed at low levels on normal cells this would predict a better therapeutic index for 692/29 and 
2-25 LE than BR96 which may mediate immune directed killing of normal cells. BR96 failed in clinical 
studies due to mAb mediated GI toxicity (Tolcher et al., 1999). 
 In order to further characterise the mechanism of direct cytotoxicity the mAbs were incubated with 
a range of cell lines and PI uptake was measured. This confirmed that both BR96 and 692/29 had the 
ability to induce PI uptake in cells directly, whereas 2-25 LE did not. BR96 was able to induce PI 
uptake in cells that it showed weak binding, whereas, 692/29 was only able to induce PI uptake in 
cells with a high expression of Lewis y/b.  
As all three mAbs displayed homophilic binding properties, the lack of killing by 2-25 LE to cells with 
high levels of antigen suggest that homophilic characteristics are not the main cause of direct cell 
death. Both 692/29 and BR96 are IgG3 that have the ability to dimerise, whereas 2-25 LE is an IgG1. 
To test if the ability of the IgG3 mAbs to cross-link was responsible for direct killing, 2-25 LE was 
cross-linked using rabbit anti-mouse Ig and goat anti-rabbit Ig mAbs. This showed that despite cross-
linking, 2-25 LE was unable to induce direct cell death, implying that the mechanism of cell death is 
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not dependent on the ability of IgG3 to cross-link, but may be antigen dependent. This suggests that 
Lewis b may not present on a functional glycolipid or glycoprotein that is capable of inducing cell 
death. 
Previous studies had shown that BR96 was able to induce rapid cell death due to mAb recycling 
(Garrigues et al., 1993). It was suggested that this was not caused by apoptosis. Therefore cells were 
incubated at 4 and 22
o
C, as 4
o
C has been suggested to be lower than the temperature required for 
apoptosis to occur. Studies have shown that at temperatures lower than 15
o
C Bax is unable to insert 
into the mitochondrial membrane, inhibiting its ability to cause cytochrome C release, and therefore 
the activation of caspases in neutrophils (Pryde et al., 2000). Incubation of C170 cells at 4
o
C with 
692/29 and BR96 failed to inhibit their ability to cause PI uptake. Furthermore, PI uptake was not 
inhibited by a pan caspase inhibitor, suggesting that both mAbs are able to induce cell death 
independently of apoptosis. In contrast, anti-Fas induced only low level apoptosis at 4°C and much 
higher levels at 37°C which were inhibited by the pan caspase inhibitor. 
Previous studies have shown that mAbs can induce the caspase-independent cell death pathway, 
oncosis. For example, RAV12, which binds the carbohydrate antigen RAAG12, binds 90% of intra-
abdominal tumours and has been shown to induce oncosis and inhibit growth of tumour xenografts 
(Loo et al., 2007). Also, the anti-porimin mAb, has been shown to cause oncosis in Jurkat cells (Zhang 
et al., 1998). mAb 84, that binds to the glycoprotein, podocalyxin-like protein 1 (PODXYL) has been 
shown to induce pore formation and oncosis in human embryonic stem cells using a range of 
different sized FITC-conjugated dextran beads (Tan et al., 2009). More recently, sera from patients 
treated with an anti-idiotype mAb mimicking the GSL NeuGc-GM3, has the ability to induce the 
production of human anti-Neu5Gc-GM3 mAbs that induce oncosis in a leukemic cell line (Hernandez 
et al., 2011). One of the hallmarks of oncosis is the formation of large pores that are unique to 
oncosis and not seen in apoptosis. Therefore the level of fluorescence of cells after incubation with 
692/29 and BR96 and various sized dextran beads was tested. Both 692/29 and BR96 mAbs 
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produced pores large enough to allow 500,000 MW dextran beads into the treated cells suggesting 
that both BR96 and 692/29 have the ability to mediate oncosis in Lewis y positive cells.  
When both the immune mediated killing and direct killing were taken into consideration our results 
would suggest that 692/29 may be the more therapeutically valuable mAb. It binds to a wide range 
of cells expressing either Lewis y or b and causes direct cell death as well as ADCC and CDC in tumour 
cells over expressing Lewis y and b antigens. However, it fails to kill low expressing cells and may 
therefore have less toxicity to low expressing normal cells.  
In conclusion, our study suggests that mAbs directed at the same antigen, display subtle differences 
in binding in vitro, which may affect tissue distribution in vivo. Furthermore, the differences in 
binding due to affinity or antigen density result in different effector functions, which may lead to 
increased toxicity in vivo. This can lead to the improved therapeutic benefit of mAbs recognising 
more than one glycan, such as the Lewis y/b mAb described in this study.  
The ability of 692/29 and BR96, both anti-glycan mAbs to cause direct cell death in antigen positive 
cell lines warrants further investigation into another mAb produced in house, 505/4, that has been 
shown to bind to a glycan epitope.  
 
 
 
 
 
 
  
146 
 
Chapter 5 Characterisation of the functional properties of an anti-
glycan mAb 
5.1 Introduction 
As previously described, it has been widely reported that glycans on cancer cells undergo significant 
changes during transformation (Dabelsteen, 1996; Hakomori, 1985; Kannagi et al., 2008). This has 
lead to certain glycans being used as tumour markers and therapeutic targets. Aberrant fucosylation 
of glycan-containing glycolipids or glycoproteins, leads to the increase in fucosylated glycans on the 
tumour cell surface, resulting in the overexpression of glycans such as Lewis x and Lewis a (Moriwaki 
& Miyoshi, 2010). For example, both Lewis a and sialyl Lewis a glycans are expressed at higher levels 
on tumour cells than on normal cells, making them good targets for monoclonal antibody (mAb) 
therapy (Kannagi et al., 2008). Furthermore, a large number of anti-glycan mAbs are capable of 
inducing direct cell death in cancers, such as the Lewis y specific mAbs 692/29 and BR96, described 
in the previous chapter and the previously mentioned F77 and RAV12 mAbs (Coberly et al., 2009; 
Zhang et al., 2010a).  
Previous immunisation with a range of colorectal cancer cell lines lead to the production of an anti-
colorectal glycolipid cancer mAb, 505/4 (unpublished data). CA19.9 is a mAb recognising sialyl Lewis 
a (also known as CA19.9 [carbohydrate antigen 19.9]; (Magnani et al., 1982)). Sialyl Lewis a has been 
shown to be overexpressed in a range of cancers, including colorectal (Yamada et al., 1997), breast 
(Jeschke et al., 2005) and ovarian (Charpin et al., 1982; Magnani et al., 1982). It is used as a serum 
ŵĂƌŬĞƌŝŶĂƌĂŶŐĞŽĨĐĂŶĐĞƌƐ ?ŝŶĐůƵĚŝŶŐĐŽůŽƌĞĐƚĂůĐĂŶĐĞƌƚŽŵĞĂƐƵƌĞĂƉĂƚŝĞŶƚ ?ƐƌĞƐƉŽŶƐĞƚŽƚŚĞƌĂƉǇ 
(Nakagoe et al., 2001). 7LE is a commercial anti-Lewis a mAb. 
In this study, we aim to further characterise the antigen, cell distribution and functional properties 
of the murine 505/4 mAb, as well as comparing the mAb with other colorectal cancer anti-glycan 
mAbs (CA19.9 and 7LE).  
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5.2 Results 
5.2.1 Analysis of 505/4 therapeutic value by normal and colorectal cancer distribution  
505/4 was produced by immunising mice with a range of colorectal cancer cell lines and was 
screened for strong binding to the cell surface of colorectal cell lines. 505/4 was incubated with a 
range of colorectal, ovarian, breast cancer cell lines, as well as normal human umbilical endothelial 
cell and fibroblast cell lines. Figure 5.1 shows that 505/4 binding was restricted to colorectal cell 
lines. Binding was also seen on the breast carcinoma cell line T47-D, but not to any other breast 
cancer cell lines or to the normal human umbilical vein endothelial cells (HUVEC).  
In order to assess the therapeutic value of 505/4, the mAb was stained on a colorectal TMA 
consisting of 462 tumours. 505/4 bound to 82% of colorectal tumours stained, 37% stained weakly, 
26% stained moderately and 19% stained strongly, with the remaining 18% showing no binding (Fig 
5.2a). Representative examples of negative, weak, moderate and strong staining are shown in figure 
5.2b-e). 
Although mAbs bind in a specific manner to their antigen, with less toxicity than traditional 
therapies, such as chemotherapy, they can cause toxicity by binding antigen expressed on normal 
tissue. Therefore, 505/4 was assessed for binding to normal tissue by immunohistochemistry. No 
staining was recorded in normal human brain, heart, prostate, testis, uterus, ovary, oesophagus, 
duodenum, ileum, jejunum, skeletal muscle, placenta or spleen (Table.5.1). 505/4 showed weak 
binding to gallbladder, cervix and rectum. Moderate staining was seen against breast, liver, tonsil 
and thymus with strong binding only seen to colon (Table 5.1). Figures 5.3b-g show examples of 
negative staining on brain (b) and heart (c), weak staining on lung (d), moderate staining to pancreas 
(e) and breast (f) and strong staining to colon (g). Despite binding to normal liver tissue by 
immunohistochemistry, 505/4 did not show binding to fresh hepatocytes, suggesting binding seen 
on normal liver tissue sections, may be to intracellular antigens (Fig 5.3). 
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Figure 5.1 505/4 binds to a range of colorectal cell lines. Cell lines were plated at 1x10
5
 cells per well and 
ŝŶĐƵďĂƚĞĚ ǁŝƚŚ  ?ʅŐ ?ŵů505/4. Binding of 505/4 to the cells was probed with an anti-mouse IgG-FITC mAb 
before analysing the cells by flow cytometry. An irrelevant IgG mAb was used as a negative control (geometric 
mean 5). Data is representative of at least 3 experiments. 
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Figure 5.2 Binding of 505/4 to colorectal tumours and normal tissues. 504/4 was screened for binding on an 
array of colorectal cancers from a cohort of 462 patients and an array of 29 normal tissues by 
immunohistochemistry (a). Binding was visualised with DAB. Representatives of negative (b), weak (c), 
moderate (d) and strong (e) staining to colorectal tumours. Representatives of negative (f, g), weak (h), 
moderate (i, j) and strong (k) staining of the normal array are displayed at x10 original magnification. Black 
arrows indicate areas of staining. 
 
k) Colon j) Breast 
h) Lung i) Pancreas 
g) Heart f) Brain 
d)  e) 
c) b)  
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Table 5.1 Summary of 505/4 binding to a panel of normal tissues using paraffin-fixed sections. Intensity of 
staining is shown as 0, 1, 2 or 3, relating to negative, weak, moderate or strong binding. 
Tissue Type Age Gender Intensity of 
staining 
Placenta 29 F 0 
Placenta  29 F 0 
Oesophagus 23 M 0 
Oesophagus 23 M 0 
Rectum 24 F 0 
Rectum 24 F 1 
Gallbladder 24 M 3 
Gallbladder 24 M 1 
Skin 83 F 0 
Skin 83 F 0 
Adipose 26 M 0 
Adipose 26 M 0 
Heart 27 M 0 
Heart 27 M 0 
Skeletal 26 M 0 
Skeletal 26 M 0 
Bladder              36 F 0 
Bladder              36 F 0 
Ileum                62 M 0 
Ileum                62 M 0 
Spleen               30 M 0 
Spleen               30 M 0 
Brain                68 M 0 
Brain                68 M 0 
Jejunum              56 M 0 
Jejunum              56 M 0 
Stomach              66 M 0 
Stomach              66 M 0 
Breast               27 F 2 
Breast               27 F 2 
Kidney               56 M 0 
Kidney               56 M 0 
Testis               32 M 0 
Testis               32 M 0 
Cerebellum           73 F 0 
Cerebellum           73 F 0 
Liver                30 M 2 
Liver                30 M 2 
Thymus               28 M 2 
Thymus               28 M 0 
Cervix               30 F 0 
Cervix               30 F 1 
Lung                 24 M 0 
Lung                 24 M 0 
Smooth Muscle        23 M 0 
Smooth Muscle        23 M 0 
Colon                28 M 3 
Colon                28 M 3 
Ovary                50 F 0 
  
151 
 
Ovary                50 F 0 
Tonsil               28 F 2 
Tonsil               28 F 0 
Diaphragm             26 M 0 
Diaphragm             26 M 0 
Pancreas             50 M 2 
Pancreas             50 M 3 
Uterus               40 F 0 
Uterus               40 F 0 
Duodenum             24 M 0 
Duodenum             24 M 0 
Thyroid              26 M 0 
Thyroid              26 M 0 
 
 
Figure 5.3 Binding of 505/4 to the gastric cell line ST16 but not to fresh hepatocytes ? ?ʅŐ ?ŵů ? ? ? ? ? ?t ? ? ? ?Žƌ
IgG1 isotype control was incubated with either 1x10
5
 ST16 cells or hepatocytes for 60min. Binding of primary 
antibody was probed with rabbit anti-mouse IgG-FITC before analysing fluorescence by flow cytometry. Data is 
representative of 3 separate experiments. 
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5.2.2 Characterisation of 505/4 antigen 
To test whether the 505/4 antigen was present on glycolipids, 505/4 binding to C170 glycolipid 
extract was tested. Glycolipid was extracted from C170 cells using chloroform: methanol. The 
extracted layers were bound to an ELISA plate and 505/4 was screened. Figure 5.4a shows that 
505/4 binds to the charged C170 glycolipid layer and to the protein layer, but not to either the 
neutral glycolipid layer or OVCA 433 glycolipid. 791T/36, an anti-CD55 mAb was used as a negative 
control, with F002, an anti-ovarian cancer glycolipid mAb produced in house used as a positive 
control. To confirm the specificity of 505/4 for a glycan C170 cells were treated with sodium 
periodate (NaIO4) to oxidise any cell surface glycans. 791T/36, a mAb directed against the protein 
antigen CD55, was resistant to NaIO4 treatment, whereas 505/4 binding was lost upon NaIO4 
treatment (Fig 5.4b).  
 
 
Figure 5.4 505/4 binds to a glycan epitope on both charged glycolipid and glycoprotein on a range of 
colorectal cancer cell lines. a) Glycolipid extract was carried out using 2:1 chloroform: methanol on C170 cells. 
The resulting layers were dried on ELISA plates before probing with 505/4. The anti-glycolipid mAb F002 was 
used as a positive control against OVCA 433 glycolipid, with the anti-CD55 mAb 791T/36 being used as a 
negative control. b) An ELISA plate coated with fixed C170 cells were incubated with 0, 0.125, 0.25 or 5mmol/L 
sodium periodate. Treated cells were then incubated 505/4 and mAb binding was probed with anti-IgG-HRP. 
ABTS colour change was used to assess the level of mAb binding. * depicts p<0.05. Results are representative 
of at least 2 experiments, error bars representing the standard deviation of quadruplicate wells are present for 
each data point, but may be obscured by marker. 
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5.2.3 Analysis of 505/4, CA19.9 and 7LE binding to the Consortium for Functional 
Glycomics array 
As the sodium periodate treatment and glycolipid ELISA suggested that 505/4 was binding to a 
glycan, the exact antigen was determined by screening 505/4 against a panel of 406 synthetic and 
naturally occurring glycans using the Consortium for Functional GlyĐŽŵŝĐƐ ?ĂƌƌĂǇ ?&ŝŐƵƌĞ ? ? ?a shows 
that binding of 505/4 to the glycan array was limited to Lewis a and its variants. Including sialyl di-
Lewis a, sialyl Lewis a (both human and mammalian sialic acids,), Lewis a, Lewis a-x and di-Lewis a. 
Table 5.2a demonstrates that the 505/4 bound most efficiently with the sialylated versions of the 
glycans. 
In order to compare 505/4 with other anti-Lewis a mAbs, the anti-Lewis a mab 7LE and anti-sialyl 
Lewis a mAb CA19.9 were acquired. The specificity of 7LE and CA19.9 was confirmed by obtaining 
array binding data from the Consortium for Functional Glycomics database. CA19.9 bound to 
sialylated precursor of Lewis a, sialylated Type 1 precursor whereas 505/4 did not. CA19.9 also 
bound to sialyl di-Lewis a (Fig 5.5b, table 5.2b) with both the human and mammalian version of sialic 
acid. 7LE bound specifically to Lewis a and its precursors (Fig 5.5c, Table 5.2c). It seemed to 
recognise a terminal Gal that is neither sulphated nor attached to sialic acid and prefers a non 
charged core of 2-4 sugars. 
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Figure 5.5 Glycan array binding data for 505/4 (a), CA19.9 (b) and 7LE (c). 505/4 shows specificity for sialyl 
Lewis a and its variants, including sialyl di-Lewis a (S-D-a), sialyl Lewis ax (S-ax) and sialyl di- Lewis ax (S-D-ax). It 
also binds to the non-sialylated variants of these glycans (Lewis a [a], Lewis ax [ax], and di-Lewis a [ax]). CA19.9 
binds to sialylated type 1 precursor (sP1) and sialyl di-Lewis a. 7LE shows specificity to Lewis a and to di-Lewis a 
as well as binding to type 1 precursor (P1). 
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Table 5.2 Describes the glycans that 505/4 (a), CA19.9 (b) and 7LE (c) bind to on the Glycome Consortium 
glycan array, the level of binding and the structures of the glycans. A blue squares represents glucosylamine, 
yellow circles represents galactose, red triangles represent fucose, green circles represent mannose and purple 
diamond represents sialic acid. Sulphation is represented by SO3 and Sp denotes the spacer between glycan 
and glass slide. 
a) 
Glycan 
No. 
Glycan Name Percentage of 
best binder (%) 
Structure 
325 Neu5Aca2-3Galb1-
3(Fuca1-4)GlcNAcb1-
3Galb1-3(Fuca1-
4)GlcNAcb-Sp0 
Sialyl Di-
Lewis a 
100 
 
216 Neu5Aca2-3Galb1-
3(Fuca1-4)GlcNAcb-Sp8 
Sialyl Lewis a 97 
 
254 Neu5Gca2-3Galb1-
3(Fuca1-4)GlcNAcb-Sp0 
Sialyl Lewis a 90 
 
114 Galb1-3(Fuca1-
4)GlcNAcb1-3Galb1-
4(Fuca1-3)GlcNAcb-Sp0 
Lewis a-x 68 
 
118 Galb1-3(Fuca1-4)GlcNAcb-
Sp8 
Lewis a 58 
 
29 [3OSO3]Galb1-3(Fuca1-
4)GlcNAcb-Sp8 
 ? ?-Sulfo 
Lewis a 
54 
 
271 Galb1-3(Fuca1-
4)GlcNAcb1-3Galb1-
3(Fuca1-4)GlcNAcb-Sp0 
Di- Lewis a 52 
 
116 Galb1-3(Fuca1-4)GlcNAcb-
Sp0 
Lewis a 49 
 
b) 
Glycan 
No. 
Glycan Name Percentage of 
best binder 
(%) 
Structure 
215 Neu5Aca2-3Galb1-
3[6OSO3]GlcNAc-Sp8 
Sialylated, 
sulfo Type-1 
precursor 
100 
 
325 Neu5Aca2-3Galb1-
3(Fuca1-4)GlcNAcb1-
3Galb1-3(Fuca1-
4)GlcNAcb-Sp0 
Sialyl Di-
Lewis a 
98 
 
255 Neu5Gca2-3Galb1-
3GlcNAcb-Sp0 
Sialylated 
Type-1 
precursor 
94 
 
ɲ ? 
SO3 
ɲ ? 
SO3 
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c) 
Glycan 
No. 
IUPAC Name Percentage 
of best 
binder (%) 
Structure 
119 Galb1-3(Galb1-
4GlcNAcb1-6)GalNAca-
Sp8 
Type-2 
precursor 
containing 
glycan 
100 
 
274 Galb1-3(Neu5Aca2-
3Galb1-4GlcNacb1-
6)GalNAca-Sp14 
Sialylated 
Type-2 
precursor 
containing 
glycan 
93 
 
118 Galb1-3(Fuca1-
4)GlcNAcb-Sp8 
Lewis a 87 
 
279 Galb1-4(Fuca1-
3)GlcNAcb1-3Galb1-
3(Fuca1-4)GlcNAcb-Sp0 
Lewis x-a 82 
 
124 Galb1-3GalNAca-Sp8 Galactose 
disaccharide 
81 
 
132 Galb1-3GlcNAcb-Sp0 Type-1 
precursor 
79 
 
131 Galb1-3GlcNAcb1-
3Galb1-4Glcb-Sp10 
Type-1 
precursor 
containing 
glycan 
78 
 
117 Galb1-3(Fuca1-4)GlcNAc-
Sp8 
Lewis a 65 
 
115 Galb1-3(Fuca1-
4)GlcNAcb1-3Galb1-
4GlcNAcb-Sp0 
Extended 
Lewis a 
44 
 
116 Galb1-3(Fuca1-
4)GlcNAcb-Sp0 
Lewis a 40 
 
61 Fuca1-2Galb1-
3GlcNAcb1-3Galb1-4Glcb-
Sp10 
Extended 
Type I H 
antigen 
26 
 
62 Fuca1-2Galb1-
3GlcNAcb1-3Galb1-4Glcb-
Sp8 
Extended 
Type I H 
antigen 
24 
 
311 Mana1-2Mana1-2Mana1-
3(Mana1-2Mana1-
6(Mana1-2Mana1-
3)Mana1-6)Mana-Sp9 
Mannose-
rich glycan 
17  
 
 
 
ɲ ? 
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5.2.4 Analysis of 505/4, CA19.9 and 7LE colorectal cell line binding 
In order to establish whether subtle differences in antigen specificity related to in vitro distribution, 
the mAbs were compared for binding to a panel of colorectal cancer cell lines. The mAbs all showed 
similar levels of binding to C170 (Fig 5.6a), Colo 201 (b) and Colo 205 (c). However only CA19.9 
bound to SW480, HT29 and MKN45 cell lines, suggesting binding of sialyl Type I precursor by CA19.9 
and not sialyl di-Lewis a. 
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Figure 5.6 505/4, 7LE and CA19.9 bind to a range of colorectal cell lines. C170 (a) Colo 201 (b) Colo 205 (c), 
SW480 (d), HT29 (e) and MKN-45 (f) cells were incubated with 0.1-3 ?ʅŐ ?ŵů ? ? ? ? ? ? ?>Žƌ ? ? ? ?ĂŶĚƉƌŽďĞĚ
for binding with FITC-labelled rabbit anti-mouse IgG. Cells were then analysed for binding using flow 
ĐǇƚŽŵĞƚƌǇ ?ǆĂŵƉůĞƐŽĨ ? ?ʅŐ ?ŵůirrelevant IgG (g), 505/4 (h), 7LE (i) and CA19.9 (j) binding histograms to C170 
cells. Data is representative of at least 3 separate experiments. 
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5.2.5 Direct killing ability of 505/4, 7LE and CA19.9 mAbs 
Several anti-glycan mAbs have the ability to induce direct cell killing, including the anti-Lewis y and 
Lewis b mAbs discussed previously in this thesis. Therefore, all three mAbs were assessed for their 
ability to kill cells without immune effector cells or complement. Figure 5.7 shows that all three 
mAbs have the ability to cause PI uptake in colorectal cancer cells. All three mAbs bind equally to 
C170 and Colo 201 cells (data not shown) but 505/4 and CA19.9 mAbs kill more effectively. In 
contrast, SW480 cells which bind very weakly to CA19.9 and not to 505/4 or 7LE are not killed. Of 
interest is Colo 205 which is a metastatic tumour derived from the same patient as Colo 201. This 
line is bound and killed by 505/4 and CA19.9 but is not directly killed by 7LE. To confirm that PI 
uptake equates to cell death, C170 cells were incubated with 505/4 for 5 days and the number of 
cells on days 0, 1, 3 and 5 were measured. Figure 5.8a showed that the uptake of PI does indeed 
reflect cell death, as the cell numbers significantly decreased from day 0 to day 1 when compared to 
a control well (p=0.038). However, the remaining viable cells then grew out at the same rate as 
untreated cells. When these cells were reanalysed for 505/4 binding they expressed similar levels of 
antigen to untreated cells (Fig 5.8b) and were equally susceptible to killing (Fig 5.8c). This suggested 
that the cells that were killed by 505/4 in the initial exposure had a lower level of antigen, possibly 
due to alteration of antigen expression throughout the cell cycle, as when they regrew they were 
susceptible to killing. 
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Figure 5.7 The three anti-Lewis a mAbs tested induce direct cell death in a range of cell. C170 (a), Colo 201 
(b), Colo 205 (c) and SW480 (d) cells were incubated overnight at 22
o
C with 505/4, 7LE and CA19.9 or isotype 
control before analysing PI uptake by flow cytometry. Histograms showing uptake of PI after isotype control 
(e), 505/4 (f), 7LE (g) or CA19.9 (h) incubation. All data are representative of at least 3 experiments. 
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Figure 5.8 505/4 induces cell death of C170 cells over 5 days and the resulting cells express the same level of 
antigen as untreated cells which can then subsequently killed by 505/4. ĞůůƐǁĞƌĞŝŶĐƵďĂƚĞĚǁŝƚŚ ? ?ʅŐ ?ŵů
505/4 and incubated at 37
o
C for 5 days. Cell numbers were assessed on days 0, 1, 3 and 5 using a trypan blue 
assay. p=0.038 (a). Binding of 505/4 to 505/4-treated and untreated cells was compared by screening cells with 
 ?ĂŶĚ  ? ?ʅŐ ?ŵů  ? ? ? ? ?ĂŶĚďŝŶĚŝŶŐƉƌŽďĞĚǁŝƚŚ ƌĂďďŝƚĂŶƚŝ-mouse IgG-FITC (b). 505/4-treated and untreated 
ĐĞůůƐ ǁĞƌĞ ŝŶĐƵďĂƚĞĚ ŽǀĞƌŶŝŐŚƚ ǁŝƚŚ Ă ĨƌĞƐŚ ĚŽƐĞ ŽĨ  ? ? ?  ? ?ʅŐ ?ŵů  ? ? ? ? ? ? W/ ǁĂƐ ƚŚĞŶ ĂĚĚĞĚ ƚŽ ĐĞůůƐ ďĞĨŽƌĞ
analysing by flow cytometry (c). Data is the average of 3 separate experiments. 
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5.2.6 Mechanism of killing of colorectal cancer cells by 505/4, 7LE and CA19.9mAbs 
The number of anti-glycan mAbs inducing direct cell death in target cells independently of apoptosis 
prompted investigation of the mechanism of Lewis a/sialyl Lewis a-mediated cell death. PI uptake 
was therefore measured over a time course between 0 and 26 hours of incubation with 505/4. 
Figure 5.9 shows that maximum PI uptake was observed in C170 cells after only 2 hours. 
Furthermore, when C170 cells were incubated with 505/4, 7LE and CA19.9, PI uptake was observed 
at both 22 and 4
o
C (Fig 5.10) suggesting that the mechanism of cell death was unlikely to be 
apoptosis. Jurkat cells treated with anti-Fas induced apoptosis at 37
o
C which was inhibited 90% using 
a pan caspase inhibitor, z-FMK-vad, whereas, the addition of the pan caspase inhibitor did not inhibit 
PI uptake mediated by 505/4, CA19.9, CA19.9 or 7LE (Fig 5.11). As other glycan antibodies can kill via 
oncosis, uptake of different size dextran beads was also investigated. Anti-Fas mediate killing of 
Jurkat cells showed a graded effect on dextran bead uptake, favouring the smaller 3k MW beads. 
Conversely, 505/4, CA19.9 and 7LE mediated the uptake of 500k MW beads (Fig 5.12).  
 
Figure 5.9 505/4 induces PI uptake in C170 cells within 2 hours. C170 cells were incubated with 3 ?ʅŐ ?ŵů
505/4 between 0 and 26 hours, propidium iodide was added and uptake measured after 30min using flow 
cytometry. Data is representative of at least 3 separate experiments. 
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Figure 5.10 505/4, 7LE and CA19.9 kill C170 cells at both 4 and 22
o
C. 5x10
4
 C170 cells were incubated with 10 
and 30ʅŐ ?ŵůŽĨ505/4 (a), 7LE (b) or CA19.9 (c) overnight at 4oC or 22oC or 5x104 Jurkat cells were incubated 
with 0, 250 and 500ng/ml anti-Fas mAb overnight at 4
o
C or 22
o
C (d). PI was added before analysing the 
percentage of dead cells using flow cytometry. Irrelevant-IgG was used as a negative control. Histograms 
representing C170 cells incubated overnight at either 4
o
C (e, f, g, h) or 22
o
C (i, j, k, l) with 30ʅŐ ?ŵůŽĨ irrelevant 
IgG (e, j) 505/4 (f, j), 7LE (g, k) or CA19.9 (h, l). Data is representative of at least 3 separate experiments. 
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Figure 5.11 505/4, 7LE and CA19.9 killing of C170 cells is not inhibited by pan caspase inhibitor. C170 cells 
were incubated with z-FMK-vad ĂŶĚ ? ?Žƌ ? ?ʅŐ ?ŵůŵďfor 24hrs ŝŶƚŚĞƉƌĞƐĞŶĐĞŽƌĂďƐĞŶĐĞŽĨ ? ?ʅD z-FMK-
vad pan-caspase inhibitor (a). Jurkat cells were incubated with 250 or 500ng/ml anti-Fas mAb for 24hrs in the 
ƉƌĞƐĞŶĐĞŽƌĂďƐĞŶĐĞŽĨ ? ?ʅD z-FMK-vad pan-caspase inhibitor (b). Data is representative of at least 3 separate 
experiments. 
 
 
Figure 5.12 505/4, CA19.9 and 7LE mediate uptake of 500K MW dextran beads in C170 cells. C170 cells were 
incuďĂƚĞĚǁŝƚŚ  ? ?ʅŐ ?ŵůŵďĂŶĚ  ? ?  ?0 and 500K MW dextran-FITC beads or PI overnight before measuring 
uptake using flow cytometry. 30min treatment with 0.4% saponin was used as a positive control. Jurkat cells 
were treated with 500ng/ml anti-Fas mAb overnight as an apoptosis control. Histograms depicting 500k MW 
dextran-FITC uptake in C170 cells after incubation with irrelevant IgG (b), 505/4 (c), 7LE (d), CA19.9 (e) and 
0.4% saponin (f) or uptake in Jurkat cells after incubation with irrelevant IgG (g) or anti-Fas (h). 
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5.3 Discussion 
The ability of anti-Lewis y and Lewis b mAbs to bind to unique epitopes on shared antigens, resulting 
in a different in vivo distribution and in vitro function as well as their ability to cause direct cell death 
of antigen positive cells prompted the investigation into the therapeutic value and specific antigen of 
505/4; a mAb produced by our group and compare ŝƚ ?Ɛ in vitro activity to other mAbs directed at 
similar antigens. Characterisation of cancer cell line binding showed specific binding to colorectal 
cancer cell lines. Therefore, 505/4 was screened on an array of 462 colorectal tumours by 
immunohistochemistry, with binding seen against 80% of tumours. To assess the possibility of 505/4 
binding to normal tissues in vivo, the mAb was screened on 29 normal tissues by 
immunohistochemistry. This revealed minimal binding of 505/4 to normal tissues, with only strong 
staining seen against colon, with moderate staining observed against liver. This could be pose a 
problem for in vivo distribution. Therefore, 505/4 was tested for binding to fresh, normal 
hepatocytes, with no cell surface binding seen. This implies that the staining seen against normal 
liver sections by immunohistochemistry may not represent binding seen in vivo. While characterising 
505/4, it was shown that it bound to both glycolipid and glycoprotein purified from cells that 
expressed the antigen, suggesting that it recognised a carbohydrate epitope. Further support for this 
hypothesis was provided by loss of binding of 505/4 when screened on sodium periodate-treated 
cells. Sodium periodate destroys cell surface carbohydrate moieties by oxidation, without altering 
protein and lipid structure (Stevenson et al., 2004). To determine the specific antigen, 505/4 was 
screened against a panel of 406 synthetic and natural glycans provided by the Consortium for 
Functional Glycomics. This revealed that 505/4 binds to sialyl di-Lewis a and its variants, including 
sialyl Lewis a and dimeric Lewis a, which has been shown to be a tumour-associated epitope (Stroud 
et al., 1991). 505/4 also bound to sialyl Lewis a where the sialic acid was non-human derived 
(NeuGc). This sialic acid has been studied as a possible target for therapy (Fernandez et al., 2010; 
Fuentes et al., 2010; Hernandez et al., 2011) due to its absence from normal human tissue as 
humans are genetically unable to produce it and has been shown to be expressed in tumours (Chou 
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et al., 1998; Devine et al., 1991; Oliva et al., 2006). It is thought that some cancers have a greater 
ability to incorporate the NeuGc from the diet into glycans through a scavenger pathway (Bardor et 
al., 2005; Gabri et al., 2009). A possible advantage and explanation of tumour cells expressing NeuGc 
may be due to immunosuppression, with the ability of NeuGc to downregulate CD4 on T cells in the 
tumour environment being observed in murine and human T cells (de Leon et al., 2006). 
The overexpression of sialyl Lewis a on a variety of digestive tract cancers, coupled with its low 
normal tissue expression, the suitability of 505/4 as an anti-cancer agent was assessed in vitro. 
Furthermore, due to the effect that antigen specificity had on the in vitro effects of anti-Lewis y and 
Lewis b mAbs, an anti-sialyl Lewis a mAb (CA19.9) and an anti-Lewis a mAb (7LE) were assessed 
alongside 505/4. Before studying these mAbs their glycan specificity was confirmed using the 
Consortium for Functional Glycomics glycan array. Array binding data for 7LE was obtained from the 
Consortium database and CA19.9 was screened. The array showed that the CA19.9 mAb used in this 
study bound to sialyl di-Lewis a, but also bound to the sialylated type 1 precursor with both human 
and non-human derived sialic acids, but not to dimeric Lewis a. The data also showed that 7LE bound 
to Lewis a, as described as well as to the type 1 precursor and Lewis a-x. The difference in fine 
specificity is reflected in cell binding with only CA19.9 binding to SW480, HT29 and MKN45, 
suggesting they express sialylated Type 1 precursor but not sialyl di Lewis a or Lewis a. 
Due to the large proportion of anti-glycan mAbs displaying anti-tumour activity in the absence of 
complement or effector cells, 505/4, 7LE and CA19.9 were assessed for their ability to kill colorectal 
cells in vitro without the need for complement or effector cells. Interestingly, all three mAbs elicited 
direct cell death of colorectal cancer cell lines but 505/4 and CA19.9 mAbs kill more effectively 
suggesting that they are more potent or that sialyl di-Lewis a and Lewis a containing lipids/proteins 
can mediate cell killing but that the latter are more efficient. In contrast, SW480 cells which bind 
very weakly to CA19.9 and not to 505/4 or 7LE are not killed suggesting that sialylated Type 1 
precursor glycolipids/proteins do not kill or that the level of binding is too weak for direct killing. Of 
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interest is Colo 205 which is a metastatic tumour derived from the same patient as Colo 201. This 
line binds and is killed by 505/4 and CA19.9 but is not directly killed by 7LE. As binding of 7LE is 
inhibited by sialylation of the Lewis a glycan, this suggests that the metastatic cell line has a greater 
level of sialylation and is more susceptible to killing by mAbs that recognise this modification. In 
order to clarify uptake of PI as cell death, 505/4 was incubated with C170 cells over 5 days, with the 
number and viability of cells observed throughout. A decrease in cell number and viability was 
observed, followed by an increase over the 5 days. The surviving cells were also susceptible to 505/4 
treatment. The survival of some cells could be due to the uptake of mAb after binding, therefore, 
surviving cells may grow in the absence of mAb and be susceptible to another dose of mAb. This 
would be useful in vivo as treatment with 505/4 may not produce a subset of mAb-resistant cells 
that could avoid further mAb treatment. 
Both 505/4 and CA19.9 mAbs may cause cell death in colorectal cancer cells independently of 
apoptosis. All three mAbs were shown to induce direct cell death at temperatures as low as 4
o
C, 
although the level of 7LE-mediated killing is reduced at 4
o
C, compared with 22
o
C, suggesting that 7LE 
may kill via apoptosis. Further to this, 7LE-mediated killing was inhibited by the pan-caspase 
inhibitor z-FMK-vad, whereas, killing with 505/4 and 7LE was not inhibited. The ability of 505/4 and 
CA19.9 to induce uptake of 500k MW dextran beads suggests that the mAbs induced large pore 
formation on the cell surface of the target cells. Treatment of Jurkat cells with anti-Fas activating 
mAb, which kills cells by apoptosis, was unable to induce uptake of the largest beads. 7LE-medaited 
uptake of 500k MW beads was minimal, further suggesting that 7LE mediates cell death in a 
mechanism distinct from that of 505/4 and CA19.9. A lower level of 3k MW bead uptake compared 
to PI was observed, which is a smaller molecule (668 MW) in 505/4 and CA19.9-treated cells and 
may be due to the ability of the 3K MW beads to move in and out of the treated cells more freely, as 
once PI enters a cell it collates to the DNA, therefore is inhibited from exiting the cell. Large pore 
formation is indicative of oncosis, an apoptosis-independent cell death mechanism. Oncosis has 
been shown to be induced by other mAbs, including mAb 84, which also demonstrated the uptake of 
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large molecular weight dextran beads (Tan et al., 2009). The ability to induce apoptosis-independent 
cell death may be therapeutically beneficial in tumours resistant to apoptosis. Furthermore, oncosis 
leads to the release of inflammatory intracellular components, providing tumour antigens. For 
example, the release of the danger molecule pattern (DAMP) proteins, heat shock protein 
70 (Hsp70) and high mobility group box 1 (HMGB1) in the UVC treated renal cell carcinoma cell line 
K1 results in Hsp70 chaperoning antigenic peptides to iDC and the maturation of DCs by both 
HMGB1 and Hsp70 and presentation of tumour associated antigens (Brusa et al., 2008). Oncosis-
mediated necrosis can also results in the release of mitochondrial antigens, such mitochondrial DNA 
rich in cytosine-phosphate-guanosine sites dinucleotides that can be recognised by TLR9 in specific 
immune cells (Zhang et al., 2010b). As well as the release of intracellular tumour antigens, cells dying 
by necrosis, but not apoptosis, also secrete IL-6, resulting in the attraction of other immune cells to 
the tumour microenvironment, such as neutrophils and macrophages, that could enhance the anti-
tumour response (Vanden Berghe et al., 2006). An example of this is the recognition that 
chemotherapy induced cell death can elicit an immune response against dying tumour cells and that 
the immune response is required for the optimal therapeutic effect of the chemotherapy (van der 
Most et al., 2008). However, as discussed in a previous chapter, the development of a pro-
inflammatory tumour microenvironment may lead to the polarisation of immune cells towards a 
tissue repair and remodelling state, therefore benefiting the tumour (Sica et al., 2008; Tesniere et 
al., 2008; Vakkila & Lotze, 2004). 
Recently, a human anti-sialyl Lewis a mAb was produced using PBMCs isolated from a breast cancer 
patient undergoing sialyl Lewis a-keyhole limpet hemocyanin (KLH) treatment (Sawada et al., 2011). 
This mAb has shown specific binding to sialyl Lewis a alone and promisingly induces ADCC and CDC 
of antigen positive cell lines as well as anti-tumour activity in a xenograft model. 
In conclusion, the murine mAb 505/4 has been shown to bind to sialyl Lewis a / di-sialyl Lewis a and 
comparison of 505/4 with other anti-Lewis a-related mAbs revealed distinct specificities between 
mAbs. Specifically the lack of 505/4 binding to Type 1 precursors suggests that it may have a better 
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distribution in vivo. 505/4 bound to a high proportion of colorectal cancer tumours, with limited 
binding to normal tissues when tested by IHC. Analysis of functionality revealed sialyl Lewis a /sialyl 
di Lewis a as a targets for mAb-mediated direct cell death, with 505/4 and CA19.9 having the ability 
to induce direct cell death via an oncosis-like mechanism. The lower level of direct cell death caused 
by 7LE suggests that sialylated versions of Lewis a may be better targets for therapy. The ability for 
anti-Lewis a mAbs to induce oncotic cell death may be an important therapeutic factor, which may 
increase the immune anti-tumour response due to the release of tumour antigens.  
Interestingly, the investigation of anti-Lewis y/b and sialyl Lewis a-related mAbs has revealed that 
these mAbs have the ability to cause rapid cell death in antigen positive cell lines in a complement 
and effector cell independent manner. This is also true of other anti-glycan mAbs, suggesting that 
glycans are good targets for functional mAbs that may be more effective in an immunosuppressive 
tumour microenvironment. 
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Chapter 6 The production of monoclonal antibodies targeted against 
ovarian cancer glycolipid 
6.1 Background 
Although, several promising glycolipid mAbs have been produced they are few in number compared 
to mAbs recognising protein antigens, yet the complexity of glycome exceeds the proteome. 
Therefore, it is our aim to develop a novel platform for the generation, selection and evaluation of 
anti-ovarian cancer glycolipid mAbs.  
Glycolipids are T cell independent antigens (TI) as they cannot be presented to T cells on MHC-II, but 
are processed by B cells and presented on CD1d, an MHC-class 1-like molecule. Studies have shown 
that TI antigens multivalently cross-link, mIg, giving B cells a primary signal which results in 
proliferation (Mond et al., 1995; Tolar et al., 2009). However, Ig affinity maturation and production 
requires further signals including ligation of CD40 and production of cytokines, which can be 
provided by helper T cells (Ahonen et al., 2002; Kawabe et al., 1994). As glycolipids are TI antigens, 
presented on CD1d and not MHC-II, the T cell help can be provided by CD40 ligand on NK and NKT 
cells and not T cells (Blanca et al., 2001; Leadbetter et al., 2008). NK cells can activate resting B cells 
to produce Ig in a contact-dependent manner, through CD40-CD40L interaction (Blanca et al., 2001). 
Glycolipid presented on CD1d can stimulate NKT cells to produce IL-4 and IFN-ɶ ? ĐĂƵƐŝŶŐ /Ő
production in B cells (Huang et al., 2004). Despite the emergence of mAbs as potent anti-cancer 
drugs, no mAbs have been approved for the treatment of ovarian cancer and as described 
previously, treatment still centres on chemotherapy. For this reason, our aim was to develop a 
platform for the production of anti-ovarian cancer glycolipid mAbs using whole cells, purified 
glycolipid and NKT/NK adjuvants to immunise mice and screen for novel glycolipid antibodies. 
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6.2 Results 
6.2.1 Glycolipid extracted from C170 cells binds both 692/29 and 505/4 mAbs 
In order to establish whether immunisation protocols yielded anti-glycolipid antibodies, a method of 
screening mouse sera and hybridoma supernatant for anti-glycolipid Ig was needed.  
To this end glycolipid was extracted using a ratio of 2:1 chloroform: methanol from the colorectal 
cell line C170. This was then centrifuged, resulting in the formation of three phases: a phase of 
sialylated glycolipids (layer 2), a plug of denaturated glycoproteins (layer 1) and a final phase of 
neutral glycolipid lipids (layer 3) (Fig 6.1a). The mouse antibodies 505/4 and F002 have been shown 
to bind glycolipid and were used, along with the anti-CD55 (protein antigen) mAb 791T/36 to 
determine the constituents of each phase. Figure 6.1b shows that antigens in all three layers were 
amenable to detection by both anti-glycolipid mAbs, showing that all three layers adhere firmly to 
the plastic plates, but not by antibodies which recognise protein conformation (791T/36).  
 
 
Figure 6.1 Production and validation of glycolipid extract. Glycolipid was extracted from C170 cells using 2:1 
chloroform: methanol before mixing overnight and centrifugation that resulted in three layers (a). The layers 
were dried and resuspended in either PBS (layers 2 and 3) or DMSO (layer 1) before plating on a 96 well flexi-
plate. Glycolipid was dried down before screening with the anti-glycolipid mAbs 505/4 and F002 and the anti-
protein mAb 791T/26 (b). Error bars representing standard deviation of quadruplicate wells are present but 
may be obscured by data bars. Data is representative of at least 3 separate experiments. * represents p<0.05. 
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6.2.2 Immunisation of BALB/c mice with ovarian cancer cells 
Immunisation with whole cancer cells has also been shown to produce antibodies against tumour 
antigens. In order to ascertain whether anti-ovarian glycolipid antibodies can be produced by this 
immunisation approach, BALB/c mice were immunised with three different ovarian cell lines. When 
sera from immunised mice were screened (Fig 6.2a and b) there was a strong response against the 
ovarian cancer cell line OVCA 433 (end point titre 1:100,000) but no response to OVAC 433 
glycolipid, suggesting that the predominant response was not against glycolipid. 
 
 
Figure 6.2 Screening of cell-immunised mouse sera (3358340) to OVCA 433 cells (a) and OVCA-433 glycolipid 
extract (b) by ELISA a) OVCA 433 cells were grown to confluency in a 96 well plate (a) or OVCA 433 glycolipid 
extract was dried onto a 96 flexi-plate (b). Plates were blocked before incubating with serial dilutions of mouse 
serum and probed with anti-mouse immunoglobulin-HRP before adding ABTS substrate. Error bars 
representing standard deviation are present, but may be obscured by marker. 
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6.2.2 Fusion (F012) of OVCA 433 immunised mouse splenocytes yields anti-ovarian 
cancer glycolipid hybridomas 
To confirm that there was not an anti-ovarian cancer glycolipid response; the splenocytes from a 
mouse that displayed a response to ovarian cancer cells were fused with NS0 cells to produce 
hybridomas.  
Hybridoma supernatants were screened by ELISA for binding to ovarian cancer cells (OVCA 433; Fig 
6.3a) and to OVCA 433 glycolipid extract (Fig 6.3b). Figure 6.3a shows that 20 hybridomas produce 
anti-OVCA 433 cell antibodies (OD >0.2), with 9 binding to OVCA 433 glycolipid extract (F012  W AA5, 
AG9, BE11, CB1, CC11, CE3, CF1, DA3, DG2; Fig 6.3b). This suggests that there was an anti-glycolipid 
response which was not detected by the glycolipid ELISA screen of mouse sera. This may have been 
related to the method of detection of anti-sera used in the two assays. Mouse sera were screened 
for IgG responses whereas the hybridomas were screened for all Ig isotypes. 
MAbs binding to cells and glycolipid have potential therapeutic value. However, if they cross react 
with glycolipids expressed on the surface of normal blood cells they will be absorbed in the blood 
and never reach the tumour. Positive mAbs were therefore screened for binding to human PBMCs. 
Figure 6.3c shows that the supernatant from hybridomas AA5, CF1 and DG2 bound to PBMCs. 
W6/32, an anti-MHC mAb was used as a positive control. 
After further analysis using an antibody isotype kit, the remaining 6 anti-glycolipid antibodies were 
found to be IgM antibodies (data not shown). These antibodies are less effective in a therapeutic 
setting as their size precludes their extravasation from the blood vessels and therefore the 
hybridomas were not cloned. 
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Figure 6.3 Binding of F012 hybridoma supernatant to OVCA 433 cells (a) and glycolipid (b) and to peripheral 
blood mononuclear cells (PBMCs) (c). a) OVCA 433 cells (a) were grown to confluency in a 96 well plate or 
OVCA 433 glycolipid (b) was extracted as described, then dried onto 96 well flexi-plates. Both plates were 
blocked before incubating with hybridoma supernatant and probed with anti-mouse Ig-HRP before adding 
ABTS substrate. The plate was then read at 405nm. Error bars representing standard deviation of 
quadruplicate wells are present, but may be obscured by data bar. c) PBMCs were isolated from whole blood 
and incubated with hybridoma supernatant, probed with anti-mouse Ig-FITC and binding analysed by flow 
cytometry. F002 was used as a positive control for ovarian cancer cell line whole cell and glycolipid binding (a) 
with W6/32 binding as a positive control for PBMC binding. 
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6.2.3 Immunisation with the mAb TIB 207 depletes mouse T cells in vivo 
In order to reduce the antibody response to protein antigen in the whole cell immunisation and 
perhaps favour an anti-glycolipid response, BALB/c mice were depleted of CD4 helper cells with TIB 
207 mAb prior to immunisation with cells. A blood sample was collected prior to the TIB 207 
immunisations and 6 days subsequent to the last immunisation. Total PBMCs were purified from 
each blood sample and probed with anti-CD4-FITC (Fig 6.4a, b and c) or without mAb (Fig 6.4d, e, f). 
The level of CD4 positive cells was calculated by subtracting the percentage of CD4+ cells (red 
histograms) from the control (green histograms) and compared to the undepleted mouse. Figure 
6.3g shows that both mice 1R and 1L had a lower level of CD4 positive cells than the untreated 
mouse, suggesting that the TIB 207 mAb had depleted CD4 cells.  
 
 
 
 
Figure 6.4 TIB 207 mediated depletion of mouse CD4 cells. Mice were immunised with  ? ? ?ʅůŽĨW^ ?WůĂŝŶ ?Ă ?
d) or  ? ? ?ʅŐd/ ? ? ?ŵď (1R and 1L; b, e, c, f) and bled on day 7. Histograms in red show level of CD4 positive 
cells (M1), with negative controls in green histograms. Levels of CD4 depletion compared to the non-
immunised mouse are shown (g). Data representative of 2 independent experiments. 
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6.2.4 Depletion of CD4 cells is ineffective at increasing the anti-ovarian cancer glycolipid 
response 
Following the depletion of CD4 cells, a group of mice were immunised with three different ovarian 
cancer cell lines. The sera was analysed for antibody response by titrating on OVCA 433 cells. Figure 
6.5a suggests that the depletion of CD4+ cells had an effect on the anti-ovarian cancer cell response, 
with only mouse 1L showing an Ig response to OVCA 433 cells. The titre of this response (end point 
titre 1:30,000) was less than achieved with the ovarian cancer cell alone immunisation (Fig 6.3a). 
However, a reduction in the anti-cell response did not generate a greater anti-ovarian cancer 
glycolipid response with none of the three mice showing an Ig response when screened against 
OVCA 433 glycolipid extract (Fig 6.5b).  
 
Figure 6.5 Binding of TIB 207, OVCA 433 cell immunised mouse serum (3676379) against OVCA 433 cells and 
OVCA 433 glycolipid. OVCA 433 cells were grown to confluency in a 96 well plate (a) or OVCA 433 glycolipid 
extract was dried onto a 96 flexi-plate (b). Plates were blocked before incubating with serial dilutions of mouse 
serum and probed with anti-mouse Ig-HRP before adding ABTS substrate. Error bars representing standard 
deviation of quadruplicate wells are present, but may be obscured by marker. 
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6.2.5 Fusion (F013) of TIB-207/OVCA 433 immunised mouse splenocytes yields anti-
ovarian cancer cell but not anti-glycolipid hybridomas 
Although, the serum did not give an IgG anti-glycolipid response (Fig 6.5b), the splenocytes were 
harvested from 1L and fused (fusion named F013) to further investigate the antibody response, 
yielding 15 hybridomas. Of these, 12 secreted antibodies that bound to at least one of the three 
immunised cell lines (Fig 6.6a). One of these bound to PBMCs (4D1; Fig 6.6a). Of the 15 hybridomas, 
none bound to ovarian cancer glycolipid (Fig 6.6b). The 3 most positive hybridomas were taken 
forward and cloned were (3H1, 3C9 and 2B8). This was based on their ability to bind a range of cell 
lines, a lack of binding to PBMCs. However, due to their inability to bind glycolipid, F013 2B8, 3C9 
and 3H1 were not investigated further in this thesis. 
 
 
Figure 6.6 Screening of F013 hybridoma supernatant for binding to OAW28, OVCA 433, OAW42 and PBMCs 
by indirect immunofluorescence and analysed by flow cytometry (a) and OAW42 glycolipid by ELISA (b). a) 
Supernatant was taken from wells with colonies and incubated with OAW28, OVCA 433, OAW42 and PBMCs. 
Binding was probed for with anti-mouse IgG-FITC and analysed by flow cytometry (FL1). b) OAW42 glycolipid 
was dried onto 96 well flexi-plate, incubated with hybridoma supernatant. Binding was probed with anti-
mouse IgG-HRP and ABTS substrate was added. The plate was then read at 405nm. Error bars representing 
standard deviation of quadruplicate wells are present, but may be obscured by data bars. W6/32 was used as a 
positive control against whole cells and F002 in the glycolipid screen. 
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6.2.7 Immunisation of BALB/c mice with an NK cell adjuvant  
Screening of T cell depleted mice revealed a possible reduction in anti-cell response, but this did not 
in turn reveal a greater anti-ovarian cancer glycolipid response. Glycolipids are classed as type II TI 
antigens and it has been shown that in order to produce an in vivo antibody response to these 
antigens, non-T cell help is required by B cells. Poly(I:C) is a synthetic analogue of double-stranded 
RNA that mimics a viral infection and acts in vivo by activating NK cells via the toll-like receptor 3. 
Activation of NK cells has been shown to provide T cell independent help to B cells in the production 
of antibodies to TI antigens, such as glycolipid, through the activation of CD40.  
 The CD4 cells of BALB/c mice were depleted as previously described, before being immunised three 
times with the ovarian cancer cell lines OVCA 433, OAW28 and OAW42 along with an NK cell 
adjuvant, poly(I:C). Serum was purified from a blood sample taken six days subsequent to the last 
immunisation. Figure 6.7 shows that there is a slight IgG response by mouse 1R against OVCA 433 
cells, but this was a low titre (1:3000). 
 
Figure 6.7 Binding of OVCA 433 cell and poly(I:C) immunised mice serum (3673323) against OVCA 433 cells. 
OVCA 433 cells were grown to confluency in a 96 well plate. Plates were blocked before incubating with serial 
dilutions of mouse serum and probed with anti-mouse Ig-HRP before adding ABTS substrate. F002 was used as 
a positive control (O.D. = 0.48). Error bars representing standard deviation of quadruplicate wells are present, 
but may be obscured by marker. 
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6.2.9 Immunisation of colorectal cancer glycolipid extract does not give an anti-glycolipid 
response 
As there was no anti-glycolipid response to ovarian cancer cells immunisation despite T cell 
depletion and NK cell help, it was decided to try an immunise directly with glycolipids. As mAbs had 
previously been made recognising colorectal glycolipid extracted from C170 cells this was the initial 
choice of immunogen.  
Using the validated glycolipid (Section 6.2.1), two groups of mice were immunised with C170 
glycolipid layer 2. Group 1 received intraperitioneal injections of C170 layer 2 glycolipid alone on 
days 1 and 7 followed by a boost with 1x10
7
 C170 cells on day 14. Group 2 received subcutaneous 
ŝŶũĞĐƚŝŽŶƐŽĨ  ? ? ? ŐůǇĐŽůŝƉŝĚ ůĂǇĞƌ  ? ǁŝƚŚ ĐŽŵƉůĞƚĞ &ƌĞƵŶĚ ?Ɛ ĂĚũƵǀĂŶƚ ŽŶ ĚĂǇ  ? ? ĨŽůůŽǁĞĚ ďǇ  ? ? ?
glycolipid layer 2 with incomplete &ƌĞƵŶĚ ?ƐĂĚũƵǀĂŶƚŽŶĚĂǇ  ?ĂŶĚĂďŽŽƐƚŽĨ  ?ǆ ? ?7 C170 cells and 
ŝŶĐŽŵƉůĞƚĞ&ƌĞƵŶĚ ?ƐĂĚũƵǀĂŶƚŽŶĚĂǇ ? ? ?dĂďůĞ6.1).  
Blood samples were taken and sera isolated before testing by ELISA against C170 glycolipid and C170 
cells using a polyclonal rabbit anti-mouse Ig HRP. Figure 6.8 shows that immunisation of glycolipid 
did not result in either an anti-C170 cell (Fig 9a) or anti-C170 glycolipid response (Fig 6.8b).  
Table 6.1 Immunisation with C170 layer 2 glycolipid.  
 
 
 
 
 
Group 
Day 
1 7 14 
1 
C170 glycolipid 
layer 2-IP 
C170 glycolipid 
layer 2-IP 
C170 cells-IP 
2 
C170 glycolipid 
layer 2 & 
complete 
&ƌĞƵŶĚ ?Ɛ
adjuvant-SC 
C170 glycolipid 
layer 2 & 
incomplete 
&ƌĞƵŶĚ ?Ɛ
adjuvant-SC 
C170 cells & 
incomplete 
FreunĚ ?Ɛ
adjuvant-SC 
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Figure 6.8 Binding of C170 glycolipid immunised mouse serum (3582907) against C170 cells (a) and C170 
glycolipid (b). C170 cells were grown to confluency in a 96 well (a) or C170 glycolipid extract was dried onto a 
96 flexi-plate (b). Plates were blocked before incubating with serial dilutions of mouse serum and probed with 
anti-mouse Ig-HRP before adding ABTS substrate. Error bars representing standard deviation of quadruplicate 
wells are present, but may be obscured by marker. 
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6.2.10 Ovarian cancer cell glycolipid immunisation 
In order to clarify whether the lack of Ig response to C170 glycolipid (Fig 6.8) was cell type specific 
ovarian cancer cell glycolipid extract was immunised. Figure 6.9a shows that F002 bound to ovarian 
cancer glycolipid layer 2, with the anti-colorectal glycolipid mAb 505/4 and the anti-protein mAb 
791T/36 not binding. This allowed the used of ovarian cancer cell glycolipid as an immunogen, using 
F002 as a control in screening assays.  
On day 0 prebleeds were taken from a group of three mice followed by an intraperitioneal injection 
of layer 2 glycolipid from the equivalent of 1x10
6
 OVCA 433 cells. On days 7, 14 and 21 mice received 
injections of OAW42, OVCAR-3 and OVCAR-4 derived glycolipid respectively. After a further 7 days 
mice were bled. Figure 6.9b shows that all three mice show a minimal response against OVCAR-3, 
OVCAR-4 and OAW42 cells. When sera (1/10) were screened against OVCA 433 glycolipid extract, 
binding was seen in all three mice (Fig 6.9c) but only at this high dilution, therefore the splenocytes 
from these mice were not fused. 
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Figure 6.9 Characterisation of F002 binding to glycolipid (a) and binding of ovarian cancer cell glycolipid 
immunised mouse serum (3673323) against a panel of ovarian cancer cell lines, either fresh or 
formaldehyde-fixed (b) and OVCA 433 glycolipid (c). a) 1x10
5
 OVCAR-3, OVCAR-4, OAW42, OVCA 433 and SK-
OV3 cells ǁĞƌĞ ŝŶĐƵďĂƚĞĚ ǁŝƚŚ  ? ?ʅů  ? P ? ? ? ƐĞƌƵŵ ĨƌŽŵ  ?W ?  ?-1R and 1- ?> ĨŝŶĂů ďůĞĞĚƐ Žƌ  ? ?ʅů  ?ʅŐ ?ŵů & ? ? ?
before probing binding with anti-IgG-FITC mAb. OVCA 433 glycolipid extract was dried onto a 96 flexi-plate. 
Plates were blocked before incubating with 1:100 mouse sera and probed with anti-mouse Ig-HRP before 
adding ABTS substrate. F002 was used as a positive control against both cells (Geometric mean=205) and 
glycolipid (O.D.=0.44). Error bars representing standard deviation of quadruplicate wells are present, but may 
be obscured by marker or data bar. 
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6.2.11 Preparation of ovarian cancer glycolipid-containing liposomes for immunisation 
The lack of response to both C170 and ovarian cancer cell glycolipid in vivo suggests that glycolipid 
alone is not potent enough as an antigen for immunisation.  
To increase the potency of cancer glycolipid in vivo it was incorporated into liposomes allowing the 
concentration of glycolipid at one point to be increased. The glycolipid extracted from a range of 
ovarian cancer cell lines (OVCA) was dried down with DPC, PC and cholesterol before resuspending 
in PBS to create liposomes (help with liposome composition was provided by Dr M Garnett, School 
of Pharmacy, University of Nottingham). To further enhance the immunogenicity of the liposomes 
ƚŚĞE<dĐĞůůĂŐŽŶŝƐƚɲ'ĂůĞƌǁĂƐŝŶĐŽƌƉŽƌĂƚĞĚŝŶƚŽƚŚĞůŝƉŽƐŽŵĞƐ ?dŽĚĞƚĞƌŵŝŶĞƚŚĞĐŽƌƌĞĐƚƌĂƚŝŽŽĨ
components mice were immunised with liposomes that contained a range of ovarian cancer cell 
ŐůǇĐŽůŝƉŝĚĞǆƚƌĂĐƚ ?ǁŝƚŚĂŶĚǁŝƚŚŽƵƚɲ'ĂůĞƌ ?ƐƵŵŵĂƌŝƐed in Table 6.2. 
 
Table 6.2 Immunisation details for OVCA glycolipid-ĐŽŶƚĂŝŶŝŶŐůŝƉŽƐŽŵĞƐĂŶĚɲ-galactoscylceramide. OVCA 
denotes glycolipid extracted from OVCA 433, OAW28, OAW42, SK-OV3 OVCAR-3 and OVCAR- ? ĐĞůůƐ ? ɲ-
galactoscylceramide is abbreviated to ɲ'ĂůĞƌ ? 
Mouse Immunisation 
1P 90% OVCA glycolipid 
1-1R 90% OVCA glycolipid + ɲGalCer 
1-1L 10% OVCA glycolipid 
2P 10% OVCA glycolipid + ɲGalCer 
2-1R 
2.5% OVCA glycolipid + OVCAR-
4 cell boost 
2-1L 
2.5% OVCA glycolipid + 
ɲGalCer+ OVCAR-4 cell boost 
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6.2.12 Immunisation with OVCA glycolipid-Ƚ
 
Six mice were immunised with liposomes (Table 6.2) on days 1 and 7 before blood samples were 
taken on day 14. The sera was then isolated and screened for mouse IgG binding against OVCA 433 
whole cells and OVCA 433 glycolipid extract (Fig 6.10). Screening revealed that mice immunised with 
liposomes containing the lowest level of glycolipid (2.5%; mice 2-1R and 2-1L) gave the best anti-
OVCA 433 cell response (Fig 6.10a), with the responses titrating out at 1:30,000 and 1:3,000 (2-1L 
and 2-1R respectively). Addition of ɲ'ĂůĞƌ seemed to enhancing the titre in mouse 2-1L compared 
to 2-1R. Both 2-1R and 2-1L also gave an anti-OVCA 433 glycolipid response (Fig 6.11b). The 2-1L 
response titrated out at 1:1000 and 2-1R at 1:300 (Fig 6.10b).  
 
 
Figure 6.10 Binding of OVCA glycolipid-containing liposomes immunised mouse serum (3694211) against 
OVCA 433 cells (a) and OVCA 433 glycolipid (b). a) OVCA 433 cells were grown to confluency in a 96 well plate 
(a) or OVCA 433 glycolipid extract was dried onto a 96 well flexi-plate (b). Plates were blocked before 
incubating with serial dilutions of mouse blood sera and probed with anti-mouse IgG-HRP before adding ABTS 
substrate. Error bars are included, but may be covered by symbols. W6/32 was used as a positive control for 
binding to cells (O.D. = 0.86). F002 was used as a positive control for OVCA 433 glycolipid binding (O.D.=4.2). 
Error bars representing standard deviation of quadruplicate wells are present, but may be obscured by marker. 
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6.2.13 Fusion of splenocytes from mice 2-1R and 2-1L 
Due to the positive response to OVCA 433 glycolipid, the splenocytes from mice 2-1R and 2-1L were 
isolated and fused with NS0 cells giving rise to F016 (2-1L derived) and F017 (2-1R derived) fusions. 
The supernatant from the resulting hybridomas was screened against whole fresh and fixed OVCA 
433 cells for IgG binding using a FITC-conjugated anti-mouse IgG mAb before analysing the cells by 
flow cytometry. This revealed that none of the hybridomas secreted IgG against OVCA 433 cells 
(data not shown). Hybridoma supernatant was then screened against whole fresh and fixed OVCA 
433 cells for total Ig binding using a FITC-conjugated anti-mouse Ig mAb before analysing the cells by 
flow cytometry. Figure 6.12 shows that a sample of positive wells from F016 (Fig 6.11a) and a sample 
of positive wells from F017 (Fig 6.11b) do not secrete Ig that binds to fresh OVCA 433 cells. However, 
after fixing OVCA 433 cells with formaldehyde, binding of IgM from the same hybridomas can be 
seen (Fig 6.11c, d), suggesting F016 and F017 secrete IgM directed against intracellular antigens. 
Furthermore, IgM binding to OVCA 433 glycolipid was seen to 16 hybridomas from the F016 fusion 
and 4 of the F017 fusion, suggesting that tumour glycolipid incorporated into liposomes is able to 
induce an anti-glycolipid response (Fig 6.11e, f). Results are summarised in Table 6.3.  
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Figure 6.12 Screening of F016 and F017 hybridoma supernatant for binding to fresh and fixed OVCA 433. 
Splenocytes were extracted from mice 2-1L and 2-1R and fused, giving rise to F016 and F017 respectively. 
Spent supernatant from F016 (a, c, e) and F017 (b, d, f) hybridomas was taken from wells with colonies and 
incubated with fresh (a, b) or fixed (c, d) OVCA 433 cells or OVCA 433 glycolipid layer 2 (e, f). Binding to fresh 
cells (a, b) was probed for with anti-mouse Ig-FITC and analysed by flow cytometry (FL1). Binding to fixed cells 
and OVCA 433 glycolipid layer 2 was analysed by ELISA. OVCA 433 cells were grown to confluence in a 96 well 
plate before being fixed or OVCA 433 glycolipid layer 2 was plated and dried. The cells or glycolipid were then 
incubated with hybridoma supernatant. Binding was probed with anti-mouse IgM-HRP and ABTS substrate was 
added. The plate was then read at 405nm. F002 was used as a control for binding to fresh and fixed cells as 
well as OVCA 433 glycolipid layer 2. Error bars representing standard deviation of quadruplicate wells are 
present, but may be obscured by marker. 
Table 6.3 Summary of F016 and F017 hybridomas. 
Assay F016 F017 
Binding to fixed OVCA 433 
cells (Ig) 
67 41 
Binding to fresh cells 0 0 
IgM binding to OVCA 433 
glycolipid 
16 4 
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6.2.14    ?Ǥ ? ?    Ƚ
  
boosted with OVCAR-4 cells  
Despite seeing an IgG response in bleeds from mice 2-1R and 2-1L (immunised with 2.5% OVCA 
ŐůǇĐŽůŝƉŝĚ ĂŶĚ ɲ'ĂůĞƌ ůŝƉŽƐŽŵĞƐ ? ƚŚĞ ƌĞƐƵůƚŝŶŐ ŚǇďƌŝĚŽŵĂƐ ƐĞĐƌĞƚĞĚ ŽŶůǇ /ŐD ĚŝƌĞcted at 
intracellular glycolipid antigen. In order to encourage class switching of Ig from IgM to IgG, mice 
were immunised with 2.5% OV ŐůǇĐŽůŝƉŝĚ ĂŶĚ ɲ'ĂůĞƌ ĐŽŶƚĂŝŶŝŶŐ ůŝƉŽƐŽŵĞƐ ŽŶ ĚĂǇƐ  ? ĂŶĚ  ? ?
followed by a whole cell boost on day 14. Blood samples were then taken on day 21. Sera were 
isolated from the blood before screening against fresh OVCAR-4 cells. An anti-mouse IgG-FITC mAb 
was used to detect the mouse IgG before analysing by flow cytometry. All three mice showed an IgG 
response that titrated out at 1:1000 (Figure 6.12a).  
As the previous immunisations produced hybridomas that secreted IgM specific for mostly 
intracellular mAbs, the serum was tested against a range of cell lines, fresh and fixed. Figure 6.12b 
shows that serum from all three mice bound to both OVCAR-3 and OVCAR-4 cells, with the greatest 
level of binding of 2-1L against fresh OVCAR-4 cells. Interestingly, on the contrary to the previous 
immunisations, cell fixation did not have a great affect on the level of binding. Low levels of binding 
are seen with the serum from all three mice against OAW28, OVCA 433 and SK-OV3 cells. 
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Figure 6.12 Binding of OVCA-ŐůǇĐŽůŝƉŝĚ ŝŵŵƵŶŝƐĞĚ ĂŶĚ  ? ? ?A? Ks ŐůǇĐŽůŝƉŝĚ ĂŶĚ ɲ'ĂůĞƌ-containing 
liposomes mouse serum (3713725) to OVCAR-4 cells (a) or fresh and fixed OVCAR-3, OVCAR-4, OAW42, 
OVCA 433 and SK-OV3 cells (b) and OVCA 433 glycolipid (c). a) Serum from mice immunised with 2-5% OVCA 
ŐůǇĐŽůŝƉŝĚ ĂŶĚ ɲ'ĂůĞƌ-containing liposomes (2-P, 2-1R and 2-1L) was titrated against OVCAR-4 cells and 
probed for antibody binding with anti-mouse IgG-FITC (Serum from mouse 1L from T cell depleted 
immunisation used as a positive control  W Geometric mean = 362). b) Serum from 2.5% OVCA glycolipid and 
ɲ'ĂůĞƌ-containing liposomes mouse serum (2P, 2-1R, 2-1L) was diluted to 1:100 and incubated with fresh or 
formaldehyde-fixed OVCAR-3, OVCAR-4, OAW42, OVCA 433 and SK-OV3 cells before incubation with anti-
mouse IgG-FITC. Cells were then analysed by flow cytometry. F002 was used as a positive control. c) Serum 
ĨƌŽŵ  ? ? ?A? Ks ŐůǇĐŽůŝƉŝĚ ĂŶĚ ɲ'ĂůĞƌ-containing liposomes mouse serum (2P, 2-1R, 2-1L) was diluted to 
1:100 and incubated with OVCA glycolipid before binding was probed with anti-mouse IgG-HRP. ABTS 
substrate was added before reading at 405nm. Error bars representing standard deviation of quadruplicate 
wells are present, but may be obscured by marker.  F002 was used as a positive control (O.D. = 0.43). 
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6.2.15 Fusion of splenocytes from 2-1L and initial screening 
AS the serum from mouse 2-1L displayed both an anti-ovarian cancer cell and ovarian cancer 
glycolipid response, with a greater level of binding seen against fresh cells, the splenocytes were 
harvested and fused to create hybridomas (F019). The resulting hybridomas were screened for IgG 
binding to fresh OVCAR-4 cells (data not shown). Of the positive wells, 9 bound to fresh OVCAR-4 
cells (Table 6.4). F019/1A7, F019/1D3 and F019/1D10 all showed binding to OVCAR-3, OVCAR-4 and 
SK-OV3, however F019/1D10 bound PBMCs (Table 6.4). Therefore, F019/1A7 and F019/1D3 were 
taken forward for further screening. Both F019/1A7 and F019/1D3 bound to the ovarian cancer cell 
lines OVCA 433 and OAW42 and also to the colorectal cell line C170. Both did not show any binding 
to HUVEC (Table 6.4). 
Table 6.4. Summary of F019 hybridomas that bind OVCA 433 cells. Wells with colonies were first screened 
against OVCA 433 cells. Those positive for binding to OVCA 433 cells were screened against PBMCs, OVCAR-4, 
OVCAR-3 and SK-OV3 cells and probed for with anti-mouse IgG-FITC. Cells were incubated with hybridoma 
supernatant before probing with anti-mouse IgG-FITC. Numbers represent the geometric mean fluorescence 
when the cells were analysed by flow cytometry. W6/32 was used as a positive control. 
 
 
 
 
 
Hybridoma well PBMCs OVCAR-4 OVCAR-3 SKOV-3 HUVEC OVCA 433 OAW42 C170 
F019/1A7 32 226 314 141 23 67 566 112 
F019/1B4 30 47 43 119 
    
F019/1D3 28 172 291 108 20 70 744 95 
F019/1D10 67 290 404 259 
    
F109/1F7 20 54 185 55 
    
F019/2C1 30 19 21 62 
    
Negative 28 9 8 6 5 8 9 6 
W6/32 1005 772 793 7347 
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6.2.16 Further characterisation and cloning of F019/1A7 and F019/1D3 
Due to the pan-cancer cell line reactivity of F019/1A7 and F019/1D3 and the lack of binding to PBMC 
and HUVEC, the hybridomas were cloned. Each hybridoma was plated at 3, 1 and 0.3 cells/well 
across 3 96 well plates. Once colonies were present, supernatant from the 0.3 cell/well plate with 30 
colonies per plate was screened against OVCAR-4 cells. Positive wells were picked from the 
F019/1A7 and F019/1D3 96 well plate and grown in 48 well plates before a second round of cloning. 
The 0.3 cell per well plate was then screened against OVCAR-4 cells. All wells from F019/1A7 were 
positive, therefore 1 well was picked and was expanded. Wells from F019/1D3 were either positive, 
or weak with small colonies, therefore, positive wells from F019/1D3 were transferred to 48 well 
plates before re-cloning. The supernatant was again screened against OVCAR-4 cells with all wells 
being positive. One well was then picked and expanded. The supernatant from F019/1A7 and 
F019/1D3 was collected and purified. Isotyping of the mAbs revealed that both F019/1A7 and 
F019/1D3 were IgG1 (data not shown). The F019/1A7 mAb was validated by titrating across the cell 
lines that F019/1A7 previously bound (OVCAR-4 and OAW42). Figure 6.13 shows that purified 
F019/1A7 has retained its ability to bind to both cell lines, saturating the antigen between 3 and 
 ? ?ʅŐ ?ŵů ?&ŝŐ ? ? ? ?Ă ) ?dŚĞŵďǁĂƐƚŚĞŶƐĐƌĞĞŶĞĚŽŶĂǁŝĚĞƌ ƌĂŶŐĞŽĨĐĞůůůŝŶĞƐ ?& ? ? ? ? ? ?ďŝŶĚƐƚŽĂůů
ovarian cancer cell lines tested as well as to the colorectal cell lines Colo 201, Colo 205, HT29 and 
LoVo but did not bind to the gastric cell line CaCO2 (Fig 6.13b). To ensure that F019/1A7 bound to 
glycolipid, glycolipid was extracted from a range of cell lines, dried onto an ELISA plate before 
incubating with F019/1A7. Binding of F019/1A7 was seen to OAW42 glycolipid, but not to any other 
cell lines tested (Fig 6.13c). As a further test for glycolipid binding, F019/1A7 was screened by 
immune dot blot against glycolipid extract layers from C170, OAW42, OVCAR-4 and OVCAR-3 cells 
with F019/1A7 binding restricted to layer 2 and layers 2 and 3 of OAW42 cells (Fig 6.13d).  
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b)  
 
 
Figure 6.13 Titration of F019/1A7 on ovarian cancer cells (a), binding of F019/1A7 after cloning to a range of 
ovarian and colorectal cell lines (b) and glycolipid from a range of cell lines by ELISA (c). a) 1 x 10
5
 OAW42 
and OVCAR-4 cells per well were incubated with 0.1- ? ?ʅŐ ?ŵů& ? ? ? ? ? ?ďĞĨŽƌĞƉƌŽďŝŶŐĨŽƌŵďďŝŶĚŝŶŐǁŝƚŚ
rabbit anti-mouse IgG-FITC. Cells were analysed by flow cytometry. b) 1x10
5
 cells were incubated with purified 
F019/1A7 at 10ʅŐ ?ŵů ďĞĨŽƌĞ ƉƌŽďŝŶŐ ǁŝƚŚ ƌĂďďŝƚ ĂŶƚŝ-mouse IgG-FITC. Cells were then analysed using flow 
cytometry (FL1). c) Glycolipid was extracted from C170, OVCAR-4, OVCA 433, OAW28 and OAW42 cell lines 
and plated at 1:100, left to dry before blocking and the addition F019/1A7 and F019/1D3 mAb. 692/29 binding 
to C170 glycolipid was used as a positive control with an irrelevant IgG used as a negative control. Binding was 
detected with rabbit anti-mouse IgG-HRP/ABTS. Error bars representing standard deviation of quadruplicate 
wells are present, but may be obscured by marker. 
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6.2.17 Screening of F019/1A7 against ovarian cancer tissue array 
To establish how ubiquitously the F019/1A7 antigen is expressed, a TMA consisting of 360 ovarian 
cancer cases was stained with F019/1A7. KĨƚŚĞĐŽŚŽƌƚŽĨ ? ? ?ƉĂƚŝĞŶƚƐ ?ĂŐĞ ranged from 24-90 years 
old, with a mean age of 62 years old. The mean survival from diagnosis was 61 months. Of the 364 
tumours, 95(27%) were FIGO (International Federation of Obstetricians and Gynaecologists) stage 1, 
with 38(11%) being stage 2, 175(48%) being stage 3 and 40(12%) unknown. In order of lethalness, 
the proportion of type of the 364 tumours was 19 (5%) borderline, 25 (7%) clear cell OVCA, 35 (10%) 
mucinous OVCA, 42 (12%) endometrioid OVCA, 178 (49%) serous OVCA 54 (15%) undifferentiated 
with 5 (1%) being other OVCA and 4 (1%) of an unknown type. Figure 6.14a-d shows examples of the 
level of staining seen on the ovarian. Staining was mainly seen in the cytoplasm. Of the 362 tumours, 
234 tumour samples were stained, with 128 lost during staining or no viable tumour was present in 
the core.  Of the 234 tumours stained, F019/1A7 bound to 88% of tumours, with strong binding seen 
to 51(22%) of tumours. 63(27%) showed moderate staining with 91(39%) and 29(12%) of tumours 
staining weakly or not at all, respectively (Fig 6.14e).  
The relationship between F019/1A7 binding and standard clinicopathological variables was 
ŵĞĂƐƵƌĞĚƵƐŝŶŐƚŚĞWĞĂƌƐŽŶʖ2 test. Binding of F019/1A7 in the tumour associated significantly with 
TNM stage and distant metastases (p=0.047, 0.005 respectively; Table 6.6). Binding of F019/1A7 
correlated with tumour type (both histological and in relation to lethalness; p=0.014 and 0.003 
respectively) as well as with tumour grade (p=0.033). No correlation was seen with FIGO stage 
however (p=0.052), or with age (p=0.894; Table 6.6). When the level of F019/1A7 binding is split into 
low (negative and low) and high (moderate and strong) groups of binding, the group with high 
binding have a significantly worse prognosis that patients with low level of F019/1A7 binding 
(p=0.005; Fig 6.15), although this was not found to be independent of stage or grade. 
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Figure 6.14 Examples of F019/1A7 staining of ovarian cancer and F019/1A7 staining levels. An ovarian TMA 
consisting of 362 tumour samples was stained with F019/1A7 and visualised with DAB (brown). Frequencies of 
negative, weak, moderate and strong staining on the ovarian cancer TMA; 22% of the cores were strong with 
27% being moderate. Only 12% of the cores were negative for F019/1A7 staining. The remaining 39% stained 
weakly with F019/1A7. Annotations denote number of cores. The TMA was scored a negative (b), weak (c), 
moderate (d) or strong (e) staining independently by two observers, magnification X20 original magnification.  
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Figure 6.15 Kaplan-Meier plot of survival. Analysis of survival in patients with either low (grey) or high (black) 
levels of F019/1A7 expression. p=0.005. 
 
 
Table 6.6 Pearson ʖ squared tests of F019/1A7 with other patient variables. 
 
Variable ʖ2 Test (p value) 
 
Age 0.894 
Histological Type 0.014 
Tumour Grade 0.033 
FIGO Stage 0.052 
Types of OVCA in order of 
lethalness in this series 
0.003 
 
 
 
 
 
 
 
 
 
 
p=0.005 
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6.2.18 Staining of normal tissue array with F019/1A7  
To be an effective therapeutic mAb, F019/1A7 would need to bind specifically to its antigen on 
tumour cells and have minimal binding to normal tissues. In order to investigate the level of binding 
to normal tissue, the mAb was stained on a tissue microarray consisting of 59 cores, representing 
samples of 38 types of tissue (Table 6.6). During staining the core of bronchus tissue (core no. 14) 
was lost. No staining of F019/1A7 was seen against 7 of 59 cores. The majority of cores (25) showed 
weak staining, with 11 and 15 showing moderate and strong staining respectively (Fig 6.16). Of the 
tissues stained, F019/1A7 bound breast, gallbladder, pancreas, kidney, oesophagus, stomach, 
appendix, colon, rectum, kidney, endometrium, adrenal gland and thyroid most strongly. Moderate 
staining was seen against subcutis, spleen, lymph node, heart and liver. Weak staining was seen 
against skin, nasal mucosa, salivary gland, tonsil, duodenum, small bowel, bladder, prostate, seminal 
vesicle, testis, cervix, salpinx, placenta and thymus. No staining was seen against brain or umbilical 
cord. Examples of F019/1A7 staining intensity can be seen in figure 6.17. To ascertain if the staining 
on the normal tissues was cell surface and therefore accessible to mAbs, normal hepatocytes, 
HUVECs and PBMCs cells were stained by indirect immunofluorescence and analysed by flow 
cytometry. Figure 6.18 shows that the staining on normal hepatocytes was very weak, and was 10 
fold lower than seen on ovarian tumour lines and no binding was seen to HUVECs (Fig 6.18; 
passage<6). Furthermore, no binding was seen against freshly isolated human PBMCs (Fig 6.19). 
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Table 6.6 List of normal tissues on microarray, tissue type and staining intensity of F019/1A7 with 505/4 
staining a positive control. 
 
Core 
Number 
Organ Associated lesion Tissue type Tissue 
type
2
 
F019/1A7 
intensity
3
 
505/4 
intensity 
1 Skin Breast cancer B 1 - 
2 Skin breast cancer Breast cancer B 1 - 
3 Subcutis Fatty abdomen A 2 - 
4 Breast  Breast cancer C 0 - 
5 Breast Breast cancer C 3 - 
6 Spleen  Stomach cancer B 2 0 
7 Spleen Stomach cancer B 1 0 
8 Lymph node Stomach cancer B 1 0 
9 Lymph node Stomach cancer B 2 0 
10 Skeletal Muscle angiosarcoma B 2 0 
11 Nasal mucosa  Chronic sinusitis A 1 - 
12 Lung Metastatic cancer of lung (from 
stomach) 
B 1 0 
13 Lung  Lung cancer C 1 0 
14 Bronchus Lung cancer C - 0 
15 Heart  No abnormal finding A 1 - 
16 Salivary gland Oropharyngeal cancer B 1 - 
17 Liver Hepatocellular carcinoma C 2 1 
18 Liver Stomach cancer B 2 0 
19 Liver Hepatocellular carcinoma C 2 0 
20 Gallbladder Rectal cancer B 3 0 
21 Pancreas Stomach cancer B 3 0 
22 Pancreas Pancreas islet cell tumour C 2 0 
23 Tonsil Chronic tonsillitis A 1 0 
24 Oesophagus Oesophageal cancer C 1 - 
25 Oesophagus Oesophageal cancer C 3 0 
26 Stomach Body stomach cancer C 3 1 
27 Stomach Body stomach cancer C 3 1 
28 Stomach Antrum stomach cancer C 2 1 
29 Stomach Smooth muscle stomach cancer C 1 0 
30 Duodenum  Ampulla of Vater cancer C 1 0 
31 Small bowel Pseudomyxoma peritonei B 2 - 
32 Small bowel Colonic diverticulosis A 1 0 
33 Appendix Metastatic cancer of ovary 
(from stomach) 
B 2 2 
34 Colon Rectal cancer C 3 3 
35 Colon Colon cancer C 3 - 
36 Rectum Rectal cancer C 3 2 
37 Kidney Cortex renal cell carcinoma C 3 2 
38 Kidney Cortex renal cell carcinoma C 3 1 
39 Kidney  Medulla renal cell carcinoma C 3 1 
                                                          
2
 Tissue type denotes the following categories; A Normal tissue from a non-cancer patient; B Normal tissue 
from a cancer patient, but the cancer involves unrelated organ; C Normal tissue adjacent to the cancer 
3
 Levels of intensity are classified as 0- negative, 1- weak, 2- moderate and 3- strong.  W denotes that scoring 
was not possible for that core. 
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40 Urinary bladder Invasive bladder carcinoma C 3 - 
41 Prostate Bladder cancer B 2 0 
42 Prostate  Bladder cancer B 2 0 
43 Seminal vesicle  Bladder cancer B 2 - 
44 Testis Prostate cancer B 2 0 
45 Endometrium Proliferative benign ovarian 
neoplasm 
A 1 0 
46 Endometrium, Secretory ovarian cancer B 2 - 
47 Myometrium Adenomyosis A 1 0 
48 Uterine cervix Leiomyoma A 1 0 
49 Salpinx Cervix cancer B 2 - 
50 Ovary Ovary cancer C 3 - 
51 Placenta Mature placenta A 1 0 
52 Placenta Mid-trimester placenta A 1 0 
53 Umbilical cord Mature placenta A 1 - 
54 Adrenal gland Renal cell carcinoma B 2 2 
55 Thyroid Thyroid cancer C 3 - 
56 Thymus Lymphoid hyperplasia A 1 0 
57 Brain White matter no abnormal 
finding 
A 1 0 
58 Brain Gray matter no abnormal 
finding 
A 1 0 
59 Cerebellum  No abnormal finding A 1 0 
 
 
 
 
Figure 6.16 Histogram of F019/1A7 staining intensity across normal tissues. Of the 58 cores stained 7 showed 
no binding of F019/1A7. F019/1A7 bound 25 cores with weak intensity with 11 cores staining moderately. 15 
cores showed strong staining of F019/1A7. 
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Figure 6.17 Examples of F019/1A7 staining intensity across normal tissues. Examples of negative staining can 
be seen against breast (a) and brain (b), with weak staining seen against lung (c) and placenta (d). Moderate 
staining is shown against liver (e) and heart (f) tissue. Strong staining can be seen against rectal (g) and kidney 
(h) tissue. 
a) Breast b) Brain 
c) Lung d) Placenta 
e) Liver f) Heart 
g)  Rectal h) Kidney 
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Figure 6.18 Analysis of F019/1A7 binding to a range of normal cells. a) 1x10
5
 human hepatocytes, HUVECs or 
OVCAR- ? ĐĞůůƐ ǁĞƌĞ ŝŶĐƵďĂƚĞĚ ǁŝƚŚ  ?ʅŐ ?ŵů & ? ? ? ? ? ? Žƌ  ? ?ʅŐ ?ŵů t  ? ? ?-PE. F019/1A7 binding was probed 
with anti-mouse IgG-FITC. Cells were then analysed for W6/32-PE or anti-mouse IgG-FITC binding by flow 
cytometry. Histograms are displayed representing isotype control binding to OVCAR-4 (b), hepatocytes (e) and 
HUVECs (h), F019/1A7 binding to OVCAR-4 (c), hepatocytes (f) and HUVECs (i), W6/32 binding to OVCAR-4 (d), 
hepatocytes (g) and HUVECs (j). Data representative of at least 2 separate experiments. 
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Figure 6.19 F019/1A7 does not bind to PBMCs. PBMCs were isolated from human blood and 1x10
5
 cells per 
well were incubated with irrelevant IgG (a), W6/32 (b )Žƌ ?ʅŐ ?ŵů& ? ? ? ? ? ?c). Data is representative of at least 3 
separate experiments. 
 
 
 
6.2.19 Evaluation of direct killing with F019/1A7 
The ability for mAbs to induce cytotoxicity in vivo relies upon the mAb being able to induce cancer 
cell death through more than one mechanism. In order to ascertain whether F019/1A7 has the 
ability to induce ovarian cancer cell death directly, 1x10
5
 OVCAR-4 and OAW42 cells were incubated 
ǁŝƚŚ ? ? ? ?ĂŶĚ ? ?ʅŐ ?ŵů& ? ? ? ? ? ?ŝŶ ? ?A?E^ƐƵƉƉůĞŵĞŶƚĞĚZWD/ŽǀĞƌŶŝŐŚƚĂƚ ? ?oC. The induction 
of cell death was measured by PI uptake and by counting the number of cells. Figure 6.20a shows 
that deƐƉŝƚĞƚŚĞĂĚĚŝƚŝŽŶŽĨ  ? ?ʅŐ ?ŵů& ? ? ? ? ? ? ?ŶŽĐĞůůĚĞĂƚŚŚĂƐŽĐĐƵƌƌĞĚ ?dŚŝƐ ŝƐŵŝƌƌŽƌĞĚŝŶƚŚĞ
cell counts, which show that the cells incubated with F019/1A7 have grown at the same rate as 
those incubated with media alone (Fig 6.20 f, g). 
h) Negative-PBMC i) W6/32-PBMC j) F019/1A7-PBMC 
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Figure 6.20 Measurement of F019/1A7 direct cytotoxicity against OVCAR-4 and 1x10
5
 OAW42 cells. OVCAR-4 
and OAW42 cells were incubated with  ? ?ĂŶĚ ? ?ʅŐ ?ŵůF019/1A7 or 0.5% H2O2 overnight at 37oC. After 30mins 
of PI incubation, cells were analysed by flow cytometry (a). Histograms showing negative controls for OVCAR-4 
(b) and OAW42 (d) as well as ŚŝƐƚŽŐƌĂŵƐ ƌĞƉƌĞƐĞŶƚŝŶŐ  ? ?ʅŐ ?ŵů & ? ? ? ? ? ? ŝŶĐƵďĂƚĞĚ ǁŝƚŚ KsZ-4 (c) and 
OAW42 cells (e). After overnight incubation of F019/1A7 counts of OVCAR-4 (f) and OAW42 (g) cells were 
taken using trypan blue. Error bars are present on each data point representing standard deviation of 3 repeat 
experiments, but may be obscured by the marker. 
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6.2.20 F019/1A7 cytotoxicity at different temperatures and with cross-linking 
As direct cell death has been seen at temperatures lower than 37
o
C with other mAbs, 1x10
5
 OVCAR-
4 anĚKt ? ?ĐĞůůƐǁĞƌĞ ŝŶĐƵďĂƚĞĚǁŝƚŚ  ? ?  ? ?ĂŶĚ  ? ?ʅŐ ?ŵů& ? ? ? ?  ? ŝŶ  ? ?A?E^ƐƵƉƉůĞŵĞŶƚĞĚ
RPMI overnight at RT (approximately 22
o
C). The induction of cell death was measured by PI uptake 
and by counting the number of cells. Figure 6.21a shows that despite a reduction in temperature, 
ƚŚĞĂĚĚŝƚŝŽŶŽĨ ? ?ʅŐ ?ŵů& ? ? ? ? ? ?ŚĂƐŶŽƚŝŶĚƵĐĞĚĐĞůůĚĞĂƚŚ ? 
As F019/1A7 is an IgG1, it is unable to dimerise via the Fc receptor, which may have an effect on its 
ability to cause direct cell death. OVCAR-4 cells were incubated with F019/1A7, a rabbit anti-mouse 
Ig mAb and a goat anti-rabbit Ig mAb to encourage cross-linking of mAbs on the cell surface. Cells 
were incubated overnight at 37
o
C before measuring PI uptake and analysing the cells with flow 
cytometry. Figure 6.21b shows that despite the addition of cross-linking mAbs, no increase in cell 
death was seen. 
 
Figure 6.19 Measurement of F019/1A7 cytotoxicity at room temperature and when incubated with cross-
linking mAbs. PI uptake was measured after overnight incubation of OVCAR-4 and OAW42 cells with F019/1A7 
at RT (a). PI uptake was measured after incubation of OVCAR-4 cells with F019/1A7 and rabbit anti-mouse Ig 
and goat anti-rabbit Ig mAbs at 37
o-
C. Data representative of at least 3 experiments. 
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6.2.21 Ability of F019/1A7 to induce ADCC in target cells with cross-linking 
A number of studies have shown the importance of a mAb to induce ADCC in target cells in vivo. 
Therefore, F019/1A7 was assessed for its ability to cause cell death in OVCAR-4 cells. Figure 6.20 
ƐŚŽǁƐƚŚĂƚĞǀĞŶĂƚĂĐŽŶĐĞŶƚƌĂƚŝŽŶŽĨ ? ?ʅŐ ?ŵů ?& ? ? ? ? ? ?ŝƐƵŶĂďůĞƚŽŝŶĚƵĐĞWD-mediated cell 
lysis. However, with the addition of a rabbit anti-mouse antibody, cross-linked F019/1A7 is able to 
induce cell lysis (Fig 6.22). 
 
Figure 6.22 F019/1A7 mediated ADCC of OVCAR-4 cells after cross-linking with rabbit anti-mouse Ig. 1x10
5
 
Chr
51
 labelled OVCAR-4 cells were incubated with PBMCs isolated from human blood with either F019/1A7 or 
irrelevant IgG with or without rabbit anti-mouse Ig for 4 hours. Cell lysis was measured as a percentage of 
maximum  W spontaneous Cr51 release. Error bars representing standard deviation of triplicate wells are present 
but may be obscured by data points. Data is representative of at least 2 experiments. 
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6.3 Discussion 
In order to produce new ovarian anti-glycolipid mAbs, mice were immunised with whole cancer cells. 
It is well known that this is a good method for producing mAbs against cancer cells. The screening of 
mouse sera against whole ovarian cancer cells showed that immunisation with whole ovarian cancer 
cells gave a very strong antibody response. The resulting fusion yielded 3 anti-glycolipid mAbs that 
displayed good tumour selectivity, but were of the IgM isotype. IgM are too large for efficient 
tumour targeting, due to their inability to extravasate and were not further developed. These results 
suggested that although an anti-glycolipid antibody response was being induced they were not 
receiving the correct cytokine milieu to affinity maturate and subclass switch to an IgG response. In 
order to increase the level of antibodies directed at non-protein targets, T cells were depleted in 
mice using an anti-CD4 mAb, in order to reduce the level of T cell help for B cell response to protein 
antigens and with the aim of allowing more of a T cell independent response. Despite drastic 
reduction in the number of T cells, antibodies against cells and not to the glycolipid extract were still 
produced, resulting in no anti-glycolipid mAbs. T cell-independent help has been shown to be 
provided by NK and iNKT cells increasing the level of B cell proliferation and IgG antibody production 
against TI antigens (Leadbetter et al., 2008; Mond et al., 1995). Studies have shown that poly(I:C), a 
synthetic homologue of double-stranded RNA is a potent stimulator of NK cells in vivo (Miyake et al., 
2009; Wulff et al., 2010). Used as an adjuvant it has the ability to stimulate NK cells to interact with B 
ĐĞůůƐĞŝƚŚĞƌĚŝƌĞĐƚůǇŽƌŝŶĚŝƌĞĐƚůǇ ?ďǇƉƌŽĚƵĐŝŶŐ/&EɶĂŶĚ/>-4) which would provide a second signal to 
B cells (the first being Ig receptor clustering on the B cell surface (Mond et al., 1979; Iber & Gruhn, 
2006). This would stimulate B cells to produce antibodies and proliferate. In order to increase the T 
cell independent response immunisations included poly(I:C) along with whole ovarian cancer cells 
after CD4 depletion.  
Although glycolipids were present in whole cell immunisations, protein antigens elicited the greatest 
response in vivo. Despite depleting T cells and the addition of an NK cell adjuvant to provide T cell 
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independent antigen help to B cells, a mouse anti-glycolipid response was not observed. Therefore, 
in order to create anti-glycolipid mAbs and remove the possibility of anti-protein mAbs being 
generated with whole cell immunisation, glycolipid was extracted from whole cancer cells for 
immunisation using a chloroform: methanol extraction. Previous studies have utilised immunisation 
of glycans to produce and antibody response to these antigens. An example being the sialyl Lewis a-
keyhole limpet (KHL) conjugate immunised with a saponin adjuvant, which gave rise to both an IgM 
and an IgG immune response in mice (Ragupathi et al., 2009). Colorectal cancer cell derived 
glycolipid was first used for immunisation due to the ability to use both 505/4 and 692/29 as positive 
controls for glycolipid binding in screening assays. Immunising with colorectal cancer-glycolipid alone 
to increase the level of mAbs to glycolipid proved unsuccessful with no response to either glycolipid 
or whole cells. With the in-house characterisation of an anti-ovarian cancer glycolipid mAb, F002, it 
was possible to immunise with ovarian cancer glycolipid extract, using F002 as a positive control in 
screening assays. Immunisation with ovarian cancer glycolipid was undertaken to ensure that the 
lack of response to colorectal cancer glycolipid observed was not tissue specific, however, no 
response to either cell or glycolipid extract was observed. Studies have shown that activation of B 
cells requires the clustering of BcRs upon antigen binding (Mond et al., 2005; Barral et al., 2008). This 
along with our results suggested that glycolipid alone is unable to stimulate B cells to proliferate or 
produce antibodies. In order to increase the chance of BcR clustering, ovarian cancer cell glycolipid 
was incorporated into liposomes. This has previously been reported when 
isoglobotetraosylceramide, a tumour-associated glycolipid, was inserted into liposomes which 
resulted in an array of anti-cancer cell antibodies (Brodin et al., 1986). As well as tumour-associated 
glycolipid, ɲGalCer was also incorporated into the liposomes to provide stimulation of NKT cells. 
ɲ'ĂůĞƌ ?ĂŐůǇĐŽƐƉŚŝŶŐŽůŝƉŝĚ originally isolated from the marine sponge Agelas mauritianus, is a is a 
potent stimulator of NKT cells due to its long half-life and strong binding to the iNKT TCR (Sidobre et 
al., 2004). It has been shown to be presented by the ɴ ?-microglobulin-associated class I-like 
molecule, CD1d, to NKT cells, leading to their activation in vivo (Leadbetter et al., 2008; Naidenko et 
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al., 2000). The activation of NKT cells would lead to the production of IL- ?ĂŶĚ/&Eɶ ?ƐƚŝŵƵůĂƚŝŶŐ
cells in the absence of T cell help (Barral et al., 2008; Huang et al., 2004). Ovarian cancer cell 
glycolipid was incorporated into liposomes yielding an immune response to ovarian cancer cells. 
Liposomes with 2.5% ovarian cancer glycolipid alone stimulated a response to both cells and 
glycolipid with an improved response with ƚŚĞĂĚĚŝƚŝŽŶŽĨɲ'ĂůĞƌ ?Fusions yielded IgM antibodies 
that bound to fixed but not fresh cells suggesting that the response was to intracellular antigens and 
CSR had not been achieved. /ŵŵƵŶŝƐĂƚŝŽŶ ǁŝƚŚ  ? ? ?A? ŽǀĂƌŝĂŶ ĐĂŶĐĞƌ ŐůǇĐŽůŝƉŝĚ ĂŶĚ ɲ'ĂůĞƌ ǁĂƐ
repeated with the addition of a whole cell boost in order to encourage class switching from IgM to 
IgG. This yielded an IgG response and the splenocytes were fused. The resulting hybridomas yielded 
F019/1A7 and F019/1D3 that bound to fresh ovarian cancer cells as well as glycolipid and not to 
PBMCs or HUVEC. Both F0191/1A7 and F019/1D3 bound to a range of ovarian cancer cell lines but 
not OVCA 433 cells and less strongly to a range of colorectal cell lines, including Colo 201, Colo 205 
and LoVo. Cell line distribution suggested that F019/1A7 and F019/1D3 were in fact binding to the 
same antigen so F019/1A7 was taken forward. Despite binding to OVCAR-3, OVCAR-4, OAW28 and 
OAW42 cells, anti-glycolipid ELISA revealed that F019/1A7 only bound to OAW42 glycolipid extract. 
However, subsequent work and increased sensitivity of the anti-glycolipid screen has shown that 
F019/1A7 does bind to glycolipid extracted from F019/1A7 antigen positive cell lines (unpublished 
data). To study whether the F019/1A7 functions similarly to the anti-glycolipid mAbs 692/29 and 
505/4, the direct killing activity of F019/1A7 was assessed. No direct cell death activity was observed 
when F019/1A7 was incubated overnight with OVCAR-4 or OAW42 cells, with no increase in PI 
uptake or decrease in cell number observed. Further characterisation of F019/1A7 revealed an 
inability of the mAb to induce ADCC or CDC in ovarian cancer cells. However, with the addition of a 
cross-linking antibody, cell lysis was observed. This inability to induce ADCC without a cross-linking 
agent may be due to low affinity of the mAb. It has been shown that a large proportion of TI antigen-
directed mAbs have a low level of hypermutation (Stein, 1992; Toellner et al., 2002), therefore have 
not been affinity maturated. This has since been confirmed by sequencing F019/1A7 which had a 
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low level of mutation from germline (unpublished data). Random site mutagenesis may increase the 
affinity of F019/1A7, increasing its effector functions. In order to determine the distribution that 
could be expected in vivo, F019/1A7 was screened on 362 samples of ovarian cancer tissue by TMA. 
This revealed that F019/1A7 bound to 88% of the ovarian tumours stained, with only 12% showing 
no staining. This suggests that F019/1A7 could bind to a high proportion of ovarian tumours in vivo, 
with binding to all types and grades of ovarian cancer. However, screening of F019/1A7 against a 
panel of normal tissue by TMA showed that the mAb bound to a range of normal tissues. This may 
make F019/1A7 unsuitable for therapy. However, F019/1A7 was screened against fresh, normal 
hepatocytes and PBMCs with minimal binding seen, despite binding moderately to liver and weakly 
to tonsil on the TMA. The disparity between the two results may be due to F019/1A7 binding to 
intracellular antigen on the TMA, which would be inaccessible therapeutically. Furthermore, if 
F019/1A7 binds to a carbohydrate moiety on glycolipids and glycoproteins, incomplete synthesised 
glycans can be present in the ER and Golgi apparatus of normal tissues and may be bound by 
F019/1A7, but once completely synthesised and presented on the cell surface, F019/1A7 may no 
longer bind. In cancer, the carbohydrate antigen may not be completely synthesised, allowing it to 
be bound by F019/1A7. Another factor to take into account is whether IHC binding reflects in vivo 
binding. EGFR is overexpressed on a range of epithelial-derived tumours and despite the presence of 
EGFR on normal cells, the chimeric, anti-EGFR mAb cetuximab shows restricted toxicity to the skin 
(Busam et al., 2001; Gullick, 1991). Interestingly, the level of F019/1A7 staining showed an inverse 
correlation with survival, with lower levels of staining predicting a better survival. F019/1A7 also 
correlated with tumour grade and type. These results and the ability of F019/1A7 to bind to 
glycolipid pose the question of whether its antigen is a carbohydrate involved in adhesion or 
metastasis, leading to decreased survival with more expression. Similar examples are mucin-4 and 
Lewis y which are involved in the adhesion and metastasis of ovarian cancers (Li et al., 2011; 
Ponnusamy et al., 2010). 
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Despite the binding of F019/1A7 to normal tissue, the method of incorporating liposomes with 
ŽǀĂƌŝĂŶĐĂŶĐĞƌŐůǇĐŽůŝƉŝĚĂŶĚɲ'ĂůĞƌŚĂƐƐŚŽǁŶƚŚĂƚĂŶƚŝ-glycolipid mAbs can be produced. Further 
development of the immunisation protocol may yield promising, tumour-specific mAbs, with the 
ability to bind glycolipid, with the possibility of mAbs causing direct cell death as observed with 
other anti-glycan mAbs. One way in which to increase the efficacy of the immunisation protocol may 
be to alter the immunisation schedule. Studies have shown that repeated immunisation with 
ɲ'ĂůĞƌ ĐŽƵůĚ ůĞĂĚ ƚŽ E<d ĐĞůů ĂŶĞƌŐǇ ? ǁŝƚŚ Ă ĚĞĐƌĞĂƐĞ ŝŶ ĐǇƚŽŬŝŶĞ ƉƌŽĚƵĐƚŝŽŶ ĂŶĚ ƌĞĚƵĐĞĚ
proliferation of NKT cells (Parekh et al., 2005; Uldrich et al., 2005). However, these studies use 
ƐŽůƵďůĞ ɲ'ĂůĞƌ ? ǁŚĞƌĞĂƐ Ă ŵŽƌĞ ƌĞĐĞŶƚ ƐƚƵĚǇ ŚĂƐ ƐŚown that immunising repeatedly with 
ŶĂŶŽƉĂƌƚŝĐůĞ ĨŽƌŵƵůĂƚĞĚ ɲ'ĂůĞƌ ůĞĂĚƐ ƚŽ ƌĞƉĞĂƚĞĚ ĂĐƚŝǀĂƚŝŽŶ ŽĨ E<d ĐĞůůƐ ? ǁŝƚŚŽƵƚ ĂŶǇ ŽďƐĞƌǀĞĚ
anergy (Thapa et al., 2009) ? dŚŝƐ ŵŽĚĞů ǁŽƵůĚ ďĞ ĐůŽƐĞƌ ƚŽ ŽƵƌ ŵŽĚĞů ǁŚŝĐŚ ƵƐĞƐ ɲ'ĂůĞƌ
ŝŶĐŽƌƉŽƌĂƚĞĚ ŝŶƚŽ ůŝƉŽƐŽŵĞƐ ?DŽƌĞ ŝŵƉŽƌƚĂŶƚĂƌĞĞĨĨĞĐƚƐŽĨɲ'ĂůĞƌŽŶƚŚĞĚǇŶĂŵŝĐƐŽĨE<dĐĞůůƐ ?
with studies showing a nearly complete loss of NKT cells due to transient expression of the iNKT cell 
receptor, followed by reappearance after 24-48 hours, before proliferation of NKT cells to 10-times 
their normal levels after 3 days, before reducing to normal levels by day 6-9 (Uldrich et al., 2005). 
/ŵŵƵŶŝƐĂƚŝŽŶǁŝƚŚɲ'ĂůĞƌ-containing liposomes 3 days before immunising with tumour glycolipid-
containing liposomes could make most use of the activated NKT cells. Modification of the glycolipid 
extraction method may lead to a better immunogen. For example, isolation and glycolipid extraction 
of the plasma membrane or lipid rafts may provide a more limited immunogen directed at more 
functional glycolipids. TI antigens lack T cell help, resulting in a predominantly IgM response, with 
low somatic hypermutation, resulting in a low affinity response. This is evidenced by the low level of 
mutation observed in the sequence of F019/1A7. Adjuvants could be used to increase class switching 
and somatic hypermutation, resulting in higher affinity mAbs. One example is the administration of 
anti-CD40 mAb alongside the immunogen. The anti-CD40 mAb could substitute T cell help, providing 
a second signal to the B cells. Evidence from a study immunising mice with bacterial pathogens and 
an anti-CD40 mAb displayed an increased antigen-specific antibody response to the pathogen with 
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an increase in class switching to IgG, showing that the anti-CD40 mAb could substitute for T cell 
(Dullforce et al., 1998).  
In conclusion, anti-glycolipid antibodies are proven to bind tumour cells specifically and can induce 
direct killing of those cells. This study outlines a series of immunisation methods with the aim of 
producing anti-glycolipid mAbs. Cell based immunisations produce a good anti-tumour cell response, 
but only an IgM anti-glycolipid response. Glycolipid is a poor immunogen if immunised alone, 
however if incorporated into liposomes ĂůŽŶŐǁŝƚŚɲ'ĂůĞƌand immunised followed by a whole cell 
boost, an IgG anti-glycolipid response can be observed. This study has shown that fusion of 
responding splenocytes can be fused and cloned, producing anti-glycolipid mAbs that have the 
ability to bind to a large proportion of ovarian cancers, with binding not restricted to one type or 
grade of cancer. Unfortunately, the mAb produced in this instance bound to a range of normal 
tissue, although the significance of this on in vivo effect could be further assessed. Further 
development of the technique may yield more specific mAbs, with the ability to bind to cancer 
glycolipid and cause cancer cell death either independently or in combination with human PBMCs or 
complement.  
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Chapter 7 Final Discussion 
What is the therapeutic potential of mAbs? 
The growth of mAb production for therapeutic use has seen great success with 22 mAbs being 
approved for treatment in the last 25 years. These mAbs have revolutionised the treatment of 
cancer, greatly increasing the response rate compared to standard therapy alone. Examples include 
rituximab and cetuximab which are used in first-line treatments of cancer (Coiffier et al., 2002; NICE, 
2009; Van Cutsem et al., 2009). Success of therapeutic mAbs is owed to their ability to bind their 
target with high affinity and functionality and their generally lower toxicity than traditional 
therapies. The number of mAbs entering clinical trials is increasing each year and they have a higher 
approval success rate compared to new small-molecule drugs; chimeric and humanised mAbs have 
an FDA approval rate of 26 and 18% respectively, with small-molecule drugs having a FDA-approval 
rate of 11%; (Reichert & Pavolu, 2004; Reichert, 2011; Reichert et al., 2005). These factors show that 
mAb therapy remains an important area of research. 
Why target glycolipids? 
Glycolipids have been shown to be overexpressed on the surface of many tumour types (Hakomori & 
Zhang, 1997; Hakomori, 2008). Studies have shown that glycolipids are good targets for mAb therapy 
(Durrant et al., 2006; Loo et al., 2007; Zhang et al., 2010a). All mAbs approved to date, have protein 
targets, illustrating that membrane glycolipids are a potential area for novel mAb target discovery. 
Furthermore, studies into the functional role of glycolipids has shown that they form glycosynapses 
on the cell membrane and associate with functional proteins that effect a wide range of cellular 
processes, such as cell adhesion, growth and proliferation (Hakomori, 2008). In addition, a 
remarkable number of mAbs generated against glycolipids have the ability to induce direct cell death 
in target cells without the need for effector cells or complement (Alvarez-Rueda et al., 2007; Chou et 
al., 1998; Hellstrom et al., 1990; Loo et al., 2007; Zhang et al., 2010a; Zhong et al., 2001). 
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The premise of this thesis therefore, was to further characterise two anti-cancer associated 
glycolipid-targeted murine mAbs produced in-house. One aspect of this was to assess whether their 
ability to cause direct cell death would be useful by evaluating the level of apoptosis in colorectal 
cancer. Furthermore, this thesis set out to develop a platform for the production of anti-cancer 
associated glycolipid mAbs. By combining these two areas, this thesis aimed to determine whether 
cancer-associated glycolipid targeted mAbs would be viable therapeutics.  
What are the ideal antigens? 
In both the characterisation of existing mAbs and the development of new mAbs, the criteria for a 
therapeutically valuable mAb remain the same. The properties of such a mAb can be distilled into 
two main properties; efficacy and safety. The most important factor in mAb 
production/characterisation is the target antigen and its specificity which relates to both efficacy 
and safety. Ideally the target antigen would be expressed at high levels on the cell surface and be 
specific to cancer cells, thereby reducing toxicity caused by binding normal cells. Desirably, the 
target antigen would be expressed on a high percentage of tumours and not be limited to one 
subset (e.g. type or grade) of the target cancer. Even more desirable would be the expression of the 
antigen on a range of cancers originated in different sites. An example of this is the use of cetuximab 
in the treatment of both colorectal and head and neck cancers (Blick & Scott, 2007). In this thesis 
two anti-glycolipid mAbs have been characterised and compared to mAbs with similar target 
antigens. 505/4 and 692/29 have been shown to bind to both glycolipids and glycoproteins. Analysis 
by glycan array binding (Consortium For Functional Glycomics) revealed that 505/4 binds to the sialyl 
Lewis a glycan and other related molecules, with 692/29 binding to a unique epitope on both Lewis y 
and Lewis b glycans. Lewis antigens are good targets as they are overexpressed on a range of cancers 
and are expressed at low levels of expression normal tissues. In vitro distribution studies showed 
that 505/4 bound to 90% of colorectal cancer tissues and had limited binding to normal tissues. In 
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vitro cell line analysis of 692/29 showed a good distribution across the majority of colorectal and 
some ovarian cancer cell lines, suggesting that both mAbs could have good in vivo distribution.  
As well as tumour-specificity, a mAb would have a functional effect, killing the cancer cells by a 
variety of mechanisms, as most approved mAbs cause tumour cell death by more than one 
mechanism.  
Functionality of the anti-tumour mAb 
The ability to induce cytotoxicity by more than one mechanism increases the efficacy of a mAb, for 
example through the induction of ADCC, CDC, inhibition of angiogenesis, blocking intracellular 
signalling and induction of direct cell death. A good example of this is the anti-CD20 mAb rituximab 
which is one of the most successful mAbs in cancer therapy. Rituximab has been shown to eliminate 
CD20+ B cells via three different mechanisms; ADCC, CDC and direct cell death (Pescovitz, 2006). 
ADCC has been shown to be a key factor in antibody-mediated cytotoxicity in a number of approved 
mAbs. For example, cancers can become resistant to trastuzumab treatment and this has been 
shown to be mediated by an increased resistance to perforin and granzyme-mediated cell death, 
suggesting that resistance to ADCC significantly reduces the efficacy of trastuzumab in vivo 
(Kawaguchi et al., 2009). Evidence has also shown ƚŚĂƚƚŚĞ&ĐɶZ///ĂƌĞĐĞƉƚŽƌ ? ? ?sĂůůŽƚǇƉĞĚŝƐƉůĂǇƐĂ
ŚŝŐŚĞƌ ĂĨĮŶŝƚǇ ĨŽƌ ŚƵŵĂŶ /Ő' ? ĂŶĚ ŝŶĐƌĞĂƐĞĚ (Koene et al., 1997) and rituximab-mediated 
response was greater in patients with this polymorphism than those without, highlighting the 
importance of ADCC as an effector function (Cartron et al., 2002). As well as inducing cellular 
cytotoxicity via effector cells mAbs can cause the formation of MAC complexes on target cells by 
activating the complement cascade. The anti-CD20 mAbs rituximab and ofatumumab have been 
shown to induce potent CDC, contributing to their in vivo efficacy (Lin, 2010; Pescovitz, 2006). 
As well as the traditional mechanisms of action described above, mAbs can have antigen-associated 
effects. An example of this is the growth inhibition seen in cells that have been blocked with 
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trastuzumab. By binding HER2 trastuzumab has the ability to block intracellular signalling involved in 
cell growth, proliferation and apoptosis (Delord et al., 2005). By binding to all isoforms of VEGF, 
often overexpressed by tumours and tumour-associated stromal cells (Fukumura et al., 1998; Hicklin 
& Ellis, 2005), bevacizumab blocks binding of VEGF to its receptor, VEGFR, therefore inhibiting 
angiogenesis, resulting in a reduction in tumour growth (Shih & Lindley, 2006).  
As well as potently inducing ADCC and CDC rituximab has also been shown to induce direct cell 
death in target cells, although the mechanism by which this occurs has been disputed. Conflicting 
evidence suggest a role of translocation of CD20 into lipid rafts bound by anti-CD20 mAbs resulting 
in signalling via p38 MAP-kinase (Cardarelli et al., 2002; Pedersen et al., 2002). However, other 
studies have suggested that rituximab-mediated cell death is independent of caspases and lipid raft 
translocation (Chan et al., 2003; Daniels et al., 2008). 
A greater number of effector mechanisms, however, do not necessarily result in a better therapeutic 
response. An example is the fully human IgG2 mAb panitumumab, which binds to EGFR with a very 
high affinity and is a good competitive inhibitor of EGF (Yang et al., 2001). If it were engineered as an 
IgG1 in order to induce ADCC, it may induce toxicity to normal cells due to its high affinity for the 
antigen (Cohenuram & Saif, 2007). Although studies into the mechanism of action of rituximab have 
shown an important role for CDC, a study investigating the importance of ADCC demonstrated that 
rituximab-mediated C3b deposition on CD20+ cells inhibited the interaction between NK cells and 
the Fc region of rituximab, therefore inhibiting ADCC (Wang et al., 2008). Defucosylation of IgG can 
lead to an increase in ADCC in vitro, therefore creating classes of IgG that could induce ADCC and not 
CDC (IgG2 and IgG4; (Niwa et al., 2005)).The engineering of a defucosylated, IgG2 or IgG4, anti CD20-
specific mAb capable of mediating potent ADCC and not CDC, may increase efficacy in vivo of anti-
CD20 mAbs. 
Both 505/4 and 692/29 show direct killing activity, with evidence suggesting that this is independent 
of apoptosis. This may be of therapeutic value, especially as a hallmark of tumour development is 
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resistance to apoptosis (Fulda, 2009). Results of this thesis suggest that tumours with a lower level of 
caspase-3 activation significantly correlate with a worse prognosis. Therefore, 505/4 and 692/29 
may be able to improve survival rates in a group that have a worse prognosis. 
Both 505/4 and 692/29 bind to highly expressed antigens on cancer cells, with minimal binding to 
normal cells and the ability to cause direct cell death. Interestingly, other mAbs tested in this thesis 
directed against Lewis y, Lewis a and sialyl Lewis a have been able to induce direct cell death in an 
apoptosis-independent manner (BR96 and CA19.9). Other mAbs have also been shown to cause 
similar toxicity. RAV12, a chimeric mAb recognises a minimal epitope of Galɴ1-3GlcNAcɴ1-3Gal (a 
Lewis antigen precursor) on the N-linked carbohydrate antigen RAAG12 and induces oncosis of 
target cells. RAV12 has been shown to induce oncosis in colorectal cancer cell lines (Loo et al., 2007). 
F77, a chimeric mAb has been shown to induce oncosis by binding a prostate cancer-specific 
glycolipid (Zhang et al., 2010a). These studies as well as this thesis show a trend for anti-Lewis mAbs 
to induce oncosis-like cell death in target cells, suggesting that Lewis antigens have a functional role 
on the cell surface, as part of an altered glycoprotein or glycolipid. The mechanism of direct cell 
death caused by anti-glycan mAbs is as yet undiscovered. 
The anti-glycan mAbs described above have all been show to kill independently of apoptosis, with an 
oncosis-like mechanism being a common theme. BR96 and the recently described human anti-sialyl 
Lewis a mAb, 5B1, have both been shown to be internalised upon binding to antigen on the target 
cell (Garrigues et al., 1993; Sawada et al., 2011). Furthermore, BR96 has been shown to be degraded 
by lysosomes once internalised (Garrigues et al., 1993). These observations may suggest that binding 
of mAb to the cell surface causes cellular stress or activates an intracellular pathway, leading to the 
formation of an autophagosome, which is then degraded by the lysosome. This would facilitate the 
uptake of PI or dextran beads observed in this study and the degradation of BR96 observed 
previously, although it does not account for the cellular swelling observed after mAb treatment. One 
of the hallmarks of oncosis is the depletion of ATP, leading to Na
+
 and Ca
2+
 intake, followed by 
cellular and organelle swelling (Eguchi et al., 1997; Majno & Joris, 1995). Anti-glycan mAbs may 
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initiate oncosis through the internalisation of mAb and membrane, prompting the cell to synthesise 
more membrane components, such as cholesterol, sphingomyelin, ceramide, in an ATP-dependent 
manner. This could lead to the depletion of ATP, resulting in cellular swelling and ultimately cell 
death. The calpain family of proteins are Ca
2+
-dependent proteases that have been shown to be 
activated in oncosis (Liu et al., 2004). Increased cytoplasmic levels of Ca
2+
 leads to the activation of 
calpains, which have a number of substrates. These include components of the actin cytoskeleton-
plasma membrane junction. Calpain-mediated proteolysis of these proteins can lead to increased 
plasma membrane permeability (Liu & Schnellmann, 2003). The binding of anti-glycan mAbs may 
lead to the influx of Ca
2+
 and calpain activation, followed by cytoskeleton-associated plasma 
membrane permeability. 
Further investigation into the mechanism by which anti-glycan mAbs induce apoptosis-independent 
cell death is warranted. 
The mAbs 505/4 and 692/29 were compared to other mAbs directed at similar antigens, whose 
binding was first analysed on a glycan array. Upon in vitro comparison sialyl Lewis a, Lewis a and 
Lewis y-directed mAbs all mediated direct cell death in the absence of effector cells or complement. 
2-25 LE, directed at Lewis b failed to induce direct cell death, despite binding at similar levels. This 
suggests that Lewis y, Lewis a and sialyl Lewis a, but not Lewis b, in this instance, are functional 
targets for mAb therapy with mAb binding initiating direct cell death. The specificity of 692/29 to 
both Lewis y and Lewis b may relate to better in vivo efficacy than that seen with the BR96-
doxirubicin mAb conjugate (Tolcher et al., 1999). In this study, BR96 showed cytotoxic effects against 
cell lines with high and low levels of antigen by ADCC, CDC and direct cytotoxicity, compared to 
692/29 that showed cytotoxicity only in cell lines with a high expression of Lewis y/b. 
Human mAbs 
In order to transfer into the clinic, chimerising or humanising the mAbs would further increase their 
efficacy. Producing chimerised, IgG1 versions of the mAbs in a FUT8 knockout could increase the 
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ability of the mAbs to induce ADCC in vivo, as well as reduce immunogenicity, increasing their in vivo 
half-life. An interesting feature of all anti-Lewis mAbs tested in this thesis was the ability for them to 
bind cells at very high levels, without saturating the antigen. Furthermore, the mAbs had the ability 
to bind to cells that have already been incubated with a high concentration of mAb. These are 
properties of homophilic mAbs, which have been previously described against glycolipid antigens 
(Kaminski et al., 1999). It would be important to test any chimerised or humanised mAbs for their 
ability to bind target cells as well as their murine counterparts, as the homophilic property of the 
murine mAbs may affect their in vivo efficacy. 
The type of antibody used also has an effect on the efficacy and safety of a therapeutic mAb. The 
first mAbs to be used were fully murine, grown as hybridomas. However, immunogenicity and Fc 
incompatibility of murine mAbs reduced their in vivo potency. However, murine mAbs have been 
approved for treatment, including muromonab-CD3 and 
131
I-tositumomab. The success of 
muromonab-CD3 was partly due to the fact that patients undergoing kidney transplant were also 
administered with immunosuppressants, reducing the HAMA response. 
131
I-tositumomab was 
successful due to its radioactive isotope which allow only small amounts of mAb to be administered, 
with a good anti-tumour response (Cheung et al., 2009). Engineering of chimeric mAbs showed a 
reduced level of HAMA response, with humanised mAbs further reducing the level of 
immunogenicity (Hwang & Foote, 2005). Fully human mAbs have been shown to be the least 
immunogenic, for example panitumumab, which has shown no HAHA response and very low levels 
of toxicity in clinical studies (Cohenuram & Saif, 2007). Some human mAbs can still elicit an antibody 
response, although HAHA levels are generally low and results do depend on detection methods 
(Scott & De Groot, 2010). 
Serum half-life 
As well as the ability to bind specifically to cancer cells and to cause cytotoxicity to those cells, mAbs 
need to have a long half-life in order to reach the target and have increased efficacy. As well as 
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increasing efficacy, a longer half-life decreases the administration frequency that could result in a 
decreased in HAMA/HAHA response, depending on the nature of the mAb. Engineering of the Fc 
region to increase affinity for the FcRn at pH 6.0, resulting in FcRn mediated recycling of the mAb 
into circulation could also increase the half-life of a mAb (Dall'Acqua et al., 2006). 
Other potential targets 
During the characterisation of 505/4 and 692/29, this thesis investigated the level of apoptosis in a 
cohort of colorectal cancers. Results showed that the level of apoptosis in the tumour significantly 
correlated to patient survival. However, a low level of apoptosis in the tumour-associated stroma 
rather than the tumour itself was an independent marker of bad prognosis. The tumour 
microenvironment has become more and more studied over the past decade. It is accepted that 
tumours are able to evade immune detection by manipulating their microenvironment through the 
release of cytokines and other soluble factors in order to create an immunosuppressive environment 
as well as downregulating stress molecules on their surface (Ostman & Augsten, 2009; Watson et al., 
2006c). The creation of an immunosuppressive environment involves the production of pro-tumour 
phenotype of a variety of cell types. The creation of cancer-associated stromal cells may be an 
interesting source of new mAb targets. Therapeutics aimed at the microenvironment have been 
tested, targeting a range of stromal elements. An example is the humanised mAb sibrotuzumab 
which is directed at the CAF-associated protein FAPɲ and showed good in vivo distribution in 
patients with the mAb targeted at tumour-associated stroma and minimal normal tissue binding 
(Scott et al., 2003), although no anti-tumour responses have been observed with  sibrotuzumab in 
vivo (Hofheinz et al., 2003). However, a more recent anti-FAP mAb-maytansinoid (tubulin binding 
cytotoxic agent) conjugate, FAP5-DM1, showed inhibition of tumour growth in various solid tumour 
xenograft models (Ostermann et al., 2008) as did PF-5412, a mAb targeted at iŶƚĞŐƌŝŶɲ ?ɴ ? ?ǁŚŝĐŚŝƐ
overexpressed on both tumour-associated stroma and tumour cells (Li et al., 2010). These studies 
show that mAb therapy targeted at tumour-associated cells could inhibit establishment of the 
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tumour microenvironment by recruiting immune effector cells and destruction of pro-tumour cells. 
Studies have shown that incubation of fibroblasts with tumour cells can lead to the transformation 
of fibroblasts into CAFs (Tyan et al., 2011). Extraction of in vitro-activated CAF glycolipid and 
immunisation could lead to an anti-CAF mAb response. Any resulting mAbs directed at glycolipid 
may have direct killing ability, as observed in other anti-glycan mAbs. Due to the close proximity of 
the tumour and its environment the possibility of a bi-specific mAb targeting more than one 
molecule could produce a potent anti-tumour response, with the previously described 
catumaxomab demonstrating proof of principle of this type of mAb. 
As well as the characterisation of previously produced mAbs 505/4 and 692/29 this thesis set out to 
develop an immunisation protocol to produce anti-ovarian cancer-associated glycolipid mAbs in 
order to find novel tumour-associated targets for mAb therapy. Results suggested that immunisation 
of glycolipid alone is a weak immunogen, but by incorporating tumour glycolipid into liposomes and 
ŝŵŵƵŶŝƐŝŶŐǁŝƚŚƚŚĞE<dĐĞůůĂĚũƵǀĂŶƚ ?ɲ'ĂůĞƌ ?ĂŶƚŝ-cancer glycolipid mAbs could be produced. The 
level of IgG response was lower than with whole cell immunisation and there was a tendency for IgG 
to be targeted to intracellular antigens. Despite this, an anti-cancer associated glycolipid mAbs was 
produced, with good levels of binding to a large percentage of ovarian cancer tumours. This provides 
a unique method for the production of mAbs targeted tumour cell glycolipids. Regrettably, F019/1A7 
bound to a range of normal tissues by immunohistochemistry, although this would need to be 
validated in another setting. Further investigation of the immunisation protocol, using more cell 
surface-specific cancer-associated glycolipids and adjustments to adjuvant help may provide an 
immunisation protocol capable of producing mAbs directed at novel, functional cancer-specific 
glycolipid molecules on a range of cancers.  
Summary 
Therapeutically valuable mAbs work by employing a variety of effector functions to reduce tumour 
size and growth. The 692/29 and 505/4 anti-colorectal cancer mAbs were produced in house and 
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previously characterised to various degrees. 692/29 was shown to bind to a large proportion of 
colorectal tumours, with minimal binding observed to normal tissues by IHC. Preliminary antigen 
discovery using TLC revealed specificity for both Lewis y and Lewis b blood group antigens. 505/4 
was selected as a candidate for further characterisation due to its ability to bind to a number of 
colorectal cell lines and colorectal cancer cell line glycolipid. Preliminary TLC analysis of antigen 
specificity showed binding of 505/4 to a sialyltetrasylceramide. 
In chapters 4 and 5 the Consortium for Functional Glycomics glycan array was used to confirm the 
fine specificity of 692/29, with results showing binding predominantly to Lewis b as well as Lewis y-
containing glycans. Furthermore, using this resource allowed the discovery of the specificity of 505/4 
to sialyl Lewis a as well as sialyl di-Lewis a, with no cross-reactivity with other blood group antigens. 
Comparison with other anti-Lewis mAbs directed at Lewis y, Lewis b and Lewis a revealed that the 
fine specificity of the mAbs differed, despite apparent binding to the same antigen (Fig 7.1). Figure 
6.1 shows that the anti-Lewis y and Lewis b mAbs appear to recognise different aspects of the 
antigens, with 2-25 LE showing specificity for the minimal epitope 'Ăůɴ ?- ?'ůĐEĐĂŶĚZ ? ?'Ăůɴ ?-
4GlcNAc. 505/4 shows specificity for the sialyl Lewis a glycan, with CA19.9 recognising sialylated 
'Ăůɴ ?-3GlcNAc. 692/29 and 7LE, however, do not have an obvious binding specificity when the three 
top-binding glycans are compared. The effect of differences in fine specificity of the mAbs was 
assessed in this study, with varying levels of cell binding or death observed. This was most apparent 
with anti-Lewis y and Lewis b mAbs, with anti-sialyl Lewis a/Lewis a mAbs showing similar patterns 
of in vitro characteristics. Although there may be a difference to in vivo binding due to abundance or 
accessibility of certain glycans on the cell surface, the glycan array is a useful tool in easily identifying 
anti-glycan mAb targets and their fine specificity.  
This study provided preliminary evidence of non-saturable mAb binding to tumour cells, termed 
homophilic binding, by the anti-Lewis mAbs analysed. The results suggested that despite a large 
number of mAb molecules, antigen saturation was not achieved. Further characterisation of this  
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692/29   
  
 
Lewis b Lewis y-x-x Lewis x-containing 
2-25 LE   
   
   
Lewis b Lewis a Lewis a 
BR96   
   
   
Lewis y Lewis y-x Lewis y 
505/4   
   
   
Sialyl di-Lewis a Sialyl Lewis a Sialyl Lewis a 
7LE   
  
 
   
Type II precursor Sialylated Type II precursor Lewis a 
CA19.9   
 
  
   
Sialylated, sulfo Type-1 
precursor 
Sialyl di-Lewis a Sialylated Type-1 precursor 
Figure 7.1 The binding of anti-Lewis mAbs to their antigens according to The Consortium for Functional 
'ůǇĐŽŵŝĐ ?Ɛ ĂƌƌĂǇ ďŝŶĚŝŶŐ ĚĂƚĂ ? The binding of 692/29, 2-25 LE, BR96, 505/4, 7LE and CA19.9 to the glycan 
array is represented by the glycans bound most strongly by the mAbs (Strongest-weaker binding; left to right). 
A blue squares represents glucosylamine, yellow circles represents galactose, red triangles represent fucose, 
green circles represent mannose and purple diamond represents sialic acid.  
 
ɲ ? 
ɲ ? 
SO3 ɲ ? 
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phenomenon could provide evidence of a mAb property that may be therapeutically useful, 
providing the mAb with a greater avidity in vivo. Conversely, the ability to bind homophilically may 
reduce the ability of the mAb to penetrate a solid tumour, resulting in a lower efficacy. Further 
characterisation of the mAbs using antigen to inhibit self-self binding or modelling and site-directed 
mutagenesis may provide further evidence for homophilic binding. 
An interesting mechanism displayed by a number of approved mAbs is the ability to cause direct cell 
death of target cells, without the need for immune cells or complement. Previous studies with the 
anti-Lewis y mAb, BR96, revealed its ability to cause direct cell death of antigen positive cell lines.  
This prompted the analysis of the ability of 692/29 and 505/4 to cause direct cell death. Chapters 4 
and 5 of this thesis revealed that both 505/4 and 692/29 mAbs were able to induce direct cell death 
in antigen positive cell lines. Further to this, investigation into the mechanism of cell death 
suggested that both mAbs may cause direct cell death independently of apoptosis. One hallmark of 
oncosis is the formation of large pores on the cell surface of mAb-bound cells. Analysis using 
electron microscopy may provide further evidence of mAb-mediated oncosis.  
Other mAbs have been shown to induce direct cell death in an apoptosis independent manner. An 
example being rituximab, which has been shown to induce direct cell death independently of 
apoptosis (Daniels et al., 2008). /Ŷ ŽƌĚĞƌ ƚŽ ĚĞƚĞƌŵŝŶĞ ƚŚĞ ƚŚĞƌĂƉĞƵƚŝĐ ǀĂůƵĞ ŽĨ Ă ŵď ?Ɛ ĂďŝůƚǇ ƚŽ
induce direct cell death independently of apoptosis, this study determined the level of apoptosis in 
colorectal cancer using a large TMA cohort. Results in chapter 3 revealed that the level of apoptosis 
in the tumour-associated stroma is an independent prognostic factor for patient survival in 
colorectal cancer. In addition this study revealed a strong correlation of apoptosis with the immune 
marker MHC-II, suggesting a role of an immunosuppressive environment in tumour progression. 
Therefore, the ability of a mAb to induce direct cell death may be vital in tumours with an immune 
suppressed environment. This study demonstrated the importance of the tumour microenvironment 
in tumour progression. This may be a represent target for therapy either alone or combined with 
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anti-tumour agents. One limitation of this study is the possible variability of CC3 in different areas of 
a tumour. As this study used TMA technology, only one area of a tumour was assessed. Whole 
sections, analysing the level of apoptosis across a larger area, or a larger cohort of patients may 
further validate the results of this study. 
Glycans and as a result, glycolipids are aberrantly expressed on the cell surface. A growing area of 
research has shown the importance of glycolipids on the cell surface of cells in vitro as part of 
functional sub-domains, which exist to allow optimal function of a number of membrane proteins. 
Disruption of membrane protein-associated glycolipids has been shown to have a functional effect. 
In order to take advantage of binding a functional glycolipid and perhaps discover novel, tumour-
associated glycolipids, this study performed a series of investigations to improve the immunogenicity 
of tumour-associated glycolipid with the aim of developing a protocol for the production of anti-
glycolipid mAbs. Previously anti-glycolipid mAbs have been produced from whole cell immunisations 
or isolated from patient serum and identified as anti-glycolipid mAbs. Chapter 6 resulted in the 
production of a new anti-glycolipid mAb, F019/1A7, providing proof of principle that the novel 
immunisation protocol incorporating tumour glycolipid into liposomes with an iNKT cell adjuvant, 
ɲ'ĂůĞƌ ?ĐĂŶǇŝĞůĚĂnti-glycolipid mAbs. A limitation of this protocol is that a small number of anti-
glycolipid mAbs were produced. A direct comparison to a whole cell immunisation would allow 
quantification of the effectiveness of the protocol developed. Further to the work carried out in this 
thesis, the group have been successful in producing a number of anti-glycolipid mAbs against 
ovarian, pancreatic and gastric cancers, using a protocol based on the one developed in this thesis. It 
would be interesting to see results of further characterisation of these mAbs show good tissue 
distribution and any anti-tumour effects. Future development of this protocol should centre on 
improving the reaction of antibodies produced with cell surface antigens with a functional effect. 
This may be achieved by immunising with cell membrane sub-domains that may contain more 
functional, cell surface glycolipid molecules. 
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